



FINAL

Oregon Department of Environmental Quality

Offsite Investigation Report

Former JH Baxter & Co. Facility

Eugene, Oregon

ECSI No. 55

September 30, 2024

Prepared by:



650 NE Holladay Street, Suite 900, Portland, OR 97232

FINAL

Offsite Investigation Report

Former JH Baxter & Co. Facility
Eugene, Oregon
ECSI No. 55

Prepared for Oregon Department of Environmental Quality

Prepared by:



RENEWAL DATE: 12/31/2024

Christopher Martin, PE
Project Manager and Site Engineer
GSI Water Solutions, Inc.

Contents

| | |
|--|----|
| SECTION 1: Introduction..... | 1 |
| 1.1 Purpose..... | 1 |
| 1.2 Limitations | 1 |
| SECTION 2: Background..... | 2 |
| 2.1 Baxter Facility History..... | 2 |
| 2.2 DEQ Offsite Involvement..... | 4 |
| 2.3 EPA Offsite Involvement..... | 4 |
| 2.4 PCDD/F Action Levels..... | 4 |
| SECTION 3: Offsite Investigations and Results..... | 5 |
| 3.1 June 2022 Offsite Investigation | 5 |
| 3.1.1 ISM Sampling (0- to 6-inch bgs intervals) | 5 |
| 3.1.2 Composite Sampling (6- to 12-inch bgs intervals) | 6 |
| 3.1.3 Analytical Results..... | 6 |
| 3.2 April 2023 Supplemental Offsite Investigation | 7 |
| 3.2.1 Push Probe Soil Collection | 8 |
| 3.2.2 Composite Sampling | 8 |
| 3.2.3 Analytical Results..... | 8 |
| 3.2.4 Arborist Consultation | 10 |
| SECTION 4: Data Screening..... | 11 |
| 4.1 TCDD TEQ Calculation..... | 11 |
| 4.2 Screening Levels | 11 |
| 4.3 RA Depths | 11 |
| 4.4 Quality Assurance/Quality Control | 12 |
| SECTION 5: Recommendations | 14 |
| 5.1 Soil Removal Depth..... | 14 |
| 5.2 Import Soil | 14 |
| 5.3 Vegetation Removal | 14 |
| 5.4 Vegetation Protection | 15 |
| 5.5 City ROW RAs..... | 15 |
| SECTION 6: References..... | 16 |

Tables

| | |
|---------|---|
| Table 1 | Previous Offsite Investigation Sample Locations |
| Table 2 | Total TCDD TEQ June 2022 |
| Table 3 | Total TCDD TEQ April 2023 |

Figures

| | |
|----------|---------------------|
| Figure 1 | Site Vicinity Map |
| Figure 2 | Soil Removal Depths |

Appendices

| | |
|------------|--|
| Appendix A | Data Tables |
| Appendix B | Laboratory Reports and Data Validation |
| Appendix C | June 2022 Discrete and Increment Sample Locations |
| Appendix D | April 2023 Discrete and Increment Sample Locations |
| Appendix E | Arborist Reports |

Abbreviations and Acronyms

| | |
|----------|---|
| AP | Alva Park (decision unit) |
| Baxter | JH Baxter & Co. |
| BB&A | BB&A Associates |
| bgs | below ground surface |
| City | City of Eugene, Oregon |
| CUL | cleanup level |
| DEQ | Oregon Department of Environmental Quality |
| DU | decision unit |
| EMPC | estimated maximum possible concentration |
| EPA | U.S. Environmental Protection Agency |
| Frontier | Frontier Analytical Laboratory |
| GSI | GSI Water Solutions, Inc. |
| ISM | incremental sampling methodology |
| ITRC | Interstate Technology and Regulatory Council |
| LRAPA | Lane Regional Air Protection Agency |
| MRL | method reporting limit |
| OHA | Oregon Health Authority |
| Pace | Pace Analytical National |
| PCDD/F | polychlorinated dibenzo-p-dioxin and polychlorinated dibenzofuran |
| PCP | pentachlorophenol |
| pg/g | picograms per gram |
| QA/QC | quality assurance/quality control |
| QAPP | Quality Assurance Project Plan |
| RA | removal action |
| RBSL | Risk-Based Screening Level |
| ROD | Record of Decision |
| ROW | right-of-way |
| SO | step out (decision unit) |
| TCDD | 2,3,7,8-tetrachlorodibenzo-p-dioxin |
| TEF | toxicity equivalency factor |
| TEQ | toxicity equivalence quotient |
| WHO | World Health Organization |

SECTION 1: Introduction

This report describes offsite investigation activities and analytical results that were collected in preparation of residential soil removal activities north of the former JH Baxter & Co. (Baxter) facility in Eugene, Oregon (Figure 1). The properties identified by these offsite investigations consist of the first offsite soil removal action (RA) to be completed by the Oregon Department of Environmental Quality (DEQ).

This report also contains an assessment of the data results, as well as recommendations to DEQ for the RA activities associated with elevated polychlorinated dibenzo-p-dioxin and polychlorinated dibenzofuran (PCDD/F) concentration in soil at residential properties north of the Baxter facility. The recommendations provided in this report include the extent and depth of soil removal proposed for each decision unit (DU).

1.1 Purpose

In accordance with the Offsite Investigation Work Plan (GSI, 2022) and Offsite Investigation Work Plan Addendum #1 (GSI, 2023), the purpose of the offsite investigations was to delineate the PCDD/F concentrations in surface and shallow soil at residential properties immediately north of the Baxter facility. These locations had a high potential for air deposition based on modeling performed by the Lane Regional Air Protection Agency (LRAPA) in support of the Cleaner Air Oregon air emissions evaluations at the Baxter facility. Data from the 2022 and 2023 soil sampling investigations, a prior surface soil sampling investigation completed by Baxter in 2020 and 2021, and the U.S. Environmental Protection Agency's (EPA's) Removal Program investigations in 2022 and 2023 were used to support evaluations of human health risk to residents and for planning future RAs.

1.2 Limitations

The offsite investigations and this summary report have been prepared for DEQ. Work for this project was performed in accordance with generally accepted professional practices relating to the nature of work completed at the same or similar localities. It is intended for the exclusive use of DEQ and for specific application to the site. No other warranty, express or implied, is made.

SECTION 2: Background

This section provides a summary of the Baxter facility's history and previous offsite investigation activities conducted near the Baxter facility. For a more detailed description of the Baxter facility and previous facility activities, refer to DEQ's Record of Decision (ROD) issued for the Baxter facility (DEQ, 2019).

2.1 Baxter Facility History

The JH Baxter & Co. facility is a former wood treating facility located at 85 Baxter Street in Eugene, Oregon (Figure 1). The Baxter facility produced treated wood products using a variety of additives, including pentachlorophenol (PCP), which results in the generation of PCDD/Fs as part of the PCP manufacturing process. Further, unauthorized evaporation of PCP was performed in the retorts, which resulted in airborne releases of PCP (and in turn PCDD/Fs) that are suspected of depositing in the neighborhood to the north of the facility, immediately across Roosevelt Boulevard (DEQ, 2022b).

Offsite Soil Investigation. In 2020 and 2021, Baxter, to meet the conditions of the ROD, began investigating the potential impacts of facility operations on the surrounding area to confirm releases to offsite areas in the direction of prevailing wind patterns. Sampling activities included investigating adjacent drainage ditches to the north and south of the facility and close-in residential properties, as well as collecting background samples to understand area-wide depositional patterns (DEQ, 2019). Contaminants of interest included chemicals related to wood treatment (metals [arsenic, chromium, copper, and zinc], polycyclic aromatic hydrocarbons, PCP, and PCDD/Fs).

Baxter collected offsite surface soil samples from the locations listed in Table 1 in 2020 (GSI, 2020) and 2021 (GSI, 2021). This report does not present data collected from these previous investigations, except where detected surface soil concentrations indicated a risk that was investigated further in subsequent offsite investigations.

Table 1. Previous Offsite Investigation Sample Locations

| Sample Type | Sample Name | Location |
|-----------------------------------|-------------|--|
| 2020 Offsite Investigation | | |
| Offsite Surface Soil | DU-1 | Lark City Park northeast of site. |
| | DU-2 | Public right-of-way along West 1st Avenue, south of site. |
| | DU-3 | Within ditch along south side of Site from outfall entry into ditch to west property line fence. |
| | DU-4 | Public right-of-way along Roosevelt Boulevard, north of site. |
| | DU-5 | Residential area right-of-way north of site (archived). |
| | DU-6 | Within ditch along northwest side of Site at discharge of outfall. |
| Background Surface Soil | BKGD-1/DU-7 | Uplands southeast of site. |
| | BKGD-2/DU-8 | Within ditch along south side of site from east property line fence to immediately prior to Outfall 1 water entering ditch (archived). |

| Sample Type | Sample Name | Location |
|-----------------------------------|-------------|--|
| 2021 Offsite Investigation | | |
| Offsite Surface Soil | DU-02 | South shoulder of Roosevelt Boulevard in unpaved areas immediately beyond the facility fence line with northwesterly wind direction potential air deposition. |
| | DU-03 | South shoulder of Roosevelt Boulevard in unpaved areas immediately beyond the facility fence line with northwesterly wind direction potential air deposition. |
| | DU-04 | Undeveloped north bank soil of Roosevelt channel above the assumed high water elevation with northwesterly wind direction potential air deposition. Location also evaluates potential concentration gradients away from DU-02. |
| | DU-05 | Undeveloped north bank soil of Roosevelt channel above the assumed high water elevation with northly wind direction potential air deposition. Location also evaluates potential concentration gradients away from DU-02 and DU-03. |
| | DU-06 | Undeveloped north bank soil of Roosevelt channel above the assumed high water elevation with northeasterly wind direction potential air deposition. Location also evaluates potential concentration gradients away from DU-03. |
| | DU-07 | Unimproved and unutilized lot in residential area. Location evaluates northwesterly wind direction potential air deposition. Location also evaluates potential concentration gradients away from DU-04. |
| | DU-08 | Residential lot north of site. Location also evaluates potential concentration gradients away from DU-05. |
| | DU-10 | Residential lot north of site. Location also evaluates potential concentration gradients away from DU-05. |
| | DU-11 | Residential lot north of site. Location also evaluates potential concentration gradients away from DU-05. |
| | DU-12 | Residential lot north of site. Location also evaluates potential concentration gradients away from DU-05 and DU-06. |
| | DU-15 | Residential lot north of site. Location also evaluates potential concentration gradients away from DU-11. |
| | DU-16 | Residential lot north of site. Location also evaluates potential concentration gradients away from DU-11 and DU-12. |
| Background Surface Soil | BKGD-04 | Peterson City Park north of site |
| | BKGD-05 | Residential Property northwest of the site |
| | BKGD-06 | Trainsong City Park northeast of the site |
| | BKGD-07 | North slope Roosevelt Ditch north of the site |
| | BKGD-08 | Emerald Park northeast of the site |
| | BKGD-09 | Hawkins Heights City Park south of the site |

Notes

BKGD = background

DU = decision unit

Elevated PCDD/F contamination was identified in soil samples collected from drainage ditches and residential yards immediately north of the Baxter facility. PCDD/F concentrations were highest in the 2021 samples in drainage ditches and yards within areas where air deposition modeling completed by the LRAPA predicted predominant summer wind direction and deposition from the Baxter facility (GSI, 2020).

Drainage ditches and a few residential yards exceeded DEQ's Risk-Based Screening Levels (RBSLs) for direct contact with soil in residential settings for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxicity equivalence quotient (TEQ), which is 4.7 picograms per gram (pg/g). Arsenic was also detected in residential yards above RBSLs; however, these concentrations were below regional background concentrations (DEQ, 2013).

Following these investigations, Baxter was directed to perform residential soil removal and replacement in accordance with the ROD.

2.2 DEQ Offsite Involvement

In January 2022, Baxter notified DEQ they would not be able to implement cleanup at the residential yards in a timely manner and suspended wood treatment activities at its facility. DEQ subsequently declared the Baxter facility an Orphan Site to enable utilization of the Industrial Orphan Site Account (DEQ, 2022a) to complete the RAs at the offsite residential properties. Two supplemental investigations, which are detailed in this report, were completed by GSI Water Solutions, Inc. (GSI), under contract to DEQ.

2.3 EPA Offsite Involvement

In May 2022, EPA's Removal Program began assisting DEQ with the Baxter offsite property investigation. EPA's work expanded on the surface soil sampling previously conducted by Baxter and focused on delineating the extent of contamination in the neighborhood north of the former Baxter facility. Analytical data provided by EPA has added to the extent of RAs to be conducted. To date, EPA has collected soil samples from 52 properties.

2.4 PCDD/F Action Levels

The Oregon Health Authority (OHA) identified a 40 pg/g TCDD TEQ value to warrant expedited cleanup of residential properties near the Baxter facility (OHA, 2023). The value was based on the consideration of increased non-cancer human health risks related to children under 6 years of age regularly exposed to residential soil. DEQ subsequently adopted the 40 pg/g value as an early action cleanup level (CUL) for initial Baxter offsite RA activities.

After a property was identified as requiring early action soil removal, the total depth of soil removal was determined by the maximum vertical depth where PCDD/F concentrations exceeded DEQ's RBSLs for direct contact by residential receptors of 4.7 pg/g (DEQ, 2023).

SECTION 3: Offsite Investigations and Results

The offsite investigations described in this report focused on properties initially identified in Baxter's and EPA's offsite investigations. GSI completed two rounds of investigation activities with DEQ. The first investigation was completed in June 2022 and included five residential properties north of the Baxter facility. The second investigation was completed in April 2023 and included seven residential properties. Each residential property was investigated as a single DU, with two sub-DUs for vertical delineation sampling. A DU defines an exposure area upon which risk decisions to potential receptors (i.e., humans and/or ecological receptors) are based. Analytical results from the two offsite investigations are summarized below; complete data results tables from the investigations are included in Appendix A. Analytical laboratory reports and data validation reports are included in Appendix B.

3.1 June 2022 Offsite Investigation

On June 20 and 21, 2022, GSI completed an offsite investigation at five residential properties near the Baxter facility. Soil samples were collected from the ground surface to depths up to 12 inches below ground surface (bgs) to identify the extent of PCDD/F in surface soil. The DUs and associated property addresses included:

- DU-09 (█████ Baxter Street)
- DU-10 (█████ Baxter Street)
- DU-11 (█████ Baxter Street)
- DU-14 (█████ Baxter Street)
- DU-15 (█████ Baxter Street)

At DU-09, DU-14, and the backyard of DU-11, previous sampling had not been conducted and soil was assessed for PCDD/F concentrations in the 0- to 6-inch bgs depth zone using an incremental sampling methodology (ISM) approach (ITRC, 2020; DEQ, 2020). At DU-10, DU-15, and the front yard of DU-11, ISM sampling from 0 to 6 inches was previously completed during the 2021 investigation by Baxter. All five DUs had not previously been characterized within the 6- to 12-inch depth interval and sampling was performed in this depth zone during this investigation using a multi-point composite sampling approach. The individual sample locations collected per DU during the June 2022 investigation are presented on the figures included in Appendix C.

3.1.1 ISM Sampling (0- to 6-inch bgs intervals)

Surface soil from DU-09, DU-14, and the backyard of DU-11 were characterized using ISM, which is a structured composite sampling and processing protocol that reduces data variability, increases sample representativeness, and reduces the chance of missing potential elevated concentrations of PCDD/Fs in a volume of soil targeted for sampling. The composite sample from each DU consisted of 50 soil increments collected in accordance with DEQ's *Decision Unit Characterization* Internal Management Directive (DEQ, 2020) and Interstate Technology and Regulatory Council's (ITRC's) ISM Update (ITRC, 2020).

Each DU was divided into a grid pattern consisting of 50 approximately equal-sized grid cells. An increment was collected from within each of the grid cells using a systematic random grid pattern.

Soil for the incremental surface samples were collected using a small wood auger bit attached to an electric drill. The auger attachment was decontaminated between sampling each DU. At each increment location, surface vegetation, debris, and/or larger gravels and cobbles were removed prior to sample collection. In

addition to surface vegetation and gravel, significant root mass was removed from the soil surface and discarded; however, degraded or fine organic materials were left for sample collection. The sampling device was then advanced to a depth of 6 inches from the cleared soil surface. Soil was extruded from the sampling device and placed into a decontaminated stainless steel bowl for homogenization and observation of soil conditions. After homogenization, an increment of approximately equal volume was removed from the bowl. Soil sample volumes were then placed in a single laboratory-supplied certified-clean glass sample container (approximately 4 liters). This process was repeated for all 50 increments.

Field replicate samples (i.e., duplicate and triplicate samples) were collected from the backyard of DU-11 in accordance with DEQ's *Decision Unit Characterization* Internal Management Directive (DEQ, 2020) to assess data variability. To collect duplicate and triplicate samples, the field team collected a total of three increment samples from each grid square, rather than one. This was performed by collecting the initial 50-increment sample (no duplicate or triplicate increments) from all grids and compositing into a common sample jar. Then the field team returned to each grid to collect soil for the duplicate sample (increments for the duplicate were obtained approximately a foot north of the original increments). Following collection of the duplicate sample, the triplicate sample was collected approximately one foot west of the original increments.

ISM samples were submitted under chain of custody to Apex Analytical Laboratory of Tigard, Oregon, for processing and analysis. Processing included grinding and homogenizing the entire soil volume in accordance with ITRC's ISM standards (ITRC, 2020). The processed soil was then submitted under chain of custody to Frontier Analytical Laboratory (Frontier) of El Dorado Hill, California, for chemical analysis.

3.1.2 Composite Sampling (6- to 12-inch bgs intervals)

Each of the original five DUs were subdivided into two sub-DUs (i.e., front yard, backyard) for composite sampling at the deeper intervals. Each composite sample comprised five discrete soil increments (similar to ISM sampling) collected from 6 to 12 inches bgs. For each sub-DU, the total surface soil area was divided into five areas of approximately equal size. Composite sample increments were collected from near the center of each area.

The composite soil samples within each DU were collected using the same tooling and sampling procedures as described for ISM sampling. Surface vegetation, debris, and the top 6 inches of soil were completely removed using a decontaminated stainless steel hand trowel. Loose debris and soil from the top 6 inches of soil were fully removed to prevent sluffing and cross-contamination of the lower 6-inch sample increment. The 6- to 12-inch sample depth interval was then collected and placed in a large stainless-steel bowl for field homogenization. An aliquot of the soil sample was then placed in a laboratory-supplied 1-liter glass sample container. All aliquots from each composite increment were of equal volume and were placed in a single sample container, with total volume sufficient to fill the 1-liter sample container.

Composite samples were submitted under chain of custody to Pace Analytical National (Pace) of Mt. Juliet, Tennessee, for ISM processing (pulverizing and homogenizing sample material) and chemical analysis under Price Agreement #8903 with the State of Oregon.

3.1.3 Analytical Results

Soil samples were submitted to Frontier and Pace and analyzed for PCDD/F by EPA Method 1613B. Total TCDD TEQ was calculated using World Health Organization's (WHO's) 2005 summation rules (see Section 4.1). CUL decision concentrations have been determined to be 40 pg/g, as discussed in Section 2.4. A summary of TCDD TEQ values and CUL exceedances is provided in Table 2. Complete analytical results are presented in Table A-1 in Appendix A.

Table 2. Total TCDD TEQ June 2022

| Decision Unit | Sample Interval (inches bgs) | TCDD TEQ (pg/g) |
|--------------------------------------|---------------------------------|--------------------|
| DU-09 | 0–6 | 30.9 |
| DU-09A | 6–12 | 18.0 |
| DU-09B | 6–12 | 62.3 |
| DU-10 ¹ | 0–6 | 62.2 |
| DU-10A | 6–12 | 27.6 |
| DU-10B | 6–12 | 30.9 |
| DU-11 (front yard only) ¹ | 0–6 | 116 |
| DU-11 (backyard only) | 0–6 | 60.4 |
| DU-11A | 6–12 | 35.1 |
| DU-11B | 6–12 | 32.9 |
| DU-14 | 0–6 | 14.9 |
| DU-14A | 6–12 | 11.0 |
| DU-14B | 6–12 | 10.3 |
| DU-15 ¹ | 0–6 | 67.7 |
| DU-15A | 6–12 | 26.2 |
| DU-15B | 6–12 | 19.8 |

Notes

Yellow highlighted cells indicate TCDD TEQ concentration above 40 pg/g.

¹ Sample collected in September 2021 during Baxter-funded investigation.

bgs = below ground surface

DU = decision unit

pg/g = picograms per gram

TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin

TEQ = toxicity equivalence quotient

The results of the June 2022 investigation indicated that additional soil data was required to fully delineate the vertical extent of PCDD/F contamination to the RBSL threshold. Additional data needs prompted a supplemental investigation to be performed in April 2023. Results from DU-14 indicate no early RA was required and further investigation was not performed in this DU.

3.2 April 2023 Supplemental Offsite Investigation

DU-09, DU-10, DU-11, and DU-15 were carried forward to the supplemental offsite investigation based on the soil results summarized above. Additionally, DUs step out (SO) -06 (Baxter Street), SO-07 (Baxter Street), and Alva Park (AP) -01 (Alva Park Drive) were also identified as having surface soil TCDD TEQ concentration above 40 pg/g through the 2022 EPA sampling program. EPA sampling design was to collect soil samples to 6 inches bgs only in order to maximize the number of properties initially screened. Based on the results of EPA's initial efforts, these three DUs were added to the DEQ 2023 supplemental investigation. The individual sample locations collected per DU during the April 2023 investigation are presented on the figures included in Appendix D.

The purpose of the supplemental offsite investigation was to determine the vertical extent and magnitude of PCDD/F concentrations in shallow soil in properties north of the Baxter facility to support future removal depth requirements during the RA.

Separately, the supplemental investigation included characterization of trees and shrubs within DUs where RA is anticipated to determine the potential impacts RA may have on viability. To support this assessment, consultation with a certified arborist was conducted to identify vegetation that may be at risk during RA and develop procedures and mitigation measures for critical root structure protection within affected properties.

3.2.1 Push Probe Soil Collection

GSI subcontracted with BB&A Associates (BB&A) of Eugene, Oregon, to complete shallow push probe activities. BB&A is an Oregon-licensed driller in accordance with Oregon Water Resources Department regulations (Oregon Administrative Rule 690-240). BB&A mobilized a direct push drill rig and electric jackhammer with probe attachment to complete 10 direct push cores (five cores for each of the two sub-DUs) on each property for composite sample collection. A GSI representative was present to observe and document the direct push activities and subsurface conditions.

Each property was divided into two sub-DUs (i.e., front yard, backyard) matching the June 2022 sampling approach for composite sampling. Composite samples consisted of five individual aliquots. The total surface area of each sub-DU was divided into five sample areas of approximately equal size, where one sample aliquot was obtained from each of the five areas. The sample location of each aliquot was generally located near its center. All cores were drilled to 3 feet bgs.

3.2.2 Composite Sampling

The objective of composite sampling was to determine the concentrations of PCDD/F at various depth intervals within each sub-DU. Each composite sample consisted of combining aliquots of soil from five individual sample locations representing the sub-DU within depth zones. Composite sample depth intervals included soil from 0.5 to 1 foot bgs from EPA-identified DUs only (SO-06, SO-07, and AP-01), and from 1 to 1.5 feet, 1.5 to 2 feet, 2 to 2.5 feet, and 2.5 to 3 feet bgs in all DUs identified for the 2023 supplemental offsite investigation. Aliquots for each 6-inch depth composite were collected by removing soil from direct push cores obtained by the drilling subcontractor within the identified discrete intervals. The aliquots were then placed in a labeled, laboratory-supplied sample containers specific to each depth interval. All aliquots from each composite increment were of equal volume and were placed in a single sample container, with total volume sufficient to fill the 1-liter sample container.

Composite samples were submitted under chain of custody to Pace for ISM processing and chemical analysis under Price Agreement #8903 with the State of Oregon. Upon receipt at the laboratory, Pace performed ISM laboratory homogenization methodology prior to analysis.

3.2.3 Analytical Results

Soil samples were submitted to Pace for PCDD/F analysis by EPA Method 1613B. Total TCDD TEQ was calculated using WHO's 2005 summation rules (Van den Berg et al., 2006). A summary of TCDD TEQ data from the April 2023 investigation is provided in Table 3. Because each of the DUs investigated in the April 2023 offsite investigation have qualified for early action, the table below indicates exceedance of DEQs Risk-Based Concentrations for direct contact (4.7 pg/g) that is used to determine the depth of soil removal. Complete analytical results are presented on Table A-1 in Appendix A.

Table 3. Total TCDD TEQ April 2023

| Decision Unit | Sample Interval (inches bgs) | TCDD TEQ (pg/g) |
|--------------------|---------------------------------|--------------------|
| DU-09A | 12-18 | 11.4 |
| | 18-24 | 1.60 |
| DU-09B | 12-18 | 15.4 |
| | 18-24 | 3.89 |
| DU-10A | 12-18 | 4.81 |
| | 18-24 | 1.85 |
| DU-10B | 12-18 | 1.94 |
| | 18-24 | 2.00 |
| DU-11A | 12-18 | 4.76 |
| | 18-24 | 6.49 |
| | 24-30 | 2.94 |
| | 30-36 | 1.03 |
| DU-11B | 12-18 | 1.24 |
| | 18-24 | 0.707 |
| DU-15A | 12-18 | 1.99 |
| | 18-24 | 1.52 |
| DU-15B | 12-18 | 1.95 |
| | 18-24 | 0.729 |
| SO-06 ¹ | 0-6 | 124 |
| SO-06A | 6-12 | 1.19 |
| | 12-18 | 0.533 |
| SO-06B | 6-12 | 3.48 |
| | 12-18 | 0.678 |
| | 18-24 | 0.423 |
| SO-07 ¹ | 0-6 | 18.6 |
| SO-07A | 6-12 | 5.01 |
| | 12-18 | 1.39 |
| SO-07B | 6-12 | 4.69 |
| | 12-18 | 1.40 |
| AP-01 ¹ | 0-6 | 27.6 |
| AP-01A | 6-12 | 0.905 |
| | 12-18 | 0.599 |
| AP-01B | 6-12 | 3.78 |
| | 12-18 | 0.803 |

Notes

Yellow highlighted cells indicate TCDD TEQ concentration above 4.7 pg/g.

¹ Sample collected by EPA in November 2022.

AP = Alva Park bgs = below ground surface DU = decision unit pg/g = picograms per gram
 SO = step out TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin TEQ = toxicity equivalence quotient

3.2.4 Arborist Consultation

Established trees and their associated critical root structures are expected to be encountered on all or nearly all properties where RA is anticipated. This includes root structures from trees located on neighboring properties and from trees within the City of Eugene (City) right-of-way (ROW). The City has a municipal code designed to protect existing ROW trees and critical root structures during development activities. Depending on how RA activities are classified by the City and whether trees within the ROW are affected, the level of protection and planning may differ. GSI subcontracted with an International Society of Arboriculture-certified arborist, Spade Tree Preservation, of Brownsville, Oregon, to identify trees that may require protective measures and best management practices to minimize impacts to established vegetation that will remain during the RA.

Spade Tree Preservation prepared outlined procedures the earthwork contractor should take during RA to protect existing trees while removing as much soil as possible from removal areas. The arborist also outlined backfill requirements and completed an International Society of Arboriculture Basic Tree Risk Assessment Form for each potentially affected tree within a DU.

SECTION 4: Data Screening

All PCDD/F results from the 2022 and 2023 investigations completed by GSI, historical offsite investigation results, and initial EPA data collected from current offsite investigation DUs are included in Table A-1 in Appendix A. An evaluation of the results was performed by GSI with input from DEQ, as described below.

4.1 TCDD TEQ Calculation

TCDD TEQ values are used as screening criteria to evaluate risk from PCDD/F exposure. The WHO has provided standardized guidance on how to calculate a TCDD TEQ value. DEQ has determined that the WHO's 2005 TCDD TEQ criteria (Van den Berg et al., 2006) is the most appropriate summation approach to be used for TEQ calculations.

Individual PCDD/F congener data were reported by the analytical laboratory for 17 congeners. The TCDD TEQ was calculated using the WHO's summation rules. The TCDD TEQ calculation assigns toxicity equivalency factor (TEF) to each individual PCDD/F congener. The detected values of the individual congeners are multiplied by their TEF and summed together to calculate the TCDD TEQ. The TEF values for individual congeners are shown in Table A-1 in Appendix A.

Individual congeners that were reported as non-detect by the laboratory are represented in the TCDD TEQ calculation by using half of the estimated detection limit, which is presented in the laboratory report. Concentrations above the laboratory detection limit but below the laboratory method reporting limit (MRL), are estimate (i.e., J-flagged). In some instances, matrix interference resulted in concentrations being estimated and biased high (i.e., J+flagged). Where these qualifiers exist for individual congeners, the qualifier is also applied to the total TCDD TEQ value.

4.2 Screening Levels

DEQ used a CUL of 40 pg/g TCDD TEQ, as derived by OHA. The 40 pg/g value was used to evaluate all shallow soil results and determine if RA would be prioritized for the property. After a DU was selected for RA, the complete set of data from the DU was used to determine the total depth of removal. DEQ's RBSL for TCDD TEQ of 4.7 pg/g was used to determine the total depth of the RA removal. The maximum total depth of soil removal considered was 3 feet bgs, as that is seen as the zone of potential exposure for residential receptors (DEQ, 2017a).

4.3 RA Depths

Seven DUs have been identified for inclusion in the initial RA with soil concentrations at or above 40 pg/g TCDD TEQ within at least one depth interval analyzed in samples from 2020 to 2022. These seven properties were then included in the supplemental offsite investigation in April 2023 to determine total depth of soil removal. The soil removal depths for each DU, presented on Figure 2, are as follows:

- 6-inch soil removal will occur at SO-06 (██████████ Baxter Street) in both the front and backyard, SO-07 (██████████ Baxter Street) in the backyard, and AP-01 (██████████ Park Drive) in both the front and backyard.
- 12-inch soil removal will occur at DU-10 (██████████ Baxter Street) in the backyard, DU-11 (██████████ Baxter Street) in the backyard, DU-15 (██████████ Baxter Street) in both the front and backyard, and SO-07 (██████████ Baxter Street) in the front yard.
- 18-inch soil removal will occur at DU-09 (██████████ Baxter Street) in both the front and backyard, and DU-10 (██████████ Baxter Street) in the front yard.

- 24-inch soil removal will occur at DU-11 (█████ Baxter Street) in the front yard.

4.4 Quality Assurance/Quality Control

Soil samples were collected and analyzed in accordance with DEQ's Quality Assurance Project Plan (QAPP) for EPA Preliminary Assessment/Site Inspection investigations (DEQ, 2017b). The QAPP presents quality objectives and procedures for sampling and analysis of sites that involve DEQ funding.

Data Quality Objectives. The data quality and quality assurance objectives for the offsite investigations were used to develop and implement procedures for obtaining and evaluating data of a specified quality, which could then be used to determine the magnitude and extent of contamination and evaluate risks posed to human health. To collect such information, analytical data required an appropriate degree of accuracy and reproducibility, samples collected needed to be representative of actual field conditions, and samples needed to be collected and analyzed using unbroken chain-of-custody procedures.

Field Quality Assurance/Quality Control (QA/QC). Disposable or decontaminated sampling equipment were used to the extent practicable to minimize or eliminate cross-contamination. Samples were labeled with sample-specific identifying information and chain of custody was maintained at all times.

For precision, the QAPP requires field duplicate samples be collected at a frequency of at least 1 for every 20 samples analyzed. The duplicates are then compared to the primary sample to determine the precision of the analytical results. For concentrations or measurements that are five times greater than the MRL, the control limit for field duplicate samples is set as relative percent difference of +/- 50 percent for organic solid compounds. For concentrations or measurements less than five times greater than the MRL, the control limits are set at a difference no greater than twice the absolute value of the difference. QA/QC samples are shown on Table A-2 in Appendix A.

To determine representativeness of sample results, the QAPP requires equipment blank samples (also referred to as rinsate blanks) to be collected at a frequency of at least 1 for every 20 samples analyzed. The blank sample results are compared to samples collected from the same sampling event to determine whether insufficient decontamination procedures may have resulted in cross-contamination of samples. Analytes in the equipment blank should be below the MRL or any detections should be less than 10 percent of the lowest concentration identified in any sample.

During the June 2022 offsite investigation, duplicate and triplicate samples were collected from DU-11 at the 0- to 6-inch depth interval. These duplicate samples were processed and analyzed by the same procedures as the primary sample. The results of the duplicate and triplicate samples were within the QAPP parameters for field duplicates and therefore representative according to the QAPP (Table A-2 in Appendix A). In June 2022, an equipment blank was obtained using laboratory supplied deionized water passing over decontaminated auger equipment and collected for analysis of PCDD/Fs. Low-level detections of certain PCDD/F congeners were reported in the equipment blank sample. These results are below 10 percent of the lowest detection in any sample from the same event. As such, the samples are representative.

In April 2023, a duplicate sample was collected and analyzed from DU-10A at the 12- to 18-inch depth interval and from DU-06A at the 18- to 24-inch depth interval. These duplicate samples were processed and analyzed by the same procedures as the primary sample. The results of the duplicate samples were within the QAPP parameters for field duplicates and therefore representative according to the QAPP (Table A-2 in Appendix A). Two equipment blanks were obtained using laboratory supplied deionized water passing over decontaminated push probe equipment and collected for analysis of PCDD/Fs. Low-level detections of certain PCDD/F congeners were reported in the equipment blank samples. These results are below

10 percent of the lowest detection in any sample from the same event. As such, the samples are representative.

Laboratory QA/QC. The laboratory also performed QC analyses (e.g., matrix spikes and method blanks) per the requirements of the analytical method. Detection limits were consistent with industry standards and, when practicable, below or comparable to promulgated regulatory standards, unless raised due to high analyte concentrations in the sample or matrix effects.

Data Validation. GSI conducted Stage 2A/B Data Validation on laboratory reports to confirm data usability. The results of the data validation are included in Appendix B for each of the laboratory reports. The laboratory provided an estimated maximum possible concentrations (EMPCs) for congeners where the ion abundance ratio was out of specifications and where polychlorinated diphenyl ether was present. These EMPCs were flagged by GSI's data validation review as estimated values that are biased high (J+). J+-flagged concentrations were used in the TCDD TEQ calculation, with the resultant TCDD TEQ calculation also flagged as J+.

SECTION 5: Recommendations

The findings from the offsite investigations determined where RA is required, determined the depth of soil removal on each DU included for RA, and identified protective measures for trees and/or shrubs during the RA. Additional RA recommendations are also discussed below.

5.1 Soil Removal Depth

The recommended soil removal depths, shown in Figure 2, were determined from the analytical results from data collected over multiple investigations. In general, deeper soil removal is required from properties closer to the Baxter facility. The deepest soil removal will occur at DU-11 in the front yard and southern portion of the backyard where 24 inches of soil will be removed and replaced with clean soil.

DU-09 and DU-10 are also the along the southern-most offsite properties and closest to the Baxter facility. At these locations, 18 inches of soil will be removed and replaced. From the analytical results, only 12 inches of soil will be removed from the backyard of DU-10.

The northern portion of DU-11 backyard, DU-15, and the southern portion of SO-07 will also require 12 inches of soil removal. These DUs are adjacent to each other along the east side of Baxter Street.

The northern portion of SO-07 (backyard) will require 6 inches of soil removal. DUs SO-06 and AP-01 will also require 6 inches of soil removal. These are the northernmost DUs identified for RA and furthest from the Baxter facility.

5.2 Import Soil

Clean topsoil will be imported to replace the top 6 to 12 inches of soil removed for the RA. For deeper soils, another clean fill soil source will be identified and imported. Commercially available topsoil and clean fill sources were tested for PCDD/F prior to implementing the RA. The results of the source soil sampling will be included in the Offsite Removal Action Construction Completion Report.

5.3 Vegetation Removal

The Arborist Reports (Appendix E) outlines which trees were recommended for removal from properties and whether tree removal should occur before or during RA due to a high risk of tree death or instability resulting from soil excavation. Of 44 trees assessed in the report, 16 trees were recommended for removal. These include smaller trees with deformities or poor placement, as well as larger varieties, including Coast redwood (*Sequoia sempervirens*), Eastern black walnut (*Juglans nigra*), and Douglas fir (*Pseudotsuga menziesii*). Shrubs were also evaluated in the Arborist Reports in Appendix E. The arborist declined to recommend action on three trees three were identified to be within the City ROW. These three trees will be protected during the RA.

5.4 Vegetation Protection



Spade Tree Preservation determined the procedures necessary to keep trees and shrubs where possible, as outlined in the Arborist Reports (Appendix E). Sixteen of 44 trees assessed and several shrubs were deemed appropriate for transplantation. This would involve removing the plant by digging out the entire root ball, shaking out excess root ball soil, potting the specimen after removal, and either replanting following the RA, or keeping the plant potted until the optimal planting season (fall or winter). For the 9 trees recommended to be kept in the ground during the RA and 3 trees within the City ROW, root structures should be protected from heavy equipment by excavating using an air knife or via hand removal within the critical root zone of the tree. The root systems shall be kept moist, and soil under trees shall not be removed greater than 12 inches for structural safety purposes.

5.5 City ROW RAs

Each DU where RA is proposed is adjacent to an unpaved portion of City ROW. The ROW was not included in the offsite investigation and consultation with the City will be required to determine the necessary actions that are amenable by the City. Options include, but are not limited to, removing soil between the DUs and the paved roadway to at least 6 inches and replacing this area with imported gravel or topsoil.

SECTION 6: References

- DEQ. 2013. Development of Oregon Background Metals Concentrations in Soil. Technical Report. March 2013.
- DEQ. 2017a. Risk-Based Decision Making for the Remediation of Contaminated Sites. Revised October 2, 2017.
- DEQ. 2017b. *Quality Assurance Project Plan EPA PA/SI Investigations*. Oregon Department of Environmental Quality, Operations Division, Environmental Cleanup Program. December 2017.
- DEQ. 2019. Record of Decision for J.H. Baxter & Co. Facility, Eugene, OR, ECSI #55. Oregon Department of Environmental Quality, Western Region Office. October 2019.
- DEQ. 2020. *Decision Unit Characterization Internal Management Directive*. Oregon Department of Environmental Quality, Land Quality Division, Cleanup Program. September 14, 2020.
- DEQ. 2022a. Request for Orphan Site Designation – JH Baxter & Co – Eugene. Oregon Department of Environmental Quality, Western Region Office. February 2022.
- DEQ. 2022b. Amended Notice of Civil Penalty Assessment and Order for J.H. Baxter & Co. Facility, Eugene, OR, ECSI #55. Oregon Department of Environmental Quality, Western Region Office. May 4, 2022.
- DEQ. 2023. Excel® Spreadsheet for Risk-Based Concentrations for Individual Chemicals. Amended June 2023.
- GSI. 2020. *Sampling and Analysis Plan*. Prepared for JH Baxter & Co. Wood Treating Facility, Eugene, Oregon. February 2020.
- GSI. 2021. *Sampling and Analysis Plan*. Prepared for JH Baxter & Co. Wood Treating Facility, Eugene, Oregon. August 2021.
- GSI. 2022. *Offsite Investigation Work Plan. Former JH Baxter & Co.* Prepared for DEQ. June 6, 2022.
- GSI. 2023. *Offsite Investigation Work Plan Addendum #1, Former JH Baxter & Co.* January 17, 2023.
- ITRC. 2020. *Technical and Regulatory Guidance. Incremental Sampling Methodology Update*. Interstate Technology and Regulatory Council. October 2020.
- OHA. 2023. Health Consultation Initial and Public Comment Release. JH Baxter Neighborhood Investigation, Eugene, Oregon. February 2023.
- Van den Berg, M., L.S. Birnbaum, M. Denison, et al. 2006. The 2005 World Health Organization Re-evaluation of Human and Mammalian Toxic Equivalency Factors for Dioxins and Dioxin-Like Compounds. *Toxicological Sciences* 93(2):223–241. Available at <https://doi.org/10.1093/toxsci/kfl055>.



LEGEND

- City Boundary
- Railroad
- Major Road
- Watercourse
- Waterbody

Date: January 10, 2023
 Data Sources: BLM, ESRI, ODOT,
 USGS, Maxar Imagery (2021), City of Eugene





FIGURE 1


Site Vicinity Map

Former JH Baxter & Co. Facility
 Offsite Investigation
 Eugene, OR





LEGEND

 Decision Unit

Surface Soil Removal Depth

 6-inch

 12-inch


 18-inch

 24-inch

FIGURE 2

Soil Removal Depths
Former JH Baxter & Co. Facility
Offsite Investigation
Eugene, OR

Date: May 30, 2023
Data Sources: BLM, ESRI, ODOT,
USGS, Aerial Photo 2019, City of Eugene



APPENDIX A

Data Tables

Table A-2. Field Collected QA/QC Samples
Offsite Investigation Report
Former JH Baxter & Co. Facility
Eugene, Oregon

| Laboratory Sample Designation | QC Sample Type | Sample Date | Sample Depth | Compounds | | | | | | | | | | | | | | | | | | GSI Total Dioxin TEQ (U=0) 2020 | GSI Total Dioxin TEQ (U=1/2) 2020 |
|---|--|-------------|--------------|---------------------|---------------------|---------------------|-------------------|-------------------|------------------------|-------------------|-------------------|-------------------|-----------------|-----------------|-------------------|-----------------|--------------|--------------|--------|--------|--------|---------------------------------|-----------------------------------|
| | | | | 1,2,3,4,6,7,8-HpCDD | 1,2,3,4,6,7,8-HpCDF | 1,2,3,4,7,8,9-HpCDF | 1,2,3,4,7,8-HxCDD | 1,2,3,4,7,8-HxCDF | 1,2,3,6,7,8-HxCDD | 1,2,3,6,7,8-HxCDF | 1,2,3,7,8,9-HxCDD | 1,2,3,7,8,9-HxCDF | 1,2,3,7,8-PeCDD | 1,2,3,7,8-PeCDF | 2,3,4,6,7,8-HxCDF | 2,3,4,7,8-PeCDF | 2,3,7,8-TCDD | 2,3,7,8-TCDF | OCDD | OCDF | | | |
| TCDD TEQ Factor | | | | 0.01 | 0.01 | 0.01 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 1 | 0.03 | 0.1 | 0.3 | 1 | 0.1 | 0.0003 | 0.0003 | — | — | |
| June 2022 Field Duplicate Samples | | | | | | | | | Concentrations in pg/g | | | | | | | | | | | | | | |
| DU-11 | | | | | | | | | | | | | | | | | | | | | | | |
| ISM-011_0622 | Primary | 6/21/2022 | 0-0 ft | 1,380 | 295 | 21.2 | 11.6 | 71.4 | 53 | 17.4 | 24.1 | 11.7 | 4.97 | 3.98 | 23 | 18.6 | 8.08 | 1.33 | 10,600 | 548 | 60.4 | 60.4 | |
| ISM-111_0622 | Duplicate | 6/21/2022 | 0-0 ft | 1,430 | 283 | 20.4 | 11.4 | 71.1 | 53.9 | 17.3 | 23.3 | 11.8 | 5.24 | 3.79 | 21.9 | 18.3 | 7.35 | 1.35 | 11,000 | 512 | 60.2 | 60.2 | |
| ISM-211_0622 | Triplicate | 6/21/2022 | 0-0 ft | 1,110 | 244 | 16.7 | 9.37 | 57.4 | 43.1 | 14.1 | 18.5 | 9.46 | 4 | 3.12 | 18.6 | 14.2 | 5.85 | 1.06 | 8,590 | 458 | 47.8 | 47.8 | |
| MRL (primary) | | | | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 2.48 | 0.495 | 0.495 | 4.95 | 4.95 | | | |
| Greater than 5 times MRL? | | | | yes | yes | yes | no | yes | yes | yes | yes | no | no | no | yes | yes | yes | no | yes | yes | — | — | |
| Duplicate Sample | RPD Duplicate | | | 3.6% | 4.2% | 3.8% | — | 0.4% | 1.7% | 0.6% | 3.4% | — | — | — | 4.9% | 1.6% | 9.5% | — | 3.7% | 6.8% | 0.3% | 0.3% | |
| | Average Concentration | | | | | | 11.50 | | | | | 11.75 | 5.11 | 3.89 | | | | 1.34 | | | | | |
| | Is Average Less than MRL? | | | | | | no | | | | | no | no | no | | | | no | | | | | |
| | Absolute Difference | | | | | | 0.2 | | | | | 0.1 | 0.27 | 0.19 | | | | 0.02 | | | | | |
| | Is Absolute Difference less than 2x MRL? | | | | | | yes | | | | | yes | yes | yes | | | | yes | | | | | |
| Triplicate Sample | RPD Triplicate | | | 21.7% | 18.9% | 23.7% | — | 21.7% | 20.6% | 21.0% | 26.3% | — | — | — | 21.2% | 26.8% | 32.0% | — | 20.9% | 17.9% | 23.3% | 23.3% | |
| | Average Concentration | | | | | | 10.49 | | | | | 10.58 | 4.49 | 3.55 | | | | 1.20 | | | | | |
| | Is Average Less than MRL? | | | | | | no | | | | | no | no | no | | | | no | | | | | |
| | Absolute Difference | | | | | | 2.23 | | | | | 2.24 | 0.97 | 0.86 | | | | 0.27 | | | | | |
| | Is Absolute Difference less than 2x MRL? | | | | | | yes | | | | | yes | yes | yes | | | | yes | | | | | |
| April 2023 Field Duplicate Samples | | | | | | | | | | | | | | | | | | | | | | | |
| DU-10 | | | | | | | | | | | | | | | | | | | | | | | |
| DU-10A-1.0-1.5_0423 | Primary | 4/5/2023 | 1-1.5 ft | 71 | 26 | 1.4 | 0.90 | 1.2 | 2.5 | 0.23 | 1.7 | 0.25 | 0.43 | 0.13 | 0.56 | 0.082 | 2.7 | 0.12 | 740 | 79 | 5.07 | 5.1 | |
| DU-110A-1.0-1.5_0423 | Duplicate | 4/5/2023 | 1-1.5 ft | 91 | 28 | 1.9 | 0.65 | 1.2 | 2.3 | 2.2 | 1.6 | 0.39 | 0.27 | 0.46 | 0.40 | 0.40 | 1.2 | 0.39 | 1100 | 120 | 4.04 | 4.1 | |
| MRL (primary) | | | | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 0.98 | 0.98 | 9.8 | 9.8 | | | |
| Greater than 5 times MRL? | | | | yes | yes | no | no | no | no | no | no | no | no | no | no | no | no | no | yes | yes | — | — | |
| RPD Duplicate | | | | 24.7% | 7.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | 39.1% | 41.2% | 22.6% | 22.5% | |
| Average Concentration | | | | | | 1.65 | 0.78 | 1.20 | 2.40 | 1.22 | 1.65 | 0.32 | 0.35 | 0.30 | 0.48 | 0.24 | 1.95 | 0.26 | | | | | |
| Is Average Less than MRL? | | | | | | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | | | | | |
| Absolute Difference | | | | | | 0.5 | 0.25 | 0 | 0.2 | 1.97 | 0.1 | 0.14 | 0.16 | 0.33 | 0.16 | 0.318 | 1.5 | 0.27 | | | | | |
| Is Absolute Difference less than 2x MRL? | | | | | | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | | | | | |
| SO-06 | | | | | | | | | | | | | | | | | | | | | | | |
| DU-06B-1.5-2.0_0423 | Primary | 4/5/2023 | 1.5-2 ft | 6.6 | 1.2 | 0.4 | 0.22 | 0.11 | 0.19 | 0.11 | 0.15 | 0.18 | 0.23 | 0.15 | 0.091 | 0.16 | 0.21 | 0.14 | 73 | 4.5 | 0.19 | 0.45 | |
| DU-106B-1.5-2.0_0423 | Duplicate | 4/5/2023 | 1.5-2 ft | 7.0 | 1.0 | 0.21 | 0.19 | 0.13 | 0.18 | 0.11 | 0.19 | 0.088 | 0.28 | 0.17 | 0.1 | 0.17 | 0.28 | 0.16 | 62 | 4.0 | 0.16 | 0.49 | |
| MRL (primary) | | | | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 0.98 | 0.98 | 9.8 | 9.8 | | | |
| Greater than 5 times MRL? | | | | no | no | no | no | no | no | no | no | no | no | no | no | no | no | no | yes | no | — | — | |
| RPD Duplicate | | | | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 16.3% | — | 17.5% | 8.9% | |
| Average Concentration | | | | 6.80 | 1.10 | 0.31 | 0.21 | 0.12 | 0.19 | 0.11 | 0.17 | 0.13 | 0.26 | 0.16 | 0.10 | 0.17 | 0.25 | 0.15 | | | | | |
| Is Average Less than MRL? | | | | no | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | | | | | |
| Absolute Difference | | | | 0.4 | 0.2 | 0.19 | 0.03 | 0.02 | 0.01 | 0 | 0.04 | 0.092 | 0.05 | 0.02 | 0.009 | 0.01 | 0.07 | 0.02 | | | | | |
| Is Absolute Difference less than 2x MRL? | | | | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | | | | | |
| June 2022 and April 2023 Equipment Rinsate Blank Samples | | | | | | | | | | | | | | | | | | | | | | | |
| Concentrations in pg/L (parts per quadrillion) | | | | | | | | | | | | | | | | | | | | | | | |
| Equipment Blanks | | | | | | | | | | | | | | | | | | | | | | | |
| EB-01_0622 | Blank | 6/21/2022 | — | 1.70 | 2.00 | 2.70 | 2.00 | 0.900 | 1.30 | 0.760 | 1.10 | 1.00 | 0.710 | 0.400 | 0.520 | 0.280 | 0.550 | 0.310 | 21.0 | 3.00 | 0.206 | 1.21 | |
| Is value less than 10% of any detection in samples from this event? | | | | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | |
| EB-01-0423 | Blank | 4/5/2023 | — | 5.90 | 2.50 | 4.20 | 1.40 | 1.60 | 1.60 | 1.60 | 1.50 | 2.00 | 1.60 | 1.60 | 1.30 | 1.20 | 2.50 | 1.60 | 30.0 | 6.60 | 0.0680 | 2.99 | |
| Is value less than 10% of any detection in samples from this event? | | | | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | |
| EB-02-0423 | Blank | 4/5/2023 | — | 15.0 | 79.0 | 2.60 | 3.30 | 1.30 | 1.40 | 1.60 | 1.50 | 2.10 | 1.60 | 1.40 | 1.60 | 0.79 | 1.30 | 0.94 | 160 | 72.0 | 1.48 | 3.53 | |
| Is value less than 10% of any detection in samples from this event? | | | | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | |

Notes

Bold concentrations are detected or estimated values between the laboratory method detection limit and method reporting limit.

Non-bolded values were not detected above the laboratory method detection limit.

yes

Green shaded "yes" cell indicates value passes QAPP criteria.

The QAPP identifies RPD of less than 50% for solid organics.

— = not applicable

DU = decision unit

pg/g = picograms per gram (parts per trillion)

pg/L = picograms per liter (parts per quadrillion)

QC = quality control

TCDD TEQ = 2,3,7,8- tetrachlorodibenzodioxin toxicity equivalence quotient

APPENDIX B

Laboratory Reports and Data Validation



Test Report



July 15, 2022

Mr. Philip Nerenberg
Apex Laboratories
6700 S.W. Sandburg Street
Tigard, OR 97223

Dear Mr. Nerenberg,

The following results are associated with Frontier Analytical Laboratory project **14487**. This corresponds to your project number **A2F0755**. Five soil samples were received on 6/28/2022. These samples were extracted and analyzed by EPA Method 1613 for tetra through octa chlorinated dibenzo dioxins and furans. The Toxic Equivalency (TEQ) for these samples has been calculated using the 2005 World Health Organization's (WHO's) toxic equivalency factors (TEFs). A turnaround time of fifteen business days was requested for this project.

The following report consists of an Analytical Data section and a Sample Receipt section. The Analytical Data section contains our sample tracking log and the analytical results. The Sample Receipt section contains your chain of custodies, our sample login form and a sample photo. The attached results and electronic data deliverable (EDD) are specifically for the samples referenced in this report only. These results meet all National Environmental Laboratory Accreditation Program (NELAP) requirements and shall not be reproduced except in full. Frontier Analytical Laboratory's State of Oregon NELAP certificate number is **4041** and our State of California ELAP certificate number is **2934**. This report and the EDD have been emailed to you. A hardcopy of this report will not be sent to you unless specifically requested.

If you have any questions regarding project **14487**, please contact me at (916) 934-0900. Thank you for choosing Frontier Analytical Laboratory for your analytical testing needs.

Sincerely,

A handwritten signature in black ink that reads "Thomas C. Crabtree".

Thomas C. Crabtree
Director

Frontier Analytical Laboratory

Sample Tracking Log

FAL Project ID: **14487**

Received on: **06/28/2022**

Project Due: **07/21/2022**

Storage: **R-4**

| FAL Sample ID | Dup | Client Project ID | Client Sample ID | Requested Method | Matrix | Sampling Date | Sampling Time | Hold Time Due Date |
|------------------|-----|----------------------|---------------------|---------------------|--------|------------------|------------------|-----------------------|
| 14487-001-SA | 0 | A2F0755 | ISM-009_0622 | EPA 1613 D/F | Soil | 06/20/2022 | 12:45 pm | 06/20/2023 |
| 14487-002-SA | 0 | A2F0755 | ISM-014_0622 | EPA 1613 D/F | Soil | 06/20/2022 | 04:00 pm | 06/20/2023 |
| 14487-003-SA | 0 | A2F0755 | ISM-011_0622 | EPA 1613 D/F | Soil | 06/21/2022 | 04:00 pm | 06/21/2023 |
| 14487-004-SA | 0 | A2F0755 | ISM-111_0622 | EPA 1613 D/F | Soil | 06/21/2022 | 04:15 pm | 06/21/2023 |
| 14487-005-SA | 0 | A2F0755 | ISM-211_0622 | EPA 1613 D/F | Soil | 06/21/2022 | 04:30 pm | 06/21/2023 |

EPA Method 1613 PCDD/F



FAL ID: 14487-001-MB
Client ID: Method Blank
Matrix: Soil
Batch No: X6137

Date Extracted: 07-12-2022
Date Received: NA
Amount: 10.0 g

ICal: PCDDFAL3-4-29-22
GC Column: DB5MS
Units: pg/g

Acquired: 07-13-2022
2005 WHO TEQ: 0.0
Basis: Dry Weight

| Compound | Conc | DL | Qual | 2005 WHO Tox | MDL | Compound | Conc | DL | Qual |
|---------------------|------|--------|------|-----------------|--------|-------------|------|--------|------|
| 2,3,7,8-TCDD | ND | 0.123 | | - | 0.0286 | | | | |
| 1,2,3,7,8-PeCDD | ND | 0.165 | | - | 0.0515 | | | | |
| 1,2,3,4,7,8-HxCDD | ND | 0.181 | | - | 0.0555 | | | | |
| 1,2,3,6,7,8-HxCDD | ND | 0.196 | | - | 0.0558 | Total TCDD | ND | 0.123 | |
| 1,2,3,7,8,9-HxCDD | ND | 0.175 | | - | 0.0528 | Total PeCDD | ND | 0.165 | |
| 1,2,3,4,6,7,8-HpCDD | ND | 0.275 | | - | 0.0712 | Total HxCDD | ND | 0.196 | |
| OCDD | ND | 0.342 | | - | 0.195 | Total HpCDD | ND | 0.275 | |
| 2,3,7,8-TCDF | ND | 0.0684 | | - | 0.0231 | | | | |
| 1,2,3,7,8-PeCDF | ND | 0.136 | | - | 0.0324 | | | | |
| 2,3,4,7,8-PeCDF | ND | 0.143 | | - | 0.0322 | | | | |
| 1,2,3,4,7,8-HxCDF | ND | 0.130 | | - | 0.0339 | | | | |
| 1,2,3,6,7,8-HxCDF | ND | 0.140 | | - | 0.0340 | | | | |
| 2,3,4,6,7,8-HxCDF | ND | 0.120 | | - | 0.0353 | | | | |
| 1,2,3,7,8,9-HxCDF | ND | 0.163 | | - | 0.0451 | Total TCDF | ND | 0.0684 | |
| 1,2,3,4,6,7,8-HpCDF | ND | 0.117 | | - | 0.0350 | Total PeCDF | ND | 0.143 | |
| 1,2,3,4,7,8,9-HpCDF | ND | 0.137 | | - | 0.0421 | Total HxCDF | ND | 0.163 | |
| OCDF | ND | 0.216 | | - | 0.0820 | Total HpCDF | ND | 0.137 | |

| Internal Standards | % Rec | QC Limits | Qual |
|-------------------------|-------|------------|------|
| 13C-2,3,7,8-TCDD | 81.5 | 25.0 - 164 | |
| 13C-1,2,3,7,8-PeCDD | 102 | 25.0 - 181 | |
| 13C-1,2,3,4,7,8-HxCDD | 106 | 32.0 - 141 | |
| 13C-1,2,3,6,7,8-HxCDD | 101 | 28.0 - 130 | |
| 13C-1,2,3,4,6,7,8-HpCDD | 90.3 | 23.0 - 140 | |
| 13C-OCDD | 73.0 | 17.0 - 157 | |
| 13C-2,3,7,8-TCDF | 102 | 24.0 - 169 | |
| 13C-1,2,3,7,8-PeCDF | 101 | 24.0 - 185 | |
| 13C-2,3,4,7,8-PeCDF | 98.7 | 21.0 - 178 | |
| 13C-1,2,3,4,7,8-HxCDF | 117 | 26.0 - 152 | |
| 13C-1,2,3,6,7,8-HxCDF | 110 | 26.0 - 123 | |
| 13C-2,3,4,6,7,8-HxCDF | 123 | 28.0 - 136 | |
| 13C-1,2,3,7,8,9-HxCDF | 110 | 29.0 - 147 | |
| 13C-1,2,3,4,6,7,8-HpCDF | 105 | 28.0 - 143 | |
| 13C-1,2,3,4,7,8,9-HpCDF | 105 | 26.0 - 138 | |
| 13C-OCDF | 85.2 | 17.0 - 157 | |

Cleanup Surrogate

37Cl-2,3,7,8-TCDD 108 35.0 - 197

- A Isotopic Labeled Standard outside QC range but signal to noise ratio is >10:1
- B Analyte is present in Method Blank
- C Chemical Interference
- D Presence of Diphenyl Ethers
- DNQ Analyte concentration is below calibration range
- E Analyte concentration is above calibration range
- F Analyte confirmation on secondary column
- J Analyte concentration is below calibration range
- M Maximum possible concentration
- ND Analyte Not Detected at Detection Limit Level
- NP Not Provided
- P Pre-filtered through a Whatman 0.7um GF/F filter
- S Sample acceptance criteria not met
- X Matrix interferences
- * Result taken from dilution or reinjection

Analyst: 

Date: 7/19/2022

Reviewed By: 

Date: 7/19/2022

EPA Method 1613 PCDD/F



FAL ID: 14487-001-OPR
Client ID: OPR
Matrix: Soil
Batch No: X6137


Date Extracted: 07-12-2022
Date Received: NA
Amount: 10.00 g


ICal: PCDDFAL3-4-29-22
GC Column: DB5MS
Units: ng/ml

Acquired: 07-13-2022
2005 WHO TEQ: NA

| Compound | Conc | QC Limits | Qual |
|-------------------------|-------|-------------|------|
| 2,3,7,8-TCDD | 10.2 | 6.70 - 15.8 | |
| 1,2,3,7,8-PeCDD | 48.4 | 35.0 - 71.0 | |
| 1,2,3,4,7,8-HxCDD | 51.1 | 35.0 - 82.0 | |
| 1,2,3,6,7,8-HxCDD | 52.6 | 38.0 - 67.0 | |
| 1,2,3,7,8,9-HxCDD | 50.9 | 32.0 - 81.0 | |
| 1,2,3,4,6,7,8-HpCDD | 53.9 | 35.0 - 70.0 | |
| OCDD | 109 | 78.0 - 144 | |
| 2,3,7,8-TCDF | 9.83 | 7.50 - 15.8 | |
| 1,2,3,7,8-PeCDF | 51.6 | 40.0 - 67.0 | |
| 2,3,4,7,8-PeCDF | 52.0 | 34.0 - 80.0 | |
| 1,2,3,4,7,8-HxCDF | 53.0 | 36.0 - 67.0 | |
| 1,2,3,6,7,8-HxCDF | 52.4 | 42.0 - 65.0 | |
| 2,3,4,6,7,8-HxCDF | 53.6 | 35.0 - 78.0 | |
| 1,2,3,7,8,9-HxCDF | 53.7 | 39.0 - 65.0 | |
| 1,2,3,4,6,7,8-HpCDF | 53.4 | 41.0 - 61.0 | |
| 1,2,3,4,7,8,9-HpCDF | 53.4 | 39.0 - 69.0 | |
| OCDF | 109 | 63.0 - 170 | |
| Internal Standards | % Rec | QC Limits | Qual |
| 13C-2,3,7,8-TCDD | 97.1 | 20.0 - 175 | |
| 13C-1,2,3,7,8-PeCDD | 102 | 21.0 - 227 | |
| 13C-1,2,3,4,7,8-HxCDD | 103 | 21.0 - 193 | |
| 13C-1,2,3,6,7,8-HxCDD | 98.0 | 25.0 - 163 | |
| 13C-1,2,3,4,6,7,8-HpCDD | 89.6 | 26.0 - 166 | |
| 13C-OCDD | 68.0 | 13.0 - 198 | |
| 13C-2,3,7,8-TCDF | 97.5 | 22.0 - 152 | |
| 13C-1,2,3,7,8-PeCDF | 103 | 21.0 - 192 | |
| 13C-2,3,4,7,8-PeCDF | 99.8 | 13.0 - 328 | |
| 13C-1,2,3,4,7,8-HxCDF | 112 | 19.0 - 202 | |
| 13C-1,2,3,6,7,8-HxCDF | 106 | 21.0 - 159 | |
| 13C-2,3,4,6,7,8-HxCDF | 115 | 22.0 - 176 | |
| 13C-1,2,3,7,8,9-HxCDF | 111 | 17.0 - 205 | |
| 13C-1,2,3,4,6,7,8-HpCDF | 98.4 | 21.0 - 158 | |
| 13C-1,2,3,4,7,8,9-HpCDF | 100 | 20.0 - 186 | |
| 13C-OCDF | 81.7 | 13.0 - 198 | |
| Cleanup Surrogate | | | |
| 37Cl-2,3,7,8-TCDD | 104 | 31.0 - 191 | |

- A Isotopic Labeled Standard outside QC range but signal to noise ratio is >10:1
- B Analyte is present in Method Blank
- C Chemical Interference
- D Presence of Diphenyl Ethers
- DNQ Analyte concentration is below calibration range
- E Analyte concentration is above calibration range
- F Analyte confirmation on secondary column
- J Analyte concentration is below calibration range
- M Maximum possible concentration
- ND Analyte Not Detected at Detection Limit Level
- NP Not Provided
- P Pre-filtered through a Whatman 0.7um GF/F filter
- S Sample acceptance criteria not met
- X Matrix interferences
- * Result taken from dilution or reinjection

Analyst: 
Date: 7/19/2022

Reviewed By: 
Date: 7/19/2022

EPA Method 1613 PCDD/F



FAL ID: 14487-001-SA
Client ID: ISM-009_0622
Matrix: Soil
Batch No: X6137

Date Extracted: 07-12-2022
Date Received: 06-28-2022
Amount: 10.1 g
% Solids: 96.86

ICal: PCDDFAL3-4-29-22
GC Column: DB5MS
Units: pg/g

Acquired: 07-14-2022
2005 WHO TEQ: 30.9
Basis: Dry Weight

| Compound | Conc | DL | Qual | 2005 WHO Tox | MDL | Compound | Conc | DL | Qual |
|---------------------|-------|----|------|-----------------|--------|-------------|------|----|------|
| 2,3,7,8-TCDD | 6.23 | - | | 6.23 | 0.0286 | | | | |
| 1,2,3,7,8-PeCDD | 5.21 | - | | 5.21 | 0.0515 | | | | |
| 1,2,3,4,7,8-HxCDD | 8.97 | - | | 0.897 | 0.0555 | | | | |
| 1,2,3,6,7,8-HxCDD | 25.2 | - | | 2.52 | 0.0558 | Total TCDD | 20.4 | - | |
| 1,2,3,7,8,9-HxCDD | 16.9 | - | | 1.69 | 0.0528 | Total PeCDD | 28.8 | - | |
| 1,2,3,4,6,7,8-HpCDD | 644 | - | | 6.44 | 0.0712 | Total HxCDD | 161 | - | |
| OCDD | 4930 | - | | 1.48 | 0.195 | Total HpCDD | 1150 | - | |
| 2,3,7,8-TCDF | 0.529 | - | | 0.0529 | 0.0231 | | | | |
| 1,2,3,7,8-PeCDF | 1.09 | - | J | 0.0327 | 0.0324 | | | | |
| 2,3,4,7,8-PeCDF | 2.44 | - | J | 0.732 | 0.0322 | | | | |
| 1,2,3,4,7,8-HxCDF | 11.2 | - | | 1.12 | 0.0339 | | | | |
| 1,2,3,6,7,8-HxCDF | 8.02 | - | | 0.802 | 0.0340 | | | | |
| 2,3,4,6,7,8-HxCDF | 9.00 | - | | 0.900 | 0.0353 | | | | |
| 1,2,3,7,8,9-HxCDF | 1.89 | - | J | 0.189 | 0.0451 | Total TCDF | 11.4 | - | |
| 1,2,3,4,6,7,8-HpCDF | 222 | - | | 2.22 | 0.0350 | Total PeCDF | 28.8 | - | |
| 1,2,3,4,7,8,9-HpCDF | 10.8 | - | | 0.108 | 0.0421 | Total HxCDF | 192 | - | |
| OCDF | 907 | - | | 0.272 | 0.0820 | Total HpCDF | 718 | - | |

| Internal Standards | % Rec | QC Limits | Qual |
|-------------------------|-------|------------|------|
| 13C-2,3,7,8-TCDD | 104 | 25.0 - 164 | |
| 13C-1,2,3,7,8-PeCDD | 104 | 25.0 - 181 | |
| 13C-1,2,3,4,7,8-HxCDD | 111 | 32.0 - 141 | |
| 13C-1,2,3,6,7,8-HxCDD | 107 | 28.0 - 130 | |
| 13C-1,2,3,4,6,7,8-HpCDD | 105 | 23.0 - 140 | |
| 13C-OCDD | 103 | 17.0 - 157 | |
| 13C-2,3,7,8-TCDF | 108 | 24.0 - 169 | |
| 13C-1,2,3,7,8-PeCDF | 103 | 24.0 - 185 | |
| 13C-2,3,4,7,8-PeCDF | 103 | 21.0 - 178 | |
| 13C-1,2,3,4,7,8-HxCDF | 124 | 26.0 - 152 | |
| 13C-1,2,3,6,7,8-HxCDF | 116 | 26.0 - 123 | |
| 13C-2,3,4,6,7,8-HxCDF | 131 | 28.0 - 136 | |
| 13C-1,2,3,7,8,9-HxCDF | 114 | 29.0 - 147 | |
| 13C-1,2,3,4,6,7,8-HpCDF | 112 | 28.0 - 143 | |
| 13C-1,2,3,4,7,8,9-HpCDF | 115 | 26.0 - 138 | |
| 13C-OCDF | 105 | 17.0 - 157 | |

Cleanup Surrogate

37Cl-2,3,7,8-TCDD 105 35.0 - 197

- A Isotopic Labeled Standard outside QC range but signal to noise ratio is >10:1
- B Analyte is present in Method Blank
- C Chemical Interference
- D Presence of Diphenyl Ethers
- DNQ Analyte concentration is below calibration range
- E Analyte concentration is above calibration range
- F Analyte confirmation on secondary column
- J Analyte concentration is below calibration range
- M Maximum possible concentration
- ND Analyte Not Detected at Detection Limit Level
- NP Not Provided
- P Pre-filtered through a Whatman 0.7um GF/F filter
- S Sample acceptance criteria not met
- X Matrix interferences
- * Result taken from dilution or reinjection

Analyst: 

Date: 7/19/2022

Reviewed By: 

Date: 7/19/2022

EPA Method 1613 PCDD/F



FAL ID: 14487-002-SA
Client ID: ISM-014_0622
Matrix: Soil
Batch No: X6137

Date Extracted: 07-12-2022
Date Received: 06-28-2022
Amount: 10.1 g
% Solids: 97.09

ICal: PCDDFAL3-4-29-22
GC Column: DB5MS
Units: pg/g

Acquired: 07-14-2022
2005 WHO TEQ: 14.9
Basis: Dry Weight

| Compound | Conc | DL | Qual | 2005 WHO Tox | MDL | Compound | Conc | DL | Qual |
|---------------------|-------|----|------|-----------------|--------|-------------|------|----|------|
| 2,3,7,8-TCDD | 1.70 | - | | 1.70 | 0.0286 | | | | |
| 1,2,3,7,8-PeCDD | 2.34 | - | J | 2.34 | 0.0515 | | | | |
| 1,2,3,4,7,8-HxCDD | 4.86 | - | | 0.486 | 0.0555 | | | | |
| 1,2,3,6,7,8-HxCDD | 14.8 | - | | 1.48 | 0.0558 | Total TCDD | 18.5 | - | |
| 1,2,3,7,8,9-HxCDD | 8.51 | - | | 0.851 | 0.0528 | Total PeCDD | 27.8 | - | |
| 1,2,3,4,6,7,8-HpCDD | 460 | - | | 4.60 | 0.0712 | Total HxCDD | 137 | - | |
| OCDD | 4200 | - | | 1.26 | 0.195 | Total HpCDD | 1050 | - | |
| 2,3,7,8-TCDF | 0.616 | - | | 0.0616 | 0.0231 | | | | |
| 1,2,3,7,8-PeCDF | 0.745 | - | J | 0.0224 | 0.0324 | | | | |
| 2,3,4,7,8-PeCDF | 1.22 | - | J | 0.366 | 0.0322 | | | | |
| 1,2,3,4,7,8-HxCDF | 2.48 | - | | 0.248 | 0.0339 | | | | |
| 1,2,3,6,7,8-HxCDF | 2.06 | - | J | 0.206 | 0.0340 | | | | |
| 2,3,4,6,7,8-HxCDF | 2.98 | - | | 0.298 | 0.0353 | | | | |
| 1,2,3,7,8,9-HxCDF | 0.901 | - | J | 0.0901 | 0.0451 | Total TCDF | 14.3 | - | |
| 1,2,3,4,6,7,8-HpCDF | 78.2 | - | | 0.782 | 0.0350 | Total PeCDF | 17.4 | - | |
| 1,2,3,4,7,8,9-HpCDF | 3.62 | - | | 0.0362 | 0.0421 | Total HxCDF | 72.8 | - | |
| OCDF | 295 | - | | 0.0885 | 0.0820 | Total HpCDF | 264 | - | |

| Internal Standards | % Rec | QC Limits | Qual |
|-------------------------|-------|------------|------|
| 13C-2,3,7,8-TCDD | 108 | 25.0 - 164 | |
| 13C-1,2,3,7,8-PeCDD | 101 | 25.0 - 181 | |
| 13C-1,2,3,4,7,8-HxCDD | 105 | 32.0 - 141 | |
| 13C-1,2,3,6,7,8-HxCDD | 100 | 28.0 - 130 | |
| 13C-1,2,3,4,6,7,8-HpCDD | 101 | 23.0 - 140 | |
| 13C-OCDD | 108 | 17.0 - 157 | |
| 13C-2,3,7,8-TCDF | 103 | 24.0 - 169 | |
| 13C-1,2,3,7,8-PeCDF | 99.4 | 24.0 - 185 | |
| 13C-2,3,4,7,8-PeCDF | 96.3 | 21.0 - 178 | |
| 13C-1,2,3,4,7,8-HxCDF | 115 | 26.0 - 152 | |
| 13C-1,2,3,6,7,8-HxCDF | 108 | 26.0 - 123 | |
| 13C-2,3,4,6,7,8-HxCDF | 123 | 28.0 - 136 | |
| 13C-1,2,3,7,8,9-HxCDF | 108 | 29.0 - 147 | |
| 13C-1,2,3,4,6,7,8-HpCDF | 109 | 28.0 - 143 | |
| 13C-1,2,3,4,7,8,9-HpCDF | 110 | 26.0 - 138 | |
| 13C-OCDF | 105 | 17.0 - 157 | |

Cleanup Surrogate

37Cl-2,3,7,8-TCDD 107 35.0 - 197

- A Isotopic Labeled Standard outside QC range but signal to noise ratio is >10:1

B Analyte is present in Method Blank

C Chemical Interference

D Presence of Diphenyl Ethers

DNQ Analyte concentration is below calibration range

E Analyte concentration is above calibration range

F Analyte confirmation on secondary column

J Analyte concentration is below calibration range

M Maximum possible concentration

ND Analyte Not Detected at Detection Limit Level

NP Not Provided

P Pre-filtered through a Whatman 0.7um GF/F filter

S Sample acceptance criteria not met

X Matrix interferences

* Result taken from dilution or reinjection

Analyst: 

Date: 7/19/2022

Reviewed By: 

Date: 7/19/2022

EPA Method 1613 PCDD/F



FAL ID: 14487-003-SA
Client ID: ISM-011_0622
Matrix: Soil
Batch No: X6137

Date Extracted: 07-12-2022
Date Received: 06-28-2022
Amount: 10.1 g
% Solids: 95.89

ICal: PCDDFAL3-4-29-22
GC Column: DB5MS
Units: pg/g

Acquired: 07-14-2022
2005 WHO TEQ: 60.4
Basis: Dry Weight

| Compound | Conc | DL | Qual | 2005 WHO Tox | MDL | Compound | Conc | DL | Qual |
|---------------------|-------|----|------|-----------------|--------|-------------|------|----|------|
| 2,3,7,8-TCDD | 8.08 | - | | 8.08 | 0.0286 | | | | |
| 1,2,3,7,8-PeCDD | 4.97 | - | | 4.97 | 0.0515 | | | | |
| 1,2,3,4,7,8-HxCDD | 11.6 | - | | 1.16 | 0.0555 | | | | |
| 1,2,3,6,7,8-HxCDD | 53.0 | - | | 5.30 | 0.0558 | Total TCDD | 32.9 | - | |
| 1,2,3,7,8,9-HxCDD | 24.1 | - | | 2.41 | 0.0528 | Total PeCDD | 40.9 | - | |
| 1,2,3,4,6,7,8-HpCDD | 1380 | - | | 13.8 | 0.0712 | Total HxCDD | 295 | - | |
| OCDD | 10600 | - | | 3.18 | 0.195 | Total HpCDD | 2520 | - | |
| 2,3,7,8-TCDF | 1.33 | - | F | 0.133 | 0.0231 | | | | |
| 1,2,3,7,8-PeCDF | 3.98 | - | | 0.119 | 0.0324 | | | | |
| 2,3,4,7,8-PeCDF | 18.6 | - | | 5.58 | 0.0322 | | | | |
| 1,2,3,4,7,8-HxCDF | 71.4 | - | | 7.14 | 0.0339 | | | | |
| 1,2,3,6,7,8-HxCDF | 17.4 | - | | 1.74 | 0.0340 | | | | |
| 2,3,4,6,7,8-HxCDF | 23.0 | - | | 2.30 | 0.0353 | | | | |
| 1,2,3,7,8,9-HxCDF | 11.7 | - | | 1.17 | 0.0451 | Total TCDF | 31.8 | - | D,M |
| 1,2,3,4,6,7,8-HpCDF | 295 | - | | 2.95 | 0.0350 | Total PeCDF | 130 | - | |
| 1,2,3,4,7,8,9-HpCDF | 21.2 | - | | 0.212 | 0.0421 | Total HxCDF | 554 | - | D,M |
| OCDF | 548 | - | | 0.164 | 0.0820 | Total HpCDF | 915 | - | |

| Internal Standards | % Rec | QC Limits | Qual |
|-------------------------|-------|------------|------|
| 13C-2,3,7,8-TCDD | 110 | 25.0 - 164 | |
| 13C-1,2,3,7,8-PeCDD | 107 | 25.0 - 181 | |
| 13C-1,2,3,4,7,8-HxCDD | 103 | 32.0 - 141 | |
| 13C-1,2,3,6,7,8-HxCDD | 102 | 28.0 - 130 | |
| 13C-1,2,3,4,6,7,8-HpCDD | 109 | 23.0 - 140 | |
| 13C-OCDD | 123 | 17.0 - 157 | |
| 13C-2,3,7,8-TCDF | 108 | 24.0 - 169 | |
| 13C-1,2,3,7,8-PeCDF | 105 | 24.0 - 185 | |
| 13C-2,3,4,7,8-PeCDF | 105 | 21.0 - 178 | |
| 13C-1,2,3,4,7,8-HxCDF | 116 | 26.0 - 152 | |
| 13C-1,2,3,6,7,8-HxCDF | 109 | 26.0 - 123 | |
| 13C-2,3,4,6,7,8-HxCDF | 123 | 28.0 - 136 | |
| 13C-1,2,3,7,8,9-HxCDF | 112 | 29.0 - 147 | |
| 13C-1,2,3,4,6,7,8-HpCDF | 110 | 28.0 - 143 | |
| 13C-1,2,3,4,7,8,9-HpCDF | 113 | 26.0 - 138 | |
| 13C-OCDF | 110 | 17.0 - 157 | |

Cleanup Surrogate

37Cl-2,3,7,8-TCDD 115 35.0 - 197

- A Isotopic Labeled Standard outside QC range but signal to noise ratio is >10:1
- B Analyte is present in Method Blank
- C Chemical Interference
- D Presence of Diphenyl Ethers
- DNQ Analyte concentration is below calibration range
- E Analyte concentration is above calibration range
- F Analyte confirmation on secondary column
- J Analyte concentration is below calibration range
- M Maximum possible concentration
- ND Analyte Not Detected at Detection Limit Level
- NP Not Provided
- P Pre-filtered through a Whatman 0.7um GF/F filter
- S Sample acceptance criteria not met
- X Matrix interferences
- * Result taken from dilution or reinjection

Analyst: 

Date: 7/19/2022

Reviewed By: 

Date: 7/19/2022

EPA Method 1613 PCDD/F



FAL ID: 14487-004-SA
Client ID: ISM-111_0622
Matrix: Soil
Batch No: X6137

Date Extracted: 07-12-2022
Date Received: 06-28-2022
Amount: 10.0 g
% Solids: 95.66

ICal: PCDDFAL3-4-29-22
GC Column: DB5MS
Units: pg/g

Acquired: 07-14-2022
2005 WHO TEQ: 60.2
Basis: Dry Weight

| Compound | Conc | DL | Qual | 2005 WHO Tox | MDL | Compound | Conc | DL | Qual |
|---------------------|-------|----|------|-----------------|--------|-------------|------|----|------|
| 2,3,7,8-TCDD | 7.35 | - | | 7.35 | 0.0286 | | | | |
| 1,2,3,7,8-PeCDD | 5.24 | - | | 5.24 | 0.0515 | | | | |
| 1,2,3,4,7,8-HxCDD | 11.4 | - | | 1.14 | 0.0555 | | | | |
| 1,2,3,6,7,8-HxCDD | 53.9 | - | | 5.39 | 0.0558 | Total TCDD | 33.4 | - | |
| 1,2,3,7,8,9-HxCDD | 23.3 | - | | 2.33 | 0.0528 | Total PeCDD | 40.4 | - | |
| 1,2,3,4,6,7,8-HpCDD | 1430 | - | | 14.3 | 0.0712 | Total HxCDD | 295 | - | |
| OCDD | 11000 | - | | 3.30 | 0.195 | Total HpCDD | 2610 | - | |
| 2,3,7,8-TCDF | 1.35 | - | F | 0.135 | 0.0231 | | | | |
| 1,2,3,7,8-PeCDF | 3.79 | - | | 0.114 | 0.0324 | | | | |
| 2,3,4,7,8-PeCDF | 18.3 | - | | 5.49 | 0.0322 | | | | |
| 1,2,3,4,7,8-HxCDF | 71.1 | - | | 7.11 | 0.0339 | | | | |
| 1,2,3,6,7,8-HxCDF | 17.3 | - | | 1.73 | 0.0340 | | | | |
| 2,3,4,6,7,8-HxCDF | 21.9 | - | | 2.19 | 0.0353 | | | | |
| 1,2,3,7,8,9-HxCDF | 11.8 | - | | 1.18 | 0.0451 | Total TCDF | 37.9 | - | D,M |
| 1,2,3,4,6,7,8-HpCDF | 283 | - | | 2.83 | 0.0350 | Total PeCDF | 133 | - | D,M |
| 1,2,3,4,7,8,9-HpCDF | 20.4 | - | | 0.204 | 0.0421 | Total HxCDF | 547 | - | D,M |
| OCDF | 512 | - | | 0.154 | 0.0820 | Total HpCDF | 862 | - | |

| Internal Standards | % Rec | QC Limits | Qual |
|-------------------------|-------|------------|------|
| 13C-2,3,7,8-TCDD | 113 | 25.0 - 164 | |
| 13C-1,2,3,7,8-PeCDD | 106 | 25.0 - 181 | |
| 13C-1,2,3,4,7,8-HxCDD | 108 | 32.0 - 141 | |
| 13C-1,2,3,6,7,8-HxCDD | 102 | 28.0 - 130 | |
| 13C-1,2,3,4,6,7,8-HpCDD | 110 | 23.0 - 140 | |
| 13C-OCDD | 125 | 17.0 - 157 | |
| 13C-2,3,7,8-TCDF | 105 | 24.0 - 169 | |
| 13C-1,2,3,7,8-PeCDF | 105 | 24.0 - 185 | |
| 13C-2,3,4,7,8-PeCDF | 103 | 21.0 - 178 | |
| 13C-1,2,3,4,7,8-HxCDF | 116 | 26.0 - 152 | |
| 13C-1,2,3,6,7,8-HxCDF | 110 | 26.0 - 123 | |
| 13C-2,3,4,6,7,8-HxCDF | 121 | 28.0 - 136 | |
| 13C-1,2,3,7,8,9-HxCDF | 109 | 29.0 - 147 | |
| 13C-1,2,3,4,6,7,8-HpCDF | 112 | 28.0 - 143 | |
| 13C-1,2,3,4,7,8,9-HpCDF | 113 | 26.0 - 138 | |
| 13C-OCDF | 112 | 17.0 - 157 | |

Cleanup Surrogate

37Cl-2,3,7,8-TCDD 114 35.0 - 197

- A Isotopic Labeled Standard outside QC range but signal to noise ratio is >10:1
- B Analyte is present in Method Blank
- C Chemical Interference
- D Presence of Diphenyl Ethers
- DNQ Analyte concentration is below calibration range
- E Analyte concentration is above calibration range
- F Analyte confirmation on secondary column
- J Analyte concentration is below calibration range
- M Maximum possible concentration
- ND Analyte Not Detected at Detection Limit Level
- NP Not Provided
- P Pre-filtered through a Whatman 0.7um GF/F filter
- S Sample acceptance criteria not met
- X Matrix interferences
- * Result taken from dilution or reinjection

Analyst: 

Date: 7/19/2022

Reviewed By: 

Date: 7/19/2022

EPA Method 1613 PCDD/F



FAL ID: 14487-005-SA
Client ID: ISM-211_0622
Matrix: Soil
Batch No: X6137

Date Extracted: 07-12-2022
Date Received: 06-28-2022
Amount: 10.2 g
% Solids: 96.32

ICal: PCDDFAL3-4-29-22
GC Column: DB5MS
Units: pg/g

Acquired: 07-14-2022
2005 WHO TEQ: 47.8
Basis: Dry Weight

| Compound | Conc | DL | Qual | 2005 WHO Tox | MDL | Compound | Conc | DL | Qual |
|---------------------|------|----|------|-----------------|--------|-------------|------|----|------|
| 2,3,7,8-TCDD | 5.85 | - | | 5.85 | 0.0286 | | | | |
| 1,2,3,7,8-PeCDD | 4.00 | - | | 4.00 | 0.0515 | | | | |
| 1,2,3,4,7,8-HxCDD | 9.37 | - | | 0.937 | 0.0555 | | | | |
| 1,2,3,6,7,8-HxCDD | 43.1 | - | | 4.31 | 0.0558 | Total TCDD | 26.6 | - | |
| 1,2,3,7,8,9-HxCDD | 18.5 | - | | 1.85 | 0.0528 | Total PeCDD | 34.0 | - | |
| 1,2,3,4,6,7,8-HpCDD | 1110 | - | | 11.1 | 0.0712 | Total HxCDD | 242 | - | |
| OCDD | 8590 | - | | 2.58 | 0.195 | Total HpCDD | 2050 | - | |
| 2,3,7,8-TCDF | 1.06 | - | F | 0.106 | 0.0231 | | | | |
| 1,2,3,7,8-PeCDF | 3.12 | - | | 0.0936 | 0.0324 | | | | |
| 2,3,4,7,8-PeCDF | 14.2 | - | | 4.26 | 0.0322 | | | | |
| 1,2,3,4,7,8-HxCDF | 57.4 | - | | 5.74 | 0.0339 | | | | |
| 1,2,3,6,7,8-HxCDF | 14.1 | - | | 1.41 | 0.0340 | | | | |
| 2,3,4,6,7,8-HxCDF | 18.6 | - | | 1.86 | 0.0353 | | | | |
| 1,2,3,7,8,9-HxCDF | 9.46 | - | | 0.946 | 0.0451 | Total TCDF | 22.9 | - | |
| 1,2,3,4,6,7,8-HpCDF | 244 | - | | 2.44 | 0.0350 | Total PeCDF | 107 | - | |
| 1,2,3,4,7,8,9-HpCDF | 16.7 | - | | 0.167 | 0.0421 | Total HxCDF | 459 | - | |
| OCDF | 458 | - | | 0.137 | 0.0820 | Total HpCDF | 750 | - | |

| Internal Standards | % Rec | QC Limits | Qual |
|-------------------------|-------|------------|------|
| 13C-2,3,7,8-TCDD | 117 | 25.0 - 164 | |
| 13C-1,2,3,7,8-PeCDD | 111 | 25.0 - 181 | |
| 13C-1,2,3,4,7,8-HxCDD | 116 | 32.0 - 141 | |
| 13C-1,2,3,6,7,8-HxCDD | 110 | 28.0 - 130 | |
| 13C-1,2,3,4,6,7,8-HpCDD | 118 | 23.0 - 140 | |
| 13C-OCDD | 127 | 17.0 - 157 | |
| 13C-2,3,7,8-TCDF | 114 | 24.0 - 169 | |
| 13C-1,2,3,7,8-PeCDF | 111 | 24.0 - 185 | |
| 13C-2,3,4,7,8-PeCDF | 109 | 21.0 - 178 | |
| 13C-1,2,3,4,7,8-HxCDF | 129 | 26.0 - 152 | |
| 13C-1,2,3,6,7,8-HxCDF | 119 | 26.0 - 123 | |
| 13C-2,3,4,6,7,8-HxCDF | 134 | 28.0 - 136 | |
| 13C-1,2,3,7,8,9-HxCDF | 122 | 29.0 - 147 | |
| 13C-1,2,3,4,6,7,8-HpCDF | 121 | 28.0 - 143 | |
| 13C-1,2,3,4,7,8,9-HpCDF | 125 | 26.0 - 138 | |
| 13C-OCDF | 117 | 17.0 - 157 | |

Cleanup Surrogate

37Cl-2,3,7,8-TCDD 115 35.0 - 197

- A Isotopic Labeled Standard outside QC range but signal to noise ratio is >10:1
- B Analyte is present in Method Blank
- C Chemical Interference
- D Presence of Diphenyl Ethers
- DNQ Analyte concentration is below calibration range
- E Analyte concentration is above calibration range
- F Analyte confirmation on secondary column
- J Analyte concentration is below calibration range
- M Maximum possible concentration
- ND Analyte Not Detected at Detection Limit Level
- NP Not Provided
- P Pre-filtered through a Whatman 0.7um GF/F filter
- S Sample acceptance criteria not met
- X Matrix interferences
- * Result taken from dilution or reinjection

Analyst: 

Date: 7/19/2022

Reviewed By: 

Date: 7/19/2022

ET

SUBCONTRACT ORDER

Apex Laboratories

A2F0755

Acceleration

SENDING LABORATORY:

Apex Laboratories
6700 S.W. Sandburg Street
Tigard, OR 97223
Phone: (503) 718-2323
Fax: (503) 336-0745
Project Manager: Philip Nerenberg

RECEIVING LABORATORY:

Frontier Analytical
5172 Hillsdale Circle
El Dorado Hills, CA 95762
Phone : (916) 934-0900
Fax:

14487
000

Sample Name: ISM-009_0622 After Processing
Sampled: 06/20/22 12:45 (A2F0755-02)

| Analysis | Due | Expires | Comments |
|---|----------------|----------------|----------|
| 1613B Dioxins and Furans (SUB) Containers Supplied: (B)4 oz Glass Jar | 07/19/22 17:00 | 06/20/23 12:45 | |

Sample Name: ISM-014_0622 After Processing
Sampled: 06/20/22 16:00 (A2F0755-04)

| Analysis | Due | Expires | Comments |
|---|----------------|----------------|----------|
| 1613B Dioxins and Furans (SUB) Containers Supplied: (B)4 oz Glass Jar | 07/19/22 17:00 | 06/20/23 16:00 | |

Sample Name: ISM-011_0622 After Processing
Sampled: 06/21/22 16:00 (A2F0755-06)

| Analysis | Due | Expires | Comments |
|---|----------------|----------------|----------|
| 1613B Dioxins and Furans (SUB) Containers Supplied: (B)4 oz Glass Jar | 07/19/22 17:00 | 06/21/23 16:00 | |

Sample Name: ISM-111_0622 After Processing
Sampled: 06/21/22 16:15 (A2F0755-08)

| Analysis | Due | Expires | Comments |
|---|----------------|----------------|----------|
| 1613B Dioxins and Furans (SUB) Containers Supplied: (B)4 oz Glass Jar | 07/19/22 17:00 | 06/21/23 16:15 | |

Standard TAT

Soil matrix

equivalent

BASIC EDD + Envirodata EDD (if possible)

Released By [Signature] Date 6-27-22 Received By UPS Shipper Date

Released By UPS Shipper Date Received By Kathy Zap Date 6/28/22 11:25

SUBCONTRACT ORDER

Apex Laboratories

A2F0755

ES

14487

0°

Sample Name: ISM-211_0622

After Processing

Sampled: 06/21/22 16:30

(A2F0755-10)

| Analysis | Due | Expires | Comments |
|--------------------------------|----------------|----------------|----------|
| 1613B Dioxins and Furans (SUB) | 07/19/22 17:00 | 06/21/23 16:30 | |
| Containers Supplied: | | | |
| (B)4 oz Glass Jar | | | |

Standard TAT

| | | | |
|-------------|---------|-------------|---------------|
| Released By | 6-27-22 | Received By | UPS Shipper |
| UPS Shipper | | Kathy Zof | 6/28/22 11:25 |
| Released By | Date | Received By | Date |

Frontier Analytical Laboratory

Sample Login Form

FAL Project ID: **14487**

| | |
|------------------------|-------------------|
| Client: | Apex Laboratories |
| Client Project ID: | A2F0755 |
| Date Received: | 06/28/2022 |
| Time Received: | 11:25 am |
| Received By: | KZ |
| Logged In By: | KZ |
| # of Samples Received: | 5 |
| Duplicates: | 0 |
| Storage Location: | R-4 |

| | |
|--|--------------------|
| Method of Delivery: | UPS |
| Tracking Number: | 1ZX4720R0194506473 |
| Shipping Container Received Intact | Yes |
| Custody seals(s) present? | No |
| Custody seals(s) intact? | No |
| Sample Arrival Temperature (C) | 0 |
| Cooling Method | Ice |
| Chain Of Custody Present? | Yes |
| Return Shipping Container To Client | Yes |
| Test aqueous sample for residual Chlorine | No |
| Sodium Thiosulfate Added | No |
| Adequate Sample Volume | Yes |
| Appropriate Sample Container | No |
| pH Range of Aqueous Sample | N/A |
| Anomalies or additional comments: | |
| <p>Please note that the samples were received in clear glass jars. NELAP requires samples be received in amber glass bottles or jars. Although this anomaly will not affect your results, we are required by NELAP to make a note of it. We will proceed with analysis unless directed otherwise by you.</p> | |

SUBCONTRACT ORDER
Apex Laboratories
A2F0755

14487
Doc

RECEIVING LABORATORY:
Frontier Analytical
5172 Hillside Circle
El Dorado Hills, CA 95762
Phone: (916) 934-0900
Fax:

SENDING LABORATORY:
Apex Laboratories
4700 E. 51st - Suite 100
Orange, CA 92666

| Due | Expires | After Processing | Comments |
|-----|---------|-------------------------|--------------|
| | | Sampled: 06/20/22 12:45 | (A2F0755-02) |
| | | Sampled: 06/20/22 16:00 | (A2F0755-04) |
| | | Sampled: 06/21/22 16:00 | (A2F0755-06) |
| | | Sampled: 06/21/22 16:15 | (A2F0755-08) |

4 Enviro data EVD (if possible)

UPS Shipper
Received By: *Kathy Zep* Date: *6/28/22* 11:25

UPS Shipper
Received By: *Kathy Zep* Date: *6/28/22* 11:25

Page 1 of 2

A2F0755-02 B
ISM-009_0622
Sampled: 06/20/22 12:45
4 oz Glass Jar
Frontier Analytical
14487-001-SA
Client ID: ISM-009_0622
Storage: R-4 (01 of 01)

A2F0755-04 B
ISM-014_0622
Sampled: 06/20/22 16:00
4 oz Glass Jar
Frontier Analytical
14487-002-SA
Client ID: ISM-014_0622
Storage: R-4 (01 of 01)

A2F0755-06 B
ISM-011_0622
Sampled: 06/21/22 16:00
4 oz Glass Jar
Frontier Analytical
14487-003-SA
Client ID: ISM-011_0622
Storage: R-4 (01 of 01)

A2F0755-08 B
ISM-111_0622
Sampled: 06/21/22 16:15
4 oz Glass Jar
Frontier Analytical
14487-004-SA
Client ID: ISM-111_0622
Storage: R-4 (01 of 01)

A2F0755-10 B
ISM-211_0622
Sampled: 06/21/22 16:30
4 oz Glass Jar
Frontier Analytical
14487-005-SA
Client ID: ISM-211_0622
Storage: R-4 (01 of 01)

2022/06/28

Stage 2A/B Data Validation Checks
JH Baxter
Delivery Group A2F0755/14487

Comments:

- U-qualified samples assigned by the laboratory are not included in this report unless the U qualification is for some other reason other than a simple non-detect.

SUMMARY OF QUALITY CONTROL CHECKS

| Quality Control Check | Check ed By | Comment |
|--|-------------|--|
| Completeness | MBF | The data set is 100 percent complete, no results rejected. |
| Holding times | MBF | Holding times were within the method specific recommended holding times. |
| Preservation | MBF | Preservation was acceptable. |
| COC Documentation | MBF | COC was not provided in the lab report, but laboratory sample login form and did not note any discrepancies other than clear glass jar sample containers not meeting NELAP requirements. No results qualified. |
| Analytical methods | MBF | EPA 1613 Requested analytical methods were performed. |
| Initial and continuing calibrations | MBF | Not independently verified during Stage 2A/B validation. |
| Method blanks, trip blank, and field blanks | MBF | Method blanks were performed per batch and there were no detections and associated QC were within established control limits. |
| Surrogate/labeled compounds | MBF | Labeled compounds were analyzed and within control limits. |
| LCS/LCSD | MBF | An OPR was analyzed per batch. Recoveries were within established control limits. |
| MS/MSD | MBF | MS/MSD were not performed and are not required per the method. |
| Field duplicates | MBF | A field duplicate and triplicate were collected and analyzed: <ul style="list-style-type: none"> • Primary: ISM-011_0622 • Duplicate: ISM-111_0622 • Triplicate: ISM-211_0622 RSDs were within the 50% Limit for solid organic results. |
| Lab duplicates | MBF | Lab sample duplicates were not performed or required per the method. |
| Dilution | MBF | Samples did not require further dilution for analysis. |
| Qualitative Identification for HRGC/HRMS analyses only | MBF | The following results were EMPCs with the presence of diphenyl ethers: <ul style="list-style-type: none"> • ISM-011_0622 <ul style="list-style-type: none"> ○ Total TCDF ○ Total HxCDF • ISM-111_0622 <ul style="list-style-type: none"> ○ Total TCDF |

| Quality Control Check | Check ed By | Comment |
|-----------------------|-------------|--|
| | | <ul style="list-style-type: none"> ○ Total HxCDF ○ Total PeCDF <p>Results were qualified J+.</p> <p>The following results were confirmed on the secondary column:</p> <ul style="list-style-type: none"> • 2,3,7,8-TCDF <ul style="list-style-type: none"> ○ ISM-011_0622 ○ ISM-111_0622 ○ ISM-211_0622 <p>Results not qualified due to confirmation.</p> |

Overall Assessment

Qualifier codes added to results; table and notes below.

Notes

TABLE 1. SUMMARY OF QUALIFIED DATA


| Sample ID | Analyte | Result (pg/g) | Qualifier Assigned | Reason for Qualification |
|--------------|---|--|--------------------|--------------------------------------|
| ISM-009_0622 | 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF | 1.89, 1.09, 2.44 | J | Below reporting limit |
| ISM-011_0622 | Total TCDF, Total HxCDF | 31.8, 554 | J+ | EMPC, Presence of Diphenyl Ethers |
| ISM-014_0622 | 1,2,3,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF | 2.06, 0.901, 2.34, 0.745, 1.22 | J | Below reporting limit |
| ISM-111_0622 | Total TCDF, Total HxCDF, Total PeCDF | 37.9, 547, 133 | J+ | EMPC, Presence of Diphenyl Ethers |

Oregon Dept. of Env. Quality - ODEQ

Sample Delivery Group: L1508970
Samples Received: 06/26/2022
Project Number: 72-18-32
Description: JH Baxter Removal Action Planning

Report To: Don Hanson
165 E. 7th Avenue
Suite 100
Eugene, OR 97401

Entire Report Reviewed By:



Brian Ford
Project Manager

Results relate only to the items tested or calibrated and are reported as rounded values. This test report shall not be reproduced, except in full, without written approval of the laboratory. Where applicable, sampling conducted by Pace Analytical National is performed per guidance provided in laboratory standard operating procedures ENV-SOP-MTJL-0067 and ENV-SOP-MTJL-0068. Where sampling conducted by the customer, results relate to the accuracy of the information provided, and as the samples are received.

Pace Analytical National12065 Lebanon Rd Mount Juliet, TN 37122 615-758-5858 800-767-5859 www.pacenational.com

TABLE OF CONTENTS

| | | |
|--------------------------------|---|-----------------|
| Cp: Cover Page | 1 | ¹ Cp |
| Tc: Table of Contents | 2 | |
| Ss: Sample Summary | 3 | ² Tc |
| Cn: Case Narrative | 5 | ³ Ss |
| Gl: Glossary of Terms | 6 | ⁴ Cn |
| Al: Accreditations & Locations | 7 | ⁵ Gl |
| Sc: Sample Chain of Custody | 8 | ⁶ Al |
| | | ⁷ Sc |

SAMPLE SUMMARY

COMP-09A_0622 L1508970-01 Solid

| | | | | Collected by GS/ME | Collected date/time 06/20/22 13:00 | Received date/time 06/26/22 09:00 |
|------------------------|-----------|----------|--------------------------|-----------------------|---------------------------------------|--------------------------------------|
| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

COMP-09B_0622 L1508970-02 Solid

| | | | | Collected by GS/ME | Collected date/time 06/20/22 13:15 | Received date/time 06/26/22 09:00 |
|------------------------|-----------|----------|--------------------------|-----------------------|---------------------------------------|--------------------------------------|
| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

COMP-10A_0622 L1508970-03 Solid

| | | | | Collected by GS/ME | Collected date/time 06/21/22 10:15 | Received date/time 06/26/22 09:00 |
|------------------------|-----------|----------|--------------------------|-----------------------|---------------------------------------|--------------------------------------|
| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

COMP-10B_0622 L1508970-04 Solid

| | | | | Collected by GS/ME | Collected date/time 06/21/22 10:30 | Received date/time 06/26/22 09:00 |
|------------------------|-----------|----------|--------------------------|-----------------------|---------------------------------------|--------------------------------------|
| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

COMP-11A_0622 L1508970-05 Solid

| | | | | Collected by GS/ME | Collected date/time 06/21/22 11:00 | Received date/time 06/26/22 09:00 |
|------------------------|-----------|----------|--------------------------|-----------------------|---------------------------------------|--------------------------------------|
| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

COMP-11B_0622 L1508970-06 Solid


| | | | | Collected by GS/ME | Collected date/time 06/21/22 11:15 | Received date/time 06/26/22 09:00 |
|------------------------|-----------|----------|--------------------------|-----------------------|---------------------------------------|--------------------------------------|
| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

COMP-14A_0622 L1508970-07 Solid

| | | | | Collected by GS/ME | Collected date/time 06/20/22 16:30 | Received date/time 06/26/22 09:00 |
|------------------------|-----------|----------|--------------------------|-----------------------|---------------------------------------|--------------------------------------|
| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

COMP-14B_0622 L1508970-08 Solid

| | | | | Collected by GS/ME | Collected date/time 06/20/22 16:45 | Received date/time 06/26/22 09:00 |
|------------------------|-----------|----------|--------------------------|-----------------------|---------------------------------------|--------------------------------------|
| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |



SAMPLE SUMMARY

COMP-15A_0622 L1508970-09 Solid

Collected by
GS/ME

Collected date/time
06/21/22 08:45

Received date/time
06/26/22 09:00

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

COMP-15B_0622 L1508970-10 Solid

Collected by
GS/ME

Collected date/time
06/21/22 09:00

Received date/time
06/26/22 09:00

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG1891233 | 1 | 07/29/22 00:00 | 07/29/22 00:00 | - | Minneapolis, MN 55414 |

EB-01_0622 L1508970-11 GW

Collected by
GS/ME

Collected date/time
06/21/22 16:45

Received date/time
06/26/22 09:00

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG1886865 | 1 | 07/12/22 00:00 | 07/12/22 00:00 | - | Minneapolis, MN 55414 |



CASE NARRATIVE


All sample aliquots were received at the correct temperature, in the proper containers, with the appropriate preservatives, and within method specified holding times, unless qualified or notated within the report. Where applicable, all MDL (LOD) and RDL (LOQ) values reported for environmental samples have been corrected for the dilution factor used in the analysis. All Method and Batch Quality Control are within established criteria except where addressed in this case narrative, a non-conformance form or properly qualified within the sample results. By my digital signature below, I affirm to the best of my knowledge, all problems/anomalies observed by the laboratory as having the potential to affect the quality of the data have been identified by the laboratory, and no information or data have been knowingly withheld that would affect the quality of the data.



Brian Ford
Project Manager

Project Narrative

L1508970 -01, -02, -03, -04, -05, -06, -07, -08, -09, -10, -11 contains subout data that is included after the chain of custody.



GLOSSARY OF TERMS

Guide to Reading and Understanding Your Laboratory Report

The information below is designed to better explain the various terms used in your report of analytical results from the Laboratory. This is not intended as a comprehensive explanation, and if you have additional questions please contact your project representative.


Results Disclaimer - Information that may be provided by the customer, and contained within this report, include Permit Limits, Project Name, Sample ID, Sample Matrix, Sample Preservation, Field Blanks, Field Spikes, Field Duplicates, On-Site Data, Sampling Collection Dates/Times, and Sampling Location. Results relate to the accuracy of this information provided, and as the samples are received.

Abbreviations and Definitions

| | |
|------------------------------|---|
| SDG | Sample Delivery Group. |
| Uncertainty (Radiochemistry) | Confidence level of 2 sigma. |
| Case Narrative (Cn) | A brief discussion about the included sample results, including a discussion of any non-conformances to protocol observed either at sample receipt by the laboratory from the field or during the analytical process. If present, there will be a section in the Case Narrative to discuss the meaning of any data qualifiers used in the report. |
| Quality Control Summary (Qc) | This section of the report includes the results of the laboratory quality control analyses required by procedure or analytical methods to assist in evaluating the validity of the results reported for your samples. These analyses are not being performed on your samples typically, but on laboratory generated material. |
| Sample Chain of Custody (Sc) | This is the document created in the field when your samples were initially collected. This is used to verify the time and date of collection, the person collecting the samples, and the analyses that the laboratory is requested to perform. This chain of custody also documents all persons (excluding commercial shippers) that have had control or possession of the samples from the time of collection until delivery to the laboratory for analysis. |
| Sample Results (Sr) | This section of your report will provide the results of all testing performed on your samples. These results are provided by sample ID and are separated by the analyses performed on each sample. The header line of each analysis section for each sample will provide the name and method number for the analysis reported. |
| Sample Summary (Ss) | This section of the Analytical Report defines the specific analyses performed for each sample ID, including the dates and times of preparation and/or analysis. |

Qualifier Description

The remainder of this page intentionally left blank, there are no qualifiers applied to this SDG.



ACCREDITATIONS & LOCATIONS


Pace Analytical National 12065 Lebanon Rd Mount Juliet, TN 37122

| | | | |
|-------------------------------|-------------|-----------------------------|------------------|
| Alabama | 40660 | Nebraska | NE-OS-15-05 |
| Alaska | 17-026 | Nevada | TN000032021-1 |
| Arizona | AZ0612 | New Hampshire | 2975 |
| Arkansas | 88-0469 | New Jersey-NELAP | TN002 |
| California | 2932 | New Mexico ¹ | TN00003 |
| Colorado | TN00003 | New York | 11742 |
| Connecticut | PH-0197 | North Carolina | Env375 |
| Florida | E87487 | North Carolina ¹ | DW21704 |
| Georgia | NELAP | North Carolina ³ | 41 |
| Georgia ¹ | 923 | North Dakota | R-140 |
| Idaho | TN00003 | Ohio-VAP | CL0069 |
| Illinois | 200008 | Oklahoma | 9915 |
| Indiana | C-TN-01 | Oregon | TN200002 |
| Iowa | 364 | Pennsylvania | 68-02979 |
| Kansas | E-10277 | Rhode Island | LA000356 |
| Kentucky ^{1 6} | KY90010 | South Carolina | 84004002 |
| Kentucky ² | 16 | South Dakota | n/a |
| Louisiana | AI30792 | Tennessee ^{1 4} | 2006 |
| Louisiana | LA018 | Texas | T104704245-20-18 |
| Maine | TN00003 | Texas ⁵ | LAB0152 |
| Maryland | 324 | Utah | TN000032021-11 |
| Massachusetts | M-TN003 | Vermont | VT2006 |
| Michigan | 9958 | Virginia | 110033 |
| Minnesota | 047-999-395 | Washington | C847 |
| Mississippi | TN00003 | West Virginia | 233 |
| Missouri | 340 | Wisconsin | 998093910 |
| Montana | CERT0086 | Wyoming | A2LA |
| A2LA – ISO 17025 | 1461.01 | AIHA-LAP, LLC EMLAP | 100789 |
| A2LA – ISO 17025 ⁵ | 1461.02 | DOD | 1461.01 |
| Canada | 1461.01 | USDA | P330-15-00234 |
| EPA-Crypto | TN00003 | | |

¹ Drinking Water ² Underground Storage Tanks ³ Aquatic Toxicity ⁴ Chemical/Microbiological ⁵ Mold ⁶ Wastewater n/a Accreditation not applicable

* Not all certifications held by the laboratory are applicable to the results reported in the attached report.

* Accreditation is only applicable to the test methods specified on each scope of accreditation held by Pace Analytical.



C082

State of Oregon Chain of Custody (Pace)

| Agency, Authorized Purchaser or Agent: GSJ/Haley & Aldrich for ODEQ Send Lab Report To: Don Hanson, RG Address: 165 E. 7th Avenue, Suite 100 Eugene, OR 97401 Tel #: 541-687-7349 E-mail: don.hanson@deq.state.or.us, jbale@gsiws.com, cmartin@gsiws.com, mfaragher@gsiws.com, GIS@gsiws.com | | | | | Contract Laboratory Name: Pace Analytical National Lab Batch #: Invoice: ODEQ/Business Office 811 SW 6th Ave Portland, OR 97204 Tel. #: (800) 452-4011 | | | | | Lab Selection Criteria: Proximity (if TAT < 48 hrs) Prior work on same project Cost (for anticipated analyses) Other labs disqualified or unable to perform requested services Emergency work | | | | | Turn Around Time: 10 days (std) 5 days 72 hours 48 hours 24 hours Other _____ | | |
|---|-----------------|-----------------|--------|--------------------------|---|--|--|----------------------------|--|---|--|----------------------------|--|--|--|----------|----------|
| Project Name: OREGON DEQ-JH BAXTER REMOVAL ACTION PLANNING (72-18-32) | | | | | | | | | | | | Sample Preservative | | | | L1508970 | |
| Project #: JH Baxter Removal Action Planning Sampler Name: G Schutzius, M Elias | | | | | | | | | | | | Requested Analyses | | | | | |
| Sample ID# | Collection Date | Collection Time | Matrix | Number of Containers | ISM Prep. Dioxin/furans by 1613B | | | | | | | | | | | | Comments |
| Comp-09A_0622 | 6/20/2022 | 13:00 | SO | 1 | x | | | | | | | | | | | | - 01 |
| Comp-09B_0622 | 6/20/2022 | 13:15 | SO | 1 | x | | | | | | | | | | | | - 02 |
| Comp-10A_0622 | 6/21/2022 | 10:15 | SO | 1 | x | | | | | | | | | | | | - 03 |
| Comp-10B_0622 | 6/21/2022 | 10:30 | SO | 1 | x | | | | | | | | | | | | - 04 |
| Comp-11A_0622 | 6/21/2022 | 11:00 | SO | 1 | x | | | | | | | | | | | | - 05 |
| Comp-11B_0622 | 6/21/2022 | 11:15 | SO | 1 | x | | | | | | | | | | | | - 06 |
| Comp-14A_0622 | 6/20/2022 | 16:30 | SO | 1 | x | | | | | | | | | | | | - 07 |
| Comp-14B_0622 | 6/20/2022 | 16:45 | SO | 1 | x | | | | | | | | | | | | - 08 |
| Comp-15A_0622 | 6/21/2022 | 8:45 | SO | 1 | x | | | | | | | | | | | | - 09 |
| Comp-15B_0622 | 6/21/2022 | 9:00 | SO | 1 | x | | | | | | | | | | | | - 10 |
| EB-01_0622 | 6/21/2022 | 16:45 | W | 4 | x | | | | | | | | | | | | - 11 |
| NOTES: Conduct Incremental Sampling Methodology processing prior to analysis. Contact Josh Bale (530-276-4188, jbale@gsiws.com) or Chris Martin (503-432-5979, cmartin@gsiws.com) with questions. Include DEQ EDD with final lab report. | | | | | | | | | | | | | | | | | |
| Relinquished By: Genevieve Schutzius | | | | Agency/Agent: GSJ | | | | Received By: Keanna Ramsey | | | | Agency/Agent: | | | | | |
| Signature: [Signature] | | | | Time & Date: 6/24/22 930 | | | | Signature: P. Ramsey | | | | Time & Date: 6-25-22 PM | | | | | |
| Relinquished By: [Signature] | | | | Agency/Agent: | | | | Received By: | | | | Agency/Agent: | | | | | |
| Signature: | | | | Time & Date: | | | | Signature: | | | | Time & Date: | | | | | |

THIS PURCHASE
HEREBY INCORPORATES

Sample Receipt Checklist

COC Seal Present/Intact: ☒ Y ☐ N If Applicable
 COC Signed/Accurate: ☒ Y ☐ N VOA Zero Headspace: ☐ Y ☐ N
 Bottles arrive intact: ☒ Y ☐ N Pres. Correct/Check: ☐ Y ☐ N
 Correct bottles used: ☒ Y ☐ N
 Sufficient volume sent: ☒ Y ☐ N
 RAD Screen <0.5 mR/hr: ☒ Y ☐ N

 THE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE
 FLICHTING T'S AND C'S, EXPRESS OR IMPLIED.

 TR# 5671 5376 6779
 PMA 6 0.9+0.0=0.9

| <u>Tracking Numbers</u> | | <u>Temperature</u> |
|-----------------------------|--|--------------------|
| 5671 5376 6790 | | PmAG 29+0.0=29 |
| 5671 5376 6790 | | RRAT 5.4+0.0=5.4 |
| | | |
| | | |
| | | |
| | | |

Report Prepared for:

Client Services
Pace Analytical National
12065 Lebanon Road
Mount Juliet TN 37122

REPORT OF LABORATORY ANALYSIS FOR PCDD/PCDF

Report Prepared Date:

July 7, 2022

Report Information:


Pace Project #: 10614837
Sample Receipt Date: 06/29/2022
Client Project #: L1508970 WG1886865
Client Sub PO #: L1508970
State Cert #: MN300001

Invoicing & Reporting Options:

The report provided has been invoiced as a Level 2 PCDD/PCDF Report. If an upgrade of this report package is requested, an additional charge may be applied.

Please review the attached invoice for accuracy and forward any questions to Kongmeng Vang, your Pace Project Manager.

This report has been reviewed by:



July 12, 2022

Kongmeng Vang, Project Manager
(612) 607-6382
(612) 607-6333 (fax)



Report of Laboratory Analysis

This report should not be reproduced, except in full, without the written consent of Pace Analytical Services, Inc.

The results relate only to the samples included in this report.



DISCUSSION

This report presents the results from the analysis performed on one sample submitted by a representative of Pace Analytical National. The sample was analyzed for the presence or absence of polychlorodibenzo-p-dioxins (PCDDs) and polychlorodibenzofurans (PCDFs) using USEPA Method 1613B. The estimated detection limits (EDLs) were based on signal-to-noise measurements. Estimated maximum possible concentration (EMPC) values were treated as positives in the toxic equivalence calculations.

The recoveries of the isotopically-labeled PCDD/PCDF internal standards in the sample extract ranged from 63-121%. All of the labeled standard recoveries obtained for this project were within the target ranges specified in Method 1613B. Also, since the quantification of the native 2,3,7,8-substituted congeners was based on isotope dilution, the data were automatically corrected for recovery and accurate values were obtained.

Values were flagged "I" where incorrect isotope ratios were obtained. Concentrations below the calibration range were flagged "J" and should be regarded as estimates.

A laboratory method blank was prepared and analyzed with the sample batch as part of our routine quality control procedures. The results show the blank to contain trace levels of selected congeners. These levels were below the calibration range for the method. Sample levels similar to the corresponding blank levels were flagged "B" on the results table and may be, at least partially, attributed to the background.

Laboratory spike samples were also prepared using clean reference matrix that had been fortified with native standard materials. The results show that the spiked native compounds were recovered at 74-106% with relative percent differences of 1.2-17.3%. The recovery value obtained for 1,2,3,4,6,7,8-HpCDF in LCS-99760 was below the target range, flagged "R" on the results table, and may indicate a low bias for this congener in these determinations. Matrix spikes were not prepared with the extraction batch.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Minnesota Laboratory Certifications

| Authority | Certificate # | Authority | Certificate # |
|----------------|----------------|-----------------|----------------|
| A2LA | 2926.01 | Mississippi | MN00064 |
| Alabama | 40770 | Missouri | 10100 |
| Alaska-DW | MN00064 | Montana | CERT0092 |
| Alaska-UST | 17-009 | Nebraska | NE-OS-18-06 |
| Arizona | AZ0014 | Nevada | MN00064 |
| Arkansas - WW | 88-0680 | New Hampshire | 2081 |
| Arkansas-DW | MN00064 | New Jersey | MN002 |
| California | 2929 | New York | 11647 |
| Colorado | MN00064 | North Carolina- | 27700 |
| Connecticut | PH-0256 | North Carolina- | 530 |
| Florida | E87605 | North Dakota | R-036 |
| Georgia | 959 | Ohio-DW | 41244 |
| Hawaii | MN00064 | Ohio-VAP (170 | CL101 |
| Idaho | MN00064 | Ohio-VAP (180 | CL110 |
| Illinois | 200011 | Oklahoma | 9507 |
| Indiana | C-MN-01 | Oregon- rimary | MN300001 |
| Iowa | 368 | Oregon-Second | MN200001 |
| Kansas | E-10167 | Pennsylvania | 68-00563 |
| Kentucky-DW | 90062 | Puerto Rico | MN00064 |
| Kentucky-WW | 90062 | South Carolina | 74003 |
| Louisiana-DEQ | AI-84596 | Tennessee | TN02818 |
| Louisiana-DW | MN00064 | Texas | T104704192 |
| Maine | MN00064 | Utah | MN00064 |
| Maryland | 322 | Vermont | VT-027053137 |
| Michigan | 9909 | Virginia | 460163 |
| Minnesota | 027-053-137 | Washington | C486 |
| Minnesota-Ag | via MN 027-053 | West Virginia-D | 382 |
| Minnesota-Petr | 1240 | West Virginia-D | 9952C |
| | | Wisconsin | 999407970 |
| | | Wyoming-UST | via A2LA 2926. |

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Report No.....10614837



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix A

Sample Management

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.

| | |
|------|------|
| | P. |
| Page | 7613 |

Section A

Required Client Information:

Section C

Invoice Information:

Page : 1 Of 1

| | | |
|---|---|-------------------------------------|
| Company: Pace Analytical | Report To: Pace Analytical Subout Team | Attention: Don Hanson |
| Address: 12065 Lebanon Rd. | Copy To: | Company Name: |
| MT Juliet, TN 37122 | | Address: |
| Email: MTJLSuboutTeam@pacelabs.com | Purchase Order #: L1508970 | Pace Quote: |
| Phone: (615) 773-9756 Fax: (615) 758-5859 | Project Name: JH Baxter Removal Action Planning | Pace Project Manager: Kongmeng Vang |
| Requested Due Date: 26-Jul | Project #: 72-18-32 | Pace Profile #: 38076 |
| | | State / Location: OR |

[illegible]


WO# : 10614837



10614837

[illegible]

| | | | | | |
|----------------------------|--------------|-----------|----------------------------|--------------------------------------|----------------------------|
| SAMPLER NAME AND SIGNATURE | | TEMP in C | Received on ce (Y/N) | Custody Sealed Cooler (Y/N) | Samples intact (Y/N) |
| PRINT Name of SAMPLER: | | | | | |
| SIGNATURE of SAMPLER: | DATE Signed: | | | | |

| | |
|---|--|
|  | DC#_Title: ENV-FRM-MIN4-0150 v05_Sample Condition Upon Receipt (SCUR) |
| | Effective Date: 04/12/2022 |

| | | | |
|--|---|-------------------|--|
| Sample Condition Upon Receipt | Client Name: <u>Pace Analytical</u> | Project #: | <div style="border: 2px solid black; padding: 10px; text-align: center;"> WO#: 10614837 PM: KV Due Date: 07/21/22 CLIENT: ESC_TN </div> |
| Courier: <input checked="" type="checkbox"/> Fed Ex <input type="checkbox"/> UPS <input type="checkbox"/> USPS <input type="checkbox"/> Client <input type="checkbox"/> Pace <input type="checkbox"/> Speedee <input type="checkbox"/> Commercial | See Exceptions <input type="checkbox"/> ENV-FRM-MIN4-0142 | | |
| Tracking Number: <u>588275407700, 588275407711</u> | | | |

| | | |
|--|--|---|
| Custody Seal on Cooler/Box Present? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | Seals Intact? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | Biological Tissue Frozen? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| Packing Material: <input checked="" type="checkbox"/> Bubble Wrap <input checked="" type="checkbox"/> Bubble Bags <input type="checkbox"/> None <input type="checkbox"/> Other: | Temp Blank? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | |
| Thermometer: <input type="checkbox"/> T1(0461) <input type="checkbox"/> T2(1336) <input type="checkbox"/> T3(0459) <input type="checkbox"/> T4(0254) <input type="checkbox"/> T5(0489) <input type="checkbox"/> T6(0235) <input type="checkbox"/> T7(0042) <input type="checkbox"/> 01339252/1710 <input type="checkbox"/> 122639816 <input type="checkbox"/> 140792808 | Type of Ice: <input checked="" type="checkbox"/> Wet <input type="checkbox"/> Blue <input type="checkbox"/> None <input type="checkbox"/> Dry <input type="checkbox"/> Melted | |

| | |
|--|---|
| Did Samples Originate in West Virginia? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | Were All Container Temps Taken? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| Temp should be above freezing to 6°C Cooler Temp Read w/temp blank: _____ °C | |
| Correction Factor: <u>Time</u> Cooler Temp Corrected w/temp blank: _____ °C | |

| | |
|--|---|
| USDA Regulated Soil: <input checked="" type="checkbox"/> N/A water sample/Other: _____ | Date/Initials of Person Examining Contents: <u>PM 6/29/22</u> |
| Did samples originate in a quarantine zone within the United States: AL, AR, CA, FL, GA, ID, LA, MS, NC, NM, NY, OK, OR, SC, TN, TX or VA (check maps)? <input type="checkbox"/> Yes <input type="checkbox"/> No | Did samples originate from a foreign source (internationally, including Hawaii and Puerto Rico)? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| If Yes to either question, fill out a Regulated Soil Checklist ENV-FRM-MIN4-0154 and include with SCUR/COC paperwork. | |

| Location (check one): <input type="checkbox"/> Duluth <input checked="" type="checkbox"/> Minneapolis <input type="checkbox"/> Virginia | COMMENTS: |
|---|---|
| Chain of Custody Present and Filled Out? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 1. |
| Chain of Custody Relinquished? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 2. |
| Sampler Name and/or Signature on COC? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> N/A | 3. |
| Samples Arrived within Hold Time? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 4. If Fecal: <input type="checkbox"/> <8 hrs <input type="checkbox"/> >8hr, <24 hrs, <input type="checkbox"/> >24 hrs |
| Short Hold Time Analysis (<72 hr)? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | 5. <input type="checkbox"/> Fecal Coliform <input type="checkbox"/> HPC <input type="checkbox"/> Total Coliform/E coli <input type="checkbox"/> BOD/cBOD <input type="checkbox"/> Hex Chrome <input type="checkbox"/> Turbidity <input type="checkbox"/> Nitrate <input type="checkbox"/> Nitrite <input type="checkbox"/> Orthophos <input type="checkbox"/> Other |
| Rush Turn Around Time Requested? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | 6. |
| Sufficient Volume? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 7. |
| Correct Containers Used? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 8. |
| -Pace Containers Used? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 9. |
| Containers Intact? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 10. Is sediment visible in the dissolved container? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| Field Filtered Volume Received for Dissolved Tests? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | 11. If no, write ID/ Date/Time on Container Below: See Exception <input type="checkbox"/> ENV-FRM-MIN4-0142 |
| Is sufficient information available to reconcile the samples to the COC? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | |
| Matrix: <input checked="" type="checkbox"/> Water <input type="checkbox"/> Soil <input type="checkbox"/> Oil <input type="checkbox"/> Other- | |
| All containers needing acid/base preservation have been checked? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | 12. Sample # |
| All containers needing preservation are found to be in compliance with EPA recommendation? (HNO ₃ , H ₂ SO ₄ , <2pH, NaOH >9 Sulfide, NaOH >10 Cyanide) <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | <input type="checkbox"/> NaOH <input type="checkbox"/> HNO ₃ <input type="checkbox"/> H ₂ SO ₄ <input type="checkbox"/> Zinc Acetate |
| Exceptions: VOA, Coliform, TOC/DOC Oil and Grease, DRO/8015 (water) and Dioxin/PFAS <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | Positive for Res. <input type="checkbox"/> Yes <input type="checkbox"/> No See Exception <input type="checkbox"/> ENV-FRM-MIN4-0142 |
| | Chlorine? <input type="checkbox"/> Yes <input type="checkbox"/> No pH Paper Lot# |
| | Res. Chlorine 0-6 Roll 0-6 Strip 0-14 Strip |
| Headspace in Methyl Mercury Container? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | |
| Extra labels present on soil VOA or WIDRO containers? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | 13. See Exception <input type="checkbox"/> ENV-FRM-MIN4-0140 |
| Headspace in VOA Vials (greater than 6mm)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | |
| Trip Blank Present? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | 14. |
| Trip Blank Custody Seals Present? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | Pace Trip Blank Lot # (if purchased): _____ |

| | |
|--|--|
| CLIENT NOTIFICATION/RESOLUTION Person Contacted: _____ Comments/Resolution: _____ | Field Data Required? <input type="checkbox"/> Yes <input type="checkbox"/> No Date/Time: _____ |
|--|--|

| | |
|--|--------------------|
| Project Manager Review: _____ | Date: _____ |
| Note: Whenever there is a discrepancy affecting North Carolina compliance samples, a copy of this form will be sent to the North Carolina DEHNR Certification Office (i.e., out of hold, incorrect preservative, out of temp, incorrect containers). | |
| Labeled by: _____ | |

PM (2)

Reporting Flags

- A = Reporting Limit based on signal to noise (EDL)
- B = Less than 10x higher than method blank level
- C = Result obtained from confirmation analysis
- D = Result obtained from analysis of diluted sample
- E = Exceeds calibration range
- I = Isotope ratio out of specification
- J = Estimated value
- L = Suppressive interference, analyte may be biased low
- Nn = Value obtained from additional analysis
- P = PCDEInterference
- R = Recovery outside target range
- S = Peak saturated
- U = Analyte not detected
- V = Result verified by confirmation analysis
- X = %D Exceeds limits
- Y = Calculated using average of daily RFs
- * = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Report No.....10614837



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix B

Sample Analysis Summary

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.



Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|-------------|-----------|------------------|
| Client's Sample ID | EB-01_0622 | | |
| Lab Sample ID | 10614837001 | | |
| Filename | U220705B_04 | | |
| Injected By | MS4 | | |
| Total Amount Extracted | 969 mL | Matrix | Water |
| % Moisture | NA | Dilution | NA |
| Dry Weight Extracted | NA | Collected | 06/21/2022 16:45 |
| ICAL ID | U220611 | Received | 06/29/2022 08:50 |
| CCal Filename(s) | U220705A_17 | Extracted | 06/30/2023 11:30 |
| Method Blank ID | BLANK-99759 | Analyzed | 07/06/2022 02:18 |

| Native Isomers | Conc pg/L | EMPC pg/L | EDL pg/L | Internal Standards | ng's Added | Percent Recovery |
|---------------------|--------------|--------------|-------------|--|---------------|---------------------|
| 2,3,7,8-TCDF | ND | — | 0.31 | 2,3,7,8-TCDF-13C | 2.00 | 90 |
| Total TCDF | ND | — | 0.31 | 2,3,7,8-TCDD-13C | 2.00 | 83 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 97 |
| 2,3,7,8-TCDD | ND | — | 0.55 | 2,3,4,7,8-PeCDF-13C | 2.00 | 99 |
| Total TCDD | ND | — | 0.55 | 1,2,3,7,8-PeCDD-13C | 2.00 | 104 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 121 |
| 1,2,3,7,8-PeCDF | ND | — | 0.40 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 98 |
| 2,3,4,7,8-PeCDF | ND | — | 0.28 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 114 |
| Total PeCDF | ND | — | 0.28 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 109 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 117 |
| 1,2,3,7,8-PeCDD | ND | — | 0.71 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 109 |
| Total PeCDD | ND | — | 0.71 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 93 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 72 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.90 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 85 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.76 | OCDD-13C | 4.00 | 63 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.52 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 1.0 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | ND | — | 0.52 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 2.0 | — | 1.7 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 81 |
| 1,2,3,6,7,8-HxCDD | ND | — | 1.3 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 1.1 | | | |
| Total HxCDD | 2.0 | — | 1.1 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 2.0 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 2.7 | Equivalence: 0.23 pg/L | | |
| Total HpCDF | ND | — | 2.0 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | — | 1.9 | 1.7 U | | | |
| Total HpCDD | ND | — | 1.7 | | | |
| | | | | | | |
| OCDF | ND | — | 3.0 | | | |
| OCDD | 21 | — | 3.3 BJ | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

J = Estimated value
B = Less than 10x higher than method blank level
I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|-------------|-------------|------------------|
| Lab Sample Name | DFBLKMC | Matrix | Water |
| Lab Sample ID | BLANK-99759 | Dilution | NA |
| Filename | U220705A_08 | Extracted | 06/30/2023 11:30 |
| Total Amount Extracted | 1010 mL | Analyzed | 07/05/2022 16:04 |
| ICAL ID | U220611 | Injected By | MS4 |
| CCal Filename(s) | U220705A_01 | | |

| Native Isomers | Conc pg/L | EMPC pg/L | EDL pg/L | Internal Standards | ng's Added | Percent Recovery |
|---------------------|--------------|--------------|-------------|--|---------------|---------------------|
| 2,3,7,8-TCDF | ND | — | 0.72 | 2,3,7,8-TCDF-13C | 2.00 | 59 |
| Total TCDF | ND | — | 0.72 | 2,3,7,8-TCDD-13C | 2.00 | 54 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 68 |
| 2,3,7,8-TCDD | ND | — | 0.53 | 2,3,4,7,8-PeCDF-13C | 2.00 | 70 |
| Total TCDD | ND | — | 0.53 | 1,2,3,7,8-PeCDD-13C | 2.00 | 72 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 89 |
| 1,2,3,7,8-PeCDF | ND | — | 0.50 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 71 |
| 2,3,4,7,8-PeCDF | ND | — | 0.36 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 78 |
| Total PeCDF | ND | — | 0.36 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 79 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 76 |
| 1,2,3,7,8-PeCDD | ND | — | 0.73 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 78 |
| Total PeCDD | ND | — | 0.73 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 65 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 52 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.71 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 50 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.80 | OCDD-13C | 4.00 | 43 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.69 | | | |
| 1,2,3,7,8,9-HxCDF | 1.7 | — | 0.96 J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 1.7 | — | 0.69 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 1.2 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 79 |
| 1,2,3,6,7,8-HxCDD | ND | — | 1.2 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 1.1 | | | |
| Total HxCDD | ND | — | 1.1 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 3.6 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 5.9 | Equivalence: 0.20 pg/L | | |
| Total HpCDF | ND | — | 3.6 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | — | 2.4 | 1.5 I | | | |
| Total HpCDD | ND | — | 1.5 | | | |
| | | | | | | |
| OCDF | 3.3 | — | 2.5 J | | | |
| OCDD | 29 | — | 2.2 J | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|-------------|-------------|------------------|
| Lab Sample ID | LCS-99760 | Matrix | Water |
| Filename | U220705A_02 | Dilution | NA |
| Total Amount Extracted | 965 mL | Extracted | 06/30/2023 11:30 |
| ICAL ID | U220611 | Analyzed | 07/05/2022 11:22 |
| CCal Filename | U220705A_01 | Injected By | MS4 |
| Method Blank ID | BLANK-99759 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 9.7 | 7.5 | 15.8 | 97 |
| 2,3,7,8-TCDD | 10 | 10 | 6.7 | 15.8 | 102 |
| 1,2,3,7,8-PeCDF | 50 | 44 | 40.0 | 67.0 | 87 |
| 2,3,4,7,8-PeCDF | 50 | 45 | 34.0 | 80.0 | 90 |
| 1,2,3,7,8-PeCDD | 50 | 41 | 35.0 | 71.0 | 83 |
| 1,2,3,4,7,8-HxCDF | 50 | 43 | 36.0 | 67.0 | 86 |
| 1,2,3,6,7,8-HxCDF | 50 | 43 | 42.0 | 65.0 | 87 |
| 2,3,4,6,7,8-HxCDF | 50 | 46 | 35.0 | 78.0 | 93 |
| 1,2,3,7,8,9-HxCDF | 50 | 46 | 39.0 | 65.0 | 93 |
| 1,2,3,4,7,8-HxCDD | 50 | 45 | 35.0 | 82.0 | 90 |
| 1,2,3,6,7,8-HxCDD | 50 | 46 | 38.0 | 67.0 | 93 |
| 1,2,3,7,8,9-HxCDD | 50 | 39 | 32.0 | 81.0 | 79 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 40 | 41.0 | 61.0 | 80 R |
| 1,2,3,4,7,8,9-HpCDF | 50 | 39 | 39.0 | 69.0 | 79 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 37 | 35.0 | 70.0 | 74 |
| OCDF | 100 | 88 | 63.0 | 170.0 | 88 |
| OCDD | 100 | 79 | 78.0 | 144.0 | 79 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 7.5 | 3.1 | 19.1 | 75 |
| 2,3,7,8-TCDF-13C | 100 | 60 | 22.0 | 152.0 | 60 |
| 2,3,7,8-TCDD-13C | 100 | 55 | 20.0 | 175.0 | 55 |
| 1,2,3,7,8-PeCDF-13C | 100 | 70 | 21.0 | 192.0 | 70 |
| 2,3,4,7,8-PeCDF-13C | 100 | 69 | 13.0 | 328.0 | 69 |
| 1,2,3,7,8-PeCDD-13C | 100 | 71 | 21.0 | 227.0 | 71 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 85 | 19.0 | 202.0 | 85 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 68 | 21.0 | 159.0 | 68 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 72 | 22.0 | 176.0 | 72 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 73 | 17.0 | 205.0 | 73 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 70 | 21.0 | 193.0 | 70 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 69 | 25.0 | 163.0 | 69 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 58 | 21.0 | 158.0 | 58 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 51 | 20.0 | 186.0 | 51 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 52 | 26.0 | 166.0 | 52 |
| OCDD-13C | 200 | 92 | 26.0 | 397.0 | 46 |

Cs = Concentration Spiked (ng/mL)
Cr = Concentration Recovered (ng/mL)
Rec. = Recovery (Expressed as Percent)
Control Limit Reference: Method 1613, Table 6, 10/94 Revision
R = Recovery outside of control limits
Nn = Value obtained from additional analysis
* = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|-------------|-------------|------------------|
| Lab Sample ID | LCSD-99761 | Matrix | Water |
| Filename | U220705A_03 | Dilution | NA |
| Total Amount Extracted | 1020 mL | Extracted | 06/30/2023 11:30 |
| ICAL ID | U220611 | Analyzed | 07/05/2022 12:08 |
| CCal Filename | U220705A_01 | Injected By | MS4 |
| Method Blank ID | BLANK-99759 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 10 | 7.5 | 15.8 | 101 |
| 2,3,7,8-TCDD | 10 | 11 | 6.7 | 15.8 | 106 |
| 1,2,3,7,8-PeCDF | 50 | 45 | 40.0 | 67.0 | 91 |
| 2,3,4,7,8-PeCDF | 50 | 46 | 34.0 | 80.0 | 92 |
| 1,2,3,7,8-PeCDD | 50 | 42 | 35.0 | 71.0 | 84 |
| 1,2,3,4,7,8-HxCDF | 50 | 46 | 36.0 | 67.0 | 92 |
| 1,2,3,6,7,8-HxCDF | 50 | 47 | 42.0 | 65.0 | 94 |
| 2,3,4,6,7,8-HxCDF | 50 | 49 | 35.0 | 78.0 | 98 |
| 1,2,3,7,8,9-HxCDF | 50 | 49 | 39.0 | 65.0 | 98 |
| 1,2,3,4,7,8-HxCDD | 50 | 47 | 35.0 | 82.0 | 95 |
| 1,2,3,6,7,8-HxCDD | 50 | 48 | 38.0 | 67.0 | 95 |
| 1,2,3,7,8,9-HxCDD | 50 | 41 | 32.0 | 81.0 | 81 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 42 | 41.0 | 61.0 | 85 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 44 | 39.0 | 69.0 | 88 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 39 | 35.0 | 70.0 | 78 |
| OCDF | 100 | 96 | 63.0 | 170.0 | 96 |
| OCDD | 100 | 94 | 78.0 | 144.0 | 94 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 15 | 3.1 | 19.1 | 148 |
| 2,3,7,8-TCDF-13C | 100 | 120 | 22.0 | 152.0 | 121 |
| 2,3,7,8-TCDD-13C | 100 | 110 | 20.0 | 175.0 | 110 |
| 1,2,3,7,8-PeCDF-13C | 100 | 140 | 21.0 | 192.0 | 140 |
| 2,3,4,7,8-PeCDF-13C | 100 | 140 | 13.0 | 328.0 | 141 |
| 1,2,3,7,8-PeCDD-13C | 100 | 150 | 21.0 | 227.0 | 148 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 170 | 19.0 | 202.0 | 174 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 130 | 21.0 | 159.0 | 127 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 160 | 22.0 | 176.0 | 156 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 160 | 17.0 | 205.0 | 157 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 150 | 21.0 | 193.0 | 146 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 150 | 25.0 | 163.0 | 146 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 130 | 21.0 | 158.0 | 127 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 110 | 20.0 | 186.0 | 111 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 110 | 26.0 | 166.0 | 112 |
| OCDD-13C | 200 | 200 | 26.0 | 397.0 | 102 |

Cs = Concentration Spiked (ng/mL)
Cr = Concentration Recovered (ng/mL)
Rec. = Recovery (Expressed as Percent)
Control Limit Reference: Method 1613, Table 6, 10/94 Revision
R = Recovery outside of control limits
Nn = Value obtained from additional analysis
* = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B
Spike Recovery Relative Percent Difference (RPD) Results

Client Pace Analytical National

Spike 1 ID LCS-99760
Spike 1 Filename U220705A_02

Spike 2 ID LCSD-99761
Spike 2 Filename U220705A_03

| Compound | Spike 1 %REC | Spike 2 %REC | %RPD |
|---------------------|-----------------|-----------------|------|
| 2,3,7,8-TCDF | 97 | 101 | 4.0 |
| 2,3,7,8-TCDD | 102 | 106 | 3.8 |
| 1,2,3,7,8-PeCDF | 87 | 91 | 4.5 |
| 2,3,4,7,8-PeCDF | 90 | 92 | 2.2 |
| 1,2,3,7,8-PeCDD | 83 | 84 | 1.2 |
| 1,2,3,4,7,8-HxCDF | 86 | 92 | 6.7 |
| 1,2,3,6,7,8-HxCDF | 87 | 94 | 7.7 |
| 2,3,4,6,7,8-HxCDF | 93 | 98 | 5.2 |
| 1,2,3,7,8,9-HxCDF | 93 | 98 | 5.2 |
| 1,2,3,4,7,8-HxCDD | 90 | 95 | 5.4 |
| 1,2,3,6,7,8-HxCDD | 93 | 95 | 2.1 |
| 1,2,3,7,8,9-HxCDD | 79 | 81 | 2.5 |
| 1,2,3,4,6,7,8-HpCDF | 80 | 85 | 6.1 |
| 1,2,3,4,7,8,9-HpCDF | 79 | 88 | 10.8 |
| 1,2,3,4,6,7,8-HpCDD | 74 | 78 | 5.3 |
| OCDF | 88 | 96 | 8.7 |
| OCDD | 79 | 94 | 17.3 |

%REC = Percent Recovered

RPD = The difference between the two values divided by the mean value

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Report Prepared for:

Client Services
Pace Analytical National
12065 Lebanon Road
Mount Juliet TN 37122

REPORT OF LABORATORY ANALYSIS FOR PCDD/PCDF

Report Prepared Date:

July 28, 2022

Report Information:


Pace Project #: 10616029
Sample Receipt Date: 07/08/2022
Client Project #: L1508970 WG1891233
Client Sub PO #: L1508970
State Cert #: MN300001

Invoicing & Reporting Options:

The report provided has been invoiced as a Level 2 PCDD/PCDF Report. If an upgrade of this report package is requested, an additional charge may be applied.

Please review the attached invoice for accuracy and forward any questions to Kongmeng Vang, your Pace Project Manager.

This report has been reviewed by:



July 29, 2022

Kongmeng Vang, Project Manager
(612) 607-6382
(612) 607-6333 (fax)



Report of Laboratory Analysis

This report should not be reproduced, except in full, without the written consent of Pace Analytical Services, Inc.

The results relate only to the samples included in this report.



DISCUSSION

This report presents the results from the analyses performed on ten samples submitted by a representative of Pace Analytical National. The samples were analyzed for the presence or absence of polychlorodibenzo-p-dioxins (PCDDs) and polychlorodibenzofurans (PCDFs) using USEPA Method 1613B. The estimated detection limits (EDLs) were based on signal-to-noise measurements. Estimated maximum possible concentration (EMPC) values were treated as positives in the toxic equivalence calculations.

Second column confirmation analyses of 2,3,7,8-TCDF values obtained from the primary (DB5-MS) column are performed only when specifically requested for a project and only when the values are above the concentration of the lowest calibration standard. Typical resolution for this isomer using the DB5-MS column ranges from 25-30%.

The recoveries of the isotopically-labeled PCDD/PCDF internal standards in the sample extracts ranged from 10-98%. Except for eight low values, which were flagged "R" on the results tables, the labeled standard recoveries obtained for this project were within the target ranges specified in Method 1613B. Also, since the quantification of the native 2,3,7,8-substituted congeners was based on isotope dilution, the data were automatically corrected for recovery and accurate values were obtained.

Values were flagged "I" where incorrect isotope ratios were obtained or "P" where polychlorinated diphenyl ethers were present. Concentrations below the calibration range were flagged "J" and should be regarded as estimates. Concentrations above the calibration range were flagged "E" and should also be regarded as estimates.

A laboratory method blank was prepared and analyzed with each sample batch as part of our routine quality control procedures. The results show Blank-100015 to contain trace levels of selected congeners. These levels were below the calibration range for the method. Sample levels similar to the corresponding blank levels were flagged "B" on the results tables and may be, at least partially, attributed to the background.

A laboratory spike sample was also prepared with each sample batch using clean reference matrix that had been fortified with native standard materials. The results show that the spiked native compounds were recovered at 92-120%. These results were within the target ranges for the method. Matrix spikes were prepared with the sample batches using sample materials from separate projects; results from these analyses will be provided upon request.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Minnesota Laboratory Certifications

| Authority | Certificate # | Authority | Certificate # |
|----------------|----------------|-----------------|----------------|
| A2LA | 2926.01 | Mississippi | MN00064 |
| Alabama | 40770 | Missouri | 10100 |
| Alaska-DW | MN00064 | Montana | CERT0092 |
| Alaska-UST | 17-009 | Nebraska | NE-OS-18-06 |
| Arizona | AZ0014 | Nevada | MN00064 |
| Arkansas - WW | 88-0680 | New Hampshire | 2081 |
| Arkansas-DW | MN00064 | New Jersey | MN002 |
| California | 2929 | New York | 11647 |
| Colorado | MN00064 | North Carolina- | 27700 |
| Connecticut | PH-0256 | North Carolina- | 530 |
| Florida | E87605 | North Dakota | R-036 |
| Georgia | 959 | Ohio-DW | 41244 |
| Hawaii | MN00064 | Ohio-VAP (170 | CL101 |
| Idaho | MN00064 | Ohio-VAP (180 | CL110 |
| Illinois | 200011 | Oklahoma | 9507 |
| Indiana | C-MN-01 | Oregon- rimary | MN300001 |
| Iowa | 368 | Oregon-Second | MN200001 |
| Kansas | E-10167 | Pennsylvania | 68-00563 |
| Kentucky-DW | 90062 | Puerto Rico | MN00064 |
| Kentucky-WW | 90062 | South Carolina | 74003 |
| Louisiana-DEQ | AI-84596 | Tennessee | TN02818 |
| Louisiana-DW | MN00064 | Texas | T104704192 |
| Maine | MN00064 | Utah | MN00064 |
| Maryland | 322 | Vermont | VT-027053137 |
| Michigan | 9909 | Virginia | 460163 |
| Minnesota | 027-053-137 | Washington | C486 |
| Minnesota-Ag | via MN 027-053 | West Virginia-D | 382 |
| Minnesota-Petr | 1240 | West Virginia-D | 9952C |
| | | Wisconsin | 999407970 |
| | | Wyoming-UST | via A2LA 2926. |

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix A

Sample Management

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.

The Chain-of-Custody is a LEGAL DOCUMENT. All relevant fields must be completed accurately.

The Chain-of-Custody is a LEGAL DOCUMENT. All relevant fields must be completed accurately.

Page : 1 Of 1

Report No. A-106-00-000-1013-C-DHR Page 5 of 24

Section B

Required Project Information:

Section C

Invoice Information:

| | |
|--|-------------------|
| | Regulatory Agency |
| | State / Location |
| | Portland, OR |

| |
|-----|
| 001 |
| 002 |
| 003 |
| 004 |
| 005 |
| 006 |
| 007 |
| 008 |
| 009 |
| 010 |

Pace Analytical SDGs: L1508970
Location: Minneapolis, MN 55414

| | | | | | |
|----------------------------|--------------|-----------|-----------------------------|--------------------------------------|-----------------------------|
| SAMPLER NAME AND SIGNATURE | | TEMP in C | Received on Ice (Y/N) | Custody Sealed Cooler (Y/N) | Samples Contact (Y/N) |
| PRINT Name of SAMPLER: | | | | | |
| SIGNATURE of SAMPLER: | DATE Signed: | | | | |

WO#: 10616029





DC#_Title: ENV-FRM-MIN4-0150 v05_Sample Condition Upon Receipt (SCUR)

Effective Date: 04/12/2022

Sample Condition Upon Receipt

Client Name:

Project #:

WO#: 10616029

Courier:

☒ Fed Ex☐ UPS☐ USPS☐ Client☐ Pace☐ Speedee☐ Commercial

PM: KV

Due Date: 07/29/22

CLIENT: ESC_TN

Tracking Number:

5882 7542 6246

See Exceptions

☐ ENV-FRM-MIN4-0142

Custody Seal on Cooler/Box Present?

☒ Yes☐ No

Seals Intact?

☒ Yes☐ No

Biological Tissue Frozen?

☐ Yes☐ No☒ N/A

Packing Material:

☐ Bubble Wrap☒ Bubble Bags☐ None☒ Other: Ziplock

Temp Blank?

☒ Yes☐ No

Thermometer:

☐ T1(0461)☐ T2(1336)☐ T3(0459)☒ T4(0254)☐ T5(0489)☐ T6(0235)☐ T7 (0042)☐ 01339252/1710☐ 22639816☐ 140792808

Type of

Ice:

☒ Wet☐ Blue☐ None☐ Dry☐ MeltedDid Samples Originate in West Virginia? ☐ Yes ☒ NoWere All Container Temps Taken? ☐ Yes ☐ No ☒ N/A

Temp should be above freezing to 6°C

Cooler Temp Read w/temp blank:

2.9

°C

Average Corrected

Temp (no temp blank only):

°C

☐ See Exceptions

ENV-FRM-MIN4-0142

☐ 1 Container

Correction Factor: True

Cooler Temp Corrected w/temp blank:

2.9

°C

USDA Regulated Soil: (☒ N/A, water sample/Other: Solid)

Date/Initials of Person Examining Contents: KN 6/7/09/12

Did samples originate in a quarantine zone within the United States: AL, AR, CA, FL, GA, ID, LA.

Did samples originate from a foreign source (internationally, including

MS, NC, NM, NY, OK, OR, SC, TN, TX or VA (check maps)?

☐ Yes☐ No

Hawaii and Puerto Rico)?

☐ Yes☐ No

If Yes to either question, fill out a Regulated Soil Checklist ENV-FRM-MIN4-0154 and include with SCUR/COC paperwork.

| Location (check one): <input type="checkbox"/> Duluth <input checked="" type="checkbox"/> Minneapolis <input type="checkbox"/> Virginia | COMMENTS: |
|---|---|
| Chain of Custody Present and Filled Out? | 1. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Chain of Custody Relinquished? | 2. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Sampler Name and/or Signature on COC? | 3. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A |
| Samples Arrived within Hold Time? | 4. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Short Hold Time Analysis (<72 hr)? | 5. <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Rush Turn Around Time Requested? | 6. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Sufficient Volume? | 7. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Correct Containers Used? | 8. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| -Pace Containers Used? | 9. <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Containers Intact? | 10. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Field Filtered Volume Received for Dissolved Tests? | 11. <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| Is sufficient information available to reconcile the samples to the COC? | 12. Sample # |
| Matrix: <input type="checkbox"/> Water <input type="checkbox"/> Soil <input type="checkbox"/> Oil <input checked="" type="checkbox"/> Other: Solid | <input type="checkbox"/> NaOH <input type="checkbox"/> HNO ₃ <input type="checkbox"/> H ₂ SO ₄ <input type="checkbox"/> Zinc Acetate |
| All containers needing acid/base preservation have been checked? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| All containers needing preservation are found to be in compliance with EPA recommendation? (HNO ₃ , H ₂ SO ₄ , <2pH, NaOH >9 Sulfide, NaOH>10 Cyanide) | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| Exceptions: VOA, Coliform, TOC/DOC Oil and Grease, DRO/8015 (water) and Dioxin/PFAS | Positive for Res. <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| | Chlorine? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| | pH Paper Lot# |
| | Res. Chlorine |
| | 0-6 Roll |
| | 0-6 Strip |
| | 0-14 Strip |
| Headspace in Methyl Mercury Container? | 13. <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| Extra labels present on soil VOA or WIDRO containers? | 14. <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| Headspace in VOA Vials (greater than 6mm)? | |
| Trip Blank Present? | |
| Trip Blank Custody Seals Present? | |

CLIENT NOTIFICATION/RESOLUTION

Person Contacted:

Date/Time:

Comments/Resolution:


Field Data Required? ☐ Yes ☐ No

Project Manager Review:

Date:

Note: Whenever there is a discrepancy affecting North Carolina compliance samples, a copy of this form will be sent to the North Carolina DEHNR Certification Office (i.e., out of hold, incorrect preservative, out of temp, incorrect containers).

Labeled by:

| | | |
|---|---|---|
|  | Document Name: Regulated Soil Checklist | Document Revised: 27Apr2020 Page 1 of 2 |
| | Document No.: ENV-FRM-MIN4-0154 Rev.01 | Pace Analytical Services - Minneapolis |

USDA REGULATED SOIL CHECKLIST

To Be Completed by SR Staff:

WO: 10616029 Date: 7/24/22 Initials: PN

Sample Origin (circle one): DOMESTIC QUARANTINED FOREIGN

(Note: soil samples from Hawaii, Guam, Puerto Rico and the US Virgin Islands are considered to be of a Foreign Source)

If Domestic, circle State of Origin: AL AR CA FL GA LA MS NC NM NY OK OR SC TN TX VA

(Includes: IFA, SOD, Golden Nematode, Karnal Bunt and Witchweed)

List County: Multnomah

(USDA Permit/Compliance Agreement authorizes movement of samples from these domestic regulated zones)

If Quarantined, circle State of Origin: FL ID TX CA

List County: _____

(Includes Fruit Fly, Giant African Snail and Pale Cyst Nematode)

(Movement is not authorized for Pale Cyst Nematode [ID or Giant African Snail [FL], remaining quarantines require additional paperwork)


If Foreign, list Country of Origin: _____

(Movement from some Canadian Provinces is not allowed. Refer to CS-232 Regulated Soil Flow Chart)

| REQUIREMENT | ACTION | COMPLETED |
|--|--|-------------------|
| PPQ-530 Paperwork must be included for any samples from counties with a Fruit Fly Quarantine in TX. Refer to MN-S063 through MN-S065 | Scan PPQ-530 to the corresponding Project folder on the x drive. If PPQ-530 is not present, contact the Waste Coordinator and do not continue processing samples. | YES NO <u>N/A</u> |
| Samples from ID may not be moved from the quarantined region. Refer to MN-S055 | If samples originated in a quarantined zone, contact the Waste Coordinator and do not continue processing samples. | YES NO <u>N/A</u> |
| Samples from Giant African Snail Quarantine in FL may not be moved from the quarantined region. Refer to MN-S068 | If samples originated in a quarantined zone, contact the Waste Coordinator and do not continue processing samples. | YES NO <u>N/A</u> |

| REQUIREMENT | ACTION | COMPLETED |
|--|---|-------------------|
| "Special Handling" stickers are to be placed on all samples. | Did "special handling" stickers get placed on all sample containers? | YES <u>NO</u> |
| Samples must be segregated and stored in designated bins, shelves and coolers. | Were samples placed in a designated cooler, containers and shelves? | YES <u>NO</u> |
| Samples must be double contained to prevent accidental release. | Were there any signs of breakage or leakage (check for broken glass and/or loose soil in the cooler)? <i>If NO, ice and melt water can be disposed of by normal process (down the drain).</i> | YES <u>NO</u> |
| | If YES, were ice and melt water separated from the cooler and disposed of properly? | YES NO <u>N/A</u> |
| | Any broken glass and/or loose soil are to be bagged and placed in a USDA Regulated satellite container or active drum (see Waste Coordinator). Ice and melt water should be baked at a temperature range of 121-154°F for 2 hours and then cooled before going down the drain. | |
| Equipment and supplies that have come into contact samples must be decontaminated. | Was the cooler(s) and/or countertop(s) decontaminated using either a fresh 10% bleach solution or 70% ethanol? (Gloves and other lab supplies will be bagged and placed in the USDA Regulated satellite container or active drum). | YES <u>NO</u> |

Comments: _____

| | | |
|---|---|---|
|  | Document Name: Regulated Soil Checklist | Document Revised: 27Apr2020 Page 2 of 2 |
| | Document No.: ENV-FRM-MIN4-0154 Rev.01 | Pace Analytical Services - Minneapolis |

To Be Completed by PM and/or PC:

Sample Analysis to be conducted (circle all that apply):

MN

Subcontract Lab

Name of Subcontract Lab (s):

| REQUIREMENT | ACTION | COMPLETED |
|---|---|------------|
| Permission to ship untreated soil must be on file prior to shipping to any subcontract lab, including IR Pace Labs. | Go to: J:\SHARE\PRJ_MGR\10_Client Services Department Documents\Regulated Soils Permits – if permission to ship letter is not there, contact the Waste Coordinator. | YES NO N/A |
| Shipment must include a valid copy of the receiving lab's permit as well as permission to ship letter. | Is a copy of all needed paperwork included with the COC? Do NOT ship samples until all necessary paperwork is compiled. | YES NO N/A |

Comments:

Project Manager Signature:

Date:

Reporting Flags

- A = Reporting Limit based on signal to noise (EDL)
- B = Less than 10x higher than method blank level
- C = Result obtained from confirmation analysis
- D = Result obtained from analysis of diluted sample
- E = Exceeds calibration range
- I = Isotope ratio out of specification
- J = Estimated value
- L = Suppressive interference, analyte may be biased low
- Nn = Value obtained from additional analysis
- P = PCDEInterference
- R = Recovery outside target range
- S = Peak saturated
- U = Analyte not detected
- V = Result verified by confirmation analysis
- X = %D Exceeds limits
- Y = Calculated using average of daily RFs
- * = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix B

Sample Analysis Summary

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-09A_0622 | | |
| Lab Sample ID | 10616029001 | | |
| Filename | L220719B_08 | | |
| Injected By | MS4 | | |
| Total Amount Extracted | 10.2 g | Matrix | Solid |
| % Moisture | 4.3 | Dilution | NA |
| Dry Weight Extracted | 9.80 g | Collected | 06/20/2022 13:00 |
| ICAL ID | L220718 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | L220719A_14 | Extracted | 07/14/2022 13:00 |
| Method Blank ID | BLANK-99979 | Analyzed | 07/20/2022 09:35 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | 0.37 | — | 0.095 | J | 2,3,7,8-TCDF-13C | 2.00 | 72 |
| Total TCDF | 6.7 | — | 0.095 | | 2,3,7,8-TCDD-13C | 2.00 | 10 R |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 79 |
| 2,3,7,8-TCDD | 9.1 | — | 0.33 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 82 |
| Total TCDD | 68 | — | 0.33 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 89 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 85 |
| 1,2,3,7,8-PeCDF | 0.65 | — | 0.085 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 78 |
| 2,3,4,7,8-PeCDF | 1.3 | — | 0.10 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 72 |
| Total PeCDF | 20 | — | 0.085 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 72 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 71 |
| 1,2,3,7,8-PeCDD | 1.8 | — | 0.095 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 74 |
| Total PeCDD | 15 | — | 0.095 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 62 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 64 |
| 1,2,3,4,7,8-HxCDF | 5.4 | — | 0.096 | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 77 |
| 1,2,3,6,7,8-HxCDF | — | 3.6 | 0.13 | PJ | OCDD-13C | 4.00 | 58 |
| 2,3,4,6,7,8-HxCDF | 3.0 | — | 0.13 | J | | | |
| 1,2,3,7,8,9-HxCDF | 1.4 | — | 0.16 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 82 | — | 0.096 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 3.4 | — | 0.22 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 11 R |
| 1,2,3,6,7,8-HxCDD | 9.1 | — | 0.19 | | | | |
| 1,2,3,7,8,9-HxCDD | 6.0 | — | 0.16 | | | | |
| Total HxCDD | 79 | — | 0.16 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 68 | — | 0.15 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 4.3 | — | 0.24 | J | Equivalence: 18 ng/Kg | | |
| Total HpCDF | 220 | — | 0.15 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 230 | — | 0.056 | | | | |
| Total HpCDD | 480 | — | 0.056 | | | | |
| | | | | | | | |
| OCDF | 250 | — | 0.52 | | | | |
| OCDD | 2400 | — | 0.28 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

R = Recovery outside target range

P = PCDE Interference

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-09B_0622 | | |
| Lab Sample ID | 10616029002 | | |
| Filename | L220719B_09 | | |
| Injected By | MS4 | | |
| Total Amount Extracted | 10.2 g | Matrix | Solid |
| % Moisture | 5.3 | Dilution | NA |
| Dry Weight Extracted | 9.68 g | Collected | 06/20/2022 13:15 |
| ICAL ID | L220718 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | L220719A_14 | Extracted | 07/14/2022 13:00 |
| Method Blank ID | BLANK-99979 | Analyzed | 07/20/2022 10:34 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|---|--|------------|------------------|
| 2,3,7,8-TCDF | 0.73 | — | 0.14 | J | 2,3,7,8-TCDF-13C | 2.00 | 82 |
| Total TCDF | 21 | — | 0.14 | | 2,3,7,8-TCDD-13C | 2.00 | 33 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 88 |
| 2,3,7,8-TCDD | 8.5 | — | 0.13 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 88 |
| Total TCDD | 73 | — | 0.13 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 98 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 98 |
| 1,2,3,7,8-PeCDF | 1.8 | — | 0.11 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 90 |
| 2,3,4,7,8-PeCDF | 3.6 | — | 0.44 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 80 |
| Total PeCDF | 83 | — | 0.11 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 83 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 80 |
| 1,2,3,7,8-PeCDD | 15 | — | 0.089 | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 81 |
| Total PeCDD | 70 | — | 0.089 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 67 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 65 |
| 1,2,3,4,7,8-HxCDF | 16 | — | 0.30 | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 85 |
| 1,2,3,6,7,8-HxCDF | — | 42 | 0.24 | P | OCDD-13C | 4.00 | 65 |
| 2,3,4,6,7,8-HxCDF | 19 | — | 0.24 | | | | |
| 1,2,3,7,8,9-HxCDF | 3.4 | — | 0.25 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 420 | — | 0.24 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 22 | — | 0.46 | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 36 |
| 1,2,3,6,7,8-HxCDD | 55 | — | 0.27 | | | | |
| 1,2,3,7,8,9-HxCDD | 44 | — | 0.36 | | | | |
| Total HxCDD | 390 | — | 0.27 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 540 | — | 0.44 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 27 | — | 0.48 | | Equivalence: 67 ng/Kg | | |
| Total HpCDF | 1700 | — | 0.44 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 1200 | — | 0.027 | | | | |
| Total HpCDD | 2100 | — | 0.027 | | | | |
| | | | | | | | |
| OCDF | 2300 | — | 0.18 | | | | |
| OCDD | 11000 | — | 0.29 | E | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value
P = PCDE Interference
E = Exceeds calibration range

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-10A_0622 | | |
| Lab Sample ID | 10616029003 | | |
| Filename | L220719B_10 | | |
| Injected By | MS4 | | |
| Total Amount Extracted | 10.7 g | Matrix | Solid |
| % Moisture | 4.9 | Dilution | NA |
| Dry Weight Extracted | 10.2 g | Collected | 06/21/2022 10:15 |
| ICAL ID | L220718 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | L220719A_14 | Extracted | 07/14/2022 13:00 |
| Method Blank ID | BLANK-99979 | Analyzed | 07/20/2022 11:33 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|---|--|------------|------------------|
| 2,3,7,8-TCDF | 0.51 | — | 0.35 | J | 2,3,7,8-TCDF-13C | 2.00 | 67 |
| Total TCDF | 9.1 | — | 0.35 | | 2,3,7,8-TCDD-13C | 2.00 | 15 R |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 76 |
| 2,3,7,8-TCDD | 16 | — | 0.22 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 75 |
| Total TCDD | 61 | — | 0.22 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 82 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 75 |
| 1,2,3,7,8-PeCDF | 0.60 | — | 0.070 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 70 |
| 2,3,4,7,8-PeCDF | 1.2 | — | 0.065 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 64 |
| Total PeCDF | 22 | — | 0.065 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 67 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 64 |
| 1,2,3,7,8-PeCDD | 2.5 | — | 0.15 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 65 |
| Total PeCDD | 22 | — | 0.15 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 58 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 60 |
| 1,2,3,4,7,8-HxCDF | 3.1 | — | 0.061 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 71 |
| 1,2,3,6,7,8-HxCDF | — | 5.0 | 0.095 | P | OCDD-13C | 4.00 | 57 |
| 2,3,4,6,7,8-HxCDF | 2.9 | — | 0.12 | J | | | |
| 1,2,3,7,8,9-HxCDF | 1.1 | — | 0.065 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 75 | — | 0.061 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 4.1 | — | 0.17 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 16 R |
| 1,2,3,6,7,8-HxCDD | 13 | — | 0.14 | | | | |
| 1,2,3,7,8,9-HxCDD | 8.4 | — | 0.27 | | | | |
| Total HxCDD | 130 | — | 0.14 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 71 | — | 0.14 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 4.2 | — | 0.12 | J | Equivalence: 28 ng/Kg | | |
| Total HpCDF | 220 | — | 0.12 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 360 | — | 0.043 | | | | |
| Total HpCDD | 770 | — | 0.043 | | | | |
| | | | | | | | |
| OCDF | 240 | — | 0.21 | | | | |
| OCDD | 3100 | — | 0.15 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

R = Recovery outside target range

P = PCDE Interference

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-10B_0622 | | |
| Lab Sample ID | 10616029004 | | |
| Filename | L220719B_11 | | |
| Injected By | MS4 | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 5.0 | Dilution | NA |
| Dry Weight Extracted | 9.90 g | Collected | 06/21/2022 10:30 |
| ICAL ID | L220718 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | L220719A_14 | Extracted | 07/14/2022 13:00 |
| Method Blank ID | BLANK-99979 | Analyzed | 07/20/2022 12:31 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|---|--|------------|------------------|
| 2,3,7,8-TCDF | 0.43 | — | 0.23 | J | 2,3,7,8-TCDF-13C | 2.00 | 77 |
| Total TCDF | 11 | — | 0.23 | | 2,3,7,8-TCDD-13C | 2.00 | 17 R |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 86 |
| 2,3,7,8-TCDD | 14 | — | 0.21 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 87 |
| Total TCDD | 70 | — | 0.21 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 93 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 86 |
| 1,2,3,7,8-PeCDF | 0.80 | — | 0.057 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 81 |
| 2,3,4,7,8-PeCDF | 1.7 | — | 0.090 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 72 |
| Total PeCDF | 39 | — | 0.057 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 77 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 73 |
| 1,2,3,7,8-PeCDD | 2.3 | — | 0.049 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 75 |
| Total PeCDD | 21 | — | 0.049 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 65 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 67 |
| 1,2,3,4,7,8-HxCDF | 7.6 | — | 0.15 | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 79 |
| 1,2,3,6,7,8-HxCDF | — | 9.8 | 0.11 | P | OCDD-13C | 4.00 | 63 |
| 2,3,4,6,7,8-HxCDF | 6.7 | — | 0.11 | | | | |
| 1,2,3,7,8,9-HxCDF | 2.1 | — | 0.11 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 200 | — | 0.11 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 4.2 | — | 0.24 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 18 R |
| 1,2,3,6,7,8-HxCDD | 29 | — | 0.26 | | | | |
| 1,2,3,7,8,9-HxCDD | 10 | — | 0.18 | | | | |
| Total HxCDD | 170 | — | 0.18 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 200 | — | 0.27 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 9.5 | — | 0.55 | | Equivalence: 32 ng/Kg | | |
| Total HpCDF | 660 | — | 0.27 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 480 | — | 0.097 | | | | |
| Total HpCDD | 900 | — | 0.097 | | | | |
| | | | | | | | |
| OCDF | 570 | — | 0.28 | | | | |
| OCDD | 3300 | — | 0.24 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

R = Recovery outside target range

P = PCDE Interference

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-11A_0622 | | |
| Lab Sample ID | 10616029005 | | |
| Filename | L220719B_12 | | |
| Injected By | MS4 | | |
| Total Amount Extracted | 10.0 g | Matrix | Solid |
| % Moisture | 5.0 | Dilution | NA |
| Dry Weight Extracted | 9.55 g | Collected | 06/21/2022 11:00 |
| ICAL ID | L220718 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | L220719A_14 | Extracted | 07/14/2022 13:00 |
| Method Blank ID | BLANK-99979 | Analyzed | 07/20/2022 13:30 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|---|--|------------|------------------|
| 2,3,7,8-TCDF | 0.44 | — | 0.35 | J | 2,3,7,8-TCDF-13C | 2.00 | 68 |
| Total TCDF | 8.1 | — | 0.35 | | 2,3,7,8-TCDD-13C | 2.00 | 20 R |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 78 |
| 2,3,7,8-TCDD | 24 | — | 0.20 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 78 |
| Total TCDD | 52 | — | 0.20 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 84 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 79 |
| 1,2,3,7,8-PeCDF | 0.54 | — | 0.063 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 75 |
| 2,3,4,7,8-PeCDF | 1.2 | — | 0.071 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 67 |
| Total PeCDF | 18 | — | 0.063 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 72 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 67 |
| 1,2,3,7,8-PeCDD | 2.0 | — | 0.11 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 69 |
| Total PeCDD | 21 | — | 0.11 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 60 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 64 |
| 1,2,3,4,7,8-HxCDF | 3.4 | — | 0.12 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 75 |
| 1,2,3,6,7,8-HxCDF | — | 5.9 | 0.14 | P | OCDD-13C | 4.00 | 59 |
| 2,3,4,6,7,8-HxCDF | 2.5 | — | 0.15 | J | | | |
| 1,2,3,7,8,9-HxCDF | 1.1 | — | 0.12 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 65 | — | 0.12 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 4.3 | — | 0.41 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 23 R |
| 1,2,3,6,7,8-HxCDD | 14 | — | 0.19 | | | | |
| 1,2,3,7,8,9-HxCDD | 8.0 | — | 0.21 | | | | |
| Total HxCDD | 120 | — | 0.19 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 55 | — | 0.15 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 3.0 | — | 0.090 | J | Equivalence: 35 ng/Kg | | |
| Total HpCDF | 170 | — | 0.090 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 370 | — | 0.043 | | | | |
| Total HpCDD | 850 | — | 0.043 | | | | |
| | | | | | | | |
| OCDF | 150 | — | 0.18 | | | | |
| OCDD | 3500 | — | 0.13 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

R = Recovery outside target range

P = PCDE Interference

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-11B_0622 | | |
| Lab Sample ID | 10616029006 | | |
| Filename | U220721A_14 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.3 g | Matrix | Solid |
| % Moisture | 4.9 | Dilution | NA |
| Dry Weight Extracted | 9.79 g | Collected | 06/21/2022 11:15 |
| ICAL ID | U220611 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | U220720A_20 | Extracted | 07/15/2022 14:30 |
| Method Blank ID | BLANK-100015 | Analyzed | 07/21/2022 13:12 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|---|--|------------|------------------|
| 2,3,7,8-TCDF | 1.1 | — | 0.43 | | 2,3,7,8-TCDF-13C | 2.00 | 63 |
| Total TCDF | 15 | — | 0.43 | | 2,3,7,8-TCDD-13C | 2.00 | 59 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 74 |
| 2,3,7,8-TCDD | 8.4 | — | 0.37 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 72 |
| Total TCDD | 28 | — | 0.37 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 76 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 81 |
| 1,2,3,7,8-PeCDF | — | 1.8 | 0.19 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 57 |
| 2,3,4,7,8-PeCDF | 6.8 | — | 0.25 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 66 |
| Total PeCDF | 77 | — | 0.19 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 67 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 69 |
| 1,2,3,7,8-PeCDD | 3.9 | — | 0.25 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 67 |
| Total PeCDD | 36 | — | 0.25 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 56 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 49 |
| 1,2,3,4,7,8-HxCDF | 24 | — | 0.30 | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 61 |
| 1,2,3,6,7,8-HxCDF | 7.0 | — | 0.25 | | OCDD-13C | 4.00 | 45 |
| 2,3,4,6,7,8-HxCDF | 10 | — | 0.92 | | | | |
| 1,2,3,7,8,9-HxCDF | 5.0 | — | 0.37 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 270 | — | 0.25 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 8.2 | — | 0.89 | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 76 |
| 1,2,3,6,7,8-HxCDD | 25 | — | 1.2 | | | | |
| 1,2,3,7,8,9-HxCDD | 14 | — | 0.49 | | | | |
| Total HxCDD | 160 | — | 0.49 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 140 | — | 2.0 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 11 | — | 0.72 | | Equivalence: 33 ng/Kg | | |
| Total HpCDF | 440 | — | 0.72 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 590 | — | 0.41 | | | | |
| Total HpCDD | 1100 | — | 0.41 | | | | |
| | | | | | | | |
| OCDF | 330 | — | 0.73 | | | | |
| OCDD | 5300 | — | 0.23 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-14A_0622 | | |
| Lab Sample ID | 10616029007 | | |
| Filename | U220721A_15 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 11.9 g | Matrix | Solid |
| % Moisture | 4.9 | Dilution | NA |
| Dry Weight Extracted | 11.3 g | Collected | 06/20/2022 16:30 |
| ICAL ID | U220611 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | U220720A_20 | Extracted | 07/15/2022 14:30 |
| Method Blank ID | BLANK-100015 | Analyzed | 07/21/2022 14:00 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | — | 0.47 | 0.25 | J | 2,3,7,8-TCDF-13C | 2.00 | 63 |
| Total TCDF | 7.3 | — | 0.25 | | 2,3,7,8-TCDD-13C | 2.00 | 61 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 84 |
| 2,3,7,8-TCDD | 1.3 | — | 0.23 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 89 |
| Total TCDD | 14 | — | 0.23 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 92 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 87 |
| 1,2,3,7,8-PeCDF | 0.63 | — | 0.13 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 65 |
| 2,3,4,7,8-PeCDF | 0.95 | — | 0.10 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 74 |
| Total PeCDF | 20 | — | 0.10 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 75 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 79 |
| 1,2,3,7,8-PeCDD | 1.8 | — | 0.093 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 77 |
| Total PeCDD | 27 | — | 0.093 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 69 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 65 |
| 1,2,3,4,7,8-HxCDF | 1.6 | — | 0.25 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 80 |
| 1,2,3,6,7,8-HxCDF | 1.6 | — | 0.16 | J | OCDD-13C | 4.00 | 52 |
| 2,3,4,6,7,8-HxCDF | 2.4 | — | 0.20 | J | | | |
| 1,2,3,7,8,9-HxCDF | 0.78 | — | 0.11 | BJ | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 62 | — | 0.11 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 3.9 | — | 0.74 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 73 |
| 1,2,3,6,7,8-HxCDD | 11 | — | 0.61 | | | | |
| 1,2,3,7,8,9-HxCDD | 7.1 | — | 0.37 | | | | |
| Total HxCDD | 110 | — | 0.37 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 59 | — | 0.34 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 3.3 | — | 0.28 | J | Equivalence: 11 ng/Kg | | |
| Total HpCDF | 210 | — | 0.28 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 300 | — | 0.12 | | | | |
| Total HpCDD | 680 | — | 0.12 | | | | |
| | | | | | | | |
| OCDF | 270 | — | 0.41 | | | | |
| OCDD | 3300 | — | 0.31 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-14B_0622 | | |
| Lab Sample ID | 10616029008 | | |
| Filename | U220721A_11 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 12.1 g | Matrix | Solid |
| % Moisture | 4.4 | Dilution | NA |
| Dry Weight Extracted | 11.5 g | Collected | 06/20/2022 16:45 |
| ICAL ID | U220611 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | U220720A_20 | Extracted | 07/15/2022 14:30 |
| Method Blank ID | BLANK-100015 | Analyzed | 07/21/2022 10:51 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | — | 0.43 | 0.30 | J | 2,3,7,8-TCDF-13C | 2.00 | 61 |
| Total TCDF | 9.7 | — | 0.30 | | 2,3,7,8-TCDD-13C | 2.00 | 59 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 84 |
| 2,3,7,8-TCDD | 1.4 | — | 0.13 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 89 |
| Total TCDD | 20 | — | 0.13 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 94 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 86 |
| 1,2,3,7,8-PeCDF | — | 0.54 | 0.049 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 70 |
| 2,3,4,7,8-PeCDF | — | 0.89 | 0.085 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 74 |
| Total PeCDF | 17 | — | 0.049 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 81 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 79 |
| 1,2,3,7,8-PeCDD | 2.1 | — | 0.067 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 76 |
| Total PeCDD | 28 | — | 0.067 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 70 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 68 |
| 1,2,3,4,7,8-HxCDF | 2.1 | — | 0.14 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 81 |
| 1,2,3,6,7,8-HxCDF | 2.9 | — | 0.13 | J | OCDD-13C | 4.00 | 60 |
| 2,3,4,6,7,8-HxCDF | 2.6 | — | 0.11 | J | | | |
| 1,2,3,7,8,9-HxCDF | 0.75 | — | 0.15 | BJ | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 61 | — | 0.11 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 4.1 | — | 0.33 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 73 |
| 1,2,3,6,7,8-HxCDD | 10 | — | 0.21 | | | | |
| 1,2,3,7,8,9-HxCDD | 6.9 | — | 0.24 | | | | |
| Total HxCDD | 89 | — | 0.21 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 55 | — | 0.95 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 4.1 | — | 0.32 | J | Equivalence: 11 ng/Kg | | |
| Total HpCDF | 190 | — | 0.32 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 240 | — | 0.17 | | | | |
| Total HpCDD | 500 | — | 0.17 | | | | |
| | | | | | | | |
| OCDF | 230 | — | 0.086 | | | | |
| OCDD | 2500 | — | 0.043 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-15A_0622 | | |
| Lab Sample ID | 10616029009 | | |
| Filename | U220721A_12 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 11.7 g | Matrix | Solid |
| % Moisture | 4.5 | Dilution | NA |
| Dry Weight Extracted | 11.2 g | Collected | 06/21/2022 08:45 |
| ICAL ID | U220611 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | U220720A_20 | Extracted | 07/15/2022 14:30 |
| Method Blank ID | BLANK-100015 | Analyzed | 07/21/2022 11:38 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | 0.66 | — | 0.48 | J | 2,3,7,8-TCDF-13C | 2.00 | 62 |
| Total TCDF | 6.4 | — | 0.48 | | 2,3,7,8-TCDD-13C | 2.00 | 60 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 79 |
| 2,3,7,8-TCDD | 14 | — | 0.45 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 83 |
| Total TCDD | 37 | — | 0.45 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 87 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDF | — | 0.66 | 0.037 | IJ | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 60 |
| 2,3,4,7,8-PeCDF | 1.6 | — | 0.12 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 67 |
| Total PeCDF | 29 | — | 0.037 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 72 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 73 |
| 1,2,3,7,8-PeCDD | 2.5 | — | 0.060 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 65 |
| Total PeCDD | 35 | — | 0.060 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 62 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 62 |
| 1,2,3,4,7,8-HxCDF | — | 3.6 | 0.15 | IJ | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 72 |
| 1,2,3,6,7,8-HxCDF | 4.6 | — | 0.11 | | OCDD-13C | 4.00 | 54 |
| 2,3,4,6,7,8-HxCDF | 3.4 | — | 0.26 | J | | | |
| 1,2,3,7,8,9-HxCDF | 1.3 | — | 0.25 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 81 | — | 0.11 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 5.0 | — | 0.38 | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 73 |
| 1,2,3,6,7,8-HxCDD | 16 | — | 0.33 | | | | |
| 1,2,3,7,8,9-HxCDD | 9.4 | — | 0.34 | | | | |
| Total HxCDD | 140 | — | 0.33 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 57 | — | 0.27 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 3.9 | — | 0.23 | J | Equivalence: 27 ng/Kg | | |
| Total HpCDF | 180 | — | 0.23 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 350 | — | 0.12 | | | | |
| Total HpCDD | 900 | — | 0.12 | | | | |
| | | | | | | | |
| OCDF | 190 | — | 0.053 | | | | |
| OCDD | 3300 | — | 0.094 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------|-----------|------------------|
| Client's Sample ID | COMP-15B_0622 | | |
| Lab Sample ID | 10616029010 | | |
| Filename | U220721A_13 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.3 g | Matrix | Solid |
| % Moisture | 4.7 | Dilution | NA |
| Dry Weight Extracted | 9.79 g | Collected | 06/21/2022 09:00 |
| ICAL ID | U220611 | Received | 07/08/2022 08:50 |
| CCal Filename(s) | U220720A_20 | Extracted | 07/15/2022 14:30 |
| Method Blank ID | BLANK-100015 | Analyzed | 07/21/2022 12:25 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | 1.1 | — | 0.25 | 2,3,7,8-TCDF-13C | 2.00 | 67 |
| Total TCDF | 21 | — | 0.25 | 2,3,7,8-TCDD-13C | 2.00 | 63 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 75 |
| 2,3,7,8-TCDD | 9.6 | — | 0.66 | 2,3,4,7,8-PeCDF-13C | 2.00 | 77 |
| Total TCDD | 29 | — | 0.66 | 1,2,3,7,8-PeCDD-13C | 2.00 | 79 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 75 |
| 1,2,3,7,8-PeCDF | 1.2 | — | 0.26 J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 69 |
| 2,3,4,7,8-PeCDF | 2.2 | — | 0.26 J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 66 |
| Total PeCDF | 40 | — | 0.26 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 64 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDD | — | 2.2 | 0.14 IJ | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 66 |
| Total PeCDD | 28 | — | 0.14 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 48 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 41 |
| 1,2,3,4,7,8-HxCDF | 5.7 | — | 0.17 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 57 |
| 1,2,3,6,7,8-HxCDF | 2.8 | — | 0.26 J | OCDD-13C | 4.00 | 27 |
| 2,3,4,6,7,8-HxCDF | 3.8 | — | 0.28 J | | | |
| 1,2,3,7,8,9-HxCDF | 1.6 | — | 0.26 J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 66 | — | 0.17 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 4.8 | — | 0.63 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 77 |
| 1,2,3,6,7,8-HxCDD | 15 | — | 0.65 | | | |
| 1,2,3,7,8,9-HxCDD | 8.8 | — | 0.27 | | | |
| Total HxCDD | 130 | — | 0.27 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 63 | — | 0.46 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 4.4 | — | 0.52 J | Equivalence: 22 ng/Kg | | |
| Total HpCDF | 67 | — | 0.46 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 330 | — | 0.14 | | | |
| Total HpCDD | 730 | — | 0.14 | | | |
| | | | | | | |
| OCDF | 230 | — | 0.66 | | | |
| OCDD | 3200 | — | 0.62 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|-------------|-------------|------------------|
| Lab Sample Name | DFBLKPG | Matrix | Solid |
| Lab Sample ID | BLANK-99979 | Dilution | NA |
| Filename | U220719A_03 | Extracted | 07/14/2022 13:00 |
| Total Amount Extracted | 10.3 g | Analyzed | 07/19/2022 11:25 |
| ICAL ID | U220611 | Injected By | SMT |
| CCal Filename(s) | U220718A_27 | | |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.23 | 2,3,7,8-TCDF-13C | 2.00 | 69 |
| Total TCDF | ND | — | 0.23 | 2,3,7,8-TCDD-13C | 2.00 | 58 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 77 |
| 2,3,7,8-TCDD | ND | — | 0.34 | 2,3,4,7,8-PeCDF-13C | 2.00 | 81 |
| Total TCDD | ND | — | 0.34 | 1,2,3,7,8-PeCDD-13C | 2.00 | 104 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 74 |
| 1,2,3,7,8-PeCDF | ND | — | 0.24 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 68 |
| 2,3,4,7,8-PeCDF | ND | — | 0.18 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 63 |
| Total PeCDF | ND | — | 0.18 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 68 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 82 |
| 1,2,3,7,8-PeCDD | ND | — | 0.27 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 78 |
| Total PeCDD | ND | — | 0.27 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 74 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 73 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.92 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 103 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.99 | OCDD-13C | 4.00 | 60 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.94 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 1.2 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | ND | — | 0.92 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 1.0 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 65 |
| 1,2,3,6,7,8-HxCDD | ND | — | 0.90 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 1.00 | | | |
| Total HxCDD | ND | — | 0.90 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 0.82 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 1.3 | Equivalence: 0.00 ng/Kg | | |
| Total HpCDF | ND | — | 0.82 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | ND | — | 0.49 | | | |
| Total HpCDD | ND | — | 0.49 | | | |
| | | | | | | |
| OCDF | ND | — | 2.4 | | | |
| OCDD | ND | — | 2.6 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

Results reported on a total weight basis and are valid to no more than 2 significant figures.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample Name | DFBLKPX | Matrix | Solid |
| Lab Sample ID | BLANK-100015 | Dilution | NA |
| Filename | F220719B_06 | Extracted | 07/15/2022 14:30 |
| Total Amount Extracted | 10.7 g | Analyzed | 07/19/2022 18:08 |
| ICAL ID | F220529 | Injected By | SMT |
| CCal Filename(s) | F220719B_01 | | |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.048 | 2,3,7,8-TCDF-13C | 2.00 | 65 |
| Total TCDF | ND | — | 0.048 | 2,3,7,8-TCDD-13C | 2.00 | 57 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 67 |
| 2,3,7,8-TCDD | ND | — | 0.11 | 2,3,4,7,8-PeCDF-13C | 2.00 | 68 |
| Total TCDD | ND | — | 0.11 | 1,2,3,7,8-PeCDD-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 78 |
| 1,2,3,7,8-PeCDF | ND | — | 0.063 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 73 |
| 2,3,4,7,8-PeCDF | ND | — | 0.041 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 73 |
| Total PeCDF | ND | — | 0.041 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 69 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 65 |
| 1,2,3,7,8-PeCDD | ND | — | 0.051 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 74 |
| Total PeCDD | ND | — | 0.051 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 59 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 53 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.050 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 55 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.053 | OCDD-13C | 4.00 | 46 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.045 | | | |
| 1,2,3,7,8,9-HxCDF | 0.12 | — | 0.061 J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 0.12 | — | 0.045 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.16 | — | 0.083 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 69 |
| 1,2,3,6,7,8-HxCDD | ND | — | 0.079 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 0.075 | | | |
| Total HxCDD | 0.16 | — | 0.075 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 0.049 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.079 | Equivalence: 0.030 ng/Kg | | |
| Total HpCDF | ND | — | 0.049 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 0.18 | — | 0.085 J | | | |
| Total HpCDD | 0.18 | — | 0.085 J | | | |
| | | | | | | |
| OCDF | ND | — | 0.17 | | | |
| OCDD | 0.64 | — | 0.19 J | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

Results reported on a total weight basis and are valid to no more than 2 significant figures.

J = Estimated value

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|-------------|-------------|------------------|
| Lab Sample ID | LCS-99980 | Matrix | Solid |
| Filename | U220719A_01 | Dilution | NA |
| Total Amount Extracted | 10.5 g | Extracted | 07/14/2022 13:00 |
| ICAL ID | U220611 | Analyzed | 07/19/2022 09:52 |
| CCal Filename | U220718A_27 | Injected By | SMT |
| Method Blank ID | BLANK-99979 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 10 | 7.5 | 15.8 | 102 |
| 2,3,7,8-TCDD | 10 | 10 | 6.7 | 15.8 | 104 |
| 1,2,3,7,8-PeCDF | 50 | 53 | 40.0 | 67.0 | 106 |
| 2,3,4,7,8-PeCDF | 50 | 50 | 34.0 | 80.0 | 101 |
| 1,2,3,7,8-PeCDD | 50 | 46 | 35.0 | 71.0 | 92 |
| 1,2,3,4,7,8-HxCDF | 50 | 53 | 36.0 | 67.0 | 106 |
| 1,2,3,6,7,8-HxCDF | 50 | 56 | 42.0 | 65.0 | 112 |
| 2,3,4,6,7,8-HxCDF | 50 | 57 | 35.0 | 78.0 | 115 |
| 1,2,3,7,8,9-HxCDF | 50 | 56 | 39.0 | 65.0 | 113 |
| 1,2,3,4,7,8-HxCDD | 50 | 53 | 35.0 | 82.0 | 106 |
| 1,2,3,6,7,8-HxCDD | 50 | 53 | 38.0 | 67.0 | 107 |
| 1,2,3,7,8,9-HxCDD | 50 | 49 | 32.0 | 81.0 | 99 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 49 | 41.0 | 61.0 | 98 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 51 | 39.0 | 69.0 | 102 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 47 | 35.0 | 70.0 | 93 |
| OCDF | 100 | 93 | 63.0 | 170.0 | 93 |
| OCDD | 100 | 120 | 78.0 | 144.0 | 116 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 5.3 | 3.1 | 19.1 | 53 |
| 2,3,7,8-TCDF-13C | 100 | 68 | 22.0 | 152.0 | 68 |
| 2,3,7,8-TCDD-13C | 100 | 50 | 20.0 | 175.0 | 50 |
| 1,2,3,7,8-PeCDF-13C | 100 | 78 | 21.0 | 192.0 | 78 |
| 2,3,4,7,8-PeCDF-13C | 100 | 80 | 13.0 | 328.0 | 80 |
| 1,2,3,7,8-PeCDD-13C | 100 | 100 | 21.0 | 227.0 | 105 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 73 | 19.0 | 202.0 | 73 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 69 | 21.0 | 159.0 | 69 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 63 | 22.0 | 176.0 | 63 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 68 | 17.0 | 205.0 | 68 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 82 | 21.0 | 193.0 | 82 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 78 | 25.0 | 163.0 | 78 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 78 | 21.0 | 158.0 | 78 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 73 | 20.0 | 186.0 | 73 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 100 | 26.0 | 166.0 | 103 |
| OCDD-13C | 200 | 120 | 26.0 | 397.0 | 58 |

Cs = Concentration Spiked (ng/mL)
Cr = Concentration Recovered (ng/mL)
Rec. = Recovery (Expressed as Percent)
Control Limit Reference: Method 1613, Table 6, 10/94 Revision
R = Recovery outside of control limits
Nn = Value obtained from additional analysis
* = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample ID | LCS-100016 | Matrix | Solid |
| Filename | F220719B_02 | Dilution | NA |
| Total Amount Extracted | 10.8 g | Extracted | 07/15/2022 14:30 |
| ICAL ID | F220529 | Analyzed | 07/19/2022 15:06 |
| CCal Filename | F220719B_01 | Injected By | SMT |
| Method Blank ID | BLANK-100015 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 11 | 7.5 | 15.8 | 110 |
| 2,3,7,8-TCDD | 10 | 11 | 6.7 | 15.8 | 114 |
| 1,2,3,7,8-PeCDF | 50 | 50 | 40.0 | 67.0 | 100 |
| 2,3,4,7,8-PeCDF | 50 | 49 | 34.0 | 80.0 | 98 |
| 1,2,3,7,8-PeCDD | 50 | 50 | 35.0 | 71.0 | 101 |
| 1,2,3,4,7,8-HxCDF | 50 | 51 | 36.0 | 67.0 | 101 |
| 1,2,3,6,7,8-HxCDF | 50 | 52 | 42.0 | 65.0 | 103 |
| 2,3,4,6,7,8-HxCDF | 50 | 52 | 35.0 | 78.0 | 104 |
| 1,2,3,7,8,9-HxCDF | 50 | 51 | 39.0 | 65.0 | 102 |
| 1,2,3,4,7,8-HxCDD | 50 | 54 | 35.0 | 82.0 | 109 |
| 1,2,3,6,7,8-HxCDD | 50 | 52 | 38.0 | 67.0 | 104 |
| 1,2,3,7,8,9-HxCDD | 50 | 50 | 32.0 | 81.0 | 99 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 54 | 41.0 | 61.0 | 108 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 56 | 39.0 | 69.0 | 112 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 51 | 35.0 | 70.0 | 102 |
| OCDF | 100 | 120 | 63.0 | 170.0 | 118 |
| OCDD | 100 | 120 | 78.0 | 144.0 | 120 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 12 | 3.1 | 19.1 | 119 |
| 2,3,7,8-TCDF-13C | 100 | 110 | 22.0 | 152.0 | 108 |
| 2,3,7,8-TCDD-13C | 100 | 97 | 20.0 | 175.0 | 97 |
| 1,2,3,7,8-PeCDF-13C | 100 | 110 | 21.0 | 192.0 | 106 |
| 2,3,4,7,8-PeCDF-13C | 100 | 100 | 13.0 | 328.0 | 102 |
| 1,2,3,7,8-PeCDD-13C | 100 | 100 | 21.0 | 227.0 | 102 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 130 | 19.0 | 202.0 | 128 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 110 | 21.0 | 159.0 | 114 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 120 | 22.0 | 176.0 | 115 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 110 | 17.0 | 205.0 | 109 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 110 | 21.0 | 193.0 | 114 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 120 | 25.0 | 163.0 | 123 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 94 | 21.0 | 158.0 | 94 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 82 | 20.0 | 186.0 | 82 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 87 | 26.0 | 166.0 | 87 |
| OCDD-13C | 200 | 150 | 26.0 | 397.0 | 75 |

Cs = Concentration Spiked (ng/mL)
Cr = Concentration Recovered (ng/mL)
Rec. = Recovery (Expressed as Percent)
Control Limit Reference: Method 1613, Table 6, 10/94 Revision
R = Recovery outside of control limits
Nn = Value obtained from additional analysis
* = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Stage 2A/B Data Validation Checks
JH Baxter
Delivery Group L1508970/10616029

Comments:

- U-qualified samples assigned by the laboratory are not included in this report unless the U qualification is for some other reason other than a simple non-detect.

SUMMARY OF QUALITY CONTROL CHECKS

| Quality Control Check | Check ed By | Comment |
|---|-------------|---|
| Completeness | MBF | The data set is 100 percent complete, no results rejected. |
| Holding times | MBF | Holding times were within the method specific recommended holding times. |
| Preservation | MBF | Preservation was acceptable. |
| COC Documentation | MBF | COC was provided in the lab report. |
| Analytical methods | MBF | EPA 1613B Requested analytical methods were performed. |
| Initial and continuing calibrations | MBF | Not independently verified during Stage 2A/B validation. |
| Method blanks, trip blank, and field blanks | MBF | <p>Method blanks were performed per batch and there were no detections and associated QC were within established control limits except for:</p> <ul style="list-style-type: none"> • Blank-1000015 <ul style="list-style-type: none"> ○ 1,2,3,7,8,9-HxCDF 0.12 J ○ Total HxCDF 0.12 J ○ 1,2,3,4,7,8-HxCDD 0.16 J ○ Total HxCDD 0.16 J ○ 1,2,3,4,6,7,8-HpCDD 0.18 J, ○ Total HpCDD 0.18 J ○ OCDD 0.64 J <p>Associated sample results were greater than 3X method blank contamination. Results not qualified.</p> <ul style="list-style-type: none"> • Equipment Blank (EB-01_0622) <ul style="list-style-type: none"> ○ 1,2,3,4,7,8-HxCDD 1.7 J ○ Total HxCDD 1.1 J ○ 1,2,3,4,6,7,8-HpCDD 1.9 J+ ○ OCDD 21 J <p>Raw results not reviewed during 2A/B. Equipment blank results (pg/L) and sample results (ng/kg) not directly comparable. Results not qualified.</p> |
| Surrogate/labeled compounds | MBF | <p>Labeled compounds were analyzed and within control limits except for:</p> <ul style="list-style-type: none"> • 2,3,7,8-TCDD-13C <ul style="list-style-type: none"> ○ COMP-11A_0622 10% ○ COMP-10B_0622 15% ○ COMP-10A_0622 17% |

| Quality Control Check | Check ed By | Comment |
|--|-------------|---|
| | | <ul style="list-style-type: none"> ○ COMP-09A_0622 20% <p>Associated 2,3,7,8-TCDD analytes qualified J-.</p> <ul style="list-style-type: none"> • 2,3,7,8-TCDD-37C14 (Cleanup Recovery STD) <ul style="list-style-type: none"> ○ COMP-09A_0622 11% ○ COMP-10A_0622 16% ○ COMP-10B_0622 18% ○ COMP-11A_0622 23% <p>Unless additional qualifications were necessary, all associated sample analytes qualified J due to low CRS recovery.</p> |
| LCS/LCSD | MBF | An LCS was analyzed per batch. Recoveries were within established control limits. |
| MS/MSD | MBF | MS/MSD were not performed and are not required per the method. |
| Field duplicates | MBF | Field duplicates were not collected or analyzed. |
| Lab duplicates | MBF | Lab sample duplicates were not performed or required per the method. |
| Dilution | MBF | Samples did not require further dilution for analysis. |
| Qualitative Identification for HRGC/HRMS analyses only | MBF | <p>The following results were EMPCs with the presence of diphenyl ethers:</p> <ul style="list-style-type: none"> • 1,2,3,6,7,8-HxCDF <ul style="list-style-type: none"> ○ COMP-09A_0622 ○ COMP-09B_0622 ○ COMP-10A_0622 ○ COMP-10B_0622 ○ COMP-11A_0622 <p>Results were qualified J+.</p> <p>The following results were EMPCs with an isotope ratio out of specification:</p> <ul style="list-style-type: none"> • COMP-11B_0622 <ul style="list-style-type: none"> ○ 1,2,3,7,8-PeCDF • COMP-14A_0622 <ul style="list-style-type: none"> ○ 2,3,7,8-TCDF • COMP-14B_0622 <ul style="list-style-type: none"> ○ 1,2,3,7,8-PeCDF ○ 2,3,4,7,8-PeCDF ○ 2,3,7,8-TCDF • COMP-15A_0622 <ul style="list-style-type: none"> ○ 1,2,3,4,7,8-HxCDF ○ 1,2,3,7,8-PeCDF • COMP-15B_0622 <ul style="list-style-type: none"> ○ 1,2,3,7,8-PeCDD <p>Results qualified J+.</p> |

| Quality Control Check | Check ed By | Comment |
|-----------------------|--|---------|
| Overall Assessment | Qualifier codes added to results; table and notes below. | |

Notes

TABLE 1. SUMMARY OF QUALIFIED DATA

| Sample ID | Analyte | Result (ng/kg) | Qualifier Assigned | Reason for Qualification |
|---------------|---|--|--------------------|--|
| COMP-09A_0622 | 1,2,3,6,7,8-HxCDF | 3.6 | J+ | EMPC, Presence of PCDEs, CRS < LCL, Below reporting limit |
| COMP-09A_0622 | 1,2,3,4,7,8,9-HpCDF, 1,2,3,4,7,8-HxCDD, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD, 1,2,3,7,8-PeCDF, 2,3,4,6,7,8-HxCDF, 2,3,4,7,8-PeCDF, 2,3,7,8-TCDF | 4.3, 3.4, 1.4, 1.8, 0.65, 3.0, 1.3, 0.37 | J | CRS < LCL, Below reporting limit |
| COMP-09A_0622 | 2,3,7,8-Tcdd | 9.1 | J- | SUR < LCL, CRS < LCL |
| COMP-09A_0622 | 1,2,3,4,6,7,8-HpCDD, 1,2,3,4,6,7,8-HpCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, OCDD, OCDF, Total TCDF, Total HpCDD, Total HpCDF, Total HxCDD, Total HxCDF, Total PeCDD, Total PeCDF, Total TCDD | 230, 68, 5.4, 9.1, 6.0, 2400, 250, 6.7, 480, 220, 79, 82, 15, 20, 68 | J | CRS < LCL |
| COMP-09B_0622 | 1,2,3,6,7,8-HxCDF | 42 | J+ | EMPC, Presence of PCDEs |
| COMP-09B_0622 | 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF, 2,3,7,8-TCDF | 3.4, 1.8, 3.6, 0.73 | J | Below reporting limit |
| COMP-10A_0622 | 1,2,3,6,7,8-HxCDF | 5.0 | J+ | EMPC, Presence of PBDEs, CRS < LCL |

| | | | | |
|---------------|---|---|----|--|
| COMP-10A_0622 | 1,2,3,4,7,8,9-HpCDF, 1,2,3,4,7,8-HxCDD, 1,2,3,4,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD, 1,2,3,7,8-PeCDF, 2,3,4,6,7,8-HxCDF, 2,3,4,7,8-PeCDF, 2,3,7,8-TCDF | 4.2, 4.1, 3.1, 1.1, 2.5, 0.60, 2.9, 1.2, 0.51 | J | CRS < LCL, Below reporting limit |
| COMP-10A_0622 | 2,3,7,8-TCDD | 16 | J- | Labeled Standard < LCL, CRS < LCL |
| COMP-10A_0622 | 1,2,3,4,6,7,8-HpCDD, 1,2,3,4,6,7,8-HpCDF, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, OCDD, OCDF, Total TCDF, Total HpCDD, Total HpCDF, Total HxCDD, Total HxCDF, Total PeCDD, Total PeCDF, Total TCDD | 360, 71, 13, 8.4, 3100, 240, 9.1, 770, 220, 130, 75, 22, 22, 61 | J | CRS < LCL |
| COMP-10B_0622 | 1,2,3,6,7,8-HxCDF | 9.8 | J+ | EMPC, Presence of PCDEs, CRS < LCL |
| COMP-10B_0622 | 1,2,3,4,7,8-HxCDD, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF, 2,3,7,8-TCDF | 4.2, 2.1, 2.3, 0.80, 1.7, 0.43 | J | CRS < LCL, Below reporting limit |
| COMP-10B_0622 | 2,3,7,8-TCDD | 14 | J- | SUR < LCL, CRS < LCL |
| COMP-10B_0622 | 1,2,3,4,6,7,8-HpCDD, 1,2,3,4,6,7,8-HpCDF, 1,2,3,4,7,8,9-HpCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, 2,3,4,6,7,8-HxCDF, OCDD, OCDF, Total TCDF, Total HpCDD, Total HpCDF, Total HxCDD, Total HxCDF, Total PeCDD, | 480, 200, 9.5, 7.6, 29, 10, 6.7, 3300, 570, 11, 900, 660, 170, 200, 21, | J | CRS < LCL |

| | | | | |
|---------------|---|--|----|--|
| | Total PeCDF, Total TCDD | 39, 70 | | |
| COMP-11A_0622 | 1,2,3,6,7,8-HxCDF | 5.9 | J+ | EMPC, Presence of PCDEs, CRS < LCL |
| COMP-11A_0622 | 1,2,3,4,7,8,9-HpCDF, 1,2,3,4,7,8-HxCDD, 1,2,3,4,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD, 1,2,3,7,8-PeCDF, 2,3,4,6,7,8-HxCDF, 2,3,4,7,8-PeCDF, 2,3,7,8-TCDF | 3.0, 4.3, 3.4, 1.1, 2.0, 0.54, 2.5, 1.2, 0.44 | J | CRS < LCL, Below reporting limit |
| COMP-11A_0622 | 2,3,7,8-TCDD | 24 | J- | SUR < LCL, CRS < LCL |
| COMP-11A_0622 | 1,2,3,4,6,7,8-HpCDD, 1,2,3,4,6,7,8-HpCDF, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, OCDD, OCDF, Total TCDF, Total HpCDD, Total HpCDF, Total HxCDD, Total HxCDF, Total PeCDD, Total PeCDF, Total TCDD | 370, 55, 14, 8.0, 3500, 150, 8.1, 850, 170, 120, 65, 21, 18, 52 | J | CRS < LCL |
| COMP-11B_0622 | 1,2,3,7,8-PeCDF | 1.8 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| COMP-11B_0622 | 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD | 5.0, 3.9 | J | Below reporting limit |
| COMP-14A_0622 | 2,3,7,8-TCDF | 0.47 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| COMP-14A_0622 | 1,2,3,4,7,8,9-HpCDF, 1,2,3,4,7,8-HxCDD, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD, 1,2,3,7,8-PeCDF, 2,3,4,6,7,8-HxCDF, 2,3,4,7,8-PeCDF | 3.3, 3.9, 1.6, 1.6, 0.78, 1.8, 0.63, 2.4, 0.95 | J | Below reporting limit |


| | | | | |
|---------------|---|--|----|--|
| COMP-14B_0622 | 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF, 2,3,7,8-TCDF | 0.54, 0.89, 0.43 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| COMP-14B_0622 | 1,2,3,4,7,8,9-HpCDF, 1,2,3,4,7,8-HxCDD, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD, 2,3,4,6,7,8-HxCDF | 4.1, 4.1, 2.1, 2.9, 0.75, 2.1, 2.6 | J | Below reporting limit |
| COMP-15A_0622 | 1,2,3,4,7,8-HxCDF, 1,2,3,7,8-PeCDF | 3.6, 0.66 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| COMP-15A_0622 | 1,2,3,4,7,8,9-HpCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDD, 2,3,4,6,7,8-HxCDF, 2,3,4,7,8-PeCDF, 2,3,7,8-TCDF | 3.9, 1.3, 2.5, 3.4, 1.6, 0.66 | J | Below reporting limit |
| COMP-15B_0622 | 1,2,3,7,8-PeCDD | 2.2 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| COMP-15B_0622 | 1,2,3,4,7,8,9-HpCDF, 1,2,3,4,7,8-HxCDD, 1,2,3,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,7,8-PeCDF, 2,3,4,6,7,8-HxCDF, 2,3,4,7,8-PeCDF | 4.4, 4.8, 2.8, 1.6, 1.2, 3.8, 2.2 | J | Below reporting limit |

Oregon Dept. of Env. Quality - ODEQ

Sample Delivery Group: L1603081
Samples Received: 04/07/2023
Project Number: 02060.005.004
Description: Oregon DEQ-JH Baxter Offsite Investigation (TO #2060.005)

Report To: Don Hanson
165 E. 7th Avenue
Suite 100
Eugene, OR 97401

Entire Report Reviewed By:



Brian Ford
Project Manager

Results relate only to the items tested or calibrated and are reported as rounded values. This test report shall not be reproduced, except in full, without written approval of the laboratory. Where applicable, sampling conducted by Pace Analytical National is performed per guidance provided in laboratory standard operating procedures ENV-SOP-MTJL-0067 and ENV-SOP-MTJL-0068. Where sampling conducted by the customer, results relate to the accuracy of the information provided, and as the samples are received.

Pace Analytical National12065 Lebanon Rd Mount Juliet, TN 37122 615-758-5858 800-767-5859 www.pacenational.com

TABLE OF CONTENTS

| | | |
|--------------------------------|----|-----------------|
| Cp: Cover Page | 1 | ¹ Cp |
| Tc: Table of Contents | 2 | |
| Ss: Sample Summary | 3 | ² Tc |
| Cn: Case Narrative | 7 | ³ Ss |
| Gl: Glossary of Terms | 8 | ⁴ Cn |
| Al: Accreditations & Locations | 9 | ⁵ Gl |
| Sc: Sample Chain of Custody | 10 | ⁶ Al |
| | | ⁷ Sc |

SAMPLE SUMMARY

DU-06B-0.5-1.0_0423 L1603081-04 Solid

Collected by
GSI

Collected date/time
04/05/23 14:30

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-06B-1.0-1.5_0423 L1603081-05 Solid

Collected by
GSI

Collected date/time
04/05/23 14:35

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-01A-0.5-1.0_0423 L1603081-10 Solid

Collected by
GSI

Collected date/time
04/05/23 15:30

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-01A-1.0-1.5_0423 L1603081-11 Solid

Collected by
GSI

Collected date/time
04/05/23 15:35

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-01B-0.5-1.0_0423 L1603081-15 Solid

Collected by
GSI

Collected date/time
04/05/23 15:55

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-110A-1.0-1.5_0423 L1603081-16 Solid

Collected by
GSI

Collected date/time
04/05/23 09:50

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-10B-1.0-1.5_0423 L1603081-17 Solid

Collected by
GSI

Collected date/time
04/05/23 10:20

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |


DU-10B-1.5-2.0_0423 L1603081-18 Solid

Collected by
GSI

Collected date/time
04/05/23 09:50

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |



SAMPLE SUMMARY

DU-09A-1.0-1.5_0423 L1603081-21 Solid

Collected by
GSI

Collected date/time
04/05/23 11:30

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-09A-1.5-2.0_0423 L1603081-22 Solid

Collected by
GSI

Collected date/time
04/05/23 11:35

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-09B-1.0-1.5_0423 L1603081-25 Solid

Collected by
GSI

Collected date/time
04/05/23 12:15

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-09B-1.5-2.0_0423 L1603081-26 Solid

Collected by
GSI

Collected date/time
04/05/23 12:20

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-06A-0.5-1.0_0423 L1603081-29 Solid

Collected by
GSI

Collected date/time
04/05/23 13:00

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-06A-1.0-1.5_0423 L1603081-30 Solid

Collected by
GSI

Collected date/time
04/05/23 13:05

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-15A-1.0-1.5_0423 L1603081-31 Solid

Collected by
GSI

Collected date/time
04/05/23 10:00

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |


DU-15A-1.5-2.0_0423 L1603081-32 Solid

Collected by
GSI

Collected date/time
04/05/23 10:05

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |



SAMPLE SUMMARY

DU-15B-1.0-1.5_0423 L1603081-35 Solid

Collected by
GSI

Collected date/time
04/05/23 11:00

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-15B-1.5-2.0_0423 L1603081-36 Solid

Collected by
GSI

Collected date/time
04/05/23 11:05

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

SU-07A-0.5-1.0_0423 L1603081-39 Solid

Collected by
GSI

Collected date/time
04/05/23 11:35

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

SU-07A-1.0-1.5_0423 L1603081-40 Solid

Collected by
GSI

Collected date/time
04/05/23 11:40

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

SU-07B-0.5-1.0-0423 L1603081-44 Solid

Collected by
GSI

Collected date/time
04/05/23 12:00

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

SU-07B-1.0-1.5-0423 L1603081-45 Solid

Collected by
GSI

Collected date/time
04/05/23 12:05

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-11A-1.0-1.5_0423 L1603081-49 Solid

Collected by
GSI

Collected date/time
04/05/23 14:05

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |


DU-11A-1.5-2.0_0423 L1603081-50 Solid

Collected by
GSI

Collected date/time
04/05/23 14:10

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |



SAMPLE SUMMARY

DU-11B-1.0-1.5_0423 L1603081-53 Solid

Collected by
GSI

Collected date/time
04/05/23 14:30

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-11B-1.5-2.0_0423 L1603081-54 Solid

Collected by
GSI

Collected date/time
04/05/23 14:35

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-10A-1.0-1.5_0423 L1603081-57 Solid

Collected by
GSI

Collected date/time
04/05/23 09:30

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-10A-1.5-2.0_0423 L1603081-58 Solid

Collected by
GSI

Collected date/time
04/05/23 09:35

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |

DU-01B-1.0-1.5_0423 L1603081-61 Solid

Collected by
GSI

Collected date/time
04/05/23 16:00

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2039826 | 1 | 05/08/23 00:00 | 05/08/23 00:00 | - | Minneapolis, MN 55414 |


EB-01-0423 L1603081-65 GW

Collected by
GSI

Collected date/time
04/05/23 15:00

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2038179 | 1 | 05/03/23 00:00 | 05/03/23 00:00 | - | Minneapolis, MN 55414 |



CASE NARRATIVE


All sample aliquots were received at the correct temperature, in the proper containers, with the appropriate preservatives, and within method specified holding times, unless qualified or notated within the report. Where applicable, all MDL (LOD) and RDL (LOQ) values reported for environmental samples have been corrected for the dilution factor used in the analysis. All Method and Batch Quality Control are within established criteria except where addressed in this case narrative, a non-conformance form or properly qualified within the sample results. By my digital signature below, I affirm to the best of my knowledge, all problems/anomalies observed by the laboratory as having the potential to affect the quality of the data have been identified by the laboratory, and no information or data have been knowingly withheld that would affect the quality of the data.



Brian Ford
Project Manager

Project Narrative

L1603081-04, -05, -10, -11, -15, -16, -17, -18, -21, -22, -25, -26, -29, -30, -31, -32, -35, -36, -39, -40, -44, -45, -49, -50, -53, -54, -57, -58, -61, -65 contains subout data that is included after the chain of custody.



GLOSSARY OF TERMS

Guide to Reading and Understanding Your Laboratory Report

The information below is designed to better explain the various terms used in your report of analytical results from the Laboratory. This is not intended as a comprehensive explanation, and if you have additional questions please contact your project representative.


Results Disclaimer - Information that may be provided by the customer, and contained within this report, include Permit Limits, Project Name, Sample ID, Sample Matrix, Sample Preservation, Field Blanks, Field Spikes, Field Duplicates, On-Site Data, Sampling Collection Dates/Times, and Sampling Location. Results relate to the accuracy of this information provided, and as the samples are received.

Abbreviations and Definitions

| | |
|------------------------------|---|
| SDG | Sample Delivery Group. |
| Uncertainty (Radiochemistry) | Confidence level of 2 sigma. |
| Case Narrative (Cn) | A brief discussion about the included sample results, including a discussion of any non-conformances to protocol observed either at sample receipt by the laboratory from the field or during the analytical process. If present, there will be a section in the Case Narrative to discuss the meaning of any data qualifiers used in the report. |
| Quality Control Summary (Qc) | This section of the report includes the results of the laboratory quality control analyses required by procedure or analytical methods to assist in evaluating the validity of the results reported for your samples. These analyses are not being performed on your samples typically, but on laboratory generated material. |
| Sample Chain of Custody (Sc) | This is the document created in the field when your samples were initially collected. This is used to verify the time and date of collection, the person collecting the samples, and the analyses that the laboratory is requested to perform. This chain of custody also documents all persons (excluding commercial shippers) that have had control or possession of the samples from the time of collection until delivery to the laboratory for analysis. |
| Sample Results (Sr) | This section of your report will provide the results of all testing performed on your samples. These results are provided by sample ID and are separated by the analyses performed on each sample. The header line of each analysis section for each sample will provide the name and method number for the analysis reported. |
| Sample Summary (Ss) | This section of the Analytical Report defines the specific analyses performed for each sample ID, including the dates and times of preparation and/or analysis. |

Qualifier Description

The remainder of this page intentionally left blank, there are no qualifiers applied to this SDG.



ACCREDITATIONS & LOCATIONS


Pace Analytical National 12065 Lebanon Rd Mount Juliet, TN 37122

| | | | |
|-------------------------------|-------------|-----------------------------|------------------|
| Alabama | 40660 | Nebraska | NE-OS-15-05 |
| Alaska | 17-026 | Nevada | TN000032021-1 |
| Arizona | AZ0612 | New Hampshire | 2975 |
| Arkansas | 88-0469 | New Jersey-NELAP | TN002 |
| California | 2932 | New Mexico ¹ | TN00003 |
| Colorado | TN00003 | New York | 11742 |
| Connecticut | PH-0197 | North Carolina | Env375 |
| Florida | E87487 | North Carolina ¹ | DW21704 |
| Georgia | NELAP | North Carolina ³ | 41 |
| Georgia ¹ | 923 | North Dakota | R-140 |
| Idaho | TN00003 | Ohio-VAP | CL0069 |
| Illinois | 200008 | Oklahoma | 9915 |
| Indiana | C-TN-01 | Oregon | TN200002 |
| Iowa | 364 | Pennsylvania | 68-02979 |
| Kansas | E-10277 | Rhode Island | LA000356 |
| Kentucky ^{1,6} | KY90010 | South Carolina | 84004002 |
| Kentucky ² | 16 | South Dakota | n/a |
| Louisiana | AI30792 | Tennessee ^{1,4} | 2006 |
| Louisiana | LA018 | Texas | T104704245-20-18 |
| Maine | TN00003 | Texas ⁵ | LAB0152 |
| Maryland | 324 | Utah | TN000032021-11 |
| Massachusetts | M-TN003 | Vermont | VT2006 |
| Michigan | 9958 | Virginia | 110033 |
| Minnesota | 047-999-395 | Washington | C847 |
| Mississippi | TN00003 | West Virginia | 233 |
| Missouri | 340 | Wisconsin | 998093910 |
| Montana | CERT0086 | Wyoming | A2LA |
| A2LA – ISO 17025 | 1461.01 | AIHA-LAP, LLC EMLAP | 100789 |
| A2LA – ISO 17025 ⁵ | 1461.02 | DOD | 1461.01 |
| Canada | 1461.01 | USDA | P330-15-00234 |
| EPA-Crypto | TN00003 | | |

¹ Drinking Water ² Underground Storage Tanks ³ Aquatic Toxicity ⁴ Chemical/Microbiological ⁵ Mold ⁶ Wastewater n/a Accreditation not applicable

* Not all certifications held by the laboratory are applicable to the results reported in the attached report.

* Accreditation is only applicable to the test methods specified on each scope of accreditation held by Pace Analytical.



State of Oregon Chain of Custody (Pace)

| Agency, Authorized Purchaser or Agent: GSI for ODEQ Send Lab Report To: Don Hanson, RG Address: 165 E. 7th Avenue, Suite 100 Eugene, OR 97401 Tel #: 541-687-7349 E-mail: don.hanson@deq.state.or.us, j.bale@gsiws.com, cmartin@gsiws.com, mfargher@gsiws.com, GIS@gsiws.com | | | | | D153 | | | | | Contract Laboratory Name: Pace Analytical National Lab Batch #: Invoice: ODEQ/Business Office 811 SW 6th Ave Portland, OR 97204 Tel #: (800) 452-4011 | | | | | Lab Selection Criteria: Proximity (if TAT < 48 hrs) Prior work on same project Cost (for anticipated analyses) Other labs disqualified or unable to perform requested services Emergency work | | | | | Turn Around Time: 10 days (std) 5 days 72 hours 48 hours 24 hours Other _____ | | | | |
|--|-----------------|-----------------|--------|----------------------|---|--|--|--|--|---|--|--|--|--|---|--|--|--|---|--|--|--|--|--|
| Project Name: OREGON DEQ-JH BAXTER OFFSITE INVESTIGATION (TO #2060.005) Project #: JH Baxter Offsite Investigation Sampler Name: GSI | | | | | | | | | | Sample Preservative | | | | | | | | | | | | | | |
| | | | | | | | | | | Requested Analyses | | | | | | | | | | | | | | |
| Sample ID# | Collection Date | Collection Time | Matrix | Number of Containers | ISM Prep. Dioxin/furan s by 1613B | | | | | | | | | | | | | | | Comments | | | | |
| DU-06A-1.5-2.0-0423 | 4/5/23 | 1310 | SE | 1 | | | | | | | | | | | | | | | X | L1603081 -01 | | | | |
| DU-06A-2.0-2.5-0423 | 4/5/23 | 1315 | SE | 1 | | | | | | | | | | | | | | | X | -02 | | | | |
| DU-06A-2.5-3.0-0423 | 4/5/23 | 1320 | SE | 1 | | | | | | | | | | | | | | | X | -03 | | | | |
| DU-06B-0.5-1.0-0423 | 4/5/23 | 1430 | SE | 1 | X | | | | | | | | | | | | | | | -04 | | | | |
| DU-06B-1.0-1.5-0423 | 4/5/23 | 1435 | SE | 1 | X | | | | | | | | | | | | | | | -05 | | | | |
| DU-06B-1.5-2.0-0423 | 4/5/23 | 1440 | SE | 1 | | | | | | | | | | | | | | | X | -06 | | | | |
| DU-06B-2.0-2.5-0423 | 4/5/23 | 1445 | SE | 1 | | | | | | | | | | | | | | | X | -07 | | | | |
| DU-06B-2.5-3.0-0423 | 4/5/23 | 1450 | SE | 1 | | | | | | | | | | | | | | | X | -08 | | | | |
| DU-106B-1.5-2.0-0423 | 4/5/23 | 1455 | SE | 1 | | | | | | | | | | | | | | | X | -09 | | | | |
| DU-01A-0.5-1.0-0423 | 4/5/23 | 1530 | SE | 1 | X | | | | | | | | | | | | | | | -10 | | | | |
| DU-01A-1.0-1.5-0423 | 4/5/23 | 1535 | SE | 1 | X | | | | | | | | | | | | | | | -11 | | | | |
| DU-01A-1.5-2.0-0423 | 4/5/23 | 1540 | SE | 1 | | | | | | | | | | | | | | | X | -12 | | | | |
| DU-01A-2.0-2.5-0423 | 4/5/23 | 1545 | SE | 1 | | | | | | | | | | | | | | | X | -13 | | | | |
| DU-01A-2.5-3.0-0423 | 4/5/23 | 1550 | SE | 1 | | | | | | | | | | | | | | | X | -14 | | | | |
| DU-01B-0.5-1.0-0423 | 4/5/23 | 1555 | SE | 1 | X | | | | | | | | | | | | | | | -15 | | | | |

NOTES: Conduct Incremental Sampling Methodology processing prior to analysis.
 Contact Chris Martin (503-432-5979, cmartin@gsiws.com) or Josh Bale (530-276-4188, j.bale@gsiws.com) with questions. Include DEQ EDD with final lab report.

| | | | |
|-------------------------------|--------------------------|--|-------------------------|
| Relinquished By: G. Schutts | Agency/Agent: GSI | Received By: | Agency/Agent: |
| Signature: <i>[Signature]</i> | Time & Date: 4/6/23 1215 | Signature: | Time & Date: |
| Relinquished By: | Agency/Agent: | Received By: <i>[Signature]</i> | Agency/Agent: |
| Signature: | Time & Date: | Signature: Kaycie <i>[Signature]</i> (9) | Time & Date: 4/7/23 920 |

THIS PURC
HEREBY IN

Sample Receipt Checklist

COC Seal Present/Intact: ☒ Y ☐ N If Applicable
 COC Signed/Accurate: ☒ Y ☐ N VOA Zero Headspace: ☐ Y ☐ N
 Bottles arrive intact: ☒ Y ☐ N Pres. Correct/Check: ☐ Y ☐ N
 Correct bottles used: ☒ Y ☐ N
 Sufficient volume sent: ☒ Y ☐ N
 RAD Screen <0.5 mR/hr: ☒ Y ☐ N

 PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE
 CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

State of Oregon Chain of Custody (Pace)

| | | | | | | | |
|--|--|--|--|--|--|---|--|
| Agency, Authorized Purchaser or Agent: GSI for ODEQ | | Contract Laboratory Name: Pace Analytical National | | Lab Selection Criteria: Proximity (if TAT < 48 hrs) Prior work on same project Cost (for anticipated analyses) Other labs disqualified or unable to perform requested services Emergency work | | Turn Around Time: 10 days (std) 5 days 72 hours 48 hours 24 hours Other | |
| Send Lab Report To: Don Hanson, RG Address: 165 E. 7th Avenue, Suite 100 Eugene, OR 97401 Tel #: 541-687-7349 E-mail: don.hanson@deq.state.or.us, jbale@gsiws.com, cmartin@gsiws.com, mfargher@gsiws.com, GIS@gsiws.com | | Lab Batch #: Invoice: ODEQ/Business Office 811 SW 6th Ave Portland, OR 97204 Tel #: (800) 452-4011 | | | | | |

Project Name: OREGON DEQ-JH BAXTER OFFSITE INVESTIGATION (TO #2060.005)

Project #: JH Baxter Offsite Investigation

Sampler Name: GSI

| Sample Preservative | | | | | | Requested Analyses | | | | | | Archive | Comments |
|---------------------|-----------------|-----------------|--------|----------------------|----------------------------------|--------------------|--|--|--|--|--|---------|----------|
| Sample ID# | Collection Date | Collection Time | Matrix | Number of Containers | ISM Prep/Dioxin/furan s by 1813B | | | | | | | | |
| DU110A-1.0-1.5-0423 | 4/5/23 | 950 | SE | 1 | X | | | | | | | | L1603081 |
| DU-10B-1.0-1.5-0423 | 4/5/23 | 1020 | SE | 1 | X | | | | | | | | -16 |
| DU-10B-1.5-2.0-0423 | 4/5/23 | 1025 | SE | 1 | X | | | | | | | | -17 |
| DU-10B-2.0-2.5-0423 | 4/5/23 | 1030 | SE | 1 | | | | | | | | X | -18 |
| DU-10B-2.5-3.0-0423 | 4/5/23 | 1035 | SE | 1 | | | | | | | | X | -19 |
| DU-09A-1.0-1.5-0423 | 4/5/23 | 1130 | SE | 1 | X | | | | | | | | -20 |
| DU-09A-1.5-2.0-0423 | 4/5/23 | 1135 | SE | 1 | X | | | | | | | | -21 |
| DU-09A-2.0-2.5-0423 | 4/5/23 | 1140 | SE | 1 | | | | | | | | X | -22 |
| DU-09A-2.5-3.0-0423 | 4/5/23 | 1145 | SE | 1 | | | | | | | | X | -23 |
| DU-09B-1.0-1.5-0423 | 4/5/23 | 1215 | SE | 1 | X | | | | | | | | -24 |
| DU-09B-1.5-2.0-0423 | 4/5/23 | 1220 | SE | 1 | X | | | | | | | | -25 |
| DU-09B-2.0-2.5-0423 | 4/5/23 | 1225 | SE | 1 | | | | | | | | X | -26 |
| DU-09B-2.5-3.0-0423 | 4/5/23 | 1230 | SE | 1 | | | | | | | | X | -27 |
| DU-06A-0.5-1.0-0423 | 4/5/23 | 1300 | SE | 1 | X | | | | | | | | -28 |
| DU-06A-1.0-1.5-0423 | 4/5/23 | 1305 | SE | 1 | X | | | | | | | | -29 |
| | | | | | | | | | | | | | -30 |

NOTES: Conduct Incremental Sampling Methodology processing prior to analysis.

Contact Chris Martin (503-432-5979, cmartin@gsiws.com) or Josh Bale (530-276-4188, jbale@gsiws.com) with questions. Include DEQ EDD with final lab report.

| | | | |
|-----------------------------|--------------------------|---------------------------------|-------------------------|
| Relinquished By: G. Schmitz | Agency/Agent: GSI | Received By: | Agency/Agent: |
| Signature: [Signature] | Time & Date: 4/4/23 1215 | Signature: | Time & Date: |
| Relinquished By: | Agency/Agent: | Received By: * | Agency/Agent: |
| Signature: | Time & Date: | Signature: Kaycie [Signature] ⑨ | Time & Date: 4/7/23 920 |

THIS PURCHASE IS SUBMITTED PURSUANT TO STATE OF OREGON SOLICITATION #102-1098-07 AND PRICE AGREEMENT # 8903. THE PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE AND SHALL APPLY TO THIS PURCHASE AND SHALL TAKE PRECEDENCE OVER ALL OTHER CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

State of Oregon Chain of Custody (Pace)

Agency, Authorized Purchaser or Agent:

GSI for ODEQ

Send Lab Report To:

Don Hanson, RG

Address:

165 E. 7th Avenue, Suite 100
Eugene, OR 97401

Tel. # 541-687-7349

E-mail:

don.hanson@deq.state.or.us, j.bale@gsiws.com,
cmartin@gsiws.com, mfaragher@gsiws.com, GIS@gsiws.com

Project Name: OREGON DEQ-JH BAXTER OFFSITE INVESTIGATION (TO #2060.005)

Project #: JH Baxter Offsite Investigation

Sampler Name: G81

Contract Laboratory Name:

Pace Analytical National

Lab Batch #:

Invoice: ODEQ/Business Office
811 SW 6th Ave
Portland, OR 97204
Tel. #: (800) 452-4011

Lab Selection Criteria:

Proximity (if TAT < 48 hrs)

Prior work on same project

Cost (for anticipated analyses)

Other labs disqualified or unable

to perform requested services

Emergency work

Turn Around Time:

10 days (std.)

5 days

72 hours

48 hours

24 hours

Other

| | | | | | Sample Preservative | | | | | | | | | |
|---------------------|-----------------|-----------------|--------|----------------------|----------------------------------|----|--|--|--|--|--|--|----------|----------|
| | | | | | Solids | NA | | | | | | | | |
| | | | | | Requested Analyses | | | | | | | | | |
| Sample ID# | Collection Date | Collection Time | Matrix | Number of Containers | ISM Prep. Dioxin/furans by 1613B | | | | | | | | ANALYSIS | Comments |
| DU-ISA-1.0-1.5-0423 | 4/4/23 | 10:00 | SE | 1 | X | | | | | | | | | L1603081 |
| DU-ISA-1.5-2.0-0423 | 4/4/23 | 10:05 | SE | 1 | X | | | | | | | | | -31 |
| DU-ISA-2.0-2.5-0423 | 4/4/23 | 10:10 | SE | 1 | | | | | | | | | | -32 |
| DU-ISA-2.5-3.0-0423 | 4/4/23 | 10:15 | SE | 1 | | | | | | | | | X | -33 |
| DU-ISB-1.0-1.5-0423 | 4/4/23 | 11:00 | SE | 1 | X | | | | | | | | X | -34 |
| DU-ISB-1.5-2.0-0423 | 4/4/23 | 11:05 | SE | 1 | X | | | | | | | | | -35 |
| DU-ISB-2.0-2.5-0423 | 4/4/23 | 11:10 | SE | 1 | | | | | | | | | X | -36 |
| DU-ISB-2.5-3.0-0423 | 4/4/23 | 11:15 | SE | 1 | | | | | | | | | X | -37 |
| SU-07A-0.5-1.0-0423 | 4/4/23 | 11:35 | SE | 1 | X | | | | | | | | | -38 |
| SU-07A-1.0-1.5-0423 | 4/4/23 | 11:40 | SE | 1 | X | | | | | | | | | -39 |
| SU-07A-1.5-2.0-0423 | 4/4/23 | 11:45 | SE | 1 | | | | | | | | | X | -40 |
| SU-07A-2.0-2.5-0423 | 4/4/23 | 11:50 | SE | 1 | | | | | | | | | X | -41 |
| SU-07A-2.5-3.0-0423 | 4/4/23 | 11:55 | SE | 1 | | | | | | | | | X | -42 |
| SU-07B-0.5-1.0-0423 | 4/4/23 | 12:00 | SE | 1 | X | | | | | | | | | -43 |
| SU-07B-1.0-1.5-0423 | 4/4/23 | 12:05 | SE | 1 | X | | | | | | | | | -44 |
| | | | | | | | | | | | | | | -45 |

NOTES: Conduct Incremental Sampling Methodology processing prior to analysis.

Contact Chris Martin (503-432-5979, cmartin@gsiws.com) or Josh Bale (530-276-4188, j.bale@gsiws.com) with questions. Include DEQ EDD with final lab report.

| | | | |
|-------------------------------|---------------------------|----------------------------------|--------------------------|
| Relinquished By: G. Schutzius | Agency/Agent: G81 | Received By: | Agency/Agent: |
| Signature: [Signature] | Time & Date: 4/6/23 12:15 | Signature: | Time & Date: |
| Relinquished By: | Agency/Agent: | Received By: | Agency/Agent: |
| Signature: | Time & Date: | Signature: Kayci [Signature] (9) | Time & Date: 4/7/23 9:20 |

THIS PURCHASE IS SUBMITTED PURSUANT TO STATE OF OREGON SOLICITATION #102-1098-07 AND PRICE AGREEMENT # 8903. THE PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE AND SHALL APPLY TO THIS PURCHASE AND SHALL TAKE PRECEDENCE OVER ALL OTHER CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

State of Oregon Chain of Custody (Pace)

Agency, Authorized Purchaser or Agent:

GSI for ODEQ

Send Lab Report To:

Don Hanson, RG

Address: 165 E. 7th Avenue, Suite 100
Eugene, OR 97401

Tel. # 541-687-7349

E-mail: don.hanson@deq.state.or.us, j.bale@gsiws.com,
cmartin@gsiws.com, mfargher@gsiws.com, GIS@gsiws.com

Contract Laboratory Name:

Pace Analytical National

Lab Batch #:

Invoice: ODEQ/Business Office
811 SW 6th Ave
Portland, OR 97204
Tel. # (800) 452-4011

Lab Selection Criteria:

Proximity (if TAT < 48 hrs)

Prior work on same project

~~Cost (for anticipated analyses)~~Other labs disqualified or unable
to perform requested services

Emergency work

Turn Around Time:

10 days (std)

5 days

72 hours

48 hours

24 hours

Other

Project Name: OREGON DEQ-JH BAXTER OFFSITE INVESTIGATION (TO #2060.005)

Project #: JH Baxter Offsite Investigation

Sampler Name: GSI

| | | | | | Sample Preservative | | | | | | | | Comments |
|---------------------|-----------------|-----------------|--------|----------------------|---------------------------------|--|--|--|--|--|--|--|----------|
| | | | | | Solids NA | | | | | | | | |
| | | | | | Requested Analyses | | | | | | | | |
| Sample ID# | Collection Date | Collection Time | Matrix | Number of Containers | ISM Prep Disinfectants by 1613B | | | | | | | | |
| SU-07B-1.5-2.0-0423 | 4/4/23 | 1210 | SE | 1 | | | | | | | | | L1603081 |
| SU-07B-2.0-2.5-0423 | 4/4/23 | 1215 | SE | 1 | | | | | | | | | -46 |
| SU-07B-2.5-3.0-0423 | 4/4/23 | 1220 | SE | 1 | | | | | | | | | -47 |
| DU-11A-6.0-6.5-0423 | 4/4/23 | 1405 | SE | 1 | X | | | | | | | | -48 |
| DU-11A-1.5-2.0-0423 | 4/4/23 | 1410 | SE | 1 | X | | | | | | | | -49 |
| DU-11A-2.0-2.5-0423 | 4/4/23 | 1415 | SE | 1 | | | | | | | | | -50 |
| DU-11A-2.5-3.0-0423 | 4/4/23 | 1420 | SE | 1 | | | | | | | | | -51 |
| DU-11B-1.0-1.5-0423 | 4/4/23 | 1430 | SE | 1 | + | | | | | | | | -52 |
| DU-11B-1.5-2.0-0423 | 4/4/23 | 1435 | SE | 1 | + | | | | | | | | -53 |
| DU-11B-2.0-2.5-0423 | 4/4/23 | 1440 | SE | 1 | | | | | | | | | -54 |
| DU-11B-2.5-3.0-0423 | 4/4/23 | 1445 | SE | 1 | | | | | | | | | -55 |
| DU-10A-1.0-1.5-0423 | 4/5/23 | 930 | SE | 1 | X | | | | | | | | -56 |
| DU-10A-1.5-2.0-0423 | 4/5/23 | 935 | SE | 1 | X | | | | | | | | -57 |
| DU-10A-2.0-2.5-0423 | 4/5/23 | 940 | SE | 1 | | | | | | | | | -58 |
| DU-10A-2.5-3.0-0423 | 4/5/23 | 945 | SE | 1 | | | | | | | | | -59 |
| | | | | | | | | | | | | | -60 |

NOTES: Conduct Incremental Sampling Methodology processing prior to analysis.

Contact Chris Martin (503-432-5979, cmartin@gsiws.com) or Josh Bale (530-276-4188, j.bale@gsiws.com) with questions. Include DEQ EDD with final lab report.

| | | | |
|------------------------------|--------------------------|---------------------------------|-------------------------|
| Relinquished By: G. Schutars | Agency/Agent: GSI | Received By: | Agency/Agent: |
| Signature: [Signature] | Time & Date: 4/6/23 1215 | Signature: | Time & Date: |
| Relinquished By: | Agency/Agent: | Received By: | Agency/Agent: |
| Signature: | Time & Date: | Signature: Kaycie [Signature] 9 | Time & Date: 4/7/23 920 |

THIS PURCHASE IS SUBMITTED PURSUANT TO STATE OF OREGON SOLICITATION #102-1098-07 AND PRICE AGREEMENT # 8903. THE PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE AND SHALL APPLY TO THIS PURCHASE AND SHALL TAKE PRECEDENCE OVER ALL OTHER CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

| | | | | | | | |
|---|--|--|--|---|--|--|--|
| Agency, Authorized Purchaser or Agent: GSI for ODEQ | | Contract Laboratory Name: Pace Analytical National | | Lab Selection Criteria: Proximity (if TAT < 48 hrs) Prior work on same project Cost (for anticipated analyses) Other labs disqualified or unable to perform requested services Emergency work | | Turn Around Time: 10 days (std) 5 days 72 hours 48 hours 24 hours Other _____ | |
| Send Lab Report To: Don Hanson, RG Address: 165 E. 7th Avenue, Suite 100 Eugene, OR 97401 | | Lab Batch #: Invoice: ODEQ/Business Office 811 SW 6 th Ave Portland, OR 97204 Tel. #: (800) 452-4011 | | | | | |
| Tel. #: 541-687-7349 E-mail: don.hanson@deq.state.or.us, jhale@gsws.com, cmartin@gsws.com, mfaragher@gsws.com, GIS@gsws.com | | | | | | | |
| Project Name: OREGON DEQ - IN PAYEE OFFICE IN URGENT ACTION TO "2000 CAS" | | | | | | | |

Sampler Name: GSI

[illegible]

NOTES: Conduct Incremental Sampling Methodology processing prior to analysis.
Contact Chris Martin (503-432-5979, cmartin@gsiws.com) or Josh Bale (530-276-4188, jbale@gsiws.com) with questions. Include DEQ EDD with final lab report.

| | | | |
|------------------------------------|---------------------------------|---------------------------------|--------------------------------|
| Relinquished By: G Schutans | Agency/Agent: G51 | Received By: | Agency/Agent: |
| Signature: <i>[Signature]</i> | Time & Date: 4/6/23 1215 | Signature: | Time & Date: |
| Relinquished By: | Agency/Agent: | Received By: | Agency/Agent: |
| Signature: | Time & Date: | Signature: Kaycie J. (9) | Time & Date: 4/7/23 920 |

THIS PURCHASE IS SUBMITTED PURSUANT TO STATE OF OREGON SOLICITATION #102-1098-07 AND PRICE AGREEMENT # 8903. THE PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE AND SHALL APPLY TO THIS PURCHASE AND SHALL TAKE PRECEDENCE OVER ALL OTHER CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

L1603081

| <u>Tracking Numbers</u> | | <u>Temperature</u> |
|-----------------------------|--|--------------------|
| 0357 9924 1663 | | NSAG 3.2+0=3.2 |
| 0357 9924 1674 | | NSAG 5.1+0=5.1 |
| 0357 9924 1685 | | NSAG 1.5+0=1.5 |
| 0357 9924 1696 | | NSAG 2.5+0=2.5 |
| 0357 9924 1722 | | NSAG 4.3+0=4.3 |
| 0357 9924 1733 | | NSAG 1.8+0=1.8 |
| 0357 9924 1700 | | NSAG 1.6+0=1.6 |
| 0357 9924 1711 | | NSAG 4.6+0=4.6 |

Report Prepared for:

Client Services
Pace Analytical National
12065 Lebanon Rd
Mt. Juliet TN 37122

REPORT OF LABORATORY ANALYSIS FOR PCDD/PCDF

Report Prepared Date:

May 1, 2023

Report Information:


Pace Project #: 10648781
Sample Receipt Date: 04/11/2023
Client Project #: L1603081 WG2038179
Client Sub PO #: L1603081
State Cert #: N/A

Invoicing & Reporting Options:

The report provided has been invoiced as a Level 2 PCDD/PCDF Report. If an upgrade of this report package is requested, an additional charge may be applied.

Please review the attached invoice for accuracy and forward any questions to Kongmeng Vang, your Pace Project Manager.

This report has been reviewed by:



May 02, 2023

Kongmeng Vang, Project Manager
(612) 607-6382
(612) 607-6444 (fax)
kongmeng.vang@pacelabs.com



Report of Laboratory Analysis

This report should not be reproduced, except in full, without the written consent of Pace Analytical Services, Inc.

The results relate only to the samples included in this report.



DISCUSSION

This report presents the results from the analysis performed on one sample submitted by a representative of Pace Analytical National. The sample was analyzed for the presence or absence of polychlorodibenzo-p-dioxins (PCDDs) and polychlorodibenzofurans (PCDFs) using USEPA Method 1613B. The estimated detection limits (EDLs) were based on signal-to-noise measurements. Estimated maximum possible concentration (EMPC) values were treated as positives in the toxic equivalence calculations.

The recoveries of the isotopically-labeled PCDD/PCDF internal standards in the sample extract ranged from 46-85%. All of the labeled standard recoveries obtained for this project were within the target ranges specified in Method 1613B. Also, since the quantification of the native 2,3,7,8-substituted congeners was based on isotope dilution, the data were automatically corrected for recovery and accurate values were obtained.

Values were flagged "I" where incorrect isotope ratios were obtained. Concentrations below the calibration range were flagged "J" and should be regarded as estimates.

A laboratory method blank was prepared and analyzed with the sample batch as part of our routine quality control procedures. The results show the blank to contain trace levels of selected congeners. These levels were below the calibration range for the method. Sample levels similar to the corresponding blank levels were flagged "B" on the results table and may be, at least partially, attributed to the background.

A laboratory spike sample was also prepared using clean reference matrix that had been fortified with native standard materials. The results show that the spiked native compounds were recovered at 73-94%. These results were within the target ranges for the method. Matrix spikes were prepared with the sample batch using sample material from a separate project; results from these analyses will be provided upon request.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Minnesota Laboratory Certifications

| Authority | Certificate # | Authority | Certificate # |
|----------------|----------------|-----------------|----------------|
| A2LA | 2926.01 | Missouri | 10100 |
| Alabama | 40770 | Montana | CERT0092 |
| Alaska-DW | MN00064 | Nebraska | NE-OS-18-06 |
| Alaska-UST | 17-009 | Nevada | MN00064 |
| Arizona | AZ0014 | New Hampshire | 2081 |
| Arkansas - WW | 88-0680 | New Jersey | MN002 |
| Arkansas-DW | MN00064 | New York | 11647 |
| California | 2929 | North Carolina- | 27700 |
| Colorado | MN00064 | North Carolina- | 530 |
| Connecticut | PH-0256 | North Dakota | R-036 |
| Florida | E87605 | Ohio-DW | 41244 |
| Georgia | 959 | Ohio-VAP (170 | CL101 |
| Hawaii | MN00064 | Ohio-VAP (180 | CL110 |
| Idaho | MN00064 | Oklahoma | 9507 |
| Illinois | 200011 | Oregon-Primary | MN300001 |
| Indiana | C-MN-01 | Oregon-Second | MN200001 |
| Iowa | 368 | Pennsylvania | 68-00563 |
| Kansas | E-10167 | Puerto Rico | MN00064 |
| Kentucky-DW | 90062 | South Carolina | 74003 |
| Kentucky-WW | 90062 | Tennessee | TN02818 |
| Louisiana-DEQ | AI-84596 | Texas | T104704192 |
| Louisiana-DW | MN00064 | Utah | MN00064 |
| Maine | MN00064 | Vermont | VT-027053137 |
| Maryland | 322 | Virginia | 460163 |
| Michigan | 9909 | Washington | C486 |
| Minnesota | 027-053-137 | West Virginia-D | 382 |
| Minnesota-Ag | via MN 027-053 | West Virginia-D | 9952C |
| Minnesota-Petr | 1240 | Wisconsin | 999407970 |
| Mississippi | MN00064 | Wyoming-UST | via A2LA 2926. |

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Report No.....10648781



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix A

Sample Management

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.

WO#: 10648781



10648781

CHAIN-OF-CUSTODY / Analytical Request I

The Chain-of-Custody is a LEGAL DOCUMENT. All relevant fields must be completed.

Report # 138FC 12 dfr
Page 5 of 11

Section A

Required Client Information:

Company: Pace Analytical
Address: 12065 Lebanon Rd.
Mt Juliet, TN 37122
Email: MTJLSuboutTeam@pacelabs.com
Phone: (615) 773-9756 Fax (615) 758-5859
Requested Due Date: 28-Apr

Section B

Required Project Information:

Report To: Pace Analytical Subout Team
Copy To:
Purchase Order #: L1603081
Project Name: Oregon DEQ-JH Baxter Offsite Investigati
Project #: 02060.005.004

Section C

Invoice Information:

Attention: Don Hanson
Company Name:
Address:
Pace Quote:
Pace Project Manager: Kongmeng Vang
Pace Profile #: 38076

Regulatory/Agency

State / Location

OR

| ITEM # | SAMPLE ID One Character per box. (A-Z, 0-9 / , -) Sample Ids must be unique | MATRIX Drinking Water Water Waste Water Product Solid/Solid Oil Wipe Air Other Tissue | CODE DW WT WW P SL OL WP AR OT TS | MATRIX CODE (see valid codes to left) | SAMPLE TYPE (G=GRAB C=COMP) | COLLECTED | | | | SAMPLE TEMP AT COLLECTION | # OF CONTAINERS | Preservatives | | | | | | | | Analyses Test Y/N Dioxins and furans by 1613 | Requested Analysis Filtered (Y/N) | | | | | | | | | | Residual Chlorine (Y/N) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--------|--|---|---|---------------------------------------|-----------------------------|-----------|------|--------|-------|---------------------------|-----------------|---------------|-------|------|-----|------|---------|----------|-------|--|-----------------------------------|--|--|--|--|--|--|--|--|--|-------------------------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| | | | | | | START | | END | | | | Unpreserved | H2SO4 | HNO3 | HCl | NaOH | Na2S2O3 | Methanol | Other | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | DATE | TIME | DATE | TIME | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | EB-01-0423 | WT | | | | | | 05-Apr | 15:00 | | 1 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| ADDITIONAL COMMENTS | RELINQUISHED BY / AFFILIATION | DATE | TIME | ACCEPTED BY / AFFILIATION | DATE | TIME | SAMPLE CONDITIONS |
|----------------------------------|-------------------------------|-------|-------|---------------------------|---------|-------|-------------------|
| Pace Analytical Batch: WG2038179 | James C Huckaba | 7-Apr | 17:28 | PACE | 7/11/23 | 17:20 | 1.6 y y y |
| Pace Analytical SDGs: L1603081 | | | | | | | |
| Location: Minneapolis, MN 55414 | | | | | | | |

| | | | | | | |
|----------------------------|--------------|-----------|-----------------------------|----------------------------|-----------------|----------------------------|
| SAMPLER NAME AND SIGNATURE | | TEMP In C | Received on Ice (Y/N) | Custody Sealed (Y/N) | Cooler (Y/N) | Samples Intact (Y/N) |
| PRINT Name of SAMPLER: | | | | | | |
| SIGNATURE of SAMPLER: | DATE Signed: | | | | | |

Effective Date: 11/16/2022

| | | |
|--|---|---|
| Sample Condition Upon Receipt | Client Name: <u>PACE - National</u> | Project #: WO#: 10648781 |
| | Courier: <input checked="" type="checkbox"/> FedEx <input type="checkbox"/> UPS <input type="checkbox"/> USPS <input type="checkbox"/> Client <input type="checkbox"/> Pace <input type="checkbox"/> Speedee <input type="checkbox"/> Commercial | PM: KV Due Date: 05/02/23 CLIENT: ESC_TN |
| Tracking Number: <u>633722427960</u> <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 | | |

| | | |
|--|--|--|
| Custody Seal on Cooler/Box Present? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | Seals Intact? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | Biological Tissue Frozen? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| Packing Material: <input type="checkbox"/> Bubble Wrap <input type="checkbox"/> Bubble Bags <input type="checkbox"/> None <input type="checkbox"/> Other | Temp Blank? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | Type of Ice: <input checked="" type="checkbox"/> Wet <input type="checkbox"/> Blue <input type="checkbox"/> Dry <input type="checkbox"/> None <input type="checkbox"/> Melted |
| Thermometer: <input type="checkbox"/> T1 (0461) <input checked="" type="checkbox"/> T2 (1336) <input type="checkbox"/> T3 (0459) <input type="checkbox"/> T4 (0254) <input type="checkbox"/> T5 (0178) <input type="checkbox"/> T6 (0235) <input type="checkbox"/> T7 (0042) <input type="checkbox"/> T8 (0775) <input type="checkbox"/> T9 (0727) <input type="checkbox"/> 01339252/1710 | | |
| Did Samples Originate in West Virginia? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | Were All Container Temps Taken? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | |
| Temp should be above freezing to 6 °C | Cooler temp Read w/Temp Blank: <u>1.6</u> °C | Average Corrected Temp (no temp blank only): _____ °C |
| Correction Factor: <u>TRUE</u> | Cooler Temp Corrected w/temp blank: <u>1.6</u> °C | <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 <input type="checkbox"/> 1 Container |

USDA Regulated Soil: (☒ N/A, water sample/other: _____)Date/Initials of Person Examining Contents: TO 4/4/23Did samples originate in a quarantine zone within the United States: AL, AR, AZ CA, FL, GA, ID, LA, MS, NC, NM, NY, OK, OR, SC, TN, TX, or VA (check maps)? ☐ Yes ☐ NoDid samples originate from a foreign source (internationally, including Hawaii and Puerto Rico)? ☐ Yes ☐ No

If Yes to either question, fill out a Regulated Soil Checklist (ENV-FRM-MIN4-0154) and include with SCUR/COC paperwork.

| Location (Check one): <input type="checkbox"/> Duluth <input checked="" type="checkbox"/> Minneapolis <input type="checkbox"/> Virginia | COMMENTS |
|--|--|
| Chain of Custody Present and Filled Out? | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 1. |
| Chain of Custody Relinquished? | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 2. |
| Sampler Name and/or Signature on COC? | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> N/A 3. |
| Samples Arrived within Hold Time? | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 4. If fecal: <input type="checkbox"/> <8 hrs <input type="checkbox"/> >8 hr, <24 <input type="checkbox"/> No |
| Short Hold Time Analysis (<72 hr)? | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 5. <input type="checkbox"/> Fecal Coliform <input type="checkbox"/> HPC <input type="checkbox"/> Total Coliform/E.coli <input type="checkbox"/> BOD/cBOD <input type="checkbox"/> Hex Chrom <input type="checkbox"/> Turbidity <input type="checkbox"/> Nitrate <input type="checkbox"/> Nitrite <input type="checkbox"/> Orthophos <input type="checkbox"/> Other _____ |
| Rush Turn Around Time Requested? | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 6. |
| Sufficient Sample Volume? | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 7. |
| Correct Containers Used? | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A 8. |
| -Pace Containers Used? | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Containers Intact? | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 9. |
| Field Filtered Volume Received for Dissolved Tests? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A 10. Is sediment visible in the dissolved container? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| Is sufficient information available to reconcile the samples to the COC? | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 11. If no, write ID/Date/Time of container below: <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 |
| Matrix: <input checked="" type="checkbox"/> Water <input type="checkbox"/> Soil <input type="checkbox"/> Oil <input type="checkbox"/> Other | |
| All containers needing acid/base preservation have been checked? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A 12. Sample # <input type="checkbox"/> NaOH <input type="checkbox"/> HNO3 <input type="checkbox"/> H2SO4 <input type="checkbox"/> Zinc Acetate |
| All containers needing preservation are found to be in compliance with EPA recommendation? (HNO3, H2SO4, <2pH, NaOH >9 Sulfide, NaOH >10 Cyanide) | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| Exceptions: VOA, Coliform, TOC/DOC Oil and Grease, DRO/8015 (water) and Dioxins/PFAS (*If adding preservative to a container, it must be added to associated field and equipment blanks--verify with PM first.) | Positive for Residual Chlorine? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 pH Paper Lot # Residual Chlorine 0-6 Roll 0-6 Strip 0-14 Strip |
| Headspace in Methyl Mercury Container? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A 13. |
| Extra labels present on soil VOA or WIDRO containers? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A 14. <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 |
| Headspace in VOA Vials (greater than 6mm)? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A |
| 3 Trip Blanks Present? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A 15. |
| Trip Blank Custody Seals Present? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A Pace Trip Blank Lot # (if purchased): _____ |

CLIENT NOTIFICATION/RESOLUTION

Person Contacted: _____
Comments/Resolution: _____

Date/Time: _____

Project Manager Review: _____

Date: _____

NOTE: Whenever there is a discrepancy affecting North Carolina compliance samples, a copy of this form will be sent to the North Carolina DEHNR Certification Office (i.e., out of hold, incorrect preservative, out of temp, incorrect containers).

Labeled By: TOLine: 3

Qualtrax ID: 52742

Pace® Analytical Services, LLC

Report No.....10648781_1613BFC_L2_dfr

Page 1 of 1
Page 6 of 11



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Reporting Flags

- A = Reporting Limit based on signal to noise (EDL)
- B = Less than 10x higher than method blank level
- C = Result obtained from confirmation analysis
- D = Result obtained from analysis of diluted sample
- E = Exceeds calibration range
- H2 = Extracted outside of holding time
- I = Isotope ratio out of specification
- J = Estimated value
- L = Suppressive interference, analyte may be biased low
- Nn = Value obtained from additional analysis
- P = PCDE Interference
- R = Recovery outside target range
- S = Peak saturated
- U = Analyte not detected
- V = Result verified by confirmation analysis
- X = %D Exceeds limits
- Y = Calculated using average of daily RFs

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix B

Sample Analysis Summary

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.



Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|--------------|-----------|------------------|
| Client's Sample ID | EB-01-0423 | | |
| Lab Sample ID | 10648781001 | | |
| Filename | F230429A_10 | | |
| Injected By | JRH | | |
| Total Amount Extracted | 1010 mL | Matrix | Water |
| % Moisture | NA | Dilution | NA |
| Dry Weight Extracted | NA | Collected | 04/05/2023 15:00 |
| ICAL ID | F230426 | Received | 04/11/2023 09:20 |
| CCal Filename(s) | F230429A_02 | Extracted | 04/12/2023 14:00 |
| Method Blank ID | BLANK-105253 | Analyzed | 04/29/2023 17:53 |

| Native Isomers | Conc pg/L | EMPC pg/L | EDL pg/L | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|--------------|--------------|-------------|----|--|---------------|---------------------|
| 2,3,7,8-TCDF | ND | — | 1.6 | | 2,3,7,8-TCDF-13C | 2.00 | 68 |
| Total TCDF | ND | — | 1.6 | | 2,3,7,8-TCDD-13C | 2.00 | 63 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 69 |
| 2,3,7,8-TCDD | ND | — | 2.5 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 72 |
| Total TCDD | ND | — | 2.5 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 73 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 79 |
| 1,2,3,7,8-PeCDF | ND | — | 1.6 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 85 |
| 2,3,4,7,8-PeCDF | ND | — | 1.2 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 77 |
| Total PeCDF | ND | — | 1.2 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 68 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 65 |
| 1,2,3,7,8-PeCDD | ND | — | 1.6 | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 80 |
| Total PeCDD | ND | — | 1.6 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 60 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 54 |
| 1,2,3,4,7,8-HxCDF | ND | — | 1.6 | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 58 |
| 1,2,3,6,7,8-HxCDF | ND | — | 1.6 | | OCDD-13C | 4.00 | 46 |
| 2,3,4,6,7,8-HxCDF | ND | — | 1.3 | | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 2.0 | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 3.3 | — | 1.3 | BJ | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 1.6 | 1.4 | IJ | 2,3,7,8-TCDD-37Cl4 | 0.20 | 76 |
| 1,2,3,6,7,8-HxCDD | ND | — | 1.6 | | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 1.5 | | | | |
| Total HxCDD | ND | — | 1.4 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 2.5 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 4.2 | | Equivalence: 0.23 pg/L | | |
| Total HpCDF | ND | — | 2.5 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 5.9 | — | 3.9 | J | | | |
| Total HpCDD | 5.9 | — | 3.9 | J | | | |
| | | | | | | | |
| OCDF | ND | — | 6.6 | | | | |
| OCDD | 30 | — | 9.8 | J | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

J = Estimated value
B = Less than 10x higher than method blank level
I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample Name | DFBLKIA | Matrix | Water |
| Lab Sample ID | BLANK-105253 | Dilution | NA |
| Filename | L230420A_07 | Extracted | 04/12/2023 14:00 |
| Total Amount Extracted | 1010 mL | Analyzed | 04/20/2023 11:20 |
| ICAL ID | L230302 | Injected By | SMT |
| CCal Filename(s) | L230420A_01 | | |

| Native Isomers | Conc pg/L | EMPC pg/L | EDL pg/L | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|--------------|--------------|-------------|---|--|---------------|---------------------|
| 2,3,7,8-TCDF | ND | — | 0.59 | | 2,3,7,8-TCDF-13C | 2.00 | 59 |
| Total TCDF | ND | — | 0.59 | | 2,3,7,8-TCDD-13C | 2.00 | 55 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 71 |
| 2,3,7,8-TCDD | ND | — | 0.84 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 73 |
| Total TCDD | ND | — | 0.84 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 79 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 64 |
| 1,2,3,7,8-PeCDF | — | 1.2 | 0.54 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 59 |
| 2,3,4,7,8-PeCDF | 1.2 | — | 0.44 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 61 |
| Total PeCDF | 1.2 | — | 0.44 | J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 56 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 55 |
| 1,2,3,7,8-PeCDD | 1.5 | — | 0.67 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 59 |
| Total PeCDD | 1.5 | — | 0.67 | J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 53 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 52 |
| 1,2,3,4,7,8-HxCDF | 1.2 | — | 0.58 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 60 |
| 1,2,3,6,7,8-HxCDF | 1.00 | — | 0.51 | J | OCDD-13C | 4.00 | 44 |
| 2,3,4,6,7,8-HxCDF | 0.82 | — | 0.56 | J | | | |
| 1,2,3,7,8,9-HxCDF | 1.9 | — | 0.76 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 4.9 | — | 0.51 | J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 2.8 | — | 0.76 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 64 |
| 1,2,3,6,7,8-HxCDD | 0.82 | — | 0.52 | J | | | |
| 1,2,3,7,8,9-HxCDD | 1.1 | — | 0.61 | J | | | |
| Total HxCDD | 4.8 | — | 0.52 | J | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 1.4 | — | 0.99 | J | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 1.5 | | Equivalence: 2.9 pg/L | | |
| Total HpCDF | 1.4 | — | 0.99 | J | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | ND | — | 1.2 | | | | |
| Total HpCDD | ND | — | 1.2 | | | | |
| | | | | | | | |
| OCDF | ND | — | 3.2 | | | | |
| OCDD | ND | — | 2.3 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample ID | LCS-105254 | Matrix | Water |
| Filename | L230420A_03 | Dilution | NA |
| Total Amount Extracted | 1030 mL | Extracted | 04/12/2023 14:00 |
| ICAL ID | L230302 | Analyzed | 04/20/2023 08:22 |
| CCal Filename | L230420A_01 | Injected By | SMT |
| Method Blank ID | BLANK-105253 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 8.9 | 7.5 | 15.8 | 89 |
| 2,3,7,8-TCDD | 10 | 8.9 | 6.7 | 15.8 | 89 |
| 1,2,3,7,8-PeCDF | 50 | 43 | 40.0 | 67.0 | 86 |
| 2,3,4,7,8-PeCDF | 50 | 43 | 34.0 | 80.0 | 85 |
| 1,2,3,7,8-PeCDD | 50 | 39 | 35.0 | 71.0 | 77 |
| 1,2,3,4,7,8-HxCDF | 50 | 43 | 36.0 | 67.0 | 85 |
| 1,2,3,6,7,8-HxCDF | 50 | 43 | 42.0 | 65.0 | 86 |
| 2,3,4,6,7,8-HxCDF | 50 | 44 | 35.0 | 78.0 | 89 |
| 1,2,3,7,8,9-HxCDF | 50 | 45 | 39.0 | 65.0 | 90 |
| 1,2,3,4,7,8-HxCDD | 50 | 47 | 35.0 | 82.0 | 94 |
| 1,2,3,6,7,8-HxCDD | 50 | 43 | 38.0 | 67.0 | 85 |
| 1,2,3,7,8,9-HxCDD | 50 | 46 | 32.0 | 81.0 | 92 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 41 | 41.0 | 61.0 | 83 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 43 | 39.0 | 69.0 | 85 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 37 | 35.0 | 70.0 | 73 |
| OCDF | 100 | 77 | 63.0 | 170.0 | 77 |
| OCDD | 100 | 89 | 78.0 | 144.0 | 89 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 6.6 | 3.1 | 19.1 | 66 |
| 2,3,7,8-TCDF-13C | 100 | 64 | 22.0 | 152.0 | 64 |
| 2,3,7,8-TCDD-13C | 100 | 60 | 20.0 | 175.0 | 60 |
| 1,2,3,7,8-PeCDF-13C | 100 | 74 | 21.0 | 192.0 | 74 |
| 2,3,4,7,8-PeCDF-13C | 100 | 77 | 13.0 | 328.0 | 77 |
| 1,2,3,7,8-PeCDD-13C | 100 | 83 | 21.0 | 227.0 | 83 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 66 | 19.0 | 202.0 | 66 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 64 | 21.0 | 159.0 | 64 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 64 | 22.0 | 176.0 | 64 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 59 | 17.0 | 205.0 | 59 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 59 | 21.0 | 193.0 | 59 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 64 | 25.0 | 163.0 | 64 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 55 | 21.0 | 158.0 | 55 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 53 | 20.0 | 186.0 | 53 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 65 | 26.0 | 166.0 | 65 |
| OCDD-13C | 200 | 90 | 26.0 | 397.0 | 45 |

Cs = Concentration Spiked (ng/mL)
Cr = Concentration Recovered (ng/mL)
Rec. = Recovery (Expressed as Percent)
Control Limit Reference: Method 1613, Table 6, 10/94 Revision
R = Recovery outside of control limits
Nn = Value obtained from additional analysis
* = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Report Prepared for:

Client Services
Pace Analytical National
12065 Lebanon Rd
Mt. Juliet TN 37122

REPORT OF LABORATORY ANALYSIS FOR PCDD/PCDF

Report Prepared Date:

May 8, 2023

Report Information:


Pace Project #: 10649075
Sample Receipt Date: 04/12/2023
Client Project #: L1603081 WG2039826
Client Sub PO #: L1603081
State Cert #: N/A

Invoicing & Reporting Options:

The report provided has been invoiced as a Level 2 PCDD/PCDF Report. If an upgrade of this report package is requested, an additional charge may be applied.

Please review the attached invoice for accuracy and forward any questions to Kongmeng Vang, your Pace Project Manager.

This report has been reviewed by:



May 08, 2023

Kongmeng Vang, Project Manager
(612) 607-6382
(612) 607-6444 (fax)
kongmeng.vang@pacelabs.com



Report of Laboratory Analysis

This report should not be reproduced, except in full, without the written consent of Pace Analytical Services, Inc.

The results relate only to the samples included in this report.



DISCUSSION

This report presents the results from the analyses performed on twenty-nine samples submitted by a representative of Pace Analytical National. The samples were analyzed for the presence or absence of polychlorodibenzo-p-dioxins (PCDDs) and polychlorodibenzofurans (PCDFs) using USEPA Method 1613B. The estimated detection limits (EDLs) were based on signal-to-noise measurements. Estimated maximum possible concentration (EMPC) values were treated as positives in the toxic equivalence calculations.

The recoveries of the isotopically-labeled PCDD/PCDF internal standards in the sample extracts ranged from 33-109%. Except for one low value, which was flagged "R" on the results table, the labeled standard recoveries obtained for this project were within the target ranges specified in Method 1613B. Also, since the quantification of the native 2,3,7,8-substituted congeners was based on isotope dilution, the data were automatically corrected for recovery and accurate values were obtained.

Values were flagged "I" where incorrect isotope ratios were obtained or "P" where polychlorinated diphenyl ethers were present. Concentrations below the calibration range were flagged "J" and should be regarded as estimates.

A laboratory method blank was prepared and analyzed with each sample batch as part of our routine quality control procedures. The results show the blanks to contain trace levels of selected congeners. These levels were below the calibration range for the method. Sample levels similar to the corresponding blank levels were flagged "B" on the results table and may be, at least partially, attributed to the background.

Laboratory and matrix spike samples were also prepared using clean reference matrix or sample matrix that had been fortified with native standard materials. The recoveries of the spiked native compounds ranged from 91-144% with relative percent differences (RPDs) ranging from 0.3-7.3%. These results were within the target ranges for the method. Matrix spikes were prepared with the sample batch associated with Blank-105366 using sample material from a separate project; results from these analyses will be provided upon request.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Minnesota Laboratory Certifications

| Authority | Certificate # | Authority | Certificate # |
|----------------|----------------|-----------------|----------------|
| A2LA | 2926.01 | Missouri | 10100 |
| Alabama | 40770 | Montana | CERT0092 |
| Alaska-DW | MN00064 | Nebraska | NE-OS-18-06 |
| Alaska-UST | 17-009 | Nevada | MN00064 |
| Arizona | AZ0014 | New Hampshire | 2081 |
| Arkansas - WW | 88-0680 | New Jersey | MN002 |
| Arkansas-DW | MN00064 | New York | 11647 |
| California | 2929 | North Carolina- | 27700 |
| Colorado | MN00064 | North Carolina- | 530 |
| Connecticut | PH-0256 | North Dakota | R-036 |
| Florida | E87605 | Ohio-DW | 41244 |
| Georgia | 959 | Ohio-VAP (170 | CL101 |
| Hawaii | MN00064 | Ohio-VAP (180 | CL110 |
| Idaho | MN00064 | Oklahoma | 9507 |
| Illinois | 200011 | Oregon-Primary | MN300001 |
| Indiana | C-MN-01 | Oregon-Second | MN200001 |
| Iowa | 368 | Pennsylvania | 68-00563 |
| Kansas | E-10167 | Puerto Rico | MN00064 |
| Kentucky-DW | 90062 | South Carolina | 74003 |
| Kentucky-WW | 90062 | Tennessee | TN02818 |
| Louisiana-DEQ | AI-84596 | Texas | T104704192 |
| Louisiana-DW | MN00064 | Utah | MN00064 |
| Maine | MN00064 | Vermont | VT-027053137 |
| Maryland | 322 | Virginia | 460163 |
| Michigan | 9909 | Washington | C486 |
| Minnesota | 027-053-137 | West Virginia-D | 382 |
| Minnesota-Ag | via MN 027-053 | West Virginia-D | 9952C |
| Minnesota-Petr | 1240 | Wisconsin | 999407970 |
| Mississippi | MN00064 | Wyoming-UST | via A2LA 2926. |

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix A

Sample Management

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.

CHAIN-OF-CUSTODY / Analytical Request

The Chain-of-Custody is a LEGAL DOCUMENT. All relevant fields must be completed.

WO#: 10649075



Report No: 10649075-16-38EC-12-dfr

| | | | | | |
|---|--|--|--|-------------------------------------|--|
| Section A Required Client Information: | | Section B Required Project Information: | | Section C Invoice Information: | |
| Company: Pace Analytical | | Report To: Pace Analytical Subout Team | | Attention: Don Hanson | |
| Address: 12065 Lebanon Rd. | | Copy To: | | Company Name: | |
| City: Juliet, TN 37122 | | Purchase Order #: L1603081 | | Address: | |
| Email: MTJLSuboutTeam@pacelabs.com | | Project Name: Oregon DEQ-JH Baxter Offsite Investigation | | Pace Quote: | |
| Phone: (615) 773-9756 Fax: (615) 758-5859 | | Project #: 02060.005.004 | | Pace Project Manager: Kongmeng Vang | |
| Requested Due Date: 3-May | | Pace Profile #: 38076 | | Regulatory Agency: | |
| | | | | State / Location: | |
| | | | | OR | |

3BEC_12_dfr

ITEM #

SAMPLE ID

One Character per box.
(A-Z, 0-9 / , -)
Sample Ids must be unique

MATRIX

Drinking Water
Water
Waste Water
Product
Soil/Solid
Oil
Wipe
Air
Other
Tissue

CODE

DW
WT
WW
P
SL
OL
WP
AR
OT
TS

MATRIX CODE (see valid codes to left)

SAMPLE TYPE (G-GRAB C-COMP)

COLLECTED

START

END

DATE

TIME

DATE

TIME

SAMPLE TEMP AT COLLECTION

OF CONTAINERS

Preservatives

Unpreserved
H2SO4
HNO3
HCl
NaOH
Na2S2O3
Methanol
Other

Analyses Test

Y/N

Requested Analysis Filtered (Y/N)

Dioxins and Furans 1613

Residual Chlorine (Y/N)

1

DU-06B-0.5-1.0_0423

SL

05-Apr

14:30

1

1

X

Report No. 1064907 16 3BFC L2 dfr

Page 48 of 48

Page 48 of 48[illegible]

Report No. A064975R 6/3BEC 12.dfr Page 7 of 48

Report No. A064975R 6/3BEC 12.dfr Page 7 of 48

Report No. A064975R 6/3BEC 12.dfr Page 7 of 48

Effective Date: 11/16/2022

Sample Condition
Upon Receipt

Client Name:

Pace MT Juliet

Project #:

WO#: 10649075

PM: KV

Due Date: 05/03/23

CLIENT: ESC_TN

Courier: ☒ FedEx ☐ UPS ☐ USPS ☐ Client
☐ Pace ☐ SpeedDee ☐ Commercial

Tracking Number: 7718 17238400

☐ See Exceptions
ENV-FRM-MIN4-0142Custody Seal on Cooler/Box Present? ☒ Yes ☐ No Seals Intact? ☐ Yes ☐ NoBiological Tissue Frozen? ☐ Yes ☐ No ☒ N/APacking Material: ☐ Bubble Wrap ☒ Bubble Bags ☐ None ☐ OtherTemp Blank? ☒ Yes ☐ NoThermometer: ☐ T1 (0461) ☐ T2 (1336) ☐ T3 (0459) ☒ T4 (0254) ☐ T5 (0178)Type of Ice: ☒ Wet ☐ Blue ☐ Dry ☐ None☐ T6 (0235) ☐ T7 (0042) ☐ T8 (0775) ☐ T9 (0727) ☐ 01339252/1710☒ MeltedDid Samples Originate in West Virginia? ☐ Yes ☒ NoWere All Container Temps Taken? ☐ Yes ☐ No ☒ N/A

Temp should be above freezing to 6 °C

Cooler temp Read w/Temp Blank: 4.1, 1.3°C

Average Corrected Temp

(no temp blank only): °C

Correction Factor: add 0.1

Cooler Temp Corrected w/temp blank: 4.2, 1.4°C

☐ See Exceptions ENV-FRM-MIN4-0142 ☐ 1 ContainerUSDA Regulated Soil: (☐ N/A, water sample/other:)

Date/Initials of Person Examining Contents: 4/12/23 ADZ

Did samples originate in a quarantine zone within the United States: AL, AR, AZ CA, FL, GA, ID, LA, MS, NC, NM, NY, OK, OR, SC, TN, TX, or VA (check maps)? ☒ Yes ☒ NoDid samples originate from a foreign source (internationally, including Hawaii and Puerto Rico)? ☐ Yes ☒ No

If Yes to either question, fill out a Regulated Soil Checklist (ENV-FRM-MIN4-0154) and include with SCUR/COC paperwork.

| Location (Check one): <input type="checkbox"/> Duluth <input checked="" type="checkbox"/> Minneapolis <input type="checkbox"/> Virginia | COMMENTS |
|---|--|
| Chain of Custody Present and Filled Out? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 1. |
| Chain of Custody Relinquished? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 2. |
| Sampler Name and/or Signature on COC? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> N/A | 3. |
| Samples Arrived within Hold Time? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 4. If fecal: <input type="checkbox"/> <8 hrs <input type="checkbox"/> >8 hr, <24 <input type="checkbox"/> No |
| Short Hold Time Analysis (<72 hr)? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | 5. <input type="checkbox"/> Fecal Coliform <input type="checkbox"/> HPC <input type="checkbox"/> Total Coliform/E.coli <input type="checkbox"/> BOD/cBOD <input type="checkbox"/> Hex Chrom <input type="checkbox"/> Turbidity <input type="checkbox"/> Nitrate <input type="checkbox"/> Nitrite <input type="checkbox"/> Orthophos <input type="checkbox"/> Other |
| Rush Turn Around Time Requested? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | 6. |
| Sufficient Sample Volume? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 7. |
| Correct Containers Used? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A | 8. |
| -Pace Containers Used? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 9. |
| Containers Intact? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 10. Is sediment visible in the dissolved container? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| Field Filtered Volume Received for Dissolved Tests? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | 11. If no, write ID/Date/Time of container below: <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 |
| Is sufficient information available to reconcile the samples to the COC? Matrix: <input type="checkbox"/> Water <input checked="" type="checkbox"/> Soil <input type="checkbox"/> Oil <input type="checkbox"/> Other | 12. Sample # <input type="checkbox"/> NaOH <input type="checkbox"/> HNO3 <input type="checkbox"/> H2SO4 <input type="checkbox"/> Zinc Acetate |
| All containers needing acid/base preservation have been checked? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | Positive for Residual Chlorine? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 |
| All containers needing preservation are found to be in compliance with EPA recommendation? (HNO3, H2SO4, <2pH, NaOH >9 Sulfide, NaOH >10 Cyanide) | pH Paper Lot # |
| Exceptions: VOA, Coliform, TOC/DOC Oil and Grease, DRO/8015 (water) and Dioxins/PFAS (*If adding preservative to a container, it must be added to associated field and equipment blanks--verify with PM first.) | Residual Chlorine 0-6 Roll 0-6 Strip 0-14 Strip |
| Headspace in Methyl Mercury Container? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | 13. |
| Extra labels present on soil VOA or WIDRO containers? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | 14. <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 |
| Headspace in VOA Vials (greater than 6mm)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | 15. |
| 3 Trip Blanks Present? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | Pace Trip Blank Lot # (if purchased): |
| Trip Blank Custody Seals Present? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | |

CLIENT NOTIFICATION/RESOLUTION

Person Contacted: _____

Date/Time: _____

Comments/Resolution: _____


Project Manager Review: _____

Date: _____

NOTE: Whenever there is a discrepancy affecting North Carolina compliance samples, a copy of this form will be sent to the North Carolina DEHNR Certification Office (i.e., out of hold, incorrect preservative, out of temp, incorrect containers).

Labeled By: ADGZ

Line: 3

| | |
|--|---|
|  | DC#_Title: ENV-FRM-MIN4-0154 v02_USDA Regulated Soil Checklist |
| | Effective Date: 08/19/2022 |

USDA Regulated Soil Checklist

To be Completed by Sample Receiving:

WO: 10649075 **Date:** 5/4/2023 **Initials:** EMC2

Sample Origin (check one): ☐ DOMESTIC ☐ QUARANTINED ☐ FOREIGN

NOTE: Soil samples from Hawaii, Guam, Puerto Rico, and the US Virgin Islands are Foreign originated.

If **DOMESTIC**, circle state of origin: AL AR AZ CA FL GA LA MS NC NM NY OK OR SC TN TX VA
Includes: IFA, SOD, Golden Nematode, Karnal Bunt, and Witchweed

List County: Lane

(USDA Permit/Compliance Agreement authorizes movement of samples from these domestic regulated zones)

If **QUARANTINED**, circle state of origin: CA ID NY TX

Includes: Fruit Fly and Pale Cyst Nematode

List County: _____

(Movement is not authorized for Pale Cyst Nematode (ID)—remaining quarantines require additional paperwork)


If **FOREIGN**, list country of origin: _____

(Movement from some Canadian Provinces is not allowed. Refer to ENV-FRM-MIN4-0137 Regulated Soil Flow Chart)

| REQUIREMENT | ACTION | COMPLETED | | |
|---|--|-----------|----|------------|
| PPQ-530 Paperwork must be included for any samples from counties with a Fruit Fly Quarantine in CA, NY, and TX. Reference ENV-SOP-MIN4-0095. | Scan PPQ-530 to the corresponding Project folder on the X:drive. If PPQ-530 is not present, contact the laboratory's designated USDA permit holder. Do NOT continue processing samples. | YES | NO | <u>N/A</u> |
| Samples from ID may not be moved from the quarantined region. Reference ENV-SOP-MIN4-0095. | If samples originated in a quarantined zone, contact the laboratory's designated USDA permit holder. Do NOT continue processing samples. | YES | NO | <u>N/A</u> |

| REQUIREMENT | ACTION | COMPLETED | | |
|--|---|-----------|----|------------|
| "Special Handling" stickers are to be placed on all samples. | Did "special handling" stickers get placed on all sample containers? | YES | NO | <u>N/A</u> |
| Samples must be segregated and stored in designated bins, shelves, and coolers. | Were samples placed in a designated cooler, containers, and shelves? | YES | NO | <u>N/A</u> |
| Samples must be double contained to prevent accidental release. | Were there any signs of breakage or leakage (check for broken glass and/or loose soil in the cooler)? <i>NOTE: If NO, ice and melt water can be disposed of by normal process (ex: down the drain).</i> | YES | NO | <u>N/A</u> |
| | If YES , were ice and melt water separated from the cooler and disposed of properly? | YES | NO | <u>N/A</u> |
| | Any broken glass and/or loose soil are to be bagged and placed in a USDA Regulated satellite container or active drum (see Waste Coordinator). Ice and melt water should be baked at a temperature range of 121-154°F for 2 hours and then cooled before going down the drain. | | | |
| Equipment and supplies that have come into contact samples must be decontaminated. | Was the cooler(s) and/or countertop(s) decontaminated using either a fresh 10% bleach solution or 70% ethanol? (Gloves and other lab supplies will be bagged and placed in the USDA Regulated satellite container or active drum). | YES | | <u>N/A</u> |

COMMENTS:

| | |
|---|---|
|  | DC#_Title: ENV-FRM-MIN4-0154 v02_USDA Regulated Soil Checklist |
| | Effective Date: 08/19/2022 |

To be Completed by Project Management (PM and/or PC):

Sample analysis will be conducted (circle all that apply): MN Subcontract Lab

If subcontract, list lab(s): _____

| REQUIREMENT | ACTION | COMPLETED | | |
|---|--|-----------|----|-----|
| Permission to ship untreated soil must be on file prior to shipping to any subcontract lab, including IR Pace Labs. | Go to: S:\CLIENTSVR\10_Client Services Department Documents\Regulated Soils Permits\Permission to Ship If permission to ship letter is not there, contact the laboratory's designated USDA permit holder. | YES | NO | N/A |
| Shipment must include a valid copy of the receiving lab's permit as well as permission to ship letter. | Is a copy of all needed paperwork included with the COC? Do NOT ship samples until all necessary paperwork is compiled. | YES | NO | N/A |

COMMENTS:

PM Signature: _____ **Date:** _____



Reporting Flags

- A = Reporting Limit based on signal to noise (EDL)
- B = Less than 10x higher than method blank level
- C = Result obtained from confirmation analysis
- D = Result obtained from analysis of diluted sample
- E = Exceeds calibration range
- H2 = Extracted outside of holding time
- I = Isotope ratio out of specification
- J = Estimated value
- L = Suppressive interference, analyte may be biased low
- Nn = Value obtained from additional analysis
- P = PCDE Interference
- R = Recovery outside target range
- S = Peak saturated
- U = Analyte not detected
- V = Result verified by confirmation analysis
- X = %D Exceeds limits
- Y = Calculated using average of daily RFs

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix B

Sample Analysis Summary

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-06B-0.5-1.0_0423 | | |
| Lab Sample ID | 10649075001 | | |
| Filename | U230503C_02 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 3.9 | Dilution | NA |
| Dry Weight Extracted | 10.0 g | Collected | 04/05/2023 14:30 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/03/2023 22:54 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.16 | | 2,3,7,8-TCDF-13C | 2.00 | 72 |
| Total TCDF | 2.0 | — | 0.16 | | 2,3,7,8-TCDD-13C | 2.00 | 68 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 82 |
| 2,3,7,8-TCDD | 0.50 | — | 0.47 J | | 2,3,4,7,8-PeCDF-13C | 2.00 | 80 |
| Total TCDD | 5.6 | — | 0.47 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 89 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 71 |
| 1,2,3,7,8-PeCDF | 0.31 | — | 0.13 J | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 70 |
| 2,3,4,7,8-PeCDF | — | 0.28 | 0.088 IJ | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 69 |
| Total PeCDF | 3.4 | — | 0.088 J | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 69 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 70 |
| 1,2,3,7,8-PeCDD | 0.88 | — | 0.16 J | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 77 |
| Total PeCDD | 8.2 | — | 0.16 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 70 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 68 |
| 1,2,3,4,7,8-HxCDF | 0.80 | — | 0.13 J | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 79 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.11 | | OCDD-13C | 4.00 | 60 |
| 2,3,4,6,7,8-HxCDF | 0.73 | — | 0.13 J | | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.30 | 0.14 IJ | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 15 | — | 0.11 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 1.4 | — | 0.29 J | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 69 |
| 1,2,3,6,7,8-HxCDD | 2.9 | — | 0.16 J | | | | |
| 1,2,3,7,8,9-HxCDD | 2.2 | — | 0.25 J | | | | |
| Total HxCDD | 39 | — | 0.16 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 27 | 0.19 P | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 0.82 | — | 0.16 J | | Equivalence: 3.8 ng/Kg | | |
| Total HpCDF | 35 | — | 0.16 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 95 | — | 0.27 | | | | |
| Total HpCDD | 250 | — | 0.27 | | | | |
| | | | | | | | |
| OCDF | 49 | — | 0.39 | | | | |
| OCDD | 860 | — | 0.32 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-06B-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075002 | | |
| Filename | U230503C_03 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 4.0 | Dilution | NA |
| Dry Weight Extracted | 9.95 g | Collected | 04/05/2023 14:35 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/03/2023 23:41 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.11 | | 2,3,7,8-TCDF-13C | 2.00 | 67 |
| Total TCDF | 0.14 | — | 0.11 | J | 2,3,7,8-TCDD-13C | 2.00 | 55 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 79 |
| 2,3,7,8-TCDD | ND | — | 0.26 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 80 |
| Total TCDD | ND | — | 0.26 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 90 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 74 |
| 1,2,3,7,8-PeCDF | ND | — | 0.14 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 71 |
| 2,3,4,7,8-PeCDF | ND | — | 0.093 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 70 |
| Total PeCDF | ND | — | 0.093 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 69 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 68 |
| 1,2,3,7,8-PeCDD | ND | — | 0.31 | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 78 |
| Total PeCDD | 1.2 | — | 0.31 | J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 71 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 71 |
| 1,2,3,4,7,8-HxCDF | — | 0.14 | 0.098 | IJ | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 81 |
| 1,2,3,6,7,8-HxCDF | — | 0.23 | 0.12 | IJ | OCDD-13C | 4.00 | 63 |
| 2,3,4,6,7,8-HxCDF | 0.18 | — | 0.063 | J | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.17 | 0.070 | IJ | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 1.5 | — | 0.063 | BJ | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.41 | 0.20 | IJ | 2,3,7,8-TCDD-37Cl4 | 0.20 | 57 |
| 1,2,3,6,7,8-HxCDD | 0.60 | — | 0.15 | J | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.49 | 0.11 | IJ | | | |
| Total HxCDD | 6.6 | — | 0.11 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 5.1 | 0.18 | P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.21 | | Equivalence: 0.50 ng/Kg | | |
| Total HpCDF | 6.3 | — | 0.18 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 18 | — | 0.30 | | | | |
| Total HpCDD | 47 | — | 0.30 | | | | |
| | | | | | | | |
| OCDF | 10 | — | 0.43 | | | | |
| OCDD | 160 | — | 0.45 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-01A-0.5-1.0_0423 | | |
| Lab Sample ID | 10649075003 | | |
| Filename | U230503C_04 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.7 g | Matrix | Solid |
| % Moisture | 4.0 | Dilution | NA |
| Dry Weight Extracted | 10.2 g | Collected | 04/05/2023 15:30 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 00:28 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.14 | | 2,3,7,8-TCDF-13C | 2.00 | 71 |
| Total TCDF | 1.00 | — | 0.14 | | 2,3,7,8-TCDD-13C | 2.00 | 66 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 81 |
| 2,3,7,8-TCDD | ND | — | 0.27 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 82 |
| Total TCDD | 1.5 | — | 0.27 | B | 1,2,3,7,8-PeCDD-13C | 2.00 | 91 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDF | ND | — | 0.14 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 76 |
| 2,3,4,7,8-PeCDF | ND | — | 0.075 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 73 |
| Total PeCDF | 2.3 | — | 0.075 | J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 66 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 73 |
| 1,2,3,7,8-PeCDD | 0.26 | — | 0.14 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 82 |
| Total PeCDD | 2.2 | — | 0.14 | J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 75 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 75 |
| 1,2,3,4,7,8-HxCDF | — | 0.15 | 0.13 | IJ | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 86 |
| 1,2,3,6,7,8-HxCDF | 0.53 | — | 0.16 | J | OCDD-13C | 4.00 | 65 |
| 2,3,4,6,7,8-HxCDF | 0.20 | — | 0.15 | J | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.096 | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 4.2 | — | 0.096 | J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.49 | 0.20 | IJ | 2,3,7,8-TCDD-37Cl4 | 0.20 | 64 |
| 1,2,3,6,7,8-HxCDD | 0.78 | — | 0.19 | J | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.77 | 0.18 | IJ | | | |
| Total HxCDD | 4.6 | — | 0.18 | J | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 6.6 | 0.19 | P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.24 | | Equivalence: 0.90 ng/Kg | | |
| Total HpCDF | 7.1 | — | 0.19 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 21 | — | 0.29 | | | | |
| Total HpCDD | 50 | — | 0.29 | | | | |
| | | | | | | | |
| OCDF | 11 | — | 0.37 | | | | |
| OCDD | 220 | — | 0.83 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-01A-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075004 | | |
| Filename | U230503C_05 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 4.5 | Dilution | NA |
| Dry Weight Extracted | 9.89 g | Collected | 04/05/2023 15:35 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 01:14 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.26 | | 2,3,7,8-TCDF-13C | 2.00 | 78 |
| Total TCDF | ND | — | 0.26 | | 2,3,7,8-TCDD-13C | 2.00 | 65 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 88 |
| 2,3,7,8-TCDD | ND | — | 0.49 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 89 |
| Total TCDD | ND | — | 0.49 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 99 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDF | ND | — | 0.16 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 75 |
| 2,3,4,7,8-PeCDF | ND | — | 0.14 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 72 |
| Total PeCDF | 0.45 | — | 0.14 | J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 74 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 72 |
| 1,2,3,7,8-PeCDD | ND | — | 0.18 | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 81 |
| Total PeCDD | ND | — | 0.18 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 74 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 74 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.13 | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 85 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.13 | | OCDD-13C | 4.00 | 63 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.14 | | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.23 | 0.14 | IJ | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 0.95 | — | 0.13 | BJ | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.19 | 0.16 | IJ | 2,3,7,8-TCDD-37Cl4 | 0.20 | 68 |
| 1,2,3,6,7,8-HxCDD | 0.38 | — | 0.16 | J | | | |
| 1,2,3,7,8,9-HxCDD | 0.27 | — | 0.15 | J | | | |
| Total HxCDD | 3.0 | — | 0.15 | J | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 2.6 | 0.23 | PJ | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.27 | | Equivalence: 0.24 ng/Kg | | |
| Total HpCDF | 2.8 | — | 0.23 | J | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 8.3 | — | 0.46 | | | | |
| Total HpCDD | 18 | — | 0.46 | | | | |
| | | | | | | | |
| OCDF | 3.8 | — | 0.34 | J | | | |
| OCDD | 83 | — | 0.32 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-01B-0.5-1.0_0423 | | |
| Lab Sample ID | 10649075005 | | |
| Filename | U230503C_06 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.7 g | Matrix | Solid |
| % Moisture | 3.4 | Dilution | NA |
| Dry Weight Extracted | 10.4 g | Collected | 04/05/2023 15:55 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 02:01 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.71 | | 2,3,7,8-TCDF-13C | 2.00 | 72 |
| Total TCDF | 0.94 | — | 0.71 J | | 2,3,7,8-TCDD-13C | 2.00 | 68 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 84 |
| 2,3,7,8-TCDD | 1.8 | — | 0.46 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 88 |
| Total TCDD | 2.9 | — | 0.46 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 96 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 74 |
| 1,2,3,7,8-PeCDF | ND | — | 0.48 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 74 |
| 2,3,4,7,8-PeCDF | 0.65 | — | 0.50 J | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 70 |
| Total PeCDF | 6.0 | — | 0.48 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 67 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 73 |
| 1,2,3,7,8-PeCDD | 0.56 | — | 0.20 J | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 78 |
| Total PeCDD | 4.5 | — | 0.20 J | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 73 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 72 |
| 1,2,3,4,7,8-HxCDF | 0.91 | — | 0.092 J | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 83 |
| 1,2,3,6,7,8-HxCDF | — | 0.80 | 0.17 PJ | | OCDD-13C | 4.00 | 62 |
| 2,3,4,6,7,8-HxCDF | 0.93 | — | 0.12 J | | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.43 | 0.14 J | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 13 | — | 0.092 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.83 | 0.41 J | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 73 |
| 1,2,3,6,7,8-HxCDD | 2.3 | — | 0.36 J | | | | |
| 1,2,3,7,8,9-HxCDD | — | 1.4 | 0.37 J | | | | |
| Total HxCDD | 22 | — | 0.36 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 17 | 0.21 P | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | — | 0.60 | 0.27 J | | Equivalence: 4.1 ng/Kg | | |
| Total HpCDF | 15 | — | 0.21 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 50 | — | 0.35 | | | | |
| Total HpCDD | 110 | — | 0.35 | | | | |
| | | | | | | | |
| OCDF | 21 | — | 0.46 | | | | |
| OCDD | 480 | — | 0.34 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|----------------------|-----------|------------------|
| Client's Sample ID | DU-110A-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075006 | | |
| Filename | F230503A_08 | | |
| Injected By | SM | | |
| Total Amount Extracted | 10.7 g | Matrix | Solid |
| % Moisture | 4.1 | Dilution | NA |
| Dry Weight Extracted | 10.3 g | Collected | 04/05/2023 09:50 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230502B_18 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/03/2023 10:12 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.39 | 2,3,7,8-TCDF-13C | 2.00 | 59 |
| Total TCDF | 1.6 | — | 0.39 | 2,3,7,8-TCDD-13C | 2.00 | 33 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 71 |
| 2,3,7,8-TCDD | — | 1.2 | 0.60 I | 2,3,4,7,8-PeCDF-13C | 2.00 | 77 |
| Total TCDD | ND | — | 0.60 | 1,2,3,7,8-PeCDD-13C | 2.00 | 79 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 71 |
| 1,2,3,7,8-PeCDF | ND | — | 0.46 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 76 |
| 2,3,4,7,8-PeCDF | 0.40 | — | 0.23 J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 72 |
| Total PeCDF | 2.1 | — | 0.23 J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 62 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 67 |
| 1,2,3,7,8-PeCDD | — | 0.27 | 0.085 U | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 77 |
| Total PeCDD | 2.9 | — | 0.085 J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 67 |
| 1,2,3,4,7,8-HxCDF | 1.2 | — | 0.26 J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 75 |
| 1,2,3,6,7,8-HxCDF | — | 2.2 | 0.27 PJ | OCDD-13C | 4.00 | 62 |
| 2,3,4,6,7,8-HxCDF | — | 0.40 | 0.21 U | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.39 | 0.36 U | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 18 | — | 0.21 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.65 | 0.15 U | 2,3,7,8-TCDD-37Cl4 | 0.20 | 33 R |
| 1,2,3,6,7,8-HxCDD | 2.3 | — | 0.13 J | | | |
| 1,2,3,7,8,9-HxCDD | 1.6 | — | 0.18 J | | | |
| Total HxCDD | 24 | — | 0.13 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 28 | — | 0.74 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 1.9 | — | 0.52 J | Equivalence: 4.1 ng/Kg | | |
| Total HpCDF | 93 | — | 0.52 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 91 | — | 0.32 | | | |
| Total HpCDD | 250 | — | 0.32 | | | |
| | | | | | | |
| OCDF | 120 | — | 0.46 | | | |
| OCDD | 1100 | — | 0.56 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

R = Recovery outside target range

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-10B-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075007 | | |
| Filename | U230503C_07 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.3 g | Matrix | Solid |
| % Moisture | 3.8 | Dilution | NA |
| Dry Weight Extracted | 9.90 g | Collected | 04/05/2023 10:20 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 02:48 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.33 | | 2,3,7,8-TCDF-13C | 2.00 | 72 |
| Total TCDF | 0.51 | — | 0.33 J | | 2,3,7,8-TCDD-13C | 2.00 | 62 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 84 |
| 2,3,7,8-TCDD | — | 0.56 | 0.35 U | | 2,3,4,7,8-PeCDF-13C | 2.00 | 84 |
| Total TCDD | 1.8 | — | 0.35 B | | 1,2,3,7,8-PeCDD-13C | 2.00 | 93 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 71 |
| 1,2,3,7,8-PeCDF | ND | — | 0.20 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 69 |
| 2,3,4,7,8-PeCDF | — | 0.25 | 0.15 U | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 71 |
| Total PeCDF | 2.0 | — | 0.15 J | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 68 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 68 |
| 1,2,3,7,8-PeCDD | — | 0.25 | 0.15 U | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 77 |
| Total PeCDD | 1.6 | — | 0.15 J | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 71 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 72 |
| 1,2,3,4,7,8-HxCDF | 0.92 | — | 0.12 J | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 83 |
| 1,2,3,6,7,8-HxCDF | — | 0.30 | 0.12 PJ | | OCDD-13C | 4.00 | 65 |
| 2,3,4,6,7,8-HxCDF | 0.75 | — | 0.11 J | | | | |
| 1,2,3,7,8,9-HxCDF | 0.39 | — | 0.12 BJ | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 14 | — | 0.11 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.78 | — | 0.37 J | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 64 |
| 1,2,3,6,7,8-HxCDD | 1.8 | — | 0.43 J | | | | |
| 1,2,3,7,8,9-HxCDD | 1.4 | — | 0.27 J | | | | |
| Total HxCDD | 18 | — | 0.27 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 32 | 0.31 P | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 0.98 | — | 0.50 J | | Equivalence: 2.6 ng/Kg | | |
| Total HpCDF | 37 | — | 0.31 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 55 | — | 0.086 | | | | |
| Total HpCDD | 120 | — | 0.086 | | | | |
| | | | | | | | |
| OCDF | 71 | — | 0.22 | | | | |
| OCDD | 580 | — | 0.24 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-10B-1.5-2.0_0423 | | |
| Lab Sample ID | 10649075008 | | |
| Filename | U230503C_08 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 3.9 | Dilution | NA |
| Dry Weight Extracted | 9.99 g | Collected | 04/05/2023 09:50 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 03:35 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.17 | | 2,3,7,8-TCDF-13C | 2.00 | 74 |
| Total TCDF | ND | — | 0.17 | | 2,3,7,8-TCDD-13C | 2.00 | 45 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 84 |
| 2,3,7,8-TCDD | 0.99 | — | 0.44 J | | 2,3,4,7,8-PeCDF-13C | 2.00 | 88 |
| Total TCDD | 0.99 | — | 0.44 BJ | | 1,2,3,7,8-PeCDD-13C | 2.00 | 97 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 75 |
| 1,2,3,7,8-PeCDF | ND | — | 0.17 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 73 |
| 2,3,4,7,8-PeCDF | ND | — | 0.11 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 72 |
| Total PeCDF | ND | — | 0.11 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 67 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 70 |
| 1,2,3,7,8-PeCDD | — | 0.26 | 0.15 J | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 80 |
| Total PeCDD | 0.65 | — | 0.15 J | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 72 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 75 |
| 1,2,3,4,7,8-HxCDF | 0.42 | — | 0.23 J | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 86 |
| 1,2,3,6,7,8-HxCDF | — | 0.31 | 0.21 J | | OCDD-13C | 4.00 | 62 |
| 2,3,4,6,7,8-HxCDF | — | 0.38 | 0.22 J | | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.35 | 0.13 J | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 7.3 | — | 0.13 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.63 | 0.25 J | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 43 |
| 1,2,3,6,7,8-HxCDD | 1.4 | — | 0.26 J | | | | |
| 1,2,3,7,8,9-HxCDD | 1.1 | — | 0.24 J | | | | |
| Total HxCDD | 10 | — | 0.24 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 19 | 0.19 P | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | — | 0.52 | 0.26 J | | Equivalence: 2.4 ng/Kg | | |
| Total HpCDF | 18 | — | 0.19 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 34 | — | 0.12 | | | | |
| Total HpCDD | 68 | — | 0.12 | | | | |
| | | | | | | | |
| OCDF | 40 | — | 0.60 | | | | |
| OCDD | 340 | — | 0.20 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-09A-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075009 | | |
| Filename | U230503C_09 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 3.8 | Dilution | NA |
| Dry Weight Extracted | 9.96 g | Collected | 04/05/2023 11:30 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 04:21 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.43 | | 2,3,7,8-TCDF-13C | 2.00 | 71 |
| Total TCDF | 1.3 | — | 0.43 | | 2,3,7,8-TCDD-13C | 2.00 | 67 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 81 |
| 2,3,7,8-TCDD | 4.8 | — | 0.75 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 83 |
| Total TCDD | 4.8 | — | 0.75 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 93 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 69 |
| 1,2,3,7,8-PeCDF | ND | — | 0.63 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 70 |
| 2,3,4,7,8-PeCDF | — | 0.84 | 0.30 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 68 |
| Total PeCDF | 9.1 | — | 0.30 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 68 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 69 |
| 1,2,3,7,8-PeCDD | 0.94 | — | 0.24 | J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 76 |
| Total PeCDD | 7.5 | — | 0.24 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 70 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 67 |
| 1,2,3,4,7,8-HxCDF | 4.3 | — | 0.41 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 79 |
| 1,2,3,6,7,8-HxCDF | — | 1.2 | 0.55 | PJ | OCDD-13C | 4.00 | 60 |
| 2,3,4,6,7,8-HxCDF | 2.3 | — | 0.39 | J | | | |
| 1,2,3,7,8,9-HxCDF | 0.92 | — | 0.44 | BJ | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 59 | — | 0.39 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 2.2 | — | 0.82 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 70 |
| 1,2,3,6,7,8-HxCDD | 6.5 | — | 0.54 | | | | |
| 1,2,3,7,8,9-HxCDD | 3.7 | — | 0.46 | J | | | |
| Total HxCDD | 49 | — | 0.46 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 160 | 0.51 | P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 4.5 | — | 0.67 | J | Equivalence: 13 ng/Kg | | |
| Total HpCDF | 200 | — | 0.51 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 210 | — | 0.14 | | | | |
| Total HpCDD | 420 | — | 0.14 | | | | |
| | | | | | | | |
| OCDF | 420 | — | 0.66 | | | | |
| OCDD | 3900 | — | 0.98 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-09A-1.5-2.0_0423 | | |
| Lab Sample ID | 10649075010 | | |
| Filename | U230503C_10 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.2 g | Matrix | Solid |
| % Moisture | 3.8 | Dilution | NA |
| Dry Weight Extracted | 9.78 g | Collected | 04/05/2023 11:35 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 05:08 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.34 | | 2,3,7,8-TCDF-13C | 2.00 | 77 |
| Total TCDF | 0.40 | — | 0.34 | J | 2,3,7,8-TCDD-13C | 2.00 | 61 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 90 |
| 2,3,7,8-TCDD | ND | — | 0.51 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 92 |
| Total TCDD | 1.2 | — | 0.51 | B | 1,2,3,7,8-PeCDD-13C | 2.00 | 101 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDF | ND | — | 0.35 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 76 |
| 2,3,4,7,8-PeCDF | ND | — | 0.24 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 74 |
| Total PeCDF | 2.3 | — | 0.24 | J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 72 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 73 |
| 1,2,3,7,8-PeCDD | ND | — | 0.24 | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 82 |
| Total PeCDD | ND | — | 0.24 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 79 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 77 |
| 1,2,3,4,7,8-HxCDF | 0.87 | — | 0.30 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 92 |
| 1,2,3,6,7,8-HxCDF | — | 1.2 | 0.33 | PJ | OCDD-13C | 4.00 | 73 |
| 2,3,4,6,7,8-HxCDF | 0.45 | — | 0.23 | J | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.26 | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 12 | — | 0.23 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.64 | — | 0.28 | J | 2,3,7,8-TCDD-37Cl ₄ | 0.20 | 60 |
| 1,2,3,6,7,8-HxCDD | 1.3 | — | 0.29 | J | | | |
| 1,2,3,7,8,9-HxCDD | 1.0 | — | 0.28 | J | | | |
| Total HxCDD | 12 | — | 0.28 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 28 | 0.29 | P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 0.81 | — | 0.35 | J | Equivalence: 1.5 ng/Kg | | |
| Total HpCDF | 33 | — | 0.29 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 46 | — | 0.43 | | | | |
| Total HpCDD | 92 | — | 0.43 | | | | |
| | | | | | | | |
| OCDF | 68 | — | 1.1 | | | | |
| OCDD | 680 | — | 0.98 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

P = PCDE Interference

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-09B-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075011 | | |
| Filename | U230503C_11 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.2 g | Matrix | Solid |
| % Moisture | 3.8 | Dilution | NA |
| Dry Weight Extracted | 9.84 g | Collected | 04/05/2023 12:15 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 05:54 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.46 | 2,3,7,8-TCDF-13C | 2.00 | 67 |
| Total TCDF | 3.4 | — | 0.46 | 2,3,7,8-TCDD-13C | 2.00 | 55 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 76 |
| 2,3,7,8-TCDD | 3.7 | — | 0.74 | 2,3,4,7,8-PeCDF-13C | 2.00 | 77 |
| Total TCDD | 19 | — | 0.74 | 1,2,3,7,8-PeCDD-13C | 2.00 | 86 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 65 |
| 1,2,3,7,8-PeCDF | 0.82 | — | 0.39 J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 66 |
| 2,3,4,7,8-PeCDF | 1.5 | — | 0.14 J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 63 |
| Total PeCDF | 22 | — | 0.14 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 63 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 64 |
| 1,2,3,7,8-PeCDD | 2.7 | — | 0.30 J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 68 |
| Total PeCDD | 18 | — | 0.30 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 67 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 67 |
| 1,2,3,4,7,8-HxCDF | 7.9 | — | 0.24 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 75 |
| 1,2,3,6,7,8-HxCDF | — | 1.8 | 0.38 PJ | OCDD-13C | 4.00 | 61 |
| 2,3,4,6,7,8-HxCDF | 4.9 | — | 0.29 J | | | |
| 1,2,3,7,8,9-HxCDF | — | 1.4 | 0.36 IJ | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 120 | — | 0.24 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 5.6 | — | 0.56 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 55 |
| 1,2,3,6,7,8-HxCDD | 15 | — | 0.51 | | | |
| 1,2,3,7,8,9-HxCDD | 8.8 | — | 0.50 | | | |
| Total HxCDD | 110 | — | 0.50 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 240 | 0.39 P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 8.5 | — | 0.62 | Equivalence: 18 ng/Kg | | |
| Total HpCDF | 280 | — | 0.39 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 320 | — | 0.34 | | | |
| Total HpCDD | 640 | — | 0.34 | | | |
| | | | | | | |
| OCDF | 470 | — | 0.28 | | | |
| OCDD | 2700 | — | 0.28 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-09B-1.5-2.0_0423 | | |
| Lab Sample ID | 10649075012 | | |
| Filename | U230503C_12 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.2 g | Matrix | Solid |
| % Moisture | 3.7 | Dilution | NA |
| Dry Weight Extracted | 9.87 g | Collected | 04/05/2023 12:20 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 06:41 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.31 | | 2,3,7,8-TCDF-13C | 2.00 | 77 |
| Total TCDF | 0.71 | — | 0.31 J | | 2,3,7,8-TCDD-13C | 2.00 | 52 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 88 |
| 2,3,7,8-TCDD | 2.0 | — | 0.62 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 91 |
| Total TCDD | 5.9 | — | 0.62 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 101 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 76 |
| 1,2,3,7,8-PeCDF | ND | — | 0.28 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 74 |
| 2,3,4,7,8-PeCDF | ND | — | 0.24 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 72 |
| Total PeCDF | 0.37 | — | 0.24 J | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 72 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 73 |
| 1,2,3,7,8-PeCDD | — | 0.64 | 0.18 IJ | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 83 |
| Total PeCDD | 3.5 | — | 0.18 J | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 78 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 79 |
| 1,2,3,4,7,8-HxCDF | — | 1.2 | 0.46 IJ | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 90 |
| 1,2,3,6,7,8-HxCDF | — | 0.39 | 0.32 IJ | | OCDD-13C | 4.00 | 72 |
| 2,3,4,6,7,8-HxCDF | — | 0.74 | 0.36 IJ | | | | |
| 1,2,3,7,8,9-HxCDF | 0.54 | — | 0.31 BJ | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 20 | — | 0.31 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 1.5 | — | 0.26 J | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 46 |
| 1,2,3,6,7,8-HxCDD | 3.1 | — | 0.26 J | | | | |
| 1,2,3,7,8,9-HxCDD | — | 2.1 | 0.20 IJ | | | | |
| Total HxCDD | 25 | — | 0.20 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 44 | 0.20 P | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 1.2 | — | 0.30 J | | Equivalence: 5.0 ng/Kg | | |
| Total HpCDF | 47 | — | 0.20 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 75 | — | 0.15 | | | | |
| Total HpCDD | 160 | — | 0.15 | | | | |
| | | | | | | | |
| OCDF | 83 | — | 0.24 | | | | |
| OCDD | 720 | — | 0.43 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-06A-0.5-1.0_0423 | | |
| Lab Sample ID | 10649075013 | | |
| Filename | U230503C_13 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 4.0 | Dilution | NA |
| Dry Weight Extracted | 9.96 g | Collected | 04/05/2023 13:00 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 07:28 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.26 | 2,3,7,8-TCDF-13C | 2.00 | 77 |
| Total TCDF | ND | — | 0.26 | 2,3,7,8-TCDD-13C | 2.00 | 53 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 91 |
| 2,3,7,8-TCDD | ND | — | 0.45 | 2,3,4,7,8-PeCDF-13C | 2.00 | 91 |
| Total TCDD | 2.4 | — | 0.45 | 1,2,3,7,8-PeCDD-13C | 2.00 | 101 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 75 |
| 1,2,3,7,8-PeCDF | ND | — | 0.20 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 76 |
| 2,3,4,7,8-PeCDF | ND | — | 0.12 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 74 |
| Total PeCDF | ND | — | 0.12 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 71 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 76 |
| 1,2,3,7,8-PeCDD | 0.26 | — | 0.14 J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 82 |
| Total PeCDD | 2.7 | — | 0.14 J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 80 |
| | | | | 1,2,3,4,7,8-HpCDF-13C | 2.00 | 78 |
| 1,2,3,4,7,8-HxCDF | — | 0.30 | 0.29 U | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 91 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.28 | OCDD-13C | 4.00 | 68 |
| 2,3,4,6,7,8-HxCDF | 0.32 | — | 0.31 J | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.26 | 0.18 U | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 3.2 | — | 0.18 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.54 | — | 0.20 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 53 |
| 1,2,3,6,7,8-HxCDD | — | 1.00 | 0.15 U | | | |
| 1,2,3,7,8,9-HxCDD | 0.80 | — | 0.31 J | | | |
| Total HxCDD | 11 | — | 0.15 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 12 | 0.14 P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | — | 0.50 | 0.19 U | Equivalence: 1.1 ng/Kg | | |
| Total HpCDF | 14 | — | 0.14 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 32 | — | 0.17 | | | |
| Total HpCDD | 75 | — | 0.17 | | | |
| | | | | | | |
| OCDF | 23 | — | 0.18 | | | |
| OCDD | 340 | — | 0.25 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-06A-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075014 | | |
| Filename | U230503C_14 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.6 g | Matrix | Solid |
| % Moisture | 4.2 | Dilution | NA |
| Dry Weight Extracted | 10.1 g | Collected | 04/05/2023 13:05 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105366 | Analyzed | 05/04/2023 08:15 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.15 | 2,3,7,8-TCDF-13C | 2.00 | 75 |
| Total TCDF | 0.27 | — | 0.15 J | 2,3,7,8-TCDD-13C | 2.00 | 54 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 89 |
| 2,3,7,8-TCDD | ND | — | 0.28 | 2,3,4,7,8-PeCDF-13C | 2.00 | 88 |
| Total TCDD | ND | — | 0.28 | 1,2,3,7,8-PeCDD-13C | 2.00 | 100 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 75 |
| 1,2,3,7,8-PeCDF | ND | — | 0.12 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 74 |
| 2,3,4,7,8-PeCDF | ND | — | 0.085 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 73 |
| Total PeCDF | ND | — | 0.085 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 73 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 72 |
| 1,2,3,7,8-PeCDD | ND | — | 0.13 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 82 |
| Total PeCDD | ND | — | 0.13 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 77 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 76 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.17 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 89 |
| 1,2,3,6,7,8-HxCDF | 0.33 | — | 0.16 J | OCDD-13C | 4.00 | 67 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.18 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.16 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 1.9 | — | 0.16 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.33 | — | 0.12 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 53 |
| 1,2,3,6,7,8-HxCDD | 0.50 | — | 0.11 J | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.25 | 0.10 J | | | |
| Total HxCDD | 3.5 | — | 0.10 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 5.8 | 0.15 P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.21 | Equivalence: 0.35 ng/Kg | | |
| Total HpCDF | 7.3 | — | 0.15 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 11 | — | 0.21 | | | |
| Total HpCDD | 24 | — | 0.21 | | | |
| | | | | | | |
| OCDF | 11 | — | 0.47 | | | |
| OCDD | 130 | — | 0.10 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-15A-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075015 | | |
| Filename | U230505A_12 | | |
| Injected By | AH5 | | |
| Total Amount Extracted | 10.2 g | Matrix | Solid |
| % Moisture | 4.0 | Dilution | NA |
| Dry Weight Extracted | 9.79 g | Collected | 04/05/2023 10:00 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230505A_02 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/05/2023 17:03 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.14 | | 2,3,7,8-TCDF-13C | 2.00 | 75 |
| Total TCDF | 1.2 | — | 0.14 | | 2,3,7,8-TCDD-13C | 2.00 | 76 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 82 |
| 2,3,7,8-TCDD | 0.92 | — | 0.31 | J | 2,3,4,7,8-PeCDF-13C | 2.00 | 85 |
| Total TCDD | 2.0 | — | 0.31 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 89 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 83 |
| 1,2,3,7,8-PeCDF | ND | — | 0.15 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 76 |
| 2,3,4,7,8-PeCDF | ND | — | 0.10 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 83 |
| Total PeCDF | 1.6 | — | 0.10 | J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 76 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 82 |
| 1,2,3,7,8-PeCDD | — | 0.22 | 0.14 | IJ | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 82 |
| Total PeCDD | 2.1 | — | 0.14 | J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 75 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 74 |
| 1,2,3,4,7,8-HxCDF | 0.40 | — | 0.15 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 83 |
| 1,2,3,6,7,8-HxCDF | — | 0.50 | 0.14 | PJ | OCDD-13C | 4.00 | 74 |
| 2,3,4,6,7,8-HxCDF | 0.30 | — | 0.12 | J | | | |
| 1,2,3,7,8,9-HxCDF | 0.19 | — | 0.11 | J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 7.1 | — | 0.11 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.63 | — | 0.28 | J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 74 |
| 1,2,3,6,7,8-HxCDD | 1.6 | — | 0.34 | J | | | |
| 1,2,3,7,8,9-HxCDD | 1.0 | — | 0.37 | J | | | |
| Total HxCDD | 9.5 | — | 0.28 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 9.2 | 0.55 | P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.47 | | Equivalence: 2.2 ng/Kg | | |
| Total HpCDF | 13 | — | 0.47 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 35 | — | 0.21 | | | | |
| Total HpCDD | 94 | — | 0.21 | | | | |
| | | | | | | | |
| OCDF | 20 | — | 0.43 | | | | |
| OCDD | 400 | — | 0.63 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-15A-1.5-2.0_0423 | | |
| Lab Sample ID | 10649075016 | | |
| Filename | U230503C_15 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.7 g | Matrix | Solid |
| % Moisture | 4.2 | Dilution | NA |
| Dry Weight Extracted | 10.2 g | Collected | 04/05/2023 10:05 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230503B_17 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/04/2023 09:01 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.20 | | 2,3,7,8-TCDF-13C | 2.00 | 74 |
| Total TCDF | 0.21 | — | 0.20 J | | 2,3,7,8-TCDD-13C | 2.00 | 70 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 86 |
| 2,3,7,8-TCDD | 0.83 | — | 0.25 J | | 2,3,4,7,8-PeCDF-13C | 2.00 | 85 |
| Total TCDD | 0.83 | — | 0.25 J | | 1,2,3,7,8-PeCDD-13C | 2.00 | 95 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 84 |
| 1,2,3,7,8-PeCDF | ND | — | 0.18 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 84 |
| 2,3,4,7,8-PeCDF | ND | — | 0.13 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 78 |
| Total PeCDF | ND | — | 0.13 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 70 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 81 |
| 1,2,3,7,8-PeCDD | 0.14 | — | 0.10 J | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 88 |
| Total PeCDD | 1.5 | — | 0.10 J | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 82 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 79 |
| 1,2,3,4,7,8-HxCDF | 0.34 | — | 0.21 J | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 94 |
| 1,2,3,6,7,8-HxCDF | — | 0.47 | 0.22 PJ | | OCDD-13C | 4.00 | 68 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.23 | | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.17 | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 4.3 | — | 0.17 J | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.54 | — | 0.25 J | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 70 |
| 1,2,3,6,7,8-HxCDD | — | 0.83 | 0.24 J | | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.71 | 0.20 J | | | | |
| Total HxCDD | 8.5 | — | 0.20 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 6.6 | 0.26 P | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | — | 0.34 | 0.20 J | | Equivalence: 1.7 ng/Kg | | |
| Total HpCDF | 8.1 | — | 0.20 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 25 | — | 0.13 | | | | |
| Total HpCDD | 60 | — | 0.13 | | | | |
| | | | | | | | |
| OCDF | 13 | — | 0.24 | | | | |
| OCDD | 290 | — | 0.42 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-15B-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075017 | | |
| Filename | F230503B_06 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.3 g | Matrix | Solid |
| % Moisture | 4.1 | Dilution | NA |
| Dry Weight Extracted | 9.90 g | Collected | 04/05/2023 11:00 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 17:34 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.28 | 2,3,7,8-TCDF-13C | 2.00 | 60 |
| Total TCDF | 1.6 | — | 0.28 | 2,3,7,8-TCDD-13C | 2.00 | 53 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 67 |
| 2,3,7,8-TCDD | 1.2 | — | 0.36 | 2,3,4,7,8-PeCDF-13C | 2.00 | 77 |
| Total TCDD | 2.6 | — | 0.36 | 1,2,3,7,8-PeCDD-13C | 2.00 | 78 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 72 |
| 1,2,3,7,8-PeCDF | ND | — | 0.23 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 78 |
| 2,3,4,7,8-PeCDF | ND | — | 0.12 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 74 |
| Total PeCDF | ND | — | 0.12 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 60 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 65 |
| 1,2,3,7,8-PeCDD | ND | — | 0.16 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 81 |
| Total PeCDD | 0.60 | — | 0.16 J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 70 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 66 |
| 1,2,3,4,7,8-HxCDF | — | 0.14 | 0.13 J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 73 |
| 1,2,3,6,7,8-HxCDF | 0.53 | — | 0.15 J | OCDD-13C | 4.00 | 62 |
| 2,3,4,6,7,8-HxCDF | 0.27 | — | 0.15 J | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.26 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 3.0 | — | 0.13 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.52 | — | 0.26 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 55 |
| 1,2,3,6,7,8-HxCDD | 0.83 | — | 0.21 J | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.54 | 0.19 J | | | |
| Total HxCDD | 8.1 | — | 0.19 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 4.3 | — | 0.21 J | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.29 | Equivalence: 1.9 ng/Kg | | |
| Total HpCDF | 12 | — | 0.21 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 23 | — | 0.14 | | | |
| Total HpCDD | 60 | — | 0.14 | | | |
| | | | | | | |
| OCDF | 18 | — | 0.49 | | | |
| OCDD | 300 | — | 0.32 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-15B-1.5-2.0_0423 | | |
| Lab Sample ID | 10649075018 | | |
| Filename | F230503B_07 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 4.4 | Dilution | NA |
| Dry Weight Extracted | 9.93 g | Collected | 04/05/2023 11:05 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 18:17 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.20 | 2,3,7,8-TCDF-13C | 2.00 | 63 |
| Total TCDF | ND | — | 0.20 | 2,3,7,8-TCDD-13C | 2.00 | 57 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 63 |
| 2,3,7,8-TCDD | 0.31 | — | 0.24 J | 2,3,4,7,8-PeCDF-13C | 2.00 | 67 |
| Total TCDD | 0.31 | — | 0.24 J | 1,2,3,7,8-PeCDD-13C | 2.00 | 67 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 78 |
| 1,2,3,7,8-PeCDF | ND | — | 0.17 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 82 |
| 2,3,4,7,8-PeCDF | ND | — | 0.11 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 79 |
| Total PeCDF | 0.30 | — | 0.11 J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 64 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 74 |
| 1,2,3,7,8-PeCDD | ND | — | 0.15 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 85 |
| Total PeCDD | ND | — | 0.15 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 68 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 64 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.19 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 73 |
| 1,2,3,6,7,8-HxCDF | — | 0.36 | 0.18 PJ | OCDD-13C | 4.00 | 57 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.17 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.15 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 1.0 | — | 0.15 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 0.21 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 60 |
| 1,2,3,6,7,8-HxCDD | 0.39 | — | 0.19 J | | | |
| 1,2,3,7,8,9-HxCDD | 0.20 | — | 0.17 J | | | |
| Total HxCDD | 3.9 | — | 0.17 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 2.0 | — | 0.24 J | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.32 | Equivalence: 0.61 ng/Kg | | |
| Total HpCDF | 6.1 | — | 0.24 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 13 | — | 0.31 | | | |
| Total HpCDD | 32 | — | 0.31 | | | |
| | | | | | | |
| OCDF | 8.6 | — | 0.30 J | | | |
| OCDD | 160 | — | 0.66 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.
J = Estimated value
P = PCDE Interference

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | SU-07A-0.5-1.0_0423 | | |
| Lab Sample ID | 10649075019 | | |
| Filename | F230503B_08 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.3 g | Matrix | Solid |
| % Moisture | 3.7 | Dilution | NA |
| Dry Weight Extracted | 9.96 g | Collected | 04/05/2023 11:35 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 19:01 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | 0.94 | — | 0.33 | J | 2,3,7,8-TCDF-13C | 2.00 | 67 |
| Total TCDF | 19 | — | 0.33 | | 2,3,7,8-TCDD-13C | 2.00 | 62 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 70 |
| 2,3,7,8-TCDD | — | 0.99 | 0.22 | U | 2,3,4,7,8-PeCDF-13C | 2.00 | 73 |
| Total TCDD | 12 | — | 0.22 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 74 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 66 |
| 1,2,3,7,8-PeCDF | 0.76 | — | 0.45 | J | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 75 |
| 2,3,4,7,8-PeCDF | 1.5 | — | 0.31 | J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 75 |
| Total PeCDF | 17 | — | 0.31 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 67 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 66 |
| 1,2,3,7,8-PeCDD | — | 1.2 | 0.36 | U | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 86 |
| Total PeCDD | 13 | — | 0.36 | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 64 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 63 |
| 1,2,3,4,7,8-HxCDF | 2.9 | — | 0.30 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 73 |
| 1,2,3,6,7,8-HxCDF | — | 2.9 | 0.28 | PJ | OCDD-13C | 4.00 | 69 |
| 2,3,4,6,7,8-HxCDF | 2.2 | — | 0.24 | J | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.75 | 0.23 | U | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 41 | — | 0.23 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 2.1 | 0.36 | U | 2,3,7,8-TCDD-37Cl4 | 0.20 | 66 |
| 1,2,3,6,7,8-HxCDD | — | 5.2 | 0.38 | I | | | |
| 1,2,3,7,8,9-HxCDD | 3.6 | — | 0.35 | J | | | |
| Total HxCDD | 53 | — | 0.35 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 35 | — | 0.47 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 2.0 | — | 1.1 | J | Equivalence: 7.7 ng/Kg | | |
| Total HpCDF | 120 | — | 0.47 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 190 | — | 0.29 | | | | |
| Total HpCDD | 470 | — | 0.29 | | | | |
| | | | | | | | |
| OCDF | 110 | — | 0.39 | | | | |
| OCDD | 1900 | — | 0.42 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | SU-07A-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075020 | | |
| Filename | F230503B_09 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.2 g | Matrix | Solid |
| % Moisture | 4.1 | Dilution | NA |
| Dry Weight Extracted | 9.83 g | Collected | 04/05/2023 11:40 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 19:44 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.28 | 2,3,7,8-TCDF-13C | 2.00 | 75 |
| Total TCDF | 2.1 | — | 0.28 | 2,3,7,8-TCDD-13C | 2.00 | 67 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 88 |
| 2,3,7,8-TCDD | — | 0.30 | 0.27 J | 2,3,4,7,8-PeCDF-13C | 2.00 | 88 |
| Total TCDD | 1.3 | — | 0.27 | 1,2,3,7,8-PeCDD-13C | 2.00 | 94 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 84 |
| 1,2,3,7,8-PeCDF | ND | — | 0.28 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 88 |
| 2,3,4,7,8-PeCDF | 0.28 | — | 0.18 J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 86 |
| Total PeCDF | 0.91 | — | 0.18 J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 72 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 75 |
| 1,2,3,7,8-PeCDD | ND | — | 0.21 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 92 |
| Total PeCDD | ND | — | 0.21 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 75 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 60 |
| 1,2,3,4,7,8-HxCDF | 0.45 | — | 0.15 J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 78 |
| 1,2,3,6,7,8-HxCDF | 0.63 | — | 0.14 J | OCDD-13C | 4.00 | 57 |
| 2,3,4,6,7,8-HxCDF | — | 0.36 | 0.13 J | | | |
| 1,2,3,7,8,9-HxCDF | 0.34 | — | 0.18 J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 7.2 | — | 0.13 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.43 | 0.27 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 65 |
| 1,2,3,6,7,8-HxCDD | 1.1 | — | 0.31 J | | | |
| 1,2,3,7,8,9-HxCDD | 0.58 | — | 0.20 J | | | |
| Total HxCDD | 9.8 | — | 0.20 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 6.3 | — | 0.23 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 0.60 | — | 0.48 J | Equivalence: 1.3 ng/Kg | | |
| Total HpCDF | 21 | — | 0.23 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 37 | — | 0.22 | | | |
| Total HpCDD | 84 | — | 0.22 | | | |
| | | | | | | |
| OCDF | 23 | — | 0.42 | | | |
| OCDD | 390 | — | 0.42 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | SU-07B-0.5-1.0-0423 | | |
| Lab Sample ID | 10649075021 | | |
| Filename | F230503B_10 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.3 g | Matrix | Solid |
| % Moisture | 3.8 | Dilution | NA |
| Dry Weight Extracted | 9.94 g | Collected | 04/05/2023 12:00 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 20:27 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.59 | 2,3,7,8-TCDF-13C | 2.00 | 72 |
| Total TCDF | 6.5 | — | 0.59 | 2,3,7,8-TCDD-13C | 2.00 | 68 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 83 |
| 2,3,7,8-TCDD | ND | — | 0.48 | 2,3,4,7,8-PeCDF-13C | 2.00 | 81 |
| Total TCDD | 4.4 | — | 0.48 | 1,2,3,7,8-PeCDD-13C | 2.00 | 78 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 75 |
| 1,2,3,7,8-PeCDF | ND | — | 0.57 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 80 |
| 2,3,4,7,8-PeCDF | 0.81 | — | 0.26 J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 72 |
| Total PeCDF | 8.4 | — | 0.26 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 69 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 71 |
| 1,2,3,7,8-PeCDD | 0.80 | — | 0.22 J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 83 |
| Total PeCDD | 9.2 | — | 0.22 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 69 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 66 |
| 1,2,3,4,7,8-HxCDF | 1.8 | — | 0.099 J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 75 |
| 1,2,3,6,7,8-HxCDF | — | 3.0 | 0.13 PJ | OCDD-13C | 4.00 | 60 |
| 2,3,4,6,7,8-HxCDF | 1.8 | — | 0.079 J | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.65 | 0.22 J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 31 | — | 0.079 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 1.6 | 0.43 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 67 |
| 1,2,3,6,7,8-HxCDD | 4.6 | — | 0.49 J | | | |
| 1,2,3,7,8,9-HxCDD | 3.3 | — | 0.45 J | | | |
| Total HxCDD | 45 | — | 0.43 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 28 | — | 0.44 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 1.6 | — | 0.67 J | Equivalence: 4.9 ng/Kg | | |
| Total HpCDF | 88 | — | 0.44 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 140 | — | 0.26 | | | |
| Total HpCDD | 330 | — | 0.26 | | | |
| | | | | | | |
| OCDF | 84 | — | 0.51 | | | |
| OCDD | 1400 | — | 0.48 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | SU-07B-1.0-1.5-0423 | | |
| Lab Sample ID | 10649075022 | | |
| Filename | F230503B_11 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.6 g | Matrix | Solid |
| % Moisture | 4.2 | Dilution | NA |
| Dry Weight Extracted | 10.1 g | Collected | 04/05/2023 12:05 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 21:11 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.51 | 2,3,7,8-TCDF-13C | 2.00 | 60 |
| Total TCDF | 0.81 | — | 0.51 J | 2,3,7,8-TCDD-13C | 2.00 | 50 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 64 |
| 2,3,7,8-TCDD | ND | — | 0.46 | 2,3,4,7,8-PeCDF-13C | 2.00 | 71 |
| Total TCDD | 0.77 | — | 0.46 J | 1,2,3,7,8-PeCDD-13C | 2.00 | 69 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 93 |
| 1,2,3,7,8-PeCDF | ND | — | 0.38 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 103 |
| 2,3,4,7,8-PeCDF | 0.26 | — | 0.24 J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 89 |
| Total PeCDF | 1.2 | — | 0.24 J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 58 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 82 |
| 1,2,3,7,8-PeCDD | ND | — | 0.27 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 109 |
| Total PeCDD | ND | — | 0.27 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 88 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 69 |
| 1,2,3,4,7,8-HxCDF | — | 0.29 | 0.25 J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 88 |
| 1,2,3,6,7,8-HxCDF | — | 0.65 | 0.24 J | OCDD-13C | 4.00 | 65 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.28 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.43 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 3.0 | — | 0.24 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.49 | 0.44 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 48 |
| 1,2,3,6,7,8-HxCDD | 1.2 | — | 0.42 J | | | |
| 1,2,3,7,8,9-HxCDD | 0.85 | — | 0.28 J | | | |
| Total HxCDD | 10 | — | 0.28 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 7.4 | — | 0.43 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.78 | Equivalence: 1.0 ng/Kg | | |
| Total HpCDF | 23 | — | 0.43 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 39 | — | 0.18 | | | |
| Total HpCDD | 82 | — | 0.18 | | | |
| | | | | | | |
| OCDF | 25 | — | 0.85 | | | |
| OCDD | 380 | — | 0.56 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.
J = Estimated value
I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-11A-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075023 | | |
| Filename | F230503B_12 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.6 g | Matrix | Solid |
| % Moisture | 4.5 | Dilution | NA |
| Dry Weight Extracted | 10.1 g | Collected | 04/05/2023 14:05 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 21:54 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.28 | 2,3,7,8-TCDF-13C | 2.00 | 65 |
| Total TCDF | ND | — | 0.28 | 2,3,7,8-TCDD-13C | 2.00 | 60 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 78 |
| 2,3,7,8-TCDD | 3.7 | — | 0.39 | 2,3,4,7,8-PeCDF-13C | 2.00 | 81 |
| Total TCDD | 3.7 | — | 0.39 | 1,2,3,7,8-PeCDD-13C | 2.00 | 83 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 78 |
| 1,2,3,7,8-PeCDF | ND | — | 0.31 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 79 |
| 2,3,4,7,8-PeCDF | ND | — | 0.23 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 79 |
| Total PeCDF | 0.71 | — | 0.23 J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 72 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 73 |
| 1,2,3,7,8-PeCDD | ND | — | 0.22 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 85 |
| Total PeCDD | 0.73 | — | 0.22 J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 73 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 71 |
| 1,2,3,4,7,8-HxCDF | — | 0.56 | 0.26 IJ | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 80 |
| 1,2,3,6,7,8-HxCDF | — | 0.83 | 0.23 PJ | OCDD-13C | 4.00 | 60 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.31 | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.28 | 0.24 IJ | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 6.3 | — | 0.23 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.34 | 0.29 IJ | 2,3,7,8-TCDD-37Cl4 | 0.20 | 63 |
| 1,2,3,6,7,8-HxCDD | 1.2 | — | 0.27 J | | | |
| 1,2,3,7,8,9-HxCDD | 0.85 | — | 0.24 J | | | |
| Total HxCDD | 10 | — | 0.24 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 5.7 | — | 0.53 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.49 | Equivalence: 4.7 ng/Kg | | |
| Total HpCDF | 18 | — | 0.49 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 37 | — | 0.42 | | | |
| Total HpCDD | 87 | — | 0.42 | | | |
| | | | | | | |
| OCDF | 20 | — | 0.52 | | | |
| OCDD | 450 | — | 0.46 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-11A-1.5-2.0_0423 | | |
| Lab Sample ID | 10649075024 | | |
| Filename | F230503B_13 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.5 g | Matrix | Solid |
| % Moisture | 4.2 | Dilution | NA |
| Dry Weight Extracted | 10.0 g | Collected | 04/05/2023 14:10 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 22:38 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.59 | 2,3,7,8-TCDF-13C | 2.00 | 55 |
| Total TCDF | ND | — | 0.59 | 2,3,7,8-TCDD-13C | 2.00 | 52 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 52 |
| 2,3,7,8-TCDD | 2.9 | — | 0.46 | 2,3,4,7,8-PeCDF-13C | 2.00 | 54 |
| Total TCDD | 4.1 | — | 0.46 | 1,2,3,7,8-PeCDD-13C | 2.00 | 56 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 67 |
| 1,2,3,7,8-PeCDF | ND | — | 0.52 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 73 |
| 2,3,4,7,8-PeCDF | 1.6 | — | 0.26 J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 66 |
| Total PeCDF | 6.2 | — | 0.26 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 59 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 59 |
| 1,2,3,7,8-PeCDD | 0.48 | — | 0.26 J | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 75 |
| Total PeCDD | 2.4 | — | 0.26 J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 61 |
| 1,2,3,4,7,8-HxCDF | 5.7 | — | 0.64 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 71 |
| 1,2,3,6,7,8-HxCDF | — | 2.6 | 0.66 PJ | OCDD-13C | 4.00 | 55 |
| 2,3,4,6,7,8-HxCDF | — | 1.5 | 0.25 IJ | | | |
| 1,2,3,7,8,9-HxCDF | 1.2 | — | 0.62 J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 51 | — | 0.25 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.86 | — | 0.59 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 52 |
| 1,2,3,6,7,8-HxCDD | 2.6 | — | 0.54 J | | | |
| 1,2,3,7,8,9-HxCDD | 1.4 | — | 0.41 J | | | |
| Total HxCDD | 15 | — | 0.41 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 24 | — | 0.40 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 2.4 | — | 0.59 J | Equivalence: 6.7 ng/Kg | | |
| Total HpCDF | 84 | — | 0.40 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 79 | — | 0.31 | | | |
| Total HpCDD | 170 | — | 0.31 | | | |
| | | | | | | |
| OCDF | 59 | — | 0.59 | | | |
| OCDD | 830 | — | 0.77 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-11B-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075025 | | |
| Filename | F230503B_14 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 4.4 | Dilution | NA |
| Dry Weight Extracted | 9.91 g | Collected | 04/05/2023 14:30 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/03/2023 23:21 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.47 | 2,3,7,8-TCDF-13C | 2.00 | 62 |
| Total TCDF | ND | — | 0.47 | 2,3,7,8-TCDD-13C | 2.00 | 61 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 65 |
| 2,3,7,8-TCDD | ND | — | 0.31 | 2,3,4,7,8-PeCDF-13C | 2.00 | 68 |
| Total TCDD | 0.38 | — | 0.31 J | 1,2,3,7,8-PeCDD-13C | 2.00 | 71 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 69 |
| 1,2,3,7,8-PeCDF | ND | — | 0.44 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 72 |
| 2,3,4,7,8-PeCDF | 0.42 | — | 0.24 J | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 71 |
| Total PeCDF | 1.7 | — | 0.24 J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 64 |
| 1,2,3,7,8-PeCDD | ND | — | 0.26 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 78 |
| Total PeCDD | ND | — | 0.26 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 65 |
| 1,2,3,4,7,8-HxCDF | 1.5 | — | 0.35 J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 72 |
| 1,2,3,6,7,8-HxCDF | 0.79 | — | 0.36 J | OCDD-13C | 4.00 | 57 |
| 2,3,4,6,7,8-HxCDF | — | 0.34 | 0.29 J | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.28 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 13 | — | 0.28 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 0.38 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 60 |
| 1,2,3,6,7,8-HxCDD | — | 0.70 | 0.35 J | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.45 | 0.29 J | | | |
| Total HxCDD | 3.4 | — | 0.29 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 7.4 | — | 0.52 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.59 | Equivalence: 0.94 ng/Kg | | |
| Total HpCDF | 23 | — | 0.52 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 27 | — | 0.32 | | | |
| Total HpCDD | 63 | — | 0.32 | | | |
| | | | | | | |
| OCDF | 16 | — | 0.66 | | | |
| OCDD | 300 | — | 0.59 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-11B-1.5-2.0_0423 | | |
| Lab Sample ID | 10649075026 | | |
| Filename | F230503B_15 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 4.7 | Dilution | NA |
| Dry Weight Extracted | 9.95 g | Collected | 04/05/2023 14:35 |
| ICAL ID | F230426 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | F230503A_12 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/04/2023 00:05 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.21 | 2,3,7,8-TCDF-13C | 2.00 | 71 |
| Total TCDF | ND | — | 0.21 | 2,3,7,8-TCDD-13C | 2.00 | 70 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 74 |
| 2,3,7,8-TCDD | — | 0.18 | 0.15 J | 2,3,4,7,8-PeCDF-13C | 2.00 | 75 |
| Total TCDD | ND | — | 0.15 | 1,2,3,7,8-PeCDD-13C | 2.00 | 81 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDF | ND | — | 0.25 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 76 |
| 2,3,4,7,8-PeCDF | ND | — | 0.17 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 76 |
| Total PeCDF | 0.51 | — | 0.17 J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 70 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 72 |
| 1,2,3,7,8-PeCDD | ND | — | 0.19 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 82 |
| Total PeCDD | ND | — | 0.19 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 69 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 65 |
| 1,2,3,4,7,8-HxCDF | 0.46 | — | 0.19 J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 74 |
| 1,2,3,6,7,8-HxCDF | — | 0.37 | 0.21 PJ | OCDD-13C | 4.00 | 54 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.19 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.26 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 3.9 | — | 0.19 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 0.40 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 66 |
| 1,2,3,6,7,8-HxCDD | 0.44 | — | 0.41 J | | | |
| 1,2,3,7,8,9-HxCDD | 0.39 | — | 0.34 J | | | |
| Total HxCDD | 2.2 | — | 0.34 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 2.8 | — | 0.26 J | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.38 | Equivalence: 0.58 ng/Kg | | |
| Total HpCDF | 2.8 | — | 0.26 J | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 15 | — | 0.37 | | | |
| Total HpCDD | 34 | — | 0.37 | | | |
| | | | | | | |
| OCDF | 7.4 | — | 0.41 J | | | |
| OCDD | 160 | — | 0.26 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-10A-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075027 | | |
| Filename | U230505A_13 | | |
| Injected By | AH5 | | |
| Total Amount Extracted | 10.5 g | Matrix | Solid |
| % Moisture | 3.8 | Dilution | NA |
| Dry Weight Extracted | 10.1 g | Collected | 04/05/2023 09:30 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230505A_02 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/05/2023 17:50 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.12 | | 2,3,7,8-TCDF-13C | 2.00 | 72 |
| Total TCDF | 0.46 | — | 0.12 J | | 2,3,7,8-TCDD-13C | 2.00 | 72 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 83 |
| 2,3,7,8-TCDD | 2.7 | — | 0.36 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 85 |
| Total TCDD | 4.5 | — | 0.36 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 94 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 78 |
| 1,2,3,7,8-PeCDF | ND | — | 0.13 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 74 |
| 2,3,4,7,8-PeCDF | ND | — | 0.082 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 69 |
| Total PeCDF | 2.3 | — | 0.082 J | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 70 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 74 |
| 1,2,3,7,8-PeCDD | 0.43 | — | 0.12 J | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 75 |
| Total PeCDD | 4.0 | — | 0.12 J | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 73 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 75 |
| 1,2,3,4,7,8-HxCDF | 1.2 | — | 0.21 J | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 90 |
| 1,2,3,6,7,8-HxCDF | 0.23 | — | 0.19 J | | OCDD-13C | 4.00 | 73 |
| 2,3,4,6,7,8-HxCDF | — | 0.56 | 0.22 J | | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.25 | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 18 | — | 0.19 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.90 | — | 0.28 J | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 70 |
| 1,2,3,6,7,8-HxCDD | 2.5 | — | 0.40 J | | | | |
| 1,2,3,7,8,9-HxCDD | 1.7 | — | 0.36 J | | | | |
| Total HxCDD | 27 | — | 0.28 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 26 | 0.31 P | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | 1.4 | — | 0.42 J | | Equivalence: 5.0 ng/Kg | | |
| Total HpCDF | 48 | — | 0.31 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 71 | — | 0.45 | | | | |
| Total HpCDD | 170 | — | 0.45 | | | | |
| | | | | | | | |
| OCDF | 79 | — | 0.35 | | | | |
| OCDD | 740 | — | 0.41 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-10A-1.5-2.0_0423 | | |
| Lab Sample ID | 10649075028 | | |
| Filename | U230505A_14 | | |
| Injected By | AH5 | | |
| Total Amount Extracted | 10.3 g | Matrix | Solid |
| % Moisture | 3.9 | Dilution | NA |
| Dry Weight Extracted | 9.92 g | Collected | 04/05/2023 09:35 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230505A_02 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/05/2023 18:36 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.20 | | 2,3,7,8-TCDF-13C | 2.00 | 77 |
| Total TCDF | 0.35 | — | 0.20 | J | 2,3,7,8-TCDD-13C | 2.00 | 78 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 88 |
| 2,3,7,8-TCDD | 1.1 | — | 0.25 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 90 |
| Total TCDD | 1.9 | — | 0.25 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 99 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 87 |
| 1,2,3,7,8-PeCDF | ND | — | 0.081 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 86 |
| 2,3,4,7,8-PeCDF | ND | — | 0.056 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 84 |
| Total PeCDF | ND | — | 0.056 | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 77 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 84 |
| 1,2,3,7,8-PeCDD | — | 0.17 | 0.060 | IJ | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 93 |
| Total PeCDD | 0.62 | — | 0.060 | J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 85 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 83 |
| 1,2,3,4,7,8-HxCDF | — | 0.31 | 0.13 | IJ | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 100 |
| 1,2,3,6,7,8-HxCDF | 0.35 | — | 0.17 | J | OCDD-13C | 4.00 | 77 |
| 2,3,4,6,7,8-HxCDF | 0.30 | — | 0.11 | J | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.13 | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 6.1 | — | 0.11 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.48 | 0.23 | IJ | 2,3,7,8-TCDD-37Cl4 | 0.20 | 73 |
| 1,2,3,6,7,8-HxCDD | 1.00 | — | 0.17 | J | | | |
| 1,2,3,7,8,9-HxCDD | 0.62 | — | 0.20 | J | | | |
| Total HxCDD | 8.9 | — | 0.17 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 9.7 | 0.24 | P | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.33 | | Equivalence: 2.0 ng/Kg | | |
| Total HpCDF | 13 | — | 0.24 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 29 | — | 0.25 | | | | |
| Total HpCDD | 65 | — | 0.25 | | | | |
| | | | | | | | |
| OCDF | 23 | — | 0.36 | | | | |
| OCDD | 340 | — | 0.42 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-01B-1.0-1.5_0423 | | |
| Lab Sample ID | 10649075029 | | |
| Filename | U230505A_15 | | |
| Injected By | AH5 | | |
| Total Amount Extracted | 10.6 g | Matrix | Solid |
| % Moisture | 3.8 | Dilution | NA |
| Dry Weight Extracted | 10.2 g | Collected | 04/05/2023 16:00 |
| ICAL ID | U230503 | Received | 04/12/2023 08:50 |
| CCal Filename(s) | U230505A_02 | Extracted | 04/19/2023 14:30 |
| Method Blank ID | BLANK-105368 | Analyzed | 05/05/2023 19:23 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.24 | | 2,3,7,8-TCDF-13C | 2.00 | 76 |
| Total TCDF | ND | — | 0.24 | | 2,3,7,8-TCDD-13C | 2.00 | 76 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 88 |
| 2,3,7,8-TCDD | 0.43 | — | 0.26 J | | 2,3,4,7,8-PeCDF-13C | 2.00 | 90 |
| Total TCDD | 0.43 | — | 0.26 J | | 1,2,3,7,8-PeCDD-13C | 2.00 | 102 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 82 |
| 1,2,3,7,8-PeCDF | ND | — | 0.28 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 83 |
| 2,3,4,7,8-PeCDF | ND | — | 0.20 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 81 |
| Total PeCDF | 0.90 | — | 0.20 J | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 75 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 83 |
| 1,2,3,7,8-PeCDD | ND | — | 0.080 | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 88 |
| Total PeCDD | 1.4 | — | 0.080 J | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 82 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 82 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.17 | | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 98 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.17 | | OCDD-13C | 4.00 | 74 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.15 | | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.18 | | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 1.7 | — | 0.15 J | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.23 | — | 0.13 J | | 2,3,7,8-TCDD-37Cl4 | 0.20 | 74 |
| 1,2,3,6,7,8-HxCDD | 0.44 | — | 0.12 J | | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.20 | 0.11 J | | | | |
| Total HxCDD | 5.0 | — | 0.11 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 6.1 | 0.29 P | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.25 | | Equivalence: 0.75 ng/Kg | | |
| Total HpCDF | 5.4 | — | 0.25 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 12 | — | 0.19 | | | | |
| Total HpCDD | 29 | — | 0.19 | | | | |
| | | | | | | | |
| OCDF | 11 | — | 0.41 | | | | |
| OCDD | 160 | — | 0.57 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

P = PCDE Interference

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample Name | DFBLKJJ | Matrix | Solid |
| Lab Sample ID | BLANK-105366 | Dilution | NA |
| Filename | L230422A_07 | Extracted | 04/19/2023 14:30 |
| Total Amount Extracted | 10.4 g | Analyzed | 04/22/2023 04:52 |
| ICAL ID | L230302 | Injected By | JRH |
| CCal Filename(s) | L230421A_19 | | |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.11 | 2,3,7,8-TCDF-13C | 2.00 | 74 |
| Total TCDF | ND | — | 0.11 | 2,3,7,8-TCDD-13C | 2.00 | 49 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 89 |
| 2,3,7,8-TCDD | ND | — | 0.22 | 2,3,4,7,8-PeCDF-13C | 2.00 | 89 |
| Total TCDD | 0.23 | — | 0.22 J | 1,2,3,7,8-PeCDD-13C | 2.00 | 93 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 85 |
| 1,2,3,7,8-PeCDF | ND | — | 0.065 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 79 |
| 2,3,4,7,8-PeCDF | ND | — | 0.048 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 80 |
| Total PeCDF | ND | — | 0.048 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 68 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 70 |
| 1,2,3,7,8-PeCDD | ND | — | 0.098 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 78 |
| Total PeCDD | ND | — | 0.098 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 61 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.066 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 71 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.057 | OCDD-13C | 4.00 | 51 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.058 | | | |
| 1,2,3,7,8,9-HxCDF | 0.15 | — | 0.11 J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 0.15 | — | 0.057 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 0.11 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 48 |
| 1,2,3,6,7,8-HxCDD | ND | — | 0.10 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 0.093 | | | |
| Total HxCDD | ND | — | 0.093 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 0.095 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.14 | Equivalence: 0.015 ng/Kg | | |
| Total HpCDF | ND | — | 0.095 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | ND | — | 0.14 | | | |
| Total HpCDD | 0.25 | — | 0.14 J | | | |
| | | | | | | |
| OCDF | ND | — | 0.27 | | | |
| OCDD | — | 0.46 | 0.40 J | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

Results reported on a total weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample Name | DFBLKJK | Matrix | Solid |
| Lab Sample ID | BLANK-105368 | Dilution | NA |
| Filename | F230501A_09 | Extracted | 04/19/2023 14:30 |
| Total Amount Extracted | 20.4 g | Analyzed | 05/01/2023 13:56 |
| ICAL ID | F230426 | Injected By | SMT |
| CCal Filename(s) | F230501A_01 | | |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.077 | 2,3,7,8-TCDF-13C | 2.00 | 66 |
| Total TCDF | ND | — | 0.077 | 2,3,7,8-TCDD-13C | 2.00 | 65 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 70 |
| 2,3,7,8-TCDD | ND | — | 0.10 | 2,3,4,7,8-PeCDF-13C | 2.00 | 71 |
| Total TCDD | ND | — | 0.10 | 1,2,3,7,8-PeCDD-13C | 2.00 | 78 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 92 |
| 1,2,3,7,8-PeCDF | ND | — | 0.080 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 93 |
| 2,3,4,7,8-PeCDF | ND | — | 0.053 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 85 |
| Total PeCDF | ND | — | 0.053 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 76 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDD | ND | — | 0.048 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 97 |
| Total PeCDD | ND | — | 0.048 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 74 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 72 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.088 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 79 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.11 | OCDD-13C | 4.00 | 66 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.10 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.14 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | ND | — | 0.088 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 0.10 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 57 |
| 1,2,3,6,7,8-HxCDD | ND | — | 0.10 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 0.090 | | | |
| Total HxCDD | ND | — | 0.090 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 0.15 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.19 | Equivalence: 0.0090 ng/Kg | | |
| Total HpCDF | ND | — | 0.15 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 0.68 | — | 0.18 J | | | |
| Total HpCDD | 1.4 | — | 0.18 J | | | |
| | | | | | | |
| OCDF | — | 0.32 | 0.25 I | | | |
| OCDD | 6.9 | — | 0.31 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

Results reported on a total weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample ID | LCS-105367 | Matrix | Solid |
| Filename | L230422A_02 | Dilution | NA |
| Total Amount Extracted | 10.2 g | Extracted | 04/19/2023 14:30 |
| ICAL ID | L230302 | Analyzed | 04/22/2023 01:09 |
| CCal Filename | L230421A_19 | Injected By | JRH |
| Method Blank ID | BLANK-105366 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 10 | 7.5 | 15.8 | 103 |
| 2,3,7,8-TCDD | 10 | 10 | 6.7 | 15.8 | 104 |
| 1,2,3,7,8-PeCDF | 50 | 51 | 40.0 | 67.0 | 101 |
| 2,3,4,7,8-PeCDF | 50 | 51 | 34.0 | 80.0 | 102 |
| 1,2,3,7,8-PeCDD | 50 | 46 | 35.0 | 71.0 | 93 |
| 1,2,3,4,7,8-HxCDF | 50 | 52 | 36.0 | 67.0 | 104 |
| 1,2,3,6,7,8-HxCDF | 50 | 54 | 42.0 | 65.0 | 107 |
| 2,3,4,6,7,8-HxCDF | 50 | 53 | 35.0 | 78.0 | 105 |
| 1,2,3,7,8,9-HxCDF | 50 | 53 | 39.0 | 65.0 | 107 |
| 1,2,3,4,7,8-HxCDD | 50 | 55 | 35.0 | 82.0 | 110 |
| 1,2,3,6,7,8-HxCDD | 50 | 51 | 38.0 | 67.0 | 102 |
| 1,2,3,7,8,9-HxCDD | 50 | 54 | 32.0 | 81.0 | 108 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 49 | 41.0 | 61.0 | 99 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 50 | 39.0 | 69.0 | 100 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 46 | 35.0 | 70.0 | 91 |
| OCDF | 100 | 110 | 63.0 | 170.0 | 107 |
| OCDD | 100 | 120 | 78.0 | 144.0 | 116 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 4.0 | 3.1 | 19.1 | 40 |
| 2,3,7,8-TCDF-13C | 100 | 63 | 22.0 | 152.0 | 63 |
| 2,3,7,8-TCDD-13C | 100 | 39 | 20.0 | 175.0 | 39 |
| 1,2,3,7,8-PeCDF-13C | 100 | 82 | 21.0 | 192.0 | 82 |
| 2,3,4,7,8-PeCDF-13C | 100 | 82 | 13.0 | 328.0 | 82 |
| 1,2,3,7,8-PeCDD-13C | 100 | 93 | 21.0 | 227.0 | 93 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 73 | 19.0 | 202.0 | 73 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 68 | 21.0 | 159.0 | 68 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 68 | 22.0 | 176.0 | 68 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 59 | 17.0 | 205.0 | 59 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 62 | 21.0 | 193.0 | 62 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 70 | 25.0 | 163.0 | 70 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 63 | 21.0 | 158.0 | 63 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 59 | 20.0 | 186.0 | 59 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 68 | 26.0 | 166.0 | 68 |
| OCDD-13C | 200 | 96 | 26.0 | 397.0 | 48 |

Cs = Concentration Spiked (ng/mL)
 Cr = Concentration Recovered (ng/mL)
 Rec. = Recovery (Expressed as Percent)
 Control Limit Reference: Method 1613, Table 6, 10/94 Revision
 R = Recovery outside of control limits
 Nn = Value obtained from additional analysis
 * = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample ID | LCS-105369 | Matrix | Solid |
| Filename | F230501A_10 | Dilution | NA |
| Total Amount Extracted | 20.5 g | Extracted | 04/19/2023 14:30 |
| ICAL ID | F230426 | Analyzed | 05/01/2023 14:40 |
| CCal Filename | F230501A_01 | Injected By | SMT |
| Method Blank ID | BLANK-105368 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 11 | 7.5 | 15.8 | 107 |
| 2,3,7,8-TCDD | 10 | 11 | 6.7 | 15.8 | 112 |
| 1,2,3,7,8-PeCDF | 50 | 49 | 40.0 | 67.0 | 98 |
| 2,3,4,7,8-PeCDF | 50 | 52 | 34.0 | 80.0 | 105 |
| 1,2,3,7,8-PeCDD | 50 | 48 | 35.0 | 71.0 | 97 |
| 1,2,3,4,7,8-HxCDF | 50 | 56 | 36.0 | 67.0 | 112 |
| 1,2,3,6,7,8-HxCDF | 50 | 53 | 42.0 | 65.0 | 105 |
| 2,3,4,6,7,8-HxCDF | 50 | 56 | 35.0 | 78.0 | 113 |
| 1,2,3,7,8,9-HxCDF | 50 | 56 | 39.0 | 65.0 | 112 |
| 1,2,3,4,7,8-HxCDD | 50 | 56 | 35.0 | 82.0 | 113 |
| 1,2,3,6,7,8-HxCDD | 50 | 53 | 38.0 | 67.0 | 105 |
| 1,2,3,7,8,9-HxCDD | 50 | 52 | 32.0 | 81.0 | 103 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 54 | 41.0 | 61.0 | 109 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 54 | 39.0 | 69.0 | 108 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 50 | 35.0 | 70.0 | 101 |
| OCDF | 100 | 110 | 63.0 | 170.0 | 112 |
| OCDD | 100 | 130 | 78.0 | 144.0 | 127 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 5.7 | 3.1 | 19.1 | 57 |
| 2,3,7,8-TCDF-13C | 100 | 61 | 22.0 | 152.0 | 61 |
| 2,3,7,8-TCDD-13C | 100 | 57 | 20.0 | 175.0 | 57 |
| 1,2,3,7,8-PeCDF-13C | 100 | 66 | 21.0 | 192.0 | 66 |
| 2,3,4,7,8-PeCDF-13C | 100 | 68 | 13.0 | 328.0 | 68 |
| 1,2,3,7,8-PeCDD-13C | 100 | 72 | 21.0 | 227.0 | 72 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 81 | 19.0 | 202.0 | 81 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 87 | 21.0 | 159.0 | 87 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 63 | 22.0 | 176.0 | 63 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 61 | 17.0 | 205.0 | 61 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 73 | 21.0 | 193.0 | 73 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 91 | 25.0 | 163.0 | 91 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 72 | 21.0 | 158.0 | 72 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 65 | 20.0 | 186.0 | 65 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 76 | 26.0 | 166.0 | 76 |
| OCDD-13C | 200 | 120 | 26.0 | 397.0 | 60 |

Cs = Concentration Spiked (ng/mL)
Cr = Concentration Recovered (ng/mL)
Rec. = Recovery (Expressed as Percent)
Control Limit Reference: Method 1613, Table 6, 10/94 Revision
R = Recovery outside of control limits
Nn = Value obtained from additional analysis
* = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Spiked Sample Report

Client - Pace Analytical National

| | | | |
|------------------------|------------------------|-------------|------------------|
| Client's Sample ID | DU-15A-1.0-1.5_0423-MS | | |
| Lab Sample ID | 10649075015-MS | | |
| Filename | F230504A_07 | Matrix | Solid |
| Total Amount Extracted | 10.4 g | Dilution | NA |
| ICAL ID | F230426 | Extracted | 04/19/2023 14:30 |
| CCal Filename(s) | F230504A_01 | Analyzed | 05/04/2023 05:09 |
| Method Blank ID | BLANK-105368 | Injected By | SMT |

| Native Isomers | Qs (ng) | Qm (ng) | % Rec. | Internal Standards | ng's Added | Percent Recovery |
|---------------------|---------|---------|--------|-------------------------|------------|------------------|
| 2,3,7,8-TCDF | 0.20 | 0.21 | 104 | 2,3,7,8-TCDF-13C | 2.00 | 64 |
| Total TCDF | | | | 2,3,7,8-TCDD-13C | 2.00 | 62 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 60 |
| 2,3,7,8-TCDD | 0.20 | 0.24 | 115 | 2,3,4,7,8-PeCDF-13C | 2.00 | 65 |
| Total TCDD | | | | 1,2,3,7,8-PeCDD-13C | 2.00 | 68 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDF | 1.00 | 1.05 | 105 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 79 |
| 2,3,4,7,8-PeCDF | 1.00 | 1.04 | 104 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 79 |
| Total PeCDF | | | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 74 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 71 |
| 1,2,3,7,8-PeCDD | 1.00 | 0.96 | 96 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 85 |
| Total PeCDD | | | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 69 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 66 |
| 1,2,3,4,7,8-HxCDF | 1.00 | 1.08 | 107 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 75 |
| 1,2,3,6,7,8-HxCDF | 1.00 | 1.10 | 110 | OCDD-13C | 4.00 | 48 |
| 2,3,4,6,7,8-HxCDF | 1.00 | 1.05 | 105 | | | |
| 1,2,3,7,8,9-HxCDF | 1.00 | 1.01 | 101 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | | | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 1.00 | 1.10 | 109 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 61 |
| 1,2,3,6,7,8-HxCDD | 1.00 | 1.02 | 100 | | | |
| 1,2,3,7,8,9-HxCDD | 1.00 | 1.04 | 103 | | | |
| Total HxCDD | | | | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 1.00 | 1.15 | 115 | | | |
| 1,2,3,4,7,8,9-HpCDF | 1.00 | 0.97 | 97 | | | |
| Total HpCDF | | | | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 1.00 | 1.31 | 96 | | | |
| Total HpCDD | | | | | | |
| | | | | | | |
| OCDF | 2.00 | 2.32 | 106 | | | |
| OCDD | 2.00 | 6.62 | 132 | | | |

Qs = Quantity Spiked

Qm = Quantity Measured

Rec. = Recovery (Expressed as Percent)

Results reported on a total weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Spiked Sample Report

Client - Pace Analytical National

| | | | |
|------------------------|-------------------------|-------------|------------------|
| Client's Sample ID | DU-15A-1.0-1.5_0423-MSD | | |
| Lab Sample ID | 10649075015-MSD | | |
| Filename | F230504A_08 | Matrix | Solid |
| Total Amount Extracted | 10.5 g | Dilution | NA |
| ICAL ID | F230426 | Extracted | 04/19/2023 14:30 |
| CCal Filename(s) | F230504A_01 | Analyzed | 05/04/2023 05:52 |
| Method Blank ID | BLANK-105368 | Injected By | SMT |

| Native Isomers | Qs (ng) | Qm (ng) | % Rec. | Internal Standards | ng's Added | Percent Recovery |
|---------------------|---------|---------|--------|-------------------------|------------|------------------|
| 2,3,7,8-TCDF | 0.20 | 0.21 | 107 | 2,3,7,8-TCDF-13C | 2.00 | 63 |
| Total TCDF | | | | 2,3,7,8-TCDD-13C | 2.00 | 62 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 61 |
| 2,3,7,8-TCDD | 0.20 | 0.23 | 111 | 2,3,4,7,8-PeCDF-13C | 2.00 | 64 |
| Total TCDD | | | | 1,2,3,7,8-PeCDD-13C | 2.00 | 65 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 69 |
| 1,2,3,7,8-PeCDF | 1.00 | 0.98 | 98 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 70 |
| 2,3,4,7,8-PeCDF | 1.00 | 1.03 | 103 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 70 |
| Total PeCDF | | | | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 67 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 66 |
| 1,2,3,7,8-PeCDD | 1.00 | 0.97 | 97 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 76 |
| Total PeCDD | | | | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 60 |
| 1,2,3,4,7,8-HxCDF | 1.00 | 1.03 | 103 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 70 |
| 1,2,3,6,7,8-HxCDF | 1.00 | 1.07 | 107 | OCDD-13C | 4.00 | 49 |
| 2,3,4,6,7,8-HxCDF | 1.00 | 1.05 | 105 | | | |
| 1,2,3,7,8,9-HxCDF | 1.00 | 1.04 | 103 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | | | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 1.00 | 1.05 | 105 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 60 |
| 1,2,3,6,7,8-HxCDD | 1.00 | 1.02 | 101 | | | |
| 1,2,3,7,8,9-HxCDD | 1.00 | 1.10 | 109 | | | |
| Total HxCDD | | | | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 1.00 | 1.12 | 112 | | | |
| 1,2,3,4,7,8,9-HpCDF | 1.00 | 1.02 | 102 | | | |
| Total HpCDF | | | | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 1.00 | 1.32 | 97 | | | |
| Total HpCDD | | | | | | |
| | | | | | | |
| OCDF | 2.00 | 2.34 | 107 | | | |
| OCDD | 2.00 | 6.93 | 144 | | | |

Qs = Quantity Spiked

Qm = Quantity Measured

Rec. = Recovery (Expressed as Percent)

Results reported on a total weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444

Method 1613 Spike Sample Results

Client - Pace Analytical National

Client Sample ID DU-15A-1.0-1.5_0423
Lab Sample ID 10649075015
MS ID 10649075015-MS
MSD ID 10649075015-MSD

Sample Filename U230505A_12
MS Filename F230504A_07
MSD Filename F230504A_08

| Analyte | Quantity Spiked (ng) | Unspiked Sample Contribution | | Quantity Measured | | RPD | Subtracted Recovery | |
|---------------------|----------------------|------------------------------|-------------|-------------------|----------|-----|---------------------|---------|
| | | to MS (ng) | to MSD (ng) | MS (ng) | MSD (ng) | | MS (%) | MSD (%) |
| 2,3,7,8-TCDF | 0.20 | ND | ND | 0.21 | 0.21 | 3.4 | 104 | 107 |
| 2,3,7,8-TCDD | 0.20 | 0.00914 | 0.00926 | 0.24 | 0.23 | 3.6 | 115 | 111 |
| 1,2,3,7,8-PeCDF | 1.00 | ND | ND | 1.05 | 0.98 | 7.3 | 105 | 98 |
| 2,3,4,7,8-PeCDF | 1.00 | ND | ND | 1.04 | 1.03 | 1.8 | 104 | 103 |
| 1,2,3,7,8-PeCDD | 1.00 | 0.00276 | 0.00280 | 0.96 | 0.97 | 0.4 | 96 | 97 |
| 1,2,3,4,7,8-HxCDF | 1.00 | 0.00404 | 0.00410 | 1.08 | 1.03 | 4.5 | 107 | 103 |
| 1,2,3,6,7,8-HxCDF | 1.00 | 0.00496 | 0.00502 | 1.10 | 1.07 | 3.4 | 110 | 107 |
| 2,3,4,6,7,8-HxCDF | 1.00 | 0.00304 | 0.00308 | 1.05 | 1.05 | 0.3 | 105 | 105 |
| 1,2,3,7,8,9-HxCDF | 1.00 | 0.00185 | 0.00188 | 1.01 | 1.04 | 2.5 | 101 | 103 |
| 1,2,3,4,7,8-HxCDD | 1.00 | 0.00631 | 0.00639 | 1.10 | 1.05 | 4.5 | 109 | 105 |
| 1,2,3,6,7,8-HxCDD | 1.00 | 0.0163 | 0.0165 | 1.02 | 1.02 | 0.5 | 100 | 101 |
| 1,2,3,7,8,9-HxCDD | 1.00 | 0.0101 | 0.0102 | 1.04 | 1.10 | 6.2 | 103 | 109 |
| 1,2,3,4,6,7,8-HpCDF | 1.00 | 0.0921 | 0.0934 | 1.15 | 1.12 | 2.4 | 115 | 112 |
| 1,2,3,4,7,8,9-HpCDF | 1.00 | ND | ND | 0.97 | 1.02 | 4.3 | 97 | 102 |
| 1,2,3,4,6,7,8-HpCDD | 1.00 | 0.352 | 0.356 | 1.31 | 1.32 | 0.6 | 96 | 97 |
| OCDF | 2.00 | 0.201 | 0.204 | 2.32 | 2.34 | 0.7 | 106 | 107 |
| OCDD | 2.00 | 3.99 | 4.04 | 6.62 | 6.93 | 4.5 | 132 | 144 |

Quantity Spiked - the amount of analyte spiked into the spiked samples

Unspiked Sample Contribution - calculated based on the amount found in the sample and the extracted amounts of the spiked and unspiked samples

Quantity Measured - the total amount of analyte measured in the spiked samples

RPD - the Relative Percent Difference of the spiked sample Quantity Measured values

Subtracted Recovery - calculated after subtracting the unspiked sample contribution

Stage 2A/B Data Validation Checks
JH Baxter
Delivery Group L1603081/10649075

Comments:

- U-qualified samples assigned by the laboratory are not included in this report unless the U qualification is for some other reason other than a simple non-detect.

SUMMARY OF QUALITY CONTROL CHECKS

| Quality Control Check | Check ed By | Comment |
|---|-------------|---|
| Completeness | MBF | The data set is 100 percent complete, no results rejected. |
| Holding times | MBF | Holding times were within the method specific recommended holding times. |
| Preservation | MBF | Preservation was acceptable. |
| COC Documentation | MBF | COC was provided in the lab report. |
| Analytical methods | MBF | EPA 1613B Requested analytical methods were performed. |
| Initial and continuing calibrations | MBF | Not independently verified during Stage 2A/B validation. |
| Method blanks, trip blank, and field blanks | MBF | <p>Method blanks were performed per batch and there were no detections and associated QC were within established control limits except for:</p> <ul style="list-style-type: none"> • Blank-105366 <ul style="list-style-type: none"> ○ Total TCDD 0.23 J ○ 1,2,3,7,8,9-HxCDF 0.15 J <ul style="list-style-type: none"> ▪ DU-10B-1.0-1.5_0423 0.39 J+ ○ Total HxCDF 0.15 J ○ Total HpCDD 0.25 J ○ OCDD 0.46 J+ • Blank-105368 <ul style="list-style-type: none"> ○ 1,2,3,4,6,7,8-HpCDD 0.68 J ○ Total HpCDD 1.4 J ○ OCDF 0.32 J+ ○ OCDD 6.9 <p>Associated sample results were greater than 3X method blank contamination. Only 1 result qualified J+.</p> <ul style="list-style-type: none"> • Equipment Blank (EB-01_0423) <ul style="list-style-type: none"> ○ Total HxCDF 3.3 J ○ 1,2,3,4,7,8-HxCDD 1.6 J+ ○ 1,2,3,4,6,7,8-HpCDD 5.9 J ○ Total HpCDD 5.9 J ○ OCDD 30 J <p>Raw results not reviewed during 2A/B. Equipment blank results (pg/L) and sample results (ng/kg) not directly comparable. Results not qualified.</p> |

| Quality Control Check | Check ed By | Comment |
|--|-------------|--|
| Surrogate/labeled compounds | MBF | Labeled compounds were analyzed and within control limits except for: <ul style="list-style-type: none"> 2,3,7,8-TCDD-37C14 (Cleanup Recovery STD) <ul style="list-style-type: none"> DU-110A-1.0-1.5_0423 33% Unless additional qualifications were necessary, all associated sample analytes qualified J due to low CRS recovery. |
| LCS/LCSD | MBF | An LCS was analyzed per batch. Recoveries were within established control limits. |
| MS/MSD | MBF | MS/MSD on non-SDG samples were performed. Results were within control limits. Non-SDG sample results not used for SDG sample qualification. |
| Field duplicates | MBF | Field duplicates were collected and analyzed: <ul style="list-style-type: none"> Primary: DU-10A-1.0-1.5_0423 Duplicate: DU-110A-1.0-1.5_0423 Results were within 50% solid organic RPD limit except for: <ul style="list-style-type: none"> Total HpCDF <ul style="list-style-type: none"> 64% RPD Total TCDD <ul style="list-style-type: none"> Absolute difference of 3.9 > 2X RL (1.96) Results qualified J/UJ. |
| Lab duplicates | MBF | Lab sample duplicates were not performed or required per the method. |
| Dilution | MBF | Samples did not require further dilution for analysis. |
| Qualitative Identification for HRGC/HRMS analyses only | MBF | Due to the number of EMPC results (106), see Table 1 for sample result qualification breakdown. EMPC results either had the presence of diphenyl ethers or the isotope ratio was out of specification. EMPC results qualified J+. |

Overall Assessment

Qualifier codes added to results; table and notes below.

Notes

TABLE 1. SUMMARY OF QUALIFIED DATA

| Sample ID | Analyte | Result (ng/kg) | Qualifier Assigned | Reason for Qualification |
|---------------------|-------------------|----------------|--------------------|--------------------------|
| DU-01A-0.5-1.0_0423 | 1,2,3,6,7,8-HxCDD | 0.78 | J | Below reporting limit |
| | 1,2,3,6,7,8-HxCDF | 0.53 | | |
| | 1,2,3,7,8-PeCDD | 0.26 | | |
| | 2,3,4,6,7,8-HxCDF | 0.2 | | |
| | Total HxCDD | 4.6 | | |
| | Total HxCDF | 4.2 | | |
| | Total PeCDD | 2.2 | | |
| | Total PeCDF | 2.3 | | |

| | | | | |
|---------------------|---------------------|------|----|--|
| DU-01A-0.5-1.0_0423 | 1,2,3,4,7,8-HxCDD | 0.49 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 0.15 | | |
| | 1,2,3,7,8,9-HxCDD | 0.77 | | |
| DU-01A-0.5-1.0_0423 | 1,2,3,4,6,7,8-HpCDF | 6.6 | J+ | EMPC, Presence of PCDEs |
| DU-01A-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDD | 0.38 | J | Below reporting limit |
| | 1,2,3,7,8,9-HxCDD | 0.27 | | |
| | OCDF | 3.8 | | |
| | Total HpCDF | 2.8 | | |
| | Total HxCDD | 3 | | |
| | Total HxCDF | 0.95 | | |
| DU-01A-1.0-1.5_0423 | 1,2,3,4,7,8-HxCDD | 0.19 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,7,8,9-HxCDF | 0.23 | | |
| DU-01A-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 2.6 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-01B-0.5-1.0_0423 | 1,2,3,4,7,8-HxCDF | 0.91 | J | Below reporting limit |
| | 1,2,3,6,7,8-HxCDD | 2.3 | | |
| | 1,2,3,7,8-PeCDD | 0.56 | | |
| | 2,3,4,6,7,8-HxCDF | 0.93 | | |
| | 2,3,4,7,8-PeCDF | 0.65 | | |
| | Total TCDF | 0.94 | | |
| | Total PeCDD | 4.5 | | |
| DU-01B-0.5-1.0_0423 | 1,2,3,4,7,8,9-HpCDF | 0.6 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.83 | | |
| | 1,2,3,7,8,9-HxCDD | 1.4 | | |
| | 1,2,3,7,8,9-HxCDF | 0.43 | | |
| DU-01B-0.5-1.0_0423 | 1,2,3,4,6,7,8-HpCDF | 17 | J+ | EMPC, Presence of PCDEs |
| DU-01B-0.5-1.0_0423 | 1,2,3,6,7,8-HxCDF | 0.80 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-01B-1.0-1.5_0423 | 2,3,7,8-Tcdd | 0.43 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.23 | | |
| | 1,2,3,6,7,8-HxCDD | 0.44 | | |
| | Total HxCDF | 1.7 | | |
| | Total PeCDD | 1.4 | | |
| | Total PeCDF | 0.9 | | |
| | Total TCDD | 0.43 | | |

| | | | | |
|---------------------|---------------------|-------|----|--|
| DU-01B-1.0-1.5_0423 | 1,2,3,7,8,9-HxCDD | 0.11 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| DU-01B-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 6.1 | J+ | EMPC, Presence of PCDEs |
| DU-06A-0.5-1.0_0423 | 1,2,3,4,7,8-HxCDD | 0.54 | J | Below reporting limit |
| | 1,2,3,7,8,9-HxCDD | 0.8 | | |
| | 1,2,3,7,8-PeCDD | 0.26 | | |
| | 2,3,4,6,7,8-HxCDF | 0.32 | | |
| | Total HxCDF | 3.2 | | |
| | Total PeCDD | 2.7 | | |
| DU-06A-0.5-1.0_0423 | 1,2,3,4,7,8,9-HpCDF | 0.5 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 0.3 | | |
| | 1,2,3,6,7,8-HxCDD | 1 | | |
| | 1,2,3,7,8,9-HxCDF | 0.26 | | |
| DU-06A-0.5-1.0_0423 | 1,2,3,4,6,7,8-HpCDF | 12 | J+ | EMPC, Presence of PCDEs |
| DU-06A-1.0-1.5_0423 | 1,2,3,4,7,8-HxCDD | 0.33 | J | Below reporting limit |
| | 1,2,3,6,7,8-HxCDD | 0.5 | | |
| | 1,2,3,6,7,8-HxCDF | 0.33 | | |
| | Total TCDF | 0.27 | | |
| | Total HxCDD | 3.5 | | |
| | Total HxCDF | 1.9 | | |
| DU-06A-1.0-1.5_0423 | 1,2,3,7,8,9-HxCDD | 0.25 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| DU-06A-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 5.8 | J+ | EMPC, Presence of PCDEs |
| DU-06B-0.5-1.0_0423 | 2,3,7,8-Tcdd | 0.5 | J | Below reporting limit |
| | 1,2,3,4,7,8,9-HpCDF | 0.82 | | |
| | 1,2,3,4,7,8-HxCDD | 1.4 | | |
| | 1,2,3,4,7,8-HxCDF | 0.8 | | |
| | 1,2,3,6,7,8-HxCDD | 2.9 | | |
| | 1,2,3,7,8,9-HxCDD | 2.2 | | |
| | 1,2,3,7,8-PeCDD | 0.88 | | |
| | 1,2,3,7,8-PeCDF | 0.31 | | |
| | 2,3,4,6,7,8-HxCDF | 0.73 | | |
| | Total PeCDF | 3.4 | | |
| DU-06B-0.5-1.0_0423 | 1,2,3,7,8,9-HxCDF | 0.30, | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 2,3,4,7,8-PeCDF | 0.28 | | |

| | | | | |
|---------------------|---------------------|------|----|--|
| DU-06B-0.5-1.0_0423 | 1,2,3,4,6,7,8-HpCDF | 27 | J+ | EMPC, Presence of PCDEs |
| DU-06B-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDD | 0.6 | J | Below reporting limit |
| | 2,3,4,6,7,8-HxCDF | 0.18 | | |
| | Total TCDF | 0.14 | | |
| | Total HxCDF | 1.5 | | |
| DU-06B-1.0-1.5_0423 | Total PeCDD | 1.2 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.41 | | |
| | 1,2,3,4,7,8-HxCDF | 0.14 | | |
| | 1,2,3,6,7,8-HxCDF | 0.23 | | |
| | 1,2,3,7,8,9-HxCDD | 0.49 | | |
| DU-06B-1.0-1.5_0423 | 1,2,3,7,8,9-HxCDF | 0.17 | | |
| | | | | |
| DU-06B-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 5.1 | J+ | EMPC, Presence of PCDEs |
| DU-09A-1.0-1.5_0423 | 1,2,3,4,7,8,9-HpCDF | 4.5 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 2.2 | | |
| | 1,2,3,4,7,8-HxCDF | 4.3 | | |
| | 1,2,3,7,8,9-HxCDD | 3.7 | | |
| | 1,2,3,7,8,9-HxCDF | 0.92 | | |
| | 1,2,3,7,8-PeCDD | 0.94 | | |
| | 2,3,4,6,7,8-HxCDF | 2.3 | | |
| DU-09A-1.0-1.5_0423 | 2,3,4,7,8-PeCDF | 0.84 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| DU-09A-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 160 | J+ | EMPC, Presence of PCDEs |
| DU-09A-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDF | 1.2 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-09A-1.5-2.0_0423 | 1,2,3,4,7,8,9-HpCDF | 0.81 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.64 | | |
| | 1,2,3,4,7,8-HxCDF | 0.87 | | |
| | 1,2,3,6,7,8-HxCDD | 1.3 | | |
| | 1,2,3,7,8,9-HxCDD | 1 | | |
| | 2,3,4,6,7,8-HxCDF | 0.45 | | |
| | Total TCDF | 0.4 | | |
| | Total PeCDF | 2.3 | | |
| DU-09A-1.5-2.0_0423 | 1,2,3,4,6,7,8-HpCDF | 28 | J+ | EMPC, Presence of PCDEs |
| DU-09A-1.5-2.0_0423 | 1,2,3,6,7,8-HxCDF | 1.2 | J+ | EMPC, Presence of PCDEs, Below reporting limit |

| | | | | |
|---------------------|---------------------|------|----|--|
| DU-09B-1.0-1.5_0423 | 1,2,3,7,8-PeCDD | 2.7 | J | Below reporting limit |
| | 1,2,3,7,8-PeCDF | 0.82 | | |
| | 2,3,4,6,7,8-HxCDF | 4.9 | | |
| | 2,3,4,7,8-PeCDF | 1.5 | | |
| DU-09B-1.0-1.5_0423 | 1,2,3,7,8,9-HxCDF | 1.4 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| DU-09B-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 240 | J+ | EMPC, Presence of PCDEs |
| DU-09B-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDF | 1.8 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-09B-1.5-2.0_0423 | 1,2,3,4,7,8,9-HpCDF | 1.2 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 1.5 | | |
| | 1,2,3,6,7,8-HxCDD | 3.1 | | |
| | 1,2,3,7,8,9-HxCDF | 0.54 | | |
| | Total TCDF | 0.71 | | |
| | Total PeCDD | 3.5 | | |
| | Total PeCDF | 0.37 | | |
| DU-09B-1.5-2.0_0423 | 1,2,3,4,7,8-HxCDF | 1.2 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,6,7,8-HxCDF | 0.39 | | |
| | 1,2,3,7,8,9-HxCDD | 2.1 | | |
| | 1,2,3,7,8-PeCDD | 0.64 | | |
| | 2,3,4,6,7,8-HxCDF | 0.74 | | |
| DU-09B-1.5-2.0_0423 | 1,2,3,4,6,7,8-HpCDF | 44 | J+ | EMPC, Presence of PCDEs |
| DU-10A-1.0-1.5_0423 | 1,2,3,4,7,8,9-HpCDF | 1.4 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.9 | | |
| | 1,2,3,4,7,8-HxCDF | 1.2 | | |
| | 1,2,3,6,7,8-HxCDD | 2.5 | | |
| | 1,2,3,6,7,8-HxCDF | 0.23 | | |
| | 1,2,3,7,8,9-HxCDD | 1.7 | | |
| | 1,2,3,7,8-PeCDD | 0.43 | | |
| | Total TCDF | 0.46 | | |
| | Total PeCDD | 4 | | |
| | Total PeCDF | 2.3 | | |
| DU-10A-1.0-1.5_0423 | 2,3,4,6,7,8-HxCDF | 0.56 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| DU-10A-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 26 | J+ | EMPC, Presence of PCDEs |
| DU-10A-1.0-1.5_0423 | Total HpCDF | 48 | J | FD RPD 64% > 50% Limit, FD Absolute difference > 2X RL |
| | Total TCDD | 4.5 | | |

| | | | | |
|---------------------|---------------------|------|----|--|
| DU-10A-1.5-2.0_0423 | 1,2,3,6,7,8-HxCDD | 1 | J | Below reporting limit |
| | 1,2,3,6,7,8-HxCDF | 0.35 | | |
| | 1,2,3,7,8,9-HxCDD | 0.62 | | |
| | 2,3,4,6,7,8-HxCDF | 0.3 | | |
| | Total TCDF | 0.35 | | |
| | Total PeCDD | 0.62 | | |
| DU-10A-1.5-2.0_0423 | 1,2,3,4,7,8-HxCDD | 0.48 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 0.31 | | |
| | 1,2,3,7,8-PeCDD | 0.17 | | |
| DU-10A-1.5-2.0_0423 | 1,2,3,4,6,7,8-HpCDF | 9.7 | J+ | EMPC, Presence of PCDEs |
| DU-10B-1.0-1.5_0423 | 1,2,3,4,7,8,9-HpCDF | 0.98 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.78 | | |
| | 1,2,3,4,7,8-HxCDF | 0.92 | | |
| | 1,2,3,6,7,8-HxCDD | 1.8 | | |
| | 1,2,3,7,8,9-HxCDD | 1.4 | | |
| | 2,3,4,6,7,8-HxCDF | 0.75 | | |
| | Total TCDF | 0.51 | | |
| | Total PeCDD | 1.6 | | |
| | Total PeCDF | 2 | | |
| DU-10B-1.0-1.5_0423 | 2,3,7,8-Tcdd | 0.56 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,7,8-PeCDD | 0.25 | | |
| | 2,3,4,7,8-PeCDF | 0.25 | | |
| DU-10B-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 32 | J+ | EMPC, Presence of PCDEs |
| DU-10B-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDF | 0.30 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-10B-1.0-1.5_0423 | 1,2,3,7,8,9-HxCDF | 0.39 | J+ | Result > 2X Method Blank, Result < 3X Method Blank |
| DU-10B-1.5-2.0_0423 | 2,3,7,8-Tcdd | 0.99 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 0.42 | | |
| | 1,2,3,6,7,8-HxCDD | 1.4 | | |
| | 1,2,3,7,8,9-HxCDD | 1.1 | | |
| | Total PeCDD | 0.65 | | |
| | Total TCDD | 0.99 | | |
| DU-10B-1.5-2.0_0423 | 1,2,3,4,7,8,9-HpCDF | 0.52 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.63 | | |
| | 1,2,3,6,7,8-HxCDF | 0.31 | | |
| | 1,2,3,7,8,9-HxCDF | 0.35 | | |
| | 1,2,3,7,8-PeCDD | 0.26 | | |
| | 2,3,4,6,7,8-HxCDF | 0.38 | | |
| DU-10B-1.5-2.0_0423 | 1,2,3,4,6,7,8-HpCDF | 19 | J+ | EMPC, Presence of PCDEs |

| | | | | |
|----------------------|---------------------|------|----------|---|
| DU-110A-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDF | 2.2 | J+ | EMPC, Presence of PCDEs, CRS < LCL, Below reporting limit |
| DU-110A-1.0-1.5_0423 | 2,3,7,8-Tcdd | 1.2 | J+ | EMPC, Isotope ratio out of spec, CRS < LCL |
| DU-110A-1.0-1.5_0423 | 1,2,3,4,7,8-HxCDD | 0.65 | J+ | EMPC, Isotope ratio out of spec, CRS < LCL, Below reporting limit |
| | 1,2,3,7,8,9-HxCDF | 0.39 | | |
| | 1,2,3,7,8-PeCDD | 0.27 | | |
| | 2,3,4,6,7,8-HxCDF | 0.4 | | |
| DU-110A-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDD | 91 | J | CRS < LCL |
| | 1,2,3,4,6,7,8-HpCDF | 28 | J | |
| | 1,2,3,7,8-PeCDF | 0.46 | UJ | |
| | 2,3,7,8-TCDF | 0.39 | UJ | |
| | OCDD | 1100 | J | |
| | OCDF | 120 | J | |
| | Total TCDF | 1.6 | J | |
| | Total HpCDD | 250 | J | |
| | Total HxCDD | 24 | J | |
| | Total HxCDF | 18 | J | |
| DU-110A-1.0-1.5_0423 | 1,2,3,4,7,8,9-HpCDF | 1.9 | J | CRS < LCL, Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 1.2 | | |
| | 1,2,3,6,7,8-HxCDD | 2.3 | | |
| | 1,2,3,7,8,9-HxCDD | 1.6 | | |
| | 2,3,4,7,8-PeCDF | 0.4 | | |
| | Total PeCDD | 2.9 | | |
| | Total PeCDF | 2.1 | | |
| DU-110A-1.0-1.5_0423 | Total HpCDF | 93 | J, UJ | FD RPD 64% > 50% Limit, FD Absolute difference > 2X RL, CRS < LCL (both analytes) |
| | Total TCDD | 0.6 | | |
| DU-11A-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDD | 1.2 | J | Below reporting limit |
| | 1,2,3,7,8,9-HxCDD | 0.85 | | |
| | Total PeCDD | 0.73 | | |
| | Total PeCDF | 0.71 | | |
| DU-11A-1.0-1.5_0423 | 1,2,3,4,7,8-HxCDD | 0.34 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 0.56 | | |
| | 1,2,3,7,8,9-HxCDF | 0.28 | | |
| DU-11A-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDF | 0.83 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-11A-1.5-2.0_0423 | 1,2,3,4,7,8,9-HpCDF | 2.4 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.86 | | |
| | 1,2,3,6,7,8-HxCDD | 2.6 | | |
| | 1,2,3,7,8,9-HxCDD | 1.4 | | |
| | 1,2,3,7,8,9-HxCDF | 1.2 | | |
| | 1,2,3,7,8-PeCDD | 0.48 | | |
| | 2,3,4,7,8-PeCDF | 1.6 | | |
| | Total PeCDD | 2.4 | | |

| | | | | |
|---------------------|---------------------|------|----|--|
| DU-11A-1.5-2.0_0423 | 2,3,4,6,7,8-HxCDF | 1.5 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| DU-11A-1.5-2.0_0423 | 1,2,3,6,7,8-HxCDF | 2.6 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-11B-1.0-1.5_0423 | 1,2,3,4,7,8-HxCDF | 1.5 | J | Below reporting limit |
| | 1,2,3,6,7,8-HxCDF | 0.79 | | |
| | 2,3,4,7,8-PeCDF | 0.42 | | |
| | Total HxCDD | 3.4 | | |
| | Total PeCDF | 1.7 | | |
| DU-11B-1.0-1.5_0423 | Total TCDD | 0.38 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,6,7,8-HxCDD | 0.7 | | |
| | 1,2,3,7,8,9-HxCDD | 0.45 | | |
| DU-11B-1.5-2.0_0423 | 2,3,4,6,7,8-HxCDF | 0.34 | J | Below reporting limit |
| | 1,2,3,4,6,7,8-HpCDF | 2.8 | | |
| | 1,2,3,4,7,8-HxCDF | 0.46 | | |
| | 1,2,3,6,7,8-HxCDD | 0.44 | | |
| | 1,2,3,7,8,9-HxCDD | 0.39 | | |
| | OCDF | 7.4 | | |
| | Total HpCDF | 2.8 | | |
| | Total HxCDD | 2.2 | | |
| | Total HxCDF | 3.9 | | |
| DU-11B-1.5-2.0_0423 | Total PeCDF | 0.51 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 2,3,7,8-Tcdd | 0.18 | | |
| DU-11B-1.5-2.0_0423 | 1,2,3,6,7,8-HxCDF | 0.37 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-15A-1.0-1.5_0423 | 2,3,7,8-Tcdd | 0.92 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.63 | | |
| | 1,2,3,4,7,8-HxCDF | 0.4 | | |
| | 1,2,3,6,7,8-HxCDD | 1.6 | | |
| | 1,2,3,7,8,9-HxCDD | 1 | | |
| | 1,2,3,7,8,9-HxCDF | 0.19 | | |
| | 2,3,4,6,7,8-HxCDF | 0.3 | | |
| | Total PeCDD | 2.1 | | |
| DU-15A-1.0-1.5_0423 | Total PeCDF | 1.6 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,7,8-PeCDD | 0.22 | | |
| DU-15A-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 9.2 | J+ | EMPC, Presence of PCDEs |
| DU-15A-1.0-1.5_0423 | 1,2,3,6,7,8-HxCDF | 0.50 | J+ | EMPC, Presence of PCDEs, Below reporting limit |

| | | | | |
|---------------------|---------------------|------|----|--|
| DU-15A-1.5-2.0_0423 | 2,3,7,8-Tcdd | 0.83 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.54 | | |
| | 1,2,3,4,7,8-HxCDF | 0.34 | | |
| | 1,2,3,7,8-PeCDD | 0.14 | | |
| | Total TCDF | 0.21 | | |
| | Total HxCDF | 4.3 | | |
| | Total PeCDD | 1.5 | | |
| | Total TCDD | 0.83 | | |
| DU-15A-1.5-2.0_0423 | 1,2,3,4,7,8,9-HpCDF | 0.34 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,6,7,8-HxCDD | 0.83 | | |
| | 1,2,3,7,8,9-HxCDD | 0.71 | | |
| DU-15A-1.5-2.0_0423 | 1,2,3,4,6,7,8-HpCDF | 6.6 | J+ | EMPC, Presence of PCDEs |
| DU-15A-1.5-2.0_0423 | 1,2,3,6,7,8-HxCDF | 0.47 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| DU-15B-1.0-1.5_0423 | 1,2,3,4,6,7,8-HpCDF | 4.3 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.52 | | |
| | 1,2,3,6,7,8-HxCDD | 0.83 | | |
| | 1,2,3,6,7,8-HxCDF | 0.53 | | |
| | 2,3,4,6,7,8-HxCDF | 0.27 | | |
| | Total HxCDF | 3 | | |
| | Total PeCDD | 0.6 | | |
| DU-15B-1.0-1.5_0423 | 1,2,3,4,7,8-HxCDF | 0.14 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,7,8,9-HxCDD | 0.54 | | |
| DU-15B-1.5-2.0_0423 | 2,3,7,8-Tcdd | 0.31 | J | Below reporting limit |
| | 1,2,3,4,6,7,8-HpCDF | 2 | | |
| | 1,2,3,6,7,8-HxCDD | 0.39 | | |
| | 1,2,3,7,8,9-HxCDD | 0.2 | | |
| | OCDF | 8.6 | | |
| | Total HxCDD | 3.9 | | |
| | Total HxCDF | 1 | | |
| | Total PeCDF | 0.3 | | |
| DU-15B-1.5-2.0_0423 | Total TCDD | 0.31 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| | 1,2,3,6,7,8-HxCDF | 0.36 | | |
| SU-07A-0.5-1.0_0423 | 1,2,3,4,7,8,9-HpCDF | 2 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 2.9 | | |
| | 1,2,3,7,8,9-HxCDD | 3.6 | | |
| | 1,2,3,7,8-PeCDF | 0.76 | | |
| | 2,3,4,6,7,8-HxCDF | 2.2 | | |
| | 2,3,4,7,8-PeCDF | 1.5 | | |
| | 2,3,7,8-TCDF | 0.94 | | |
| SU-07A-0.5-1.0_0423 | 1,2,3,6,7,8-HxCDD | 5.2 | J+ | EMPC, Isotope ratio out of spec |


| | | | | |
|---------------------|---------------------|------|----|--|
| SU-07A-0.5-1.0_0423 | 2,3,7,8-Tcdd | 0.99 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 2.1 | | |
| | 1,2,3,7,8,9-HxCDF | 0.75 | | |
| | 1,2,3,7,8-PeCDD | 1.2 | | |
| SU-07A-0.5-1.0_0423 | 1,2,3,6,7,8-HxCDF | 2.9 | J+ | EMPC, Presence of PCDEs, Below reporting limit |
| | 1,2,3,4,7,8,9-HpCDF | 0.6 | | |
| SU-07A-1.0-1.5_0423 | 1,2,3,4,7,8-HxCDF | 0.45 | J | Below reporting limit |
| | 1,2,3,6,7,8-HxCDD | 1.1 | | |
| | 1,2,3,6,7,8-HxCDF | 0.63 | | |
| | 1,2,3,7,8,9-HxCDD | 0.58 | | |
| | 1,2,3,7,8,9-HxCDF | 0.34 | | |
| | 2,3,4,7,8-PeCDF | 0.28 | | |
| | Total PeCDF | 0.91 | | |
| SU-07A-1.0-1.5_0423 | 2,3,7,8-Tcdd | 0.3 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.43 | | |
| | 2,3,4,6,7,8-HxCDF | 0.36 | | |
| SU-07B-0.5-1.0-0423 | 1,2,3,4,7,8,9-HpCDF | 1.6 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 1.8 | | |
| | 1,2,3,6,7,8-HxCDD | 4.6 | | |
| | 1,2,3,7,8,9-HxCDD | 3.3 | | |
| | 1,2,3,7,8-PeCDD | 0.8 | | |
| | 2,3,4,6,7,8-HxCDF | 1.8 | | |
| SU-07B-0.5-1.0-0423 | 2,3,4,7,8-PeCDF | 0.81 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 1.6, | | |
| SU-07B-0.5-1.0-0423 | 1,2,3,7,8,9-HxCDF | 0.65 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,6,7,8-HxCDF | 3.0 | | |
| SU-07B-1.0-1.5-0423 | 1,2,3,6,7,8-HxCDD | 1.2 | J | Below reporting limit |
| | 1,2,3,7,8,9-HxCDD | 0.85 | | |
| | 2,3,4,7,8-PeCDF | 0.26 | | |
| | Total TCDF | 0.81 | | |
| | Total HxCDF | 3 | | |
| | Total PeCDF | 1.2 | | |
| | Total TCDD | 0.77 | | |
| SU-07B-1.0-1.5-0423 | 1,2,3,4,7,8-HxCDD | 0.49 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 0.29 | | |
| | 1,2,3,6,7,8-HxCDF | 0.65 | | |

Oregon Dept. of Env. Quality - ODEQ

Sample Delivery Group: L1605173
Samples Received: 04/07/2023
Project Number: 02060.005.004
Description: Oregon DEQ-JH Baxter Offsite Investigation (TO #2060.005)

Report To: Don Hanson
165 E. 7th Avenue
Suite 100
Eugene, OR 97401

Entire Report Reviewed By:



Brian Ford
Project Manager

Results relate only to the items tested or calibrated and are reported as rounded values. This test report shall not be reproduced, except in full, without written approval of the laboratory. Where applicable, sampling conducted by Pace Analytical National is performed per guidance provided in laboratory standard operating procedures ENV-SOP-MTJL-0067 and ENV-SOP-MTJL-0068. Where sampling conducted by the customer, results relate to the accuracy of the information provided, and as the samples are received.

Pace Analytical National12065 Lebanon Rd Mount Juliet, TN 37122 615-758-5858 800-767-5859 www.pacenational.com

TABLE OF CONTENTS

| | | |
|--------------------------------|----|-----------------|
| Cp: Cover Page | 1 | ¹ Cp |
| Tc: Table of Contents | 2 | |
| Ss: Sample Summary | 3 | ² Tc |
| Cn: Case Narrative | 8 | ³ Ss |
| Gl: Glossary of Terms | 9 | ⁴ Cn |
| Al: Accreditations & Locations | 10 | ⁵ Gl |
| Sc: Sample Chain of Custody | 11 | ⁶ Al |
| | | ⁷ Sc |

SAMPLE SUMMARY

DU-06A-1.5-2.0_0423 L1605173-01 Solid

Collected by
GSI

Collected date/time
04/05/23 13:10

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-06A-2.0-2.5_0423 L1605173-02 Solid

Collected by
GSI

Collected date/time
04/05/23 13:15

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-06A-2.5-3.0_0423 L1605173-03 Solid

Collected by
GSI

Collected date/time
04/05/23 13:20

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-06B-1.5-2.0_0423 L1605173-04 Solid

Collected by
GSI

Collected date/time
04/05/23 14:40

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-06B-2.0-2.5_0423 L1605173-05 Solid

Collected by
GSI

Collected date/time
04/05/23 14:45

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-06B-2.5-3.0_0423 L1605173-06 Solid

Collected by
GSI

Collected date/time
04/05/23 14:50

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-106B-1.5-2.0_0423 L1605173-07 Solid

Collected by
GSI

Collected date/time
04/05/23 14:55

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |


DU-01A-1.5-2.0_0423 L1605173-08 Solid

Collected by
GSI

Collected date/time
04/05/23 15:40

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |



SAMPLE SUMMARY

DU-01A-2.0-2.5_0423 L1605173-09 Solid

Collected by
GSI

Collected date/time
04/05/23 15:45

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-01A-2.5-3.0_0423 L1605173-10 Solid

Collected by
GSI

Collected date/time
04/05/23 15:50

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-10B-2.0-2.5_0423 L1605173-11 Solid

Collected by
GSI

Collected date/time
04/05/23 10:30

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-10B-2.5-3.0_0423 L1605173-12 Solid

Collected by
GSI

Collected date/time
04/05/23 10:35

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-09A-2.0-2.5_0423 L1605173-13 Solid

Collected by
GSI

Collected date/time
04/05/23 11:40

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-09A-2.5-3.0_0423 L1605173-14 Solid

Collected by
GSI

Collected date/time
04/05/23 11:45

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-09B-2.0-2.5_0423 L1605173-15 Solid

Collected by
GSI

Collected date/time
04/05/23 12:25

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |


DU-09B-2.5-3.0_0423 L1605173-16 Solid

Collected by
GSI

Collected date/time
04/05/23 12:30

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |



SAMPLE SUMMARY

DU-15A-2.0-2.5_0423 L1605173-17 Solid

Collected by
GSI

Collected date/time
04/04/23 10:10

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-15A-2.5-3.0_0423 L1605173-18 Solid

Collected by
GSI

Collected date/time
04/04/23 10:15

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-15B-2.0-2.5_0423 L1605173-19 Solid

Collected by
GSI

Collected date/time
04/04/23 11:10

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-15B-2.5-3.0_0423 L1605173-20 Solid

Collected by
GSI

Collected date/time
04/04/23 11:15

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

SU-07A-1.5-2.0_0423 L1605173-21 Solid

Collected by
GSI

Collected date/time
04/04/23 11:45

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

SU-07A-2.0-2.5_0423 L1605173-22 Solid

Collected by
GSI

Collected date/time
04/04/23 11:50

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

SU-07A-2.5-3.0_0423 L1605173-23 Solid

Collected by
GSI

Collected date/time
04/04/23 11:55

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |


SU-07B-1.5-2.0-0423 L1605173-24 Solid

Collected by
GSI

Collected date/time
04/04/23 12:10

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |



SAMPLE SUMMARY

SU-07B-2.0-2.5-0423 L1605173-25 Solid

Collected by
GSI

Collected date/time
04/04/23 12:15

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

SU-07B-2.5-3.0-0423 L1605173-26 Solid

Collected by
GSI

Collected date/time
04/04/23 12:20

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-11A-2.0-2.5_0423 L1605173-27 Solid

Collected by
GSI

Collected date/time
04/04/23 14:15

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-11A-2.5-3.0_0423 L1605173-28 Solid

Collected by
GSI

Collected date/time
04/04/23 14:20

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-11B-2.0-2.5_0423 L1605173-29 Solid

Collected by
GSI

Collected date/time
04/04/23 14:40

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-11B-2.5-3.0_0423 L1605173-30 Solid

Collected by
GSI

Collected date/time
04/04/23 14:45

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-10A-2.0-2.5_0423 L1605173-31 Solid

Collected by
GSI

Collected date/time
04/05/23 09:40

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |


DU-10A-2.5-3.0_0423 L1605173-32 Solid

Collected by
GSI

Collected date/time
04/05/23 09:45

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |



SAMPLE SUMMARY

DU-01B-1.5-2.0_0423 L1605173-33 Solid

Collected by
GSI

Collected date/time
04/05/23 16:05

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-01B-2.0-2.5_0423 L1605173-34 Solid

Collected by
GSI

Collected date/time
04/05/23 16:10

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |

DU-01B-2.5-3.0_0423 L1605173-35 Solid

Collected by
GSI

Collected date/time
04/05/23 16:15

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |


EB-02-0423 L1605173-36 GW

Collected by
GSI

Collected date/time
04/05/23 15:05

Received date/time
04/07/23 09:20

| Method | Batch | Dilution | Preparation date/time | Analysis date/time | Analyst | Location |
|------------------------|-----------|----------|-----------------------|--------------------|---------|-----------------------|
| Subcontracted Analyses | WG2043854 | 1 | 06/05/23 00:00 | 06/05/23 00:00 | - | Minneapolis, MN 55414 |



CASE NARRATIVE


All sample aliquots were received at the correct temperature, in the proper containers, with the appropriate preservatives, and within method specified holding times, unless qualified or notated within the report. Where applicable, all MDL (LOD) and RDL (LOQ) values reported for environmental samples have been corrected for the dilution factor used in the analysis. All Method and Batch Quality Control are within established criteria except where addressed in this case narrative, a non-conformance form or properly qualified within the sample results. By my digital signature below, I affirm to the best of my knowledge, all problems/anomalies observed by the laboratory as having the potential to affect the quality of the data have been identified by the laboratory, and no information or data have been knowingly withheld that would affect the quality of the data.



Brian Ford
Project Manager

Project Narrative

L1605173 -01, -02, -03, -04, -05, -06, -07, -08, -09, -10, -11, -12, -13, -14, -15, -16, -17, -18, -19, -20, -21, -22, -23, -24, -25, -26, -27, -28, -29, -30, -31, -32, -33, -34, -35, -36 contains subout data that is included after the chain of custody.



GLOSSARY OF TERMS

Guide to Reading and Understanding Your Laboratory Report

The information below is designed to better explain the various terms used in your report of analytical results from the Laboratory. This is not intended as a comprehensive explanation, and if you have additional questions please contact your project representative.


Results Disclaimer - Information that may be provided by the customer, and contained within this report, include Permit Limits, Project Name, Sample ID, Sample Matrix, Sample Preservation, Field Blanks, Field Spikes, Field Duplicates, On-Site Data, Sampling Collection Dates/Times, and Sampling Location. Results relate to the accuracy of this information provided, and as the samples are received.

Abbreviations and Definitions

| | |
|------------------------------|---|
| SDG | Sample Delivery Group. |
| Uncertainty (Radiochemistry) | Confidence level of 2 sigma. |
| Case Narrative (Cn) | A brief discussion about the included sample results, including a discussion of any non-conformances to protocol observed either at sample receipt by the laboratory from the field or during the analytical process. If present, there will be a section in the Case Narrative to discuss the meaning of any data qualifiers used in the report. |
| Quality Control Summary (Qc) | This section of the report includes the results of the laboratory quality control analyses required by procedure or analytical methods to assist in evaluating the validity of the results reported for your samples. These analyses are not being performed on your samples typically, but on laboratory generated material. |
| Sample Chain of Custody (Sc) | This is the document created in the field when your samples were initially collected. This is used to verify the time and date of collection, the person collecting the samples, and the analyses that the laboratory is requested to perform. This chain of custody also documents all persons (excluding commercial shippers) that have had control or possession of the samples from the time of collection until delivery to the laboratory for analysis. |
| Sample Results (Sr) | This section of your report will provide the results of all testing performed on your samples. These results are provided by sample ID and are separated by the analyses performed on each sample. The header line of each analysis section for each sample will provide the name and method number for the analysis reported. |
| Sample Summary (Ss) | This section of the Analytical Report defines the specific analyses performed for each sample ID, including the dates and times of preparation and/or analysis. |

Qualifier Description

The remainder of this page intentionally left blank, there are no qualifiers applied to this SDG.



ACCREDITATIONS & LOCATIONS


Pace Analytical National 12065 Lebanon Rd Mount Juliet, TN 37122

| | | | |
|-------------------------------|-------------|-----------------------------|------------------|
| Alabama | 40660 | Nebraska | NE-OS-15-05 |
| Alaska | 17-026 | Nevada | TN000032021-1 |
| Arizona | AZ0612 | New Hampshire | 2975 |
| Arkansas | 88-0469 | New Jersey-NELAP | TN002 |
| California | 2932 | New Mexico ¹ | TN00003 |
| Colorado | TN00003 | New York | 11742 |
| Connecticut | PH-0197 | North Carolina | Env375 |
| Florida | E87487 | North Carolina ¹ | DW21704 |
| Georgia | NELAP | North Carolina ³ | 41 |
| Georgia ¹ | 923 | North Dakota | R-140 |
| Idaho | TN00003 | Ohio-VAP | CL0069 |
| Illinois | 200008 | Oklahoma | 9915 |
| Indiana | C-TN-01 | Oregon | TN200002 |
| Iowa | 364 | Pennsylvania | 68-02979 |
| Kansas | E-10277 | Rhode Island | LA000356 |
| Kentucky ^{1 6} | KY90010 | South Carolina | 84004002 |
| Kentucky ² | 16 | South Dakota | n/a |
| Louisiana | AI30792 | Tennessee ^{1 4} | 2006 |
| Louisiana | LA018 | Texas | T104704245-20-18 |
| Maine | TN00003 | Texas ⁵ | LAB0152 |
| Maryland | 324 | Utah | TN000032021-11 |
| Massachusetts | M-TN003 | Vermont | VT2006 |
| Michigan | 9958 | Virginia | 110033 |
| Minnesota | 047-999-395 | Washington | C847 |
| Mississippi | TN00003 | West Virginia | 233 |
| Missouri | 340 | Wisconsin | 998093910 |
| Montana | CERT0086 | Wyoming | A2LA |
| A2LA – ISO 17025 | 1461.01 | AIHA-LAP, LLC EMLAP | 100789 |
| A2LA – ISO 17025 ⁵ | 1461.02 | DOD | 1461.01 |
| Canada | 1461.01 | USDA | P330-15-00234 |
| EPA-Crypto | TN00003 | | |

¹ Drinking Water ² Underground Storage Tanks ³ Aquatic Toxicity ⁴ Chemical/Microbiological ⁵ Mold ⁶ Wastewater n/a Accreditation not applicable

* Not all certifications held by the laboratory are applicable to the results reported in the attached report.

* Accreditation is only applicable to the test methods specified on each scope of accreditation held by Pace Analytical.



State of Oregon Chain of Custody (Pace)

| | | | | | | | | | | | | | | | | |
|--|-----------------|-----------------|--------|----------------------|---|--|--|--|--|--|---------|----------------------------------|--------------|--|--|--|
| Agency, Authorized Purchaser or Agent: GSI for ODEQ Send Lab Report To: Don Hanson, RG Address: 165 E. 7th Avenue, Suite 100 Eugene, OR 97401 Tel #: 541-687-7349 E-mail: don.hanson@deq.state.or.us, j.bale@gsws.com, cmartin@gsws.com, m.fargher@gsws.com, GSI@gsws.com | | | | | Contract Laboratory Name: Pace Analytical National Lab Batch #: Invoice: ODEQ/Business Office 811 SW 6th Ave Portland, OR 97204 Tel #: (800) 452-4011 | | | | | Lab Selection Criteria: Proximity (if TAT < 48 hrs) Prior work on same project Cost (for anticipated analyses) Other labs disqualified or unable to perform requested services Emergency work | | | | | Turn Around Time: 10 days (std.) 5 days 72 hours 48 hours 24 hours Other _____ | |
| D153 | | | | | | | | | | | | | | | | |
| Project Name: OREGON DEQ-JH BAXTER OFFSITE INVESTIGATION (TO #2060.005) | | | | | | | | | | | | | | | | |
| Project #: JH Baxter Offsite Investigation | | | | | | | | | | | | | | | | |
| Sampler Name: GSI | | | | | | | | | | | | | | | | |
| Sample Preservative | | | | | | | | | | | | | | | | |
| Requested Analyses | | | | | | | | | | | | | | | | |
| Sample ID# | Collection Date | Collection Time | Matrix | Number of Containers | ISM Prep/Dioxin/Muran by 1613B | | | | | | Archive | L1605173 Comments L1603081 | N 4/14/23 | | | |
| DU-06A-1.5-2.0-0423 | 4/5/23 | 1310 | SE | 1 | | | | | | | X | -01 | | | | |
| DU-06A-2.0-2.5-0423 | 4/5/23 | 1315 | SE | 1 | | | | | | | X | -02 | | | | |
| DU-06A-2.5-3.0-0423 | 4/5/23 | 1320 | SE | 1 | | | | | | | X | -03 | | | | |
| DU-06B-0.5-1.0-0423 | 4/5/23 | 1430 | SE | 1 | X | | | | | | | -04 | | | | |
| DU-06B-1.0-1.5-0423 | 4/5/23 | 1435 | SE | 1 | X | | | | | | | -05 | | | | |
| DU-06B-1.5-2.0-0423 | 4/5/23 | 1440 | SE | 1 | | | | | | | X | -06 | | | | |
| DU-06B-2.0-2.5-0423 | 4/5/23 | 1445 | SE | 1 | | | | | | | X | -07 | | | | |
| DU-06B-2.5-3.0-0423 | 4/5/23 | 1450 | SE | 1 | | | | | | | X | -08 | | | | |
| DU-106B-1.5-2.0-0423 | 4/5/23 | 1455 | SE | 1 | | | | | | | X | -09 | | | | |
| DU-01A-0.5-1.0-0423 | 4/5/23 | 1530 | SE | 1 | X | | | | | | | -10 | | | | |
| DU-01A-1.0-1.5-0423 | 4/5/23 | 1535 | SE | 1 | X | | | | | | | -11 | | | | |
| DU-01A-1.5-2.0-0423 | 4/5/23 | 1540 | SE | 1 | | | | | | | X | -12 | | | | |
| DU-01A-2.0-2.5-0423 | 4/5/23 | 1545 | SE | 1 | | | | | | | X | -13 | | | | |
| DU-01A-2.5-3.0-0423 | 4/5/23 | 1550 | SE | 1 | | | | | | | X | -14 | | | | |
| DU-01B-0.5-1.0-0423 | 4/5/23 | 1555 | SE | 1 | X | | | | | | | -15 | | | | |
| NOTES: Conduct Incremental Sampling Methodology processing prior to analysis. Contact Chris Martin (503-432-5979, cmartin@gsws.com) or Josh Bale (530-276-4186, j.bale@gsws.com) with questions. Include DEQ EDO with final lab report. | | | | | | | | | | | | | | | | |
| Relinquished By: G. Schutans | | | | | Agency/Agent: GSI | | | | | Received By: | | | | | Agency/Agent: | |
| Signature: [Signature] | | | | | Time & Date: 4/6/23 1215 | | | | | Signature: | | | | | Time & Date: | |
| Relinquished By: | | | | | Agency/Agent: | | | | | Received By: [Signature] | | | | | Agency/Agent: | |
| Signature: | | | | | Time & Date: | | | | | Signature: Kaycie [Signature] (9) | | | | | Time & Date: 4/7/23 920 | |

THIS PURC
HEREBY IN

Sample Receipt Checklist

CCC Seal Present/Intact: ☒ Y ☐ N If Applicable
 COC Signed/Accurate: ☒ Y ☐ N VOA Zero Headspace: ☐ Y ☐ N
 Bottles arrive intact: ☒ Y ☐ N Pres. Correct/Check: ☐ Y ☐ N
 Correct bottles used: ☒ Y ☐ N
 Sufficient volume sent: ☒ Y ☐ N
 RAD Screen <0.5 mR/hr: ☒ Y ☐ N

 PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE
 CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

State of Oregon Chain of Custody (Pace)

| | | | | | | | | | | | | | | | |
|---|--|-----------------|-----------------|--------|----------------------|--|--|--|--|--|--|--|---|---|----------|
| Agency, Authorized Purchaser or Agent: GSI for ODEQ | | | | | | Contract Laboratory Name: Pace Analytical National | | | | Lab Selection Criteria: Proximity (if TAT < 48 hrs) Prior work on same project Cost (for anticipated analyses) Other labs disqualified or unable to perform requested services Emergency work | | | | Turn Around Time: 10 days (std) 5 days 72 hours 48 hours 24 hours Other | |
| Send Lab Report To: Don Hanson, RG Address: 165 E 7th Avenue, Suite 100 Eugene, OR 97401 Tel #: 541-687-7349 E-mail: don.hanson@deq.state.or.us, jbaile@gsws.com, cmartine@gsws.com, mfaragher@gsws.com, GIS@gsws.com | | | | | | Lab Batch #: Invoice: ODEQ/Business Office 811 SW 6th Ave Portland, OR 97204 Tel #: (800) 452-4011 | | | | | | | | | |
| Project Name: OREGON DEQ-JH BAXTER OFFSITE INVESTIGATION (TO #2060.005) | | | | | | Sample Preservative | | | | | | | | | |
| Project #: JH Baxter Offsite Investigation | | | | | | Requested Analyses | | | | | | | | | |
| Sampler Name: GSI | | | | | | | | | | | | | | | |
| Sample ID# | | Collection Date | Collection Time | Matrix | Number of Containers | ISM Prep, Dioxin/Furan s by 1613B | | | | | | | | Archive | Comments |
| DU-110A-1.0-1.5-0423 | | 4/5/23 | 950 | SE | 1 | X | | | | | | | | | L1605173 |
| DU-10B-1.0-1.5-0423 | | 4/5/23 | 1020 | SE | 1 | X | | | | | | | | | L1603081 |
| DU-10B-1.5-2.0-0423 | | 4/5/23 | 1025 | SE | 1 | X | | | | | | | | | -16 |
| DU-10B-2.0-2.5-0423 | | 4/5/23 | 1030 | SE | 1 | | | | | | | | | | -17 |
| DU-10B-2.5-3.0-0423 | | 4/5/23 | 1035 | SE | 1 | | | | | | | | X | | -18 |
| DU-09A-1.0-1.5-0423 | | 4/5/23 | 1130 | SE | 1 | X | | | | | | | X | | 214 11 |
| DU-09A-1.5-2.0-0423 | | 4/5/23 | 1135 | SE | 1 | X | | | | | | | X | | 44 12 |
| DU-09A-2.0-2.5-0423 | | 4/5/23 | 1140 | SE | 1 | | | | | | | | | | -21 |
| DU-09A-2.5-3.0-0423 | | 4/5/23 | 1145 | SE | 1 | | | | | | | | X | | 22 |
| DU-09B-1.0-1.5-0423 | | 4/5/23 | 1215 | SE | 1 | X | | | | | | | X | | -23 13 |
| DU-09B-1.5-2.0-0423 | | 4/5/23 | 1220 | SE | 1 | X | | | | | | | X | | -24 14 |
| DU-09B-2.0-2.5-0423 | | 4/5/23 | 1225 | SE | 1 | | | | | | | | | | -25 |
| DU-09B-2.5-3.0-0423 | | 4/5/23 | 1230 | SE | 1 | | | | | | | | X | | -26 |
| DU-06A-0.5-1.0-0423 | | 4/5/23 | 1300 | SE | 1 | X | | | | | | | X | | -27 15 |
| DU-06A-1.0-1.5-0423 | | 4/5/23 | 1305 | SE | 1 | X | | | | | | | | | -28 16 |
| | | | | | | | | | | | | | | | -29 |
| | | | | | | | | | | | | | | | -30 |

NOTES: Conduct Incremental Sampling Methodology processing prior to analysis.
Contact Chris Martin (503-432-5979, cmartin@gsws.com) or Josh Baile (530-276-4188, jbaile@gsws.com) with questions. Include DEQ EDD with final lab report.

| | | | |
|-----------------------------|--------------------------|------------------------|-------------------------|
| Relinquished By: G. Schmitz | Agency/Agent: G81 | Received By: | Agency/Agent: |
| Signature: [Signature] | Time & Date: 4/6/23 1215 | Signature: | Time & Date: |
| Relinquished By: | Agency/Agent: | Received By: * | Agency/Agent: |
| Signature: | Time & Date: | Signature: [Signature] | Time & Date: 4/7/23 920 |

THIS PURCHASE IS SUBMITTED PURSUANT TO STATE OF OREGON SOLICITATION #102-1096-07 AND PRICE AGREEMENT # 8903. THE PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE AND SHALL APPLY TO THIS PURCHASE AND SHALL TAKE PRECEDENCE OVER ALL OTHER CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

State of Oregon Chain of Custody (Pace)

Agency, Authorized Purchaser or Agent:

GSI for ODEQ

Send Lab Report To:

Don Hanson, RG

Address:

165 E. 7th Avenue, Suite 100
Eugene, OR 97401

Tel #: 541-687-7349

E-mail: don.hanson@deq.state.or.us, j.bale@gsws.com,
cmartin@gsws.com, m.fargher@gsws.com, GSI@gsws.com

Contract Laboratory Name:

Pace Analytical National

Lab Batch #:

Invoice:

ODEQ/Business Office
811 SW 6th Ave
Portland, OR 97204
Tel #: (800) 452-4011

Lab Selection Criteria:

Proximity (if TAT < 48 hrs)

Prior work on same project

Cost (for anticipated analyses)

Other labs disqualified or unable
to perform requested services

Emergency work

Turn Around Time:

10 days (std)

5 days

72 hours

48 hours

24 hours

Other _____

Project Name: OREGON DEQ-JH BAXTER OFFSITE INVESTIGATION (TO #2060.005)

Project #: JH Baxter Offsite Investigation

Sampler Name:

G81

| Sample Preservative | | | | | | | | | | Requested Analyses | | Solids NA | ISMA Prep/Disposal by 1613B | Matrix | Number of Containers | Collection Time | Collection Date | Sample ID# |
|---------------------|--|--|--|--|--|--|--|--|--|--------------------|--|-----------|-----------------------------------|--------|-------------------------|--------------------|--------------------|----------------------|
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | L1605173 Comments |
| | | | | | | | | | | | | | | | | | | L1603081 |
| | | | | | | | | | | | | | | | | | | -31 |
| | | | | | | | | | | | | | | | | | | -32 |
| | | | | | | | | | | | | | | | | | | -33 17 |
| | | | | | | | | | | | | | | | | | | -34 18 |
| | | | | | | | | | | | | | | | | | | -35 |
| | | | | | | | | | | | | | | | | | | -36 |
| | | | | | | | | | | | | | | | | | | -37 19 |
| | | | | | | | | | | | | | | | | | | -38 20 |
| | | | | | | | | | | | | | | | | | | -39 |
| | | | | | | | | | | | | | | | | | | -40 |
| | | | | | | | | | | | | | | | | | | -41 21 |
| | | | | | | | | | | | | | | | | | | -42 22 |
| | | | | | | | | | | | | | | | | | | -43 23 |
| | | | | | | | | | | | | | | | | | | -44 |
| | | | | | | | | | | | | | | | | | | -45 |

NOTES: Conduct Incremental Sampling Methodology processing prior to analysis.

Contact Chris Martin (503-432-5579, cmartin@gsws.com) or Josh Bale (530-278-4186, j.bale@gsws.com) with questions. Include DEQ EDD with final lab report.

| | | | |
|------------------------------|--------------------------|-------------------------------|-------------------------|
| Relinquished By: G. Schultze | Agency/Agent: G81 | Received By: | Agency/Agent: |
| Signature: [Signature] | Time & Date: 4/6/23 1215 | Signature: | Time & Date: |
| Relinquished By: | Agency/Agent: | Received By: | Agency/Agent: |
| Signature: | Time & Date: | Signature: Kaycie [Signature] | Time & Date: 4/7/23 920 |

THIS PURCHASE IS SUBMITTED PURSUANT TO STATE OF OREGON SOLICITATION #102-1098-07 AND PRICE AGREEMENT # 8903. THE PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE AND SHALL TAKE PRECEDENCE OVER ALL OTHER CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

State of Oregon Chain of Custody (Pace)

Agency, Authorized Purchaser or Agent:

GSI for ODEQ

Send Lab Report To:

Don Hanson, RG

Address:

165 E. 7th Avenue, Suite 100

Eugene, OR 97401

Tel # 541-687-7349

E-mail: don.hanson@deq.state.or.us, j.bale@gsiws.com,

cmartin@gsiws.com, m.fargher@gsiws.com, GIS@gsiws.com

Contract Laboratory Name:

Pace Analytical National

Lab Batch #:

Invoice: ODEQ/Business Office
811 SW 6th Ave
Portland, OR 97204
Tel #: (800) 452-4011

Lab Selection Criteria:

Proximity (if TAT < 48 hrs)

Prior work on same project

Cost (for anticipated analyses)

Other labs disqualified or unable
to perform requested services

Emergency work

Turn Around Time:

10 days (std)

5 days

72 hours

48 hours

24 hours

Other

Project Name: OREGON DEQ-JH BAXTER OFFSITE INVESTIGATION (TO #2060.005)

Project #: JH Baxter Offsite Investigation

Sampler Name: GSI

| | | | | | Sample Preservative | | | | | | | | | | | |
|---------------------|-----------------|-----------------|--------|----------------------|----------------------------------|--|--|--|--|--|--|--|--|--|--|----------|
| | | | | | Solids NA | | | | | | | | | | | |
| | | | | | Requested Analyses | | | | | | | | | | | |
| Sample ID# | Collection Date | Collection Time | Matrix | Number of Containers | ISM Prep. Disinfectants by 1613B | | | | | | | | | | | |
| SA-07B-1.5-2.0-0423 | 4/4/23 | 1210 | SE | 1 | X | | | | | | | | | | | L1605173 |
| SA-07B-2.0-2.5-0423 | 4/4/23 | 1215 | SE | 1 | X | | | | | | | | | | | Comments |
| SA-07B-2.5-3.0-0423 | 4/4/23 | 1220 | SE | 1 | X | | | | | | | | | | | L1603081 |
| DU-11A-6.0-6.5-0423 | 4/4/23 | 1405 | SE | 1 | X | | | | | | | | | | | -46 24 |
| DU-11A-1.5-2.0-0423 | 4/4/23 | 1410 | SE | 1 | X | | | | | | | | | | | -47 25 |
| DU-11A-2.0-2.5-0423 | 4/4/23 | 1415 | SE | 1 | | | | | | | | | | | | -48 26 |
| DU-11A-2.5-3.0-0423 | 4/4/23 | 1420 | SE | 1 | | | | | | | | | | | | -49 |
| DU-11B-1.0-6.5-0423 | 4/4/23 | 1430 | SE | 1 | + | | | | | | | | | | | -50 |
| DU-11B-1.5-2.0-0423 | 4/4/23 | 1435 | SE | 1 | X | | | | | | | | | | | -51 27 |
| DU-11B-2.0-2.5-0423 | 4/4/23 | 1440 | SE | 1 | | | | | | | | | | | | -52 28 |
| DU-11B-2.5-3.0-0423 | 4/4/23 | 1445 | SE | 1 | | | | | | | | | | | | -53 |
| DU-10A-1.0-1.5-0423 | 4/5/23 | 930 | SE | 1 | X | | | | | | | | | | | -54 |
| DU-10A-1.5-2.0-0423 | 4/5/23 | 935 | SE | 1 | X | | | | | | | | | | | -55 29 |
| DU-10A-2.0-2.5-0423 | 4/5/23 | 940 | SE | 1 | | | | | | | | | | | | -56 30 |
| DU-10A-2.5-3.0-0423 | 4/5/23 | 945 | SE | 1 | | | | | | | | | | | | -57 |
| | | | | | | | | | | | | | | | | -58 |
| | | | | | | | | | | | | | | | | -59 31 |
| | | | | | | | | | | | | | | | | -60 32 |

NOTES: Conduct Incremental Sampling Methodology processing prior to analysis.

Contact Chris Martin (503-432-5979, cmartin@gsiws.com) or Josh Bale (530-276-4188, j.bale@gsiws.com) with questions. Include DEQ EDO with final lab report.

| | | | |
|------------------------------|--------------------------|-------------------------------|-------------------------|
| Relinquished By: G. Schutans | Agency/Agent: GSI | Received By: | Agency/Agent: |
| Signature: [Signature] | Time & Date: 4/6/23 1215 | Signature: | Time & Date: |
| Relinquished By: | Agency/Agent: | Received By: | Agency/Agent: |
| Signature: | Time & Date: | Signature: Kaycie [Signature] | Time & Date: 4/7/23 920 |

THIS PURCHASE IS SUBMITTED PURSUANT TO STATE OF OREGON SOLICITATION #102-1098-07 AND PRICE AGREEMENT # 8903. THE PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE AND SHALL APPLY TO THIS PURCHASE AND SHALL TAKE PRECEDENCE OVER ALL OTHER CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED.

[illegible]

THIS PURCHASE IS SUBMITTED PURSUANT TO STATE OF OREGON SOLICITATION #102-1088-07 AND PRICE AGREEMENT # 8903. THE PRICE AGREEMENT INCLUDING CONTRACT TERMS AND CONDITIONS AND SPECIAL CONTRACT TERMS AND CONDITIONS (T'S & C'S) CONTAINED IN THE PRICE AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE AND SHALL APPLY TO THIS PURCHASE AND SHALL TAKE PRECEDENCE OVER ALL OTHER CONFLICTING T'S AND C'S, EXPRESS OR IMPLIED

L1603081

| <u>Tracking Numbers</u> | | <u>Temperature</u> |
|-----------------------------|--|--------------------|
| 0357 9924 1063 | | NSAG 3.2+0=3.2 |
| 0357 9924 1074 | | NSAG 5.1+0=5.1 |
| 0357 9924 1085 | | NSAG 1.5+0=1.5 |
| 0357 9924 1096 | | NSAG 2.5+0=2.5 |
| 0357 9924 1722 | | NSAG 4.3+0=4.3 |
| 0357 9924 1733 | | NSAG 1.8+0=1.8 |
| 0357 9924 1700 | | NSAG 1.6+0=1.6 |
| 0357 9924 1711 | | NSAG 4.6+0=4.6 |

L1603081 OREGONDEQ re-log

R5

Please re-log all samples which are currently on HOLD to a new SDG for MISPREP "promium EDD. after misprep sample need SUB1613" as R5 due 04/21.

L1603081-66 will be matrix 1 DIOXIN rather than misprep.

Time estimate: oh

Time spent: oh

Members



Brian Ford

Comments

Andy Vann

Relogged to L1603505

14 April 2023 09:39

Report Prepared for:

Client Services
Pace Analytical National
12065 Lebanon Rd
Mt. Juliet TN 37122

REPORT OF LABORATORY ANALYSIS FOR PCDD/PCDF

Report Prepared Date:

June 1, 2023

Report Information:


Pace Project #: 10650019
Sample Receipt Date: 04/19/2023
Client Project #: L1605173 WG2043854
Client Sub PO #: L1605173
State Cert #: N/A

Invoicing & Reporting Options:

The report provided has been invoiced as a Level 2 PCDD/PCDF Report. If an upgrade of this report package is requested, an additional charge may be applied.

Please review the attached invoice for accuracy and forward any questions to Kongmeng Vang, your Pace Project Manager.

This report has been reviewed by:



June 06, 2023

Kongmeng Vang, Project Manager
(612) 607-6382
(612) 607-6444 (fax)
kongmeng.vang@pacelabs.com



Report of Laboratory Analysis

This report should not be reproduced, except in full, without the written consent of Pace Analytical Services, Inc.

The results relate only to the samples included in this report.



DISCUSSION

This report presents the results from the analyses performed on five of thirty-six samples submitted by a representative of Pace Analytical National. The samples were analyzed for the presence or absence of polychlorodibenzo-p-dioxins (PCDDs) and polychlorodibenzofurans (PCDFs) using USEPA Method 1613B. The estimated detection limits (EDLs) were based on signal-to-noise measurements. Estimated maximum possible concentration (EMPC) values were treated as positives in the toxic equivalence calculations. Per request, the analyses of the remaining samples were canceled.

The recoveries of the isotopically-labeled PCDD/PCDF internal standards in the sample extracts ranged from 50-104%. All of the labeled standard recoveries obtained for this project were within the target ranges specified in Method 1613B. Also, since the quantification of the native 2,3,7,8-substituted congeners was based on isotope dilution, the data were automatically corrected for recovery and accurate values were obtained.

Values were flagged "I" where incorrect isotope ratios were obtained. Concentrations below the calibration range were flagged "J" and should be regarded as estimates.

A laboratory method blank was prepared and analyzed with each sample batch as part of our routine quality control procedures. The results show two of the three blanks to contain trace levels of selected congeners. These levels were below the calibration range for the method. Sample levels similar to the corresponding blank levels were flagged "B" on the results tables and may be, at least partially, attributed to the background.

Laboratory spike samples were also prepared using clean reference matrix that had been fortified with native standard materials. The recoveries of the spiked native compounds ranged from 80-117% with relative percent differences (RPDs) ranging from 0.0-6.0%. These results were within the target ranges for the method. Matrix spikes were prepared with the solid sample extraction batches using canceled sample materials or sample materials from separate projects; results from these analyses will be provided upon request. Matrix spikes were not prepared with the water sample extraction batch.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Minnesota Laboratory Certifications

| Authority | Certificate # | Authority | Certificate # |
|----------------|----------------|-----------------|----------------|
| A2LA | 2926.01 | Missouri | 10100 |
| Alabama | 40770 | Montana | CERT0092 |
| Alaska-DW | MN00064 | Nebraska | NE-OS-18-06 |
| Alaska-UST | 17-009 | Nevada | MN00064 |
| Arizona | AZ0014 | New Hampshire | 2081 |
| Arkansas - WW | 88-0680 | New Jersey | MN002 |
| Arkansas-DW | MN00064 | New York | 11647 |
| California | 2929 | North Carolina- | 27700 |
| Colorado | MN00064 | North Carolina- | 530 |
| Connecticut | PH-0256 | North Dakota | R-036 |
| Florida | E87605 | Ohio-DW | 41244 |
| Georgia | 959 | Ohio-VAP (170 | CL101 |
| Hawaii | MN00064 | Ohio-VAP (180 | CL110 |
| Idaho | MN00064 | Oklahoma | 9507 |
| Illinois | 200011 | Oregon-Primary | MN300001 |
| Indiana | C-MN-01 | Oregon-Second | MN200001 |
| Iowa | 368 | Pennsylvania | 68-00563 |
| Kansas | E-10167 | Puerto Rico | MN00064 |
| Kentucky-DW | 90062 | South Carolina | 74003 |
| Kentucky-WW | 90062 | Tennessee | TN02818 |
| Louisiana-DEQ | AI-84596 | Texas | T104704192 |
| Louisiana-DW | MN00064 | Utah | MN00064 |
| Maine | MN00064 | Vermont | VT-027053137 |
| Maryland | 322 | Virginia | 460163 |
| Michigan | 9909 | Washington | C486 |
| Minnesota | 027-053-137 | West Virginia-D | 382 |
| Minnesota-Ag | via MN 027-053 | West Virginia-D | 9952C |
| Minnesota-Petr | 1240 | Wisconsin | 999407970 |
| Mississippi | MN00064 | Wyoming-UST | via A2LA 2926. |

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix A

Sample Management

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.

The Chain-of-Custody is a LEGAL DOCUMENT.

Page 5 of 25

[illegible]

Report No. 1065019-1613B-C_L2.dtt

1

1

[illegible][illegible]

103

Report No.: 10650019_1613BFC_L2_dfr

Report No.: 10650019_1613BFC_L2_dfr Page 7 of 25

Report No.: 10650019_1613BFC_L2_dfr Page 7 of 25

Report No.: 10650019_1613BFC_L2_dfr Page 7 of 25

Effective Date: 11/16/2022

| | | | |
|---|---------------------------|---|----------------------|
| Sample Condition Upon Receipt | Client Name: <u>PM TN</u> | Project #: | WO#: 10650019 |
| Courier: <input checked="" type="checkbox"/> FedEx <input type="checkbox"/> UPS <input type="checkbox"/> USPS <input type="checkbox"/> Client <input type="checkbox"/> Pace <input type="checkbox"/> Speedee <input type="checkbox"/> Commercial | | PM: KV Due Date: 05/10/23 CLIENT: ESC_TN | |
| Tracking Number: <u>63372244</u> ¹⁵¹⁸ ₁₅₂₉ | | <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 | |

| | | | | | |
|---|--|---|--|---|--|
| Custody Seal on Cooler/Box Present? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | | Seals Intact? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | | Biological Tissue Frozen? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | |
| Packing Material: <input checked="" type="checkbox"/> Bubble Wrap <input checked="" type="checkbox"/> Bubble Bags <input type="checkbox"/> None <input type="checkbox"/> Other | | Temp Blank? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | | Type of Ice: <input checked="" type="checkbox"/> Wet <input type="checkbox"/> Blue <input type="checkbox"/> Dry <input type="checkbox"/> None | |
| Thermometer: <input type="checkbox"/> T1 (0461) <input type="checkbox"/> T2 (1336) <input type="checkbox"/> T3 (0459) <input type="checkbox"/> T4 (0254) <input type="checkbox"/> T5 (0178) | | <input checked="" type="checkbox"/> T6 (0235) <input type="checkbox"/> T7 (0042) <input type="checkbox"/> T8 (0775) <input type="checkbox"/> T9 (0727) <input type="checkbox"/> 01339252/1710 | | <input type="checkbox"/> Melted | |

| | | | |
|---|--|--|--|
| Did Samples Originate in West Virginia? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | | Were All Container Temps Taken? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | |
| Temp should be above freezing to 6 °C | | Cooler temp Read w/Temp Blank: <u>27.33 °C</u> | |
| Correction Factor: <u>-1</u> | | Cooler Temp Corrected w/temp blank: <u>28.34 °C</u> | |
| | | Average Corrected Temp (no temp blank only): _____ °C | |
| | | <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 <input type="checkbox"/> 1 Container | |

USDA Regulated Soil: ☐ N/A, water sample/other: _____Date/Initials of Person Examining Contents: U/19/23Did samples originate in a quarantine zone within the United States: AL, AR, AZ, CA, FL, GA, ID, LA, MS, NC, NM, NY, OK, OR, SC, TN, TX, or VA (check maps)? ☐ Yes ☒ NoDid samples originate from a foreign source (internationally, including Hawaii and Puerto Rico)? ☐ Yes ☒ No

If Yes to either question, fill out a Regulated Soil Checklist (ENV-FRM-MIN4-0154) and include with SCUR/COC paperwork.

| | | | |
|---|--|--|--|
| Location (Check one): <input type="checkbox"/> Duluth <input checked="" type="checkbox"/> Minneapolis <input type="checkbox"/> Virginia | | COMMENTS | |
| Chain of Custody Present and Filled Out? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | | 1. | |
| Chain of Custody Relinquished? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | | 2. | |
| Sampler Name and/or Signature on COC? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> N/A | | 3. | |
| Samples Arrived within Hold Time? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | | 4. If fecal: <input type="checkbox"/> <8 hrs <input type="checkbox"/> >8 hr, <24 <input type="checkbox"/> No | |
| Short Hold Time Analysis (<72 hr)? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | | 5. <input type="checkbox"/> Fecal Coliform <input type="checkbox"/> HPC <input type="checkbox"/> Total Coliform/E.coli | |
| | | <input type="checkbox"/> BOD/cBOD <input type="checkbox"/> Hex Chrom <input type="checkbox"/> Turbidity <input type="checkbox"/> Nitrate | |
| | | <input type="checkbox"/> Nitrite <input type="checkbox"/> Orthophos <input type="checkbox"/> Other | |
| Rush Turn Around Time Requested? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | | 6. | |
| Sufficient Sample Volume? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | | 7. | |
| Correct Containers Used? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A | | 8. | |
| -Pace Containers Used? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | | | |
| Containers Intact? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | | 9. | |
| Field Filtered Volume Received for Dissolved Tests? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | | 10. Is sediment visible in the dissolved container? <input type="checkbox"/> Yes <input type="checkbox"/> No | |
| Is sufficient information available to reconcile the samples to the COC? <input type="checkbox"/> Yes <input type="checkbox"/> No | | 11. If no, write ID/Date/Time of container below: | |
| Matrix: <input type="checkbox"/> Water <input type="checkbox"/> Soil <input type="checkbox"/> Oil <input type="checkbox"/> Other | | <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 | |
| All containers needing acid/base preservation have been checked? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | | 12. Sample # | |
| All containers needing preservation are found to be in compliance with EPA recommendation? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | | <input type="checkbox"/> NaOH <input type="checkbox"/> HNO3 | |
| (HNO3, H2SO4, <2pH, NaOH >9 Sulfide, NaOH >10 Cyanide) | | <input type="checkbox"/> H2SO4 <input type="checkbox"/> Zinc Acetate | |
| Exceptions: VOA, Coliform, TOC/DOC Oil and Grease, DRO/8015 (water) and Dioxins/PFAS <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A | | Positive for Residual Chlorine? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 | |
| (*If adding preservative to a container, it must be added to associated field and equipment blanks--verify with PM first.) | | pH Paper Lot # | |
| | | Residual Chlorine | |
| | | 0-6 Roll | |
| | | 0-6 Strip | |
| | | 0-14 Strip | |
| Headspace in Methyl Mercury Container? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | | 13. | |
| Extra labels present on soil VOA or WIDRO containers? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | | 14. | |
| Headspace in VOA Vials (greater than 6mm)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | | <input type="checkbox"/> See Exceptions ENV-FRM-MIN4-0142 | |
| 3 Trip Blanks Present? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | | 15. | |
| Trip Blank Custody Seals Present? <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A | | Pace Trip Blank Lot # (if purchased): _____ | |

CLIENT NOTIFICATION/RESOLUTION

Person Contacted: _____

Date/Time: _____

Comments/Resolution: _____


Project Manager Review: _____

Date: _____

Field Data Required? ☐ Yes ☐ No

NOTE: Whenever there is a discrepancy affecting North Carolina compliance samples, a copy of this form will be sent to the North Carolina DEHNR Certification Office (i.e. out of hold, incorrect preservative, out of temp, incorrect containers).

Labeled By: MFLine: 3

| | |
|--|---|
|  | DC#_Title: ENV-FRM-MIN4-0154 v02_USDA Regulated Soil Checklist |
| | Effective Date: 08/19/2022 |

USDA Regulated Soil Checklist

To be Completed by Sample Receiving:

WO: 10650019 **Date:** 4/20/23 **Initials:** EMCL

Sample Origin (check one): ☒ DOMESTIC ☐ QUARANTINED ☐ FOREIGN

NOTE: Soil samples from Hawaii, Guam, Puerto Rico, and the US Virgin Islands are Foreign originated.

If **DOMESTIC**, circle state of origin: AL AR AZ CA FL GA LA MS NC NM NY OK OR SC TN TX VA
Includes: IFA, SOD, Golden Nematode, Karnal Bunt, and Witchweed

List County: Lane County

(USDA Permit/Compliance Agreement authorizes movement of samples from these domestic regulated zones)

If **QUARANTINED**, circle state of origin: CA ID NY TX

Includes: Fruit Fly and Pale Cyst Nematode

List County: _____

(Movement is not authorized for Pale Cyst Nematode (ID)—remaining quarantines require additional paperwork)


If **FOREIGN**, list country of origin: _____

(Movement from some Canadian Provinces is not allowed. Refer to ENV-FRM-MIN4-0137 Regulated Soil Flow Chart)

| REQUIREMENT | ACTION | COMPLETED | | |
|---|--|-----------|----|------------|
| PPQ-530 Paperwork must be included for any samples from counties with a Fruit Fly Quarantine in CA, NY, and TX. Reference ENV-SOP-MIN4-0095. | Scan PPQ-530 to the corresponding Project folder on the X:drive. If PPQ-530 is not present, contact the laboratory's designated USDA permit holder. Do NOT continue processing samples. | YES | NO | <u>N/A</u> |
| Samples from ID may not be moved from the quarantined region. Reference ENV-SOP-MIN4-0095. | If samples originated in a quarantined zone, contact the laboratory's designated USDA permit holder. Do NOT continue processing samples. | YES | NO | <u>N/A</u> |

| REQUIREMENT | ACTION | COMPLETED | | |
|--|---|-----------|----|------------|
| "Special Handling" stickers are to be placed on all samples. | Did "special handling" stickers get placed on all sample containers? | YES | NO | <u>N/A</u> |
| Samples must be segregated and stored in designated bins, shelves, and coolers. | Were samples placed in a designated cooler, containers, and shelves? | YES | NO | <u>N/A</u> |
| Samples must be double contained to prevent accidental release. | Were there any signs of breakage or leakage (check for broken glass and/or loose soil in the cooler)? <i>NOTE: If NO, ice and melt water can be disposed of by normal process (ex: down the drain).</i> | YES | NO | <u>N/A</u> |
| | If YES , were ice and melt water separated from the cooler and disposed of properly? | YES | NO | <u>N/A</u> |
| | Any broken glass and/or loose soil are to be bagged and placed in a USDA Regulated satellite container or active drum (see Waste Coordinator). Ice and melt water should be baked at a temperature range of 121-154°F for 2 hours and then cooled before going down the drain. | | | |
| Equipment and supplies that have come into contact samples must be decontaminated. | Was the cooler(s) and/or countertop(s) decontaminated using either a fresh 10% bleach solution or 70% ethanol? (Gloves and other lab supplies will be bagged and placed in the USDA Regulated satellite container or active drum). | YES | | <u>NO</u> |

COMMENTS:

| | |
|--|---|
|  | DC#_Title: ENV-FRM-MIN4-0154 v02_USDA Regulated Soil Checklist |
| | Effective Date: 08/19/2022 |

To be Completed by Project Management (PM and/or PC):

Sample analysis will be conducted (circle all that apply): MN Subcontract Lab

If **subcontract**, list lab(s):

| REQUIREMENT | ACTION | COMPLETED | | |
|---|---|-----------|----|-----|
| Permission to ship untreated soil must be on file prior to shipping to any subcontract lab, including IR Pace Labs. | Go to: <i>S:\CLIENTSVR\10_Client Services Department Documents\Regulated Soils Permits\Permission to Ship</i> If permission to ship letter is not there, contact the laboratory's designated USDA permit holder. | YES | NO | N/A |
| Shipment must include a valid copy of the receiving lab's permit as well as permission to ship letter. | Is a copy of all needed paperwork included with the COC? Do NOT ship samples until all necessary paperwork is compiled. | YES | NO | N/A |

COMMENTS:

PM Signature: _____ **Date:** _____



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Reporting Flags

- A = Reporting Limit based on signal to noise (EDL)
- B = Less than 10x higher than method blank level
- C = Result obtained from confirmation analysis
- D = Result obtained from analysis of diluted sample
- E = Exceeds calibration range
- H2 = Extracted outside of holding time
- I = Isotope ratio out of specification
- J = Estimated value
- L = Suppressive interference, analyte may be biased low
- Nn = Value obtained from additional analysis
- P = PCDE Interference
- R = Recovery outside target range
- S = Peak saturated
- U = Analyte not detected
- V = Result verified by confirmation analysis
- X = %D Exceeds limits
- Y = Calculated using average of daily RFs

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.



Pace Analytical Services, LLC
1700 Elm Street, Suite 200
Minneapolis, MN 55414
Phone: 612.607.1700
Fax: 612.607.6444
www.pacelabs.com

Appendix B

Sample Analysis Summary

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, LLC.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-06B-1.5-2.0_0423 | | |
| Lab Sample ID | 10650019004 | | |
| Filename | Y230519A_04 | | |
| Injected By | AH5 | | |
| Total Amount Extracted | 10.6 g | Matrix | Solid |
| % Moisture | 4.2 | Dilution | NA |
| Dry Weight Extracted | 10.2 g | Collected | 04/05/2023 14:40 |
| ICAL ID | Y211220 | Received | 04/19/2023 08:50 |
| CCal Filename(s) | Y230519A_02 | Extracted | 04/21/2023 14:15 |
| Method Blank ID | BLANK-105427 | Analyzed | 05/19/2023 15:53 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.14 | 2,3,7,8-TCDF-13C | 2.00 | 57 |
| Total TCDF | ND | — | 0.14 | 2,3,7,8-TCDD-13C | 2.00 | 50 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 67 |
| 2,3,7,8-TCDD | ND | — | 0.21 | 2,3,4,7,8-PeCDF-13C | 2.00 | 65 |
| Total TCDD | 0.23 | — | 0.21 J | 1,2,3,7,8-PeCDD-13C | 2.00 | 70 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 69 |
| 1,2,3,7,8-PeCDF | ND | — | 0.15 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 66 |
| 2,3,4,7,8-PeCDF | ND | — | 0.16 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 65 |
| Total PeCDF | ND | — | 0.15 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 63 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 68 |
| 1,2,3,7,8-PeCDD | ND | — | 0.23 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 66 |
| Total PeCDD | ND | — | 0.23 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 59 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 61 |
| 1,2,3,4,7,8-HxCDF | — | 0.11 | 0.094 IJ | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 59 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.11 | OCDD-13C | 4.00 | 57 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.091 | | | |
| 1,2,3,7,8,9-HxCDF | 0.18 | — | 0.099 J | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 0.18 | — | 0.091 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.22 | — | 0.14 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 55 |
| 1,2,3,6,7,8-HxCDD | — | 0.19 | 0.12 IJ | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.15 | 0.12 IJ | | | |
| Total HxCDD | 1.9 | — | 0.12 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 1.2 | — | 0.35 J | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.40 | Equivalence: 0.19 ng/Kg | | |
| Total HpCDF | 1.2 | — | 0.35 J | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 6.6 | — | 0.090 | | | |
| Total HpCDD | 17 | — | 0.090 | | | |
| | | | | | | |
| OCDF | 4.5 | — | 0.12 J | | | |
| OCDD | 73 | — | 0.14 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|----------------------|-----------|------------------|
| Client's Sample ID | DU-106B-1.5-2.0_0423 | | |
| Lab Sample ID | 10650019007 | | |
| Filename | Y230519A_05 | | |
| Injected By | AH5 | | |
| Total Amount Extracted | 10.4 g | Matrix | Solid |
| % Moisture | 4.0 | Dilution | NA |
| Dry Weight Extracted | 10.00 g | Collected | 04/05/2023 14:55 |
| ICAL ID | Y211220 | Received | 04/19/2023 08:50 |
| CCal Filename(s) | Y230519A_02 | Extracted | 04/21/2023 14:15 |
| Method Blank ID | BLANK-105427 | Analyzed | 05/19/2023 16:32 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.16 | 2,3,7,8-TCDF-13C | 2.00 | 61 |
| Total TCDF | ND | — | 0.16 | 2,3,7,8-TCDD-13C | 2.00 | 53 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 74 |
| 2,3,7,8-TCDD | ND | — | 0.28 | 2,3,4,7,8-PeCDF-13C | 2.00 | 76 |
| Total TCDD | 0.42 | — | 0.28 J | 1,2,3,7,8-PeCDD-13C | 2.00 | 80 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDF | ND | — | 0.17 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 73 |
| 2,3,4,7,8-PeCDF | ND | — | 0.17 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 73 |
| Total PeCDF | ND | — | 0.17 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 67 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 72 |
| 1,2,3,7,8-PeCDD | ND | — | 0.28 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 78 |
| Total PeCDD | ND | — | 0.28 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 69 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.13 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 63 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.11 | OCDD-13C | 4.00 | 64 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.10 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.088 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 0.33 | — | 0.088 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | — | 0.19 | 0.14 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 57 |
| 1,2,3,6,7,8-HxCDD | — | 0.18 | 0.13 J | | | |
| 1,2,3,7,8,9-HxCDD | — | 0.19 | 0.12 J | | | |
| Total HxCDD | 1.2 | — | 0.12 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 1.0 | — | 0.17 J | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.21 | Equivalence: 0.16 ng/Kg | | |
| Total HpCDF | 2.9 | — | 0.17 J | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 7.0 | — | 0.21 | | | |
| Total HpCDD | 15 | — | 0.21 | | | |
| | | | | | | |
| OCDF | 4.0 | — | 0.25 J | | | |
| OCDD | 62 | — | 0.13 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-11A-2.0-2.5_0423 | | |
| Lab Sample ID | 10650019027 | | |
| Filename | Y230519A_06 | | |
| Injected By | AH5 | | |
| Total Amount Extracted | 10.5 g | Matrix | Solid |
| % Moisture | 3.9 | Dilution | NA |
| Dry Weight Extracted | 10.1 g | Collected | 04/04/2023 14:15 |
| ICAL ID | Y211220 | Received | 04/19/2023 08:50 |
| CCal Filename(s) | Y230519A_02 | Extracted | 04/24/2023 14:30 |
| Method Blank ID | BLANK-105447 | Analyzed | 05/19/2023 17:11 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|----|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.24 | | 2,3,7,8-TCDF-13C | 2.00 | 60 |
| Total TCDF | ND | — | 0.24 | | 2,3,7,8-TCDD-13C | 2.00 | 55 |
| | | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 70 |
| 2,3,7,8-TCDD | 1.6 | — | 0.33 | | 2,3,4,7,8-PeCDF-13C | 2.00 | 70 |
| Total TCDD | 1.9 | — | 0.33 | | 1,2,3,7,8-PeCDD-13C | 2.00 | 74 |
| | | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 72 |
| 1,2,3,7,8-PeCDF | ND | — | 0.21 | | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 71 |
| 2,3,4,7,8-PeCDF | ND | — | 0.23 | | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 67 |
| Total PeCDF | 1.4 | — | 0.21 | J | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 70 |
| | | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 66 |
| 1,2,3,7,8-PeCDD | ND | — | 0.38 | | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 71 |
| Total PeCDD | 0.57 | — | 0.38 | J | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 62 |
| | | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 64 |
| 1,2,3,4,7,8-HxCDF | 0.91 | — | 0.21 | J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 57 |
| 1,2,3,6,7,8-HxCDF | 0.38 | — | 0.20 | J | OCDD-13C | 4.00 | 60 |
| 2,3,4,6,7,8-HxCDF | 0.39 | — | 0.20 | J | | | |
| 1,2,3,7,8,9-HxCDF | — | 0.21 | 0.17 | I | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 9.0 | — | 0.17 | | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.59 | — | 0.27 | BJ | 2,3,7,8-TCDD-37Cl4 | 0.20 | 53 |
| 1,2,3,6,7,8-HxCDD | 1.5 | — | 0.24 | J | | | |
| 1,2,3,7,8,9-HxCDD | 0.95 | — | 0.25 | J | | | |
| Total HxCDD | 12 | — | 0.24 | | | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 6.7 | — | 0.28 | | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.29 | | Equivalence: 2.7 ng/Kg | | |
| Total HpCDF | 20 | — | 0.28 | | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 43 | — | 0.054 | | | | |
| Total HpCDD | 92 | — | 0.054 | | | | |
| | | | | | | | |
| OCDF | 21 | — | 0.18 | | | | |
| OCDD | 390 | — | 0.23 | | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

B = Less than 10x higher than method blank level

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|---------------------|-----------|------------------|
| Client's Sample ID | DU-11A-2.5-3.0_0423 | | |
| Lab Sample ID | 10650019028 | | |
| Filename | Y230519A_07 | | |
| Injected By | AH5 | | |
| Total Amount Extracted | 10.6 g | Matrix | Solid |
| % Moisture | 4.0 | Dilution | NA |
| Dry Weight Extracted | 10.2 g | Collected | 04/04/2023 14:20 |
| ICAL ID | Y211220 | Received | 04/19/2023 08:50 |
| CCal Filename(s) | Y230519A_02 | Extracted | 04/24/2023 14:30 |
| Method Blank ID | BLANK-105447 | Analyzed | 05/19/2023 17:50 |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.25 | 2,3,7,8-TCDF-13C | 2.00 | 76 |
| Total TCDF | ND | — | 0.25 | 2,3,7,8-TCDD-13C | 2.00 | 67 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 84 |
| 2,3,7,8-TCDD | ND | — | 0.56 | 2,3,4,7,8-PeCDF-13C | 2.00 | 87 |
| Total TCDD | ND | — | 0.56 | 1,2,3,7,8-PeCDD-13C | 2.00 | 86 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 92 |
| 1,2,3,7,8-PeCDF | ND | — | 0.31 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 95 |
| 2,3,4,7,8-PeCDF | ND | — | 0.32 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 90 |
| Total PeCDF | ND | — | 0.31 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 78 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 88 |
| 1,2,3,7,8-PeCDD | ND | — | 0.57 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 99 |
| Total PeCDD | ND | — | 0.57 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 83 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 80 |
| 1,2,3,4,7,8-HxCDF | — | 0.37 | 0.26 J | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 75 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.28 | OCDD-13C | 4.00 | 73 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.31 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.31 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 1.3 | — | 0.26 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 0.39 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 66 |
| 1,2,3,6,7,8-HxCDD | — | 0.62 | 0.35 J | | | |
| 1,2,3,7,8,9-HxCDD | 0.50 | — | 0.40 J | | | |
| Total HxCDD | 2.4 | — | 0.35 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | — | 2.7 | 0.43 J | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.51 | Equivalence: 0.43 ng/Kg | | |
| Total HpCDF | 5.6 | — | 0.43 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 20 | — | 0.49 | | | |
| Total HpCDD | 43 | — | 0.49 | | | |
| | | | | | | |
| OCDF | 8.3 | — | 0.49 J | | | |
| OCDD | 170 | — | 0.59 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

Results reported on a dry weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Sample Analysis Results

Client - Pace Analytical National

| | | | |
|------------------------|--------------|-----------|------------------|
| Client's Sample ID | EB-02-0423 | | |
| Lab Sample ID | 10650019037 | | |
| Filename | U230522B_12 | | |
| Injected By | SMT | | |
| Total Amount Extracted | 979 mL | Matrix | Water |
| % Moisture | NA | Dilution | NA |
| Dry Weight Extracted | NA | Collected | 04/05/2023 15:05 |
| ICAL ID | U230517 | Received | 04/19/2023 08:50 |
| CCal Filename(s) | U230522A_18 | Extracted | 04/21/2023 11:00 |
| Method Blank ID | BLANK-105422 | Analyzed | 05/23/2023 07:17 |

| Native Isomers | Conc pg/L | EMPC pg/L | EDL pg/L | Internal Standards | ng's Added | Percent Recovery |
|---------------------|--------------|--------------|-------------|--|---------------|---------------------|
| 2,3,7,8-TCDF | ND | — | 0.94 | 2,3,7,8-TCDF-13C | 2.00 | 88 |
| Total TCDF | ND | — | 0.94 | 2,3,7,8-TCDD-13C | 2.00 | 77 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 104 |
| 2,3,7,8-TCDD | ND | — | 1.3 | 2,3,4,7,8-PeCDF-13C | 2.00 | 99 |
| Total TCDD | ND | — | 1.3 | 1,2,3,7,8-PeCDD-13C | 2.00 | 100 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 93 |
| 1,2,3,7,8-PeCDF | ND | — | 1.4 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 85 |
| 2,3,4,7,8-PeCDF | ND | — | 0.79 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 87 |
| Total PeCDF | ND | — | 0.79 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 86 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 74 |
| 1,2,3,7,8-PeCDD | ND | — | 1.6 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 81 |
| Total PeCDD | ND | — | 1.6 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 64 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 60 |
| 1,2,3,4,7,8-HxCDF | ND | — | 1.3 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 71 |
| 1,2,3,6,7,8-HxCDF | ND | — | 1.6 | OCDD-13C | 4.00 | 55 |
| 2,3,4,6,7,8-HxCDF | ND | — | 1.6 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 2.1 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | 18 | — | 1.3 J | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 3.3 | — | 1.4 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 87 |
| 1,2,3,6,7,8-HxCDD | — | 1.4 | 1.4 J | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 1.5 | | | |
| Total HxCDD | 3.3 | — | 1.4 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | 79 | — | 2.4 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 2.6 | Equivalence: 1.5 pg/L | | |
| Total HpCDF | 140 | — | 2.4 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | 15 | — | 1.3 J | | | |
| Total HpCDD | 27 | — | 1.3 J | | | |
| | | | | | | |
| OCDF | 72 | — | 4.9 J | | | |
| OCDD | 160 | — | 6.0 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).
EMPC = Estimated Maximum Possible Concentration
EDL = Estimated Detection Limit

ND = Not Detected
NA = Not Applicable
NC = Not Calculated

J = Estimated value
I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample Name | DFBLKKC | Matrix | Water |
| Lab Sample ID | BLANK-105422 | Dilution | NA |
| Filename | L230425A_12 | Extracted | 04/21/2023 11:00 |
| Total Amount Extracted | 1000 mL | Analyzed | 04/25/2023 16:41 |
| ICAL ID | L230302 | Injected By | SMT |
| CCal Filename(s) | L230425A_01 | | |

| Native Isomers | Conc pg/L | EMPC pg/L | EDL pg/L | Internal Standards | ng's Added | Percent Recovery |
|---------------------|--------------|--------------|-------------|--|---------------|---------------------|
| 2,3,7,8-TCDF | ND | — | 1.3 | 2,3,7,8-TCDF-13C | 2.00 | 72 |
| Total TCDF | ND | — | 1.3 | 2,3,7,8-TCDD-13C | 2.00 | 64 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 73 |
| 2,3,7,8-TCDD | ND | — | 1.7 | 2,3,4,7,8-PeCDF-13C | 2.00 | 75 |
| Total TCDD | ND | — | 1.7 | 1,2,3,7,8-PeCDD-13C | 2.00 | 75 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 77 |
| 1,2,3,7,8-PeCDF | ND | — | 0.91 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 76 |
| 2,3,4,7,8-PeCDF | ND | — | 0.63 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 76 |
| Total PeCDF | ND | — | 0.63 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 65 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 65 |
| 1,2,3,7,8-PeCDD | ND | — | 1.2 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 75 |
| Total PeCDD | ND | — | 1.2 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 58 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 53 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.96 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 64 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.91 | OCDD-13C | 4.00 | 46 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.67 | | | |
| 1,2,3,7,8,9-HxCDF | — | 1.5 | 1.2 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | ND | — | 0.67 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 2.0 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 70 |
| 1,2,3,6,7,8-HxCDD | ND | — | 1.7 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 1.6 | | | |
| Total HxCDD | ND | — | 1.6 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 2.7 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 3.1 | Equivalence: 0.16 pg/L | | |
| Total HpCDF | ND | — | 2.7 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | ND | — | 3.4 | | | |
| Total HpCDD | ND | — | 3.4 | | | |
| | | | | | | |
| OCDF | ND | — | 5.1 | | | |
| OCDD | 7.1 | — | 5.9 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample Name | DFBLKKM | Matrix | Solid |
| Lab Sample ID | BLANK-105447 | Dilution | NA |
| Filename | L230428B_08 | Extracted | 04/24/2023 14:30 |
| Total Amount Extracted | 20.5 g | Analyzed | 04/28/2023 21:08 |
| ICAL ID | L230302 | Injected By | JRH |
| CCal Filename(s) | L230428B_01 | | |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.069 | 2,3,7,8-TCDF-13C | 2.00 | 69 |
| Total TCDF | ND | — | 0.069 | 2,3,7,8-TCDD-13C | 2.00 | 57 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 87 |
| 2,3,7,8-TCDD | ND | — | 0.084 | 2,3,4,7,8-PeCDF-13C | 2.00 | 88 |
| Total TCDD | ND | — | 0.084 | 1,2,3,7,8-PeCDD-13C | 2.00 | 89 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 73 |
| 1,2,3,7,8-PeCDF | ND | — | 0.043 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 75 |
| 2,3,4,7,8-PeCDF | ND | — | 0.036 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 71 |
| Total PeCDF | ND | — | 0.036 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 66 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 61 |
| 1,2,3,7,8-PeCDD | ND | — | 0.062 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 71 |
| Total PeCDD | ND | — | 0.062 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 58 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 57 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.046 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 63 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.047 | OCDD-13C | 4.00 | 54 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.040 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.068 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | ND | — | 0.040 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | 0.11 | — | 0.080 J | 2,3,7,8-TCDD-37Cl4 | 0.20 | 55 |
| 1,2,3,6,7,8-HxCDD | ND | — | 0.073 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 0.081 | | | |
| Total HxCDD | 0.11 | — | 0.073 J | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 0.091 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.19 | Equivalence: 0.011 ng/Kg | | |
| Total HpCDF | ND | — | 0.091 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | ND | — | 0.090 | | | |
| Total HpCDD | ND | — | 0.090 | | | |
| | | | | | | |
| OCDF | ND | — | 0.21 | | | |
| OCDD | — | 0.39 | 0.23 I | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

Results reported on a total weight basis and are valid to no more than 2 significant figures.

J = Estimated value

I = Isotope ratio out of specification

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B Blank Analysis Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample Name | DFBLKKE | Matrix | Solid |
| Lab Sample ID | BLANK-105427 | Dilution | NA |
| Filename | L230502B_03 | Extracted | 04/21/2023 14:15 |
| Total Amount Extracted | 10.3 g | Analyzed | 05/03/2023 01:31 |
| ICAL ID | L230501 | Injected By | SMT |
| CCal Filename(s) | L230502A_24 | | |

| Native Isomers | Conc ng/Kg | EMPC ng/Kg | EDL ng/Kg | Internal Standards | ng's Added | Percent Recovery |
|---------------------|------------|------------|-----------|--|------------|------------------|
| 2,3,7,8-TCDF | ND | — | 0.16 | 2,3,7,8-TCDF-13C | 2.00 | 60 |
| Total TCDF | ND | — | 0.16 | 2,3,7,8-TCDD-13C | 2.00 | 56 |
| | | | | 1,2,3,7,8-PeCDF-13C | 2.00 | 64 |
| 2,3,7,8-TCDD | ND | — | 0.27 | 2,3,4,7,8-PeCDF-13C | 2.00 | 70 |
| Total TCDD | ND | — | 0.27 | 1,2,3,7,8-PeCDD-13C | 2.00 | 71 |
| | | | | 1,2,3,4,7,8-HxCDF-13C | 2.00 | 74 |
| 1,2,3,7,8-PeCDF | ND | — | 0.090 | 1,2,3,6,7,8-HxCDF-13C | 2.00 | 74 |
| 2,3,4,7,8-PeCDF | ND | — | 0.079 | 2,3,4,6,7,8-HxCDF-13C | 2.00 | 73 |
| Total PeCDF | ND | — | 0.079 | 1,2,3,7,8,9-HxCDF-13C | 2.00 | 61 |
| | | | | 1,2,3,4,7,8-HxCDD-13C | 2.00 | 70 |
| 1,2,3,7,8-PeCDD | ND | — | 0.14 | 1,2,3,6,7,8-HxCDD-13C | 2.00 | 82 |
| Total PeCDD | ND | — | 0.14 | 1,2,3,4,6,7,8-HpCDF-13C | 2.00 | 65 |
| | | | | 1,2,3,4,7,8,9-HpCDF-13C | 2.00 | 59 |
| 1,2,3,4,7,8-HxCDF | ND | — | 0.13 | 1,2,3,4,6,7,8-HpCDD-13C | 2.00 | 65 |
| 1,2,3,6,7,8-HxCDF | ND | — | 0.12 | OCDD-13C | 4.00 | 49 |
| 2,3,4,6,7,8-HxCDF | ND | — | 0.11 | | | |
| 1,2,3,7,8,9-HxCDF | ND | — | 0.18 | 1,2,3,4-TCDD-13C | 2.00 | NA |
| Total HxCDF | ND | — | 0.11 | 1,2,3,7,8,9-HxCDD-13C | 2.00 | NA |
| | | | | | | |
| 1,2,3,4,7,8-HxCDD | ND | — | 0.11 | 2,3,7,8-TCDD-37Cl4 | 0.20 | 60 |
| 1,2,3,6,7,8-HxCDD | ND | — | 0.13 | | | |
| 1,2,3,7,8,9-HxCDD | ND | — | 0.11 | | | |
| Total HxCDD | ND | — | 0.11 | | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDF | ND | — | 0.16 | Total 2,3,7,8-TCDD | | |
| 1,2,3,4,7,8,9-HpCDF | ND | — | 0.29 | Equivalence: 0.00 ng/Kg | | |
| Total HpCDF | ND | — | 0.16 | (Lower-bound - Using 2005 WHO Factors) | | |
| | | | | | | |
| 1,2,3,4,6,7,8-HpCDD | ND | — | 0.21 | | | |
| Total HpCDD | ND | — | 0.21 | | | |
| | | | | | | |
| OCDF | ND | — | 0.54 | | | |
| OCDD | ND | — | 0.62 | | | |

Conc = Concentration (Totals include 2,3,7,8-substituted isomers).

EMPC = Estimated Maximum Possible Concentration

EDL = Estimated Detection Limit

Results reported on a total weight basis and are valid to no more than 2 significant figures.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample ID | LCS-105423 | Matrix | Water |
| Filename | L230425A_09 | Dilution | NA |
| Total Amount Extracted | 1010 mL | Extracted | 04/21/2023 11:00 |
| ICAL ID | L230302 | Analyzed | 04/25/2023 14:27 |
| CCal Filename | L230425A_01 | Injected By | SMT |
| Method Blank ID | BLANK-105422 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 9.4 | 7.5 | 15.8 | 94 |
| 2,3,7,8-TCDD | 10 | 9.6 | 6.7 | 15.8 | 96 |
| 1,2,3,7,8-PeCDF | 50 | 47 | 40.0 | 67.0 | 93 |
| 2,3,4,7,8-PeCDF | 50 | 48 | 34.0 | 80.0 | 96 |
| 1,2,3,7,8-PeCDD | 50 | 43 | 35.0 | 71.0 | 86 |
| 1,2,3,4,7,8-HxCDF | 50 | 48 | 36.0 | 67.0 | 96 |
| 1,2,3,6,7,8-HxCDF | 50 | 49 | 42.0 | 65.0 | 98 |
| 2,3,4,6,7,8-HxCDF | 50 | 50 | 35.0 | 78.0 | 100 |
| 1,2,3,7,8,9-HxCDF | 50 | 49 | 39.0 | 65.0 | 98 |
| 1,2,3,4,7,8-HxCDD | 50 | 52 | 35.0 | 82.0 | 104 |
| 1,2,3,6,7,8-HxCDD | 50 | 48 | 38.0 | 67.0 | 97 |
| 1,2,3,7,8,9-HxCDD | 50 | 52 | 32.0 | 81.0 | 103 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 46 | 41.0 | 61.0 | 92 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 47 | 39.0 | 69.0 | 95 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 42 | 35.0 | 70.0 | 84 |
| OCDF | 100 | 99 | 63.0 | 170.0 | 99 |
| OCDD | 100 | 100 | 78.0 | 144.0 | 105 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 7.0 | 3.1 | 19.1 | 70 |
| 2,3,7,8-TCDF-13C | 100 | 75 | 22.0 | 152.0 | 75 |
| 2,3,7,8-TCDD-13C | 100 | 66 | 20.0 | 175.0 | 66 |
| 1,2,3,7,8-PeCDF-13C | 100 | 75 | 21.0 | 192.0 | 75 |
| 2,3,4,7,8-PeCDF-13C | 100 | 75 | 13.0 | 328.0 | 75 |
| 1,2,3,7,8-PeCDD-13C | 100 | 76 | 21.0 | 227.0 | 76 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 81 | 19.0 | 202.0 | 81 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 82 | 21.0 | 159.0 | 82 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 80 | 22.0 | 176.0 | 80 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 70 | 17.0 | 205.0 | 70 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 69 | 21.0 | 193.0 | 69 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 74 | 25.0 | 163.0 | 74 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 60 | 21.0 | 158.0 | 60 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 56 | 20.0 | 186.0 | 56 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 65 | 26.0 | 166.0 | 65 |
| OCDD-13C | 200 | 93 | 26.0 | 397.0 | 46 |

Cs = Concentration Spiked (ng/mL)
 Cr = Concentration Recovered (ng/mL)
 Rec. = Recovery (Expressed as Percent)
 Control Limit Reference: Method 1613, Table 6, 10/94 Revision
 R = Recovery outside of control limits
 Nn = Value obtained from additional analysis
 * = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample ID | LCS-105448 | Matrix | Solid |
| Filename | L230428B_02 | Dilution | NA |
| Total Amount Extracted | 20.4 g | Extracted | 04/24/2023 14:30 |
| ICAL ID | L230302 | Analyzed | 04/28/2023 16:42 |
| CCal Filename | L230428B_01 | Injected By | JRH |
| Method Blank ID | BLANK-105447 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|------|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 10.0 | 7.5 | 15.8 | 100 |
| 2,3,7,8-TCDD | 10 | 11 | 6.7 | 15.8 | 108 |
| 1,2,3,7,8-PeCDF | 50 | 48 | 40.0 | 67.0 | 96 |
| 2,3,4,7,8-PeCDF | 50 | 48 | 34.0 | 80.0 | 97 |
| 1,2,3,7,8-PeCDD | 50 | 47 | 35.0 | 71.0 | 93 |
| 1,2,3,4,7,8-HxCDF | 50 | 50 | 36.0 | 67.0 | 100 |
| 1,2,3,6,7,8-HxCDF | 50 | 52 | 42.0 | 65.0 | 104 |
| 2,3,4,6,7,8-HxCDF | 50 | 50 | 35.0 | 78.0 | 100 |
| 1,2,3,7,8,9-HxCDF | 50 | 49 | 39.0 | 65.0 | 98 |
| 1,2,3,4,7,8-HxCDD | 50 | 54 | 35.0 | 82.0 | 107 |
| 1,2,3,6,7,8-HxCDD | 50 | 51 | 38.0 | 67.0 | 102 |
| 1,2,3,7,8,9-HxCDD | 50 | 51 | 32.0 | 81.0 | 101 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 51 | 41.0 | 61.0 | 101 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 49 | 39.0 | 69.0 | 99 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 46 | 35.0 | 70.0 | 92 |
| OCDF | 100 | 110 | 63.0 | 170.0 | 107 |
| OCDD | 100 | 110 | 78.0 | 144.0 | 114 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 5.6 | 3.1 | 19.1 | 56 |
| 2,3,7,8-TCDF-13C | 100 | 67 | 22.0 | 152.0 | 67 |
| 2,3,7,8-TCDD-13C | 100 | 56 | 20.0 | 175.0 | 56 |
| 1,2,3,7,8-PeCDF-13C | 100 | 81 | 21.0 | 192.0 | 81 |
| 2,3,4,7,8-PeCDF-13C | 100 | 82 | 13.0 | 328.0 | 82 |
| 1,2,3,7,8-PeCDD-13C | 100 | 81 | 21.0 | 227.0 | 81 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 70 | 19.0 | 202.0 | 70 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 72 | 21.0 | 159.0 | 72 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 69 | 22.0 | 176.0 | 69 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 61 | 17.0 | 205.0 | 61 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 60 | 21.0 | 193.0 | 60 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 73 | 25.0 | 163.0 | 73 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 57 | 21.0 | 158.0 | 57 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 53 | 20.0 | 186.0 | 53 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 60 | 26.0 | 166.0 | 60 |
| OCDD-13C | 200 | 99 | 26.0 | 397.0 | 49 |

Cs = Concentration Spiked (ng/mL)
 Cr = Concentration Recovered (ng/mL)
 Rec. = Recovery (Expressed as Percent)
 Control Limit Reference: Method 1613, Table 6, 10/94 Revision
 R = Recovery outside of control limits
 Nn = Value obtained from additional analysis
 * = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample ID | LCS-105428 | Matrix | Solid |
| Filename | L230502B_01 | Dilution | NA |
| Total Amount Extracted | 10.4 g | Extracted | 04/21/2023 14:15 |
| ICAL ID | L230501 | Analyzed | 05/03/2023 00:02 |
| CCal Filename | L230502A_24 | Injected By | SMT |
| Method Blank ID | BLANK-105427 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 11 | 7.5 | 15.8 | 109 |
| 2,3,7,8-TCDD | 10 | 11 | 6.7 | 15.8 | 110 |
| 1,2,3,7,8-PeCDF | 50 | 50 | 40.0 | 67.0 | 100 |
| 2,3,4,7,8-PeCDF | 50 | 52 | 34.0 | 80.0 | 104 |
| 1,2,3,7,8-PeCDD | 50 | 49 | 35.0 | 71.0 | 98 |
| 1,2,3,4,7,8-HxCDF | 50 | 50 | 36.0 | 67.0 | 101 |
| 1,2,3,6,7,8-HxCDF | 50 | 53 | 42.0 | 65.0 | 106 |
| 2,3,4,6,7,8-HxCDF | 50 | 54 | 35.0 | 78.0 | 107 |
| 1,2,3,7,8,9-HxCDF | 50 | 53 | 39.0 | 65.0 | 106 |
| 1,2,3,4,7,8-HxCDD | 50 | 56 | 35.0 | 82.0 | 113 |
| 1,2,3,6,7,8-HxCDD | 50 | 54 | 38.0 | 67.0 | 109 |
| 1,2,3,7,8,9-HxCDD | 50 | 49 | 32.0 | 81.0 | 98 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 55 | 41.0 | 61.0 | 109 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 55 | 39.0 | 69.0 | 109 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 51 | 35.0 | 70.0 | 101 |
| OCDF | 100 | 120 | 63.0 | 170.0 | 116 |
| OCDD | 100 | 120 | 78.0 | 144.0 | 117 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 5.4 | 3.1 | 19.1 | 54 |
| 2,3,7,8-TCDF-13C | 100 | 56 | 22.0 | 152.0 | 56 |
| 2,3,7,8-TCDD-13C | 100 | 52 | 20.0 | 175.0 | 52 |
| 1,2,3,7,8-PeCDF-13C | 100 | 67 | 21.0 | 192.0 | 67 |
| 2,3,4,7,8-PeCDF-13C | 100 | 74 | 13.0 | 328.0 | 74 |
| 1,2,3,7,8-PeCDD-13C | 100 | 75 | 21.0 | 227.0 | 75 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 71 | 19.0 | 202.0 | 71 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 76 | 21.0 | 159.0 | 76 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 72 | 22.0 | 176.0 | 72 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 61 | 17.0 | 205.0 | 61 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 70 | 21.0 | 193.0 | 70 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 78 | 25.0 | 163.0 | 78 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 60 | 21.0 | 158.0 | 60 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 53 | 20.0 | 186.0 | 53 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 58 | 26.0 | 166.0 | 58 |
| OCDD-13C | 200 | 86 | 26.0 | 397.0 | 43 |

Cs = Concentration Spiked (ng/mL)
 Cr = Concentration Recovered (ng/mL)
 Rec. = Recovery (Expressed as Percent)
 Control Limit Reference: Method 1613, Table 6, 10/94 Revision
 R = Recovery outside of control limits
 Nn = Value obtained from additional analysis
 * = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.



Method 1613B Laboratory Control Spike Results

| | | | |
|------------------------|--------------|-------------|------------------|
| Lab Sample ID | LCSD-105424 | Matrix | Water |
| Filename | L230425A_10 | Dilution | NA |
| Total Amount Extracted | 987 mL | Extracted | 04/21/2023 11:00 |
| ICAL ID | L230302 | Analyzed | 04/25/2023 15:12 |
| CCal Filename | L230425A_01 | Injected By | SMT |
| Method Blank ID | BLANK-105422 | | |

| Compound | Cs | Cr | Lower Limit | Upper Limit | % Rec. |
|-------------------------|-----|-----|-------------|-------------|--------|
| 2,3,7,8-TCDF | 10 | 9.4 | 7.5 | 15.8 | 94 |
| 2,3,7,8-TCDD | 10 | 9.6 | 6.7 | 15.8 | 96 |
| 1,2,3,7,8-PeCDF | 50 | 46 | 40.0 | 67.0 | 92 |
| 2,3,4,7,8-PeCDF | 50 | 46 | 34.0 | 80.0 | 92 |
| 1,2,3,7,8-PeCDD | 50 | 43 | 35.0 | 71.0 | 86 |
| 1,2,3,4,7,8-HxCDF | 50 | 48 | 36.0 | 67.0 | 96 |
| 1,2,3,6,7,8-HxCDF | 50 | 49 | 42.0 | 65.0 | 97 |
| 2,3,4,6,7,8-HxCDF | 50 | 48 | 35.0 | 78.0 | 96 |
| 1,2,3,7,8,9-HxCDF | 50 | 49 | 39.0 | 65.0 | 99 |
| 1,2,3,4,7,8-HxCDD | 50 | 51 | 35.0 | 82.0 | 102 |
| 1,2,3,6,7,8-HxCDD | 50 | 46 | 38.0 | 67.0 | 92 |
| 1,2,3,7,8,9-HxCDD | 50 | 48 | 32.0 | 81.0 | 97 |
| 1,2,3,4,6,7,8-HpCDF | 50 | 45 | 41.0 | 61.0 | 90 |
| 1,2,3,4,7,8,9-HpCDF | 50 | 46 | 39.0 | 69.0 | 92 |
| 1,2,3,4,6,7,8-HpCDD | 50 | 40 | 35.0 | 70.0 | 80 |
| OCDF | 100 | 95 | 63.0 | 170.0 | 95 |
| OCDD | 100 | 100 | 78.0 | 144.0 | 103 |
| | | | | | |
| 2,3,7,8-TCDD-37Cl4 | 10 | 7.8 | 3.1 | 19.1 | 78 |
| 2,3,7,8-TCDF-13C | 100 | 87 | 22.0 | 152.0 | 87 |
| 2,3,7,8-TCDD-13C | 100 | 77 | 20.0 | 175.0 | 77 |
| 1,2,3,7,8-PeCDF-13C | 100 | 89 | 21.0 | 192.0 | 89 |
| 2,3,4,7,8-PeCDF-13C | 100 | 90 | 13.0 | 328.0 | 90 |
| 1,2,3,7,8-PeCDD-13C | 100 | 89 | 21.0 | 227.0 | 89 |
| 1,2,3,4,7,8-HxCDF-13C | 100 | 93 | 19.0 | 202.0 | 93 |
| 1,2,3,6,7,8-HxCDF-13C | 100 | 94 | 21.0 | 159.0 | 94 |
| 2,3,4,6,7,8-HxCDF-13C | 100 | 92 | 22.0 | 176.0 | 92 |
| 1,2,3,7,8,9-HxCDF-13C | 100 | 80 | 17.0 | 205.0 | 80 |
| 1,2,3,4,7,8-HxCDD-13C | 100 | 80 | 21.0 | 193.0 | 80 |
| 1,2,3,6,7,8-HxCDD-13C | 100 | 89 | 25.0 | 163.0 | 89 |
| 1,2,3,4,6,7,8-HpCDF-13C | 100 | 69 | 21.0 | 158.0 | 69 |
| 1,2,3,4,7,8,9-HpCDF-13C | 100 | 65 | 20.0 | 186.0 | 65 |
| 1,2,3,4,6,7,8-HpCDD-13C | 100 | 77 | 26.0 | 166.0 | 77 |
| OCDD-13C | 200 | 110 | 26.0 | 397.0 | 56 |

Cs = Concentration Spiked (ng/mL)
 Cr = Concentration Recovered (ng/mL)
 Rec. = Recovery (Expressed as Percent)
 Control Limit Reference: Method 1613, Table 6, 10/94 Revision
 R = Recovery outside of control limits
 Nn = Value obtained from additional analysis
 * = See Discussion

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Method 1613B
Spike Recovery Relative Percent Difference (RPD) Results

Client Pace Analytical National

Spike 1 ID LCS-105423
Spike 1 Filename L230425A_09

Spike 2 ID LCSD-105424
Spike 2 Filename L230425A_10

| Compound | Spike 1 %REC | Spike 2 %REC | %RPD |
|---------------------|-----------------|-----------------|------|
| 2,3,7,8-TCDF | 94 | 94 | 0.0 |
| 2,3,7,8-TCDD | 96 | 96 | 0.0 |
| 1,2,3,7,8-PeCDF | 93 | 92 | 1.1 |
| 2,3,4,7,8-PeCDF | 96 | 92 | 4.3 |
| 1,2,3,7,8-PeCDD | 86 | 86 | 0.0 |
| 1,2,3,4,7,8-HxCDF | 96 | 96 | 0.0 |
| 1,2,3,6,7,8-HxCDF | 98 | 97 | 1.0 |
| 2,3,4,6,7,8-HxCDF | 100 | 96 | 4.1 |
| 1,2,3,7,8,9-HxCDF | 98 | 99 | 1.0 |
| 1,2,3,4,7,8-HxCDD | 104 | 102 | 1.9 |
| 1,2,3,6,7,8-HxCDD | 97 | 92 | 5.3 |
| 1,2,3,7,8,9-HxCDD | 103 | 97 | 6.0 |
| 1,2,3,4,6,7,8-HpCDF | 92 | 90 | 2.2 |
| 1,2,3,4,7,8,9-HpCDF | 95 | 92 | 3.2 |
| 1,2,3,4,6,7,8-HpCDD | 84 | 80 | 4.9 |
| OCDF | 99 | 95 | 4.1 |
| OCDD | 105 | 103 | 1.9 |

%REC = Percent Recovered

RPD = The difference between the two values divided by the mean value

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full,
without the written consent of Pace Analytical Services, Inc.

Stage 2A/B Data Validation Checks
JH Baxter
Delivery Group L1605173/10650019

Comments:

- U-qualified samples assigned by the laboratory are not included in this report unless the U qualification is for some other reason other than a simple non-detect.

SUMMARY OF QUALITY CONTROL CHECKS

| Quality Control Check | Check ed By | Comment |
|---|-------------|---|
| Completeness | MBF | The data set is 100 percent complete, no results rejected. |
| Holding times | MBF | Holding times were within the method specific recommended holding times. |
| Preservation | MBF | Preservation was acceptable. |
| COC Documentation | MBF | COC was provided in the lab report. |
| Analytical methods | MBF | EPA 1613B Requested analytical methods were performed. |
| Initial and continuing calibrations | MBF | Not independently verified during Stage 2A/B validation. |
| Method blanks, trip blank, and field blanks | MBF | <p>Method blanks were performed per batch and there were no detections and associated QC were within established control limits except for:</p> <ul style="list-style-type: none"> • Blank-105422 <ul style="list-style-type: none"> ○ 1,2,3,7,8,9-HxCDF 1.5 J+ ○ OCDD 7.1 J • Blank-105477 <ul style="list-style-type: none"> ○ 1,2,3,4,7,8-HxCDD 0.11 J ○ Total HxCDD 0.073 J ○ OCDD 0.39 J+ <p>Associated sample results were greater than 5X method blank contamination.</p> <ul style="list-style-type: none"> • Equipment Blank (EB-02_0423) <ul style="list-style-type: none"> ○ Total HxCDF 18 J ○ 1,2,3,4,7,8-HxCDD 1.4 J ○ 1,2,3,6,7,8-HxCDD 1.4 J+ ○ Total HxCDD 3.3 J ○ 1,2,3,4,6,7,8-HpCDF 79 ○ Total HpCDF 140 ○ 1,2,3,4,6,7,8-HpCDD 15 J ○ Total HpCDD 27 J ○ OCDF 72 J ○ OCDD 160 <p>Raw results not reviewed during 2A/B. Equipment blank results (pg/L) and sample results (ng/kg) not directly comparable. Results not qualified.</p> |

| Quality Control Check | Check ed By | Comment |
|--|-------------|---|
| Surrogate/labeled compounds | MBF | Labeled compounds were analyzed and within control limits. |
| LCS/LCSD | MBF | An LCS was analyzed per batch. Recoveries were within established control limits. |
| MS/MSD | MBF | MS/MSD on non-SDG samples were performed and stated in the narrative to be within control limits. Results not included in lab report. |
| Field duplicates | MBF | Field duplicates were collected and analyzed: <ul style="list-style-type: none"> • Primary: DU-06B-1.5-2.0_0423 • Duplicate: DU-106B-1.5-2.0_0423 Results were within 50% solid organic RPD limit except. |
| Lab duplicates | MBF | Lab sample duplicates were not performed or required per the method. |
| Dilution | MBF | Samples did not require further dilution for analysis. |
| Qualitative Identification for HRGC/HRMS analyses only | MBF | The following results were EMPCS: <ul style="list-style-type: none"> • DU-06B-1.5-2.0_0423 <ul style="list-style-type: none"> ○ 1,2,3,4,7,8-HxCDF ○ 1,2,3,6,7,8-HxCDD ○ 1,2,3,7,8,9-HxCDD • DU-106B-1.5-2.0_0423 <ul style="list-style-type: none"> ○ 1,2,3,4,7,8-HxCDD ○ 1,2,3,6,7,8-HxCDD ○ 1,2,3,7,8,9-HxCDD • DU-11A-2.0-2.5_0423 <ul style="list-style-type: none"> ○ 1,2,3,7,8,9-HxCDF • DU-11A-2.5-3.0_0423 <ul style="list-style-type: none"> ○ 1,2,3,4,6,7,8-HpCDF ○ 1,2,3,4,7,8-HxCDF ○ 1,2,3,6,7,8-HxCDD • EB-02-0423 <ul style="list-style-type: none"> ○ 1,2,3,6,7,8-HxCDD EMPC results had isotope ratios that were out of specification. EMPC results qualified J+. |

Overall Assessment

Qualifier codes added to results; table and notes below.

Notes

TABLE 1. SUMMARY OF QUALIFIED DATA

| Sample ID | Analyte | Result (ng/kg) | Qualifier Assigned | Reason for Qualification |
|----------------------|---------------------|----------------|--------------------|--|
| DU-06B-1.5-2.0_0423 | 1,2,3,4,6,7,8-HpCDF | 1.2 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 0.22 | | |
| | 1,2,3,7,8,9-HxCDF | 0.18 | | |
| | OCDF | 4.5 | | |
| | Total HpCDF | 1.2 | | |
| | Total HxCDD | 1.9 | | |
| | Total HxCDF | 0.18 | | |
| | Total TCDD | 0.23 | | |
| DU-06B-1.5-2.0_0423 | 1,2,3,4,7,8-HxCDF | 0.11 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,6,7,8-HxCDD | 0.19 | | |
| | 1,2,3,7,8,9-HxCDD | 0.15 | | |
| DU-106B-1.5-2.0_0423 | 1,2,3,4,6,7,8-HpCDF | 1 | J | Below reporting limit |
| | OCDF | 4 | | |
| | Total HpCDF | 2.9 | | |
| | Total HxCDD | 1.2 | | |
| | Total HxCDF | 0.33 | | |
| | Total TCDD | 0.42 | | |
| DU-106B-1.5-2.0_0423 | 1,2,3,4,7,8-HxCDD | 0.19 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,6,7,8-HxCDD | 0.18 | | |
| | 1,2,3,7,8,9-HxCDD | 0.19 | | |
| DU-11A-2.0-2.5_0423 | 1,2,3,4,7,8-HxCDD | 0.59 | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 0.91 | | |
| | 1,2,3,6,7,8-HxCDD | 1.5 | | |
| | 1,2,3,6,7,8-HxCDF | 0.38 | | |
| | 1,2,3,7,8,9-HxCDD | 0.95 | | |
| | 2,3,4,6,7,8-HxCDF | 0.39 | | |
| | Total PeCDD | 0.57 | | |
| | Total PeCDF | 1.4 | | |
| DU-11A-2.0-2.5_0423 | 1,2,3,7,8,9-HxCDF | 0.21 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| DU-11A-2.5-3.0_0423 | 1,2,3,7,8,9-HxCDD | 0.5 | J | Below reporting limit |
| | OCDF | 8.3 | | |
| | Total HxCDD | 2.4 | | |
| | Total HxCDF | 1.3 | | |
| DU-11A-2.5-3.0_0423 | 1,2,3,4,6,7,8-HpCDF | 2.7 | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |
| | 1,2,3,4,7,8-HxCDF | 0.37 | | |
| | 1,2,3,6,7,8-HxCDD | 0.62 | | |
| EB-02-0423 | 1,2,3,4,6,7,8-HpCDD | 15 pg/l | J | Below reporting limit |
| | 1,2,3,4,7,8-HxCDD | 3.3 pg/l | | |
| | OCDF | 72 pg/l | | |
| | Total HpCDD | 27 pg/l | | |
| | Total HxCDD | 3.3 pg/l | | |
| | Total HxCDF | 18 pg/l | | |
| EB-02-0423 | 1,2,3,6,7,8-HxCDD | 1.4 pg/l | J+ | EMPC, Isotope ratio out of spec, Below reporting limit |

APPENDIX C


June 2022 Discrete and Increment Sample Locations



FIGURE C-1
2022 DU-09
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- ISM
 - Composite A
 - Composite B
 - Surface Soil Area (2,248 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.



Date: September 6, 2024
Data Sources: BLM, ESRI, ODOT, USGS,
OSIP Imagery (2018)





FIGURE C-2
2022 DU-10
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- Composite A
 - Composite B
 - Surface Soil Area (3,376 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.







FIGURE C-3
2022 DU-11
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- ISM
 - Composite A
 - Composite B
 - Total Surface Soil Area (8325 SF)
 - Backyard Soil Area (5,763 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.



Date: September 6, 2024
Data Sources: BLM, ESRI, ODOT, USGS,
OSIP Imagery (2018)






FIGURE C-4
2022 DU-14
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- ISM
 - Composite A
 - Composite B
 - Surface Soil Area (2,334 SF)
 - ▭ Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.



Date: September 6, 2024
Data Sources: BLM, ESRI, ODOT, USGS,
OSIP Imagery (2018)






FIGURE C-5
2022 DU-15
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

LEGEND

- ISM
- Composite A
- Composite B
- Surface Soil Area (8,321 SF)
- Decision Unit

NOTE

ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.



Date: September 6, 2024
Data Sources: BLM, ESRI, ODOT, USGS,
OSIP Imagery (2018)



APPENDIX D

April 2023 Discrete and Increment Sample Locations




FIGURE D-1
2023 DU-09
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

LEGEND

- Composite A
- Composite B
- Surface Soil Area (2,248 SF)
- Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.



Date: September 6, 2024
Data Sources: BLM, ESRI, ODOT, USGS,
OSIP Imagery (2018)





FIGURE D-2
2023 DU-10
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- Composite A
 - Composite B
 - Surface Soil Area (3,376 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.






FIGURE D-3
2023 DU-11
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- Composite A
 - Composite B
 - Total Surface Soil Area (8325 SF)
 - Backyard Soil Area (5,763 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.







FIGURE D-4
2023 DU-15
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- Composite A
 - Composite B
 - Surface Soil Area (8,321 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.



Date: September 6, 2024
Data Sources: BLM, ESRI, ODOT, USGS,
OSIP Imagery (2018)






FIGURE D-5
2023 AP-01
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- Composite A
 - Composite B
 - Surface Soil Area (8,028 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.



Date: September 6, 2024
Data Sources: BLM, ESRI, ODOT, USGS,
OSIP Imagery (2018)





FIGURE D-6
2023 SO-06
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- Composite A
 - Composite B
 - Surface Soil Area (8,522 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.






FIGURE D-7
2023 SO-07
Soil Sample Increment Locations
Former JH Baxter & Co. Facility
Offsite Investigation Report
Eugene, OR

- LEGEND**
- Composite A
 - Composite B
 - Surface Soil Area (6,886 SF)
 - Decision Unit

NOTE
ISM and Composite points locations are estimates. Point locations were collected using GPS equipment at the time of sampling; however, some data point locations have been adjusted due to GPS accuracy or variations between the GPS coordinate system and the base map imagery.



Date: September 6, 2024
Data Sources: BLM, ESRI, ODOT, USGS,
OSIP Imagery (2018)



APPENDIX E

Arborist Reports